Induction_NN
of_IN
NF-KB_NNP
during_IN
monocyte_NN
differentiation_NN
by_IN
HIV_NNP
type_NN
1_CD
infection_NN
._.
The_DT
production_NN
of_IN
human_JJ
immunodeficiency_NN
virus_NN
type_NN
1_CD
(_-LRB-
HIV-1_NN
)_-RRB-
progeny_NN
was_VBD
followed_VBN
in_IN
the_DT
U937_NNP
promonocytic_JJ
cell_NN
line_NN
after_IN
stimulation_NN
either_CC
with_IN
retinoic_JJ
acid_NN
or_CC
PMA_NNP
,_,
and_CC
in_IN
purified_VBN
human_JJ
monocytes_NNS
and_CC
macrophages_NNS
._.
Electrophoretic_NNP
mobility_NN
shift_NN
assays_IN
and_CC
Southwestern_NNP
blotting_VBG
experiments_NNS
were_VBD
used_VBN
to_TO
detect_VB
the_DT
binding_NN
of_IN
cellular_JJ
transactivation_NN
factor_NN
NF-KB_NNP
to_TO
the_DT
double_JJ
repeat-KB_NN
enhancer_NN
sequence_NN
located_VBN
in_IN
the_DT
long_JJ
terminal_NN
repeat_NN
._.
PMA_NNP
treatment_NN
,_,
and_CC
not_RB
retinoic_JJ
acid_NN
treatment_NN
of_IN
the_DT
U937_JJ
cells_NNS
acts_VBZ
in_IN
inducing_NN
NF-KB_NNP
expression_NN
in_IN
the_DT
nuclei_NNS
._.
In_IN
nuclear_JJ
extracts_NNS
from_IN
monocytes_NNS
or_CC
macrophages_NNS
,_,
induction_NN
of_IN
NF-KB_NNP
occurred_VBD
only_RB
if_IN
the_DT
cells_NNS
were_VBD
previously_RB
infected_VBN
with_IN
HIV-1_NN
._.
When_WRB
U937_DT
cells_NNS
were_VBD
infected_VBN
with_IN
HIV-1_NN
,_,
no_DT
induction_NN
of_IN
NF-KB_NNP
factor_NN
was_VBD
detected_VBN
,_,
whereas_IN
high_JJ
level_NN
of_IN
progeny_NN
virions_NNS
was_VBD
produced_VBN
,_,
suggesting_VBG
that_IN
this_DT
factor_NN
was_VBD
not_RB
required_VBN
for_IN
viral_JJ
replication_NN
._.
These_DT
results_NNS
indicate_VBP
that_IN
in_IN
monocytic_JJ
cell_NN
lineage_NN
,_,
HIV-1_NNP
could_MD
mimic_VB
some_DT
differentiation/activation_NN
stimuli_NNS
allowing_VBG
nuclear_JJ
NF-KB_NNP
expression_NN
._.
Positive_JJ
and_CC
negative_JJ
regulation_NN
of_IN
immunoglobulin_NN
gene_NN
expression_NN
by_IN
a_DT
novel_NN
B-cell-specific_NNP
enhancer_NN
element_NN
._.
A_DT
new_JJ
B-cell-specific_JJ
enhancer_NN
element_NN
has_VBZ
been_VBN
identified_VBN
3'_IN
of_IN
E4_NNP
and_CC
the_DT
octamerlike_JJ
motifs_NNS
in_IN
the_DT
human_JJ
immunoglobulin_NN
heavy-chain_JJ
gene_NN
enhancer_NN
._.
Tandem_NNP
copies_NNS
of_IN
this_DT
67-bp_CD
MnlI-AluI_JJ
fragment_NN
,_,
when_WRB
fused_VBN
to_TO
the_DT
chloramphenicol_NN
acetyltransferase_NN
gene_NN
driven_VBN
by_IN
the_DT
conalbumin_NN
promoter_NN
,_,
stimulated_VBD
transcription_NN
in_IN
B_NNP
cells_NNS
but_CC
not_RB
in_IN
Jurkat_NNP
T_NNP
cells_NNS
or_CC
HeLa_NNP
cells_NNS
._.
Footprinting_VBG
analysis_NN
revealed_VBN
that_IN
the_DT
identical_JJ
sequence_NN
CCGAAACTGAAAAGG_NNP
,_,
designated_VBN
E6_NNP
,_,
was_VBD
protected_VBN
by_IN
nuclear_JJ
extracts_NNS
from_IN
B_NNP
cells_NNS
,_,
T_NNP
cells_NNS
,_,
or_CC
HeLa_NNP
cells_NNS
._.
Gel_NNP
mobility_NN
shift_NN
assays_VBZ
using_VBG
a_DT
synthetic_JJ
E6_NNP
motif_NN
detected_VBD
a_DT
B-cell-specific_JJ
complex_NN
in_IN
addition_NN
to_TO
a_DT
ubiquitous_JJ
band_NN
found_VBD
also_RB
in_IN
T_NNP
cells_NNS
and_CC
HeLa_NNP
cells_NNS
._.
In_IN
agreement_NN
with_IN
the_DT
results_NNS
of_IN
gel_NNP
retardation_NN
assays_VBZ
,_,
tandem_NN
copies_NNS
of_IN
the_DT
E6_NNP
motif_NN
stimulated_VBD
transcription_NN
in_IN
ARH77_NN
and_CC
Raji_NNP
cells_NNS
but_CC
not_RB
in_IN
Jurkat_NNP
or_CC
HeLa_NNP
cells_NNS
._.
Furthermore_RB
,_,
a_DT
mutant_JJ
E6_NNP
motif_NN
lost_VBD
both_DT
in_IN
vitro_NN
binding_NN
activity_NN
and_CC
in_IN
vivo_JJ
enhancer_NN
activity_NN
._.
In_IN
striking_JJ
contrast_NN
to_TO
the_DT
mouse_NN
Ig_NNP
heavy-chain_JJ
enhancer_NN
,_,
in_IN
which_WDT
the_DT
octamer_NN
motif_NN
acts_VBZ
as_IN
a_DT
B-cell-specific_JJ
enhancer_NN
element_NN
,_,
the_DT
human_JJ
enhancer_NN
contains_VBZ
an_DT
octamerlike_JJ
sequence_NN
with_IN
one_CD
base_NN
substitution_NN
which_WDT
bound_VBD
octamer-binding_JJ
proteins_NNS
with_IN
only_RB
very_RB
low_JJ
affinity_NN
and_CC
showed_VBD
no_DT
enhancer_NN
activity_NN
of_IN
its_PRP$
own_JJ
._.
Interestingly_RB
,_,
the_DT
MnlI-AluI_JJ
fragment_NN
could_MD
suppress_VB
the_DT
basal-level_JJ
activity_NN
of_IN
the_DT
conalbumin_NN
promoter_NN
in_IN
both_DT
Jurkat_NNP
and_CC
HeLa_NNP
cells_NNS
._.
Moreover_RB
,_,
simian_JJ
virus_NN
40_CD
enhancer_NN
activity_NN
was_VBD
blocked_VBN
by_IN
the_DT
MnlI-AluI_JJ
fragment_NN
in_IN
HeLa_NNP
cells_NNS
but_CC
not_RB
in_IN
B_NNP
cells_NNS
._.
Thus_RB
,_,
the_DT
novel_NN
enhancer_NN
element_NN
identified_VBN
in_IN
this_DT
study_NN
is_VBZ
probably_RB
a_DT
target_NN
site_NN
for_IN
both_DT
positive_JJ
and_CC
negative_JJ
factors_NNS
._.
The_DT
NF_NNP
kappa_NN
B_NNP
independent_JJ
cis-acting_NN
sequences_NNS
in_IN
HIV-1_JJ
LTR_NNP
responsive_JJ
to_TO
T-cell_DT
activation_NN
._.
The_DT
rate_NN
of_IN
transcription_NN
initiation_NN
directed_VBN
by_IN
the_DT
long_JJ
terminal_NN
repeat_NN
(_-LRB-
LTR_NNP
)_-RRB-
of_IN
HIV-1_NN
increases_NNS
in_IN
response_NN
to_TO
mitogenic_JJ
stimuli_NNS
of_IN
T_NNP
cells_NNS
._.
Here_RB
we_PRP
show_VBP
that_IN
the_DT
response_NN
of_IN
the_DT
HIV-1_NN
LTR_NN
may_MD
be_VB
governed_VBN
by_IN
two_CD
independent_JJ
sequences_NNS
located_VBN
5'_IN
to_TO
the_DT
site_NN
of_IN
transcription_NN
initiation_NN
sequences_NNS
that_WDT
bind_VBP
either_DT
NFAT-1_NNP
or_CC
NF_NNP
kappa_NN
B_NNP
._.
The_DT
rate_NN
of_IN
LTR-directed_JJ
gene_NN
expression_NN
increased_VBD
in_IN
response_NN
to_TO
treatment_NN
with_IN
either_CC
a_DT
phorbol_NN
ester_NN
or_CC
tumor_NN
necrosis_NN
factor_NN
alpha_NN
if_IN
either_CC
the_DT
NFAT-1_NN
or_CC
NF_NNP
kappa_NN
B_NNP
binding_NN
sites_NNS
were_VBD
deleted_VBN
,_,
but_CC
failed_VBD
to_TO
respond_VB
to_TO
these_DT
mitogenic_JJ
stimuli_NNS
if_IN
both_DT
sequences_NNS
were_VBD
absent_JJ
._.
The_DT
HIV-1_NN
mutant_NN
virus_NN
containing_VBG
both_DT
NF_NNP
kappa_NN
B_NNP
and_CC
NFAT-1_NNP
deletion_NN
was_VBD
able_JJ
to_TO
replicate_VB
although_IN
at_IN
a_DT
much_JJ
decreased_VBN
growth_NN
rate_NN
,_,
while_IN
the_DT
deletion_NN
of_IN
NFAT-1_NNP
alone_RB
increased_VBD
the_DT
viral_JJ
growth_NN
rate_NN
in_IN
Jurkat_NNP
cells_NNS
._.
Neither_DT
deletion_NN
of_IN
NF_NNP
kappa_NN
B_NNP
nor_CC
deletion_NN
of_IN
NFAT-1_NNP
decreased_VBD
activation_NN
of_IN
viral_JJ
replication_NN
by_IN
phorbol_NN
ester_NN
._.
Specific_JJ
depletion_NN
of_IN
the_DT
B-cell_JJ
population_NN
induced_VBN
by_IN
aberrant_JJ
expression_NN
of_IN
human_JJ
interferon_NN
regulatory_JJ
factor_NN
1_CD
gene_NN
in_IN
transgenic_JJ
mice_NNS
._.
Interferons_NNS
(_-LRB-
IFNs_NN
)_-RRB-
are_VBP
well_RB
known_VBN
both_DT
as_IN
antiviral_JJ
proteins_NNS
and_CC
as_IN
potent_JJ
regulators_NNS
of_IN
cell_NN
growth_NN
and_CC
differentiation_NN
._.
In_IN
fact_NN
,_,
IFNs_NNP
inhibit_VBP
growth_NN
of_IN
various_JJ
normal_JJ
and_CC
transformed_VBD
cell_NN
types_NNS
._.
Previously_RB
,_,
a_DT
nuclear_JJ
factor_NN
,_,
IRF-1_NNP
(_-LRB-
interferon_NN
regulatory_JJ
factor_NN
1_CD
)_-RRB-
,_,
which_WDT
binds_VBZ
to_TO
type_NN
I_PRP
IFN_VBP
and_CC
some_DT
IFN-inducible_JJ
gene_NN
promoters_NNS
,_,
was_VBD
identified_VBN
and_CC
cloned_VBN
._.
Since_IN
the_DT
IRF-1_NNP
gene_NN
is_VBZ
both_DT
virus_NN
and_CC
IFN_NNP
inducible_JJ
,_,
an_DT
intriguing_JJ
issue_NN
is_VBZ
raised_VBN
as_IN
to_TO
whether_IN
the_DT
IRF-1_NNP
gene_NN
is_VBZ
functioning_VBG
in_IN
IFN-mediated_JJ
regulation_NN
of_IN
cell_NN
growth_NN
and_CC
differentiation_NN
._.
In_IN
this_DT
study_NN
,_,
we_PRP
generated_VBD
transgenic_JJ
mice_NNS
carrying_VBG
the_DT
human_JJ
IRF-1_NNP
gene_NN
linked_VBN
to_TO
the_DT
human_JJ
immunoglobulin_NN
heavy-chain_NN
enhancer_NN
._.
In_IN
the_DT
transgenic_JJ
mice_NNS
,_,
all_DT
the_DT
lymphoid_JJ
tissues_NNS
examined_VBN
showed_VBD
a_DT
dramatic_JJ
reduction_NN
in_IN
the_DT
number_NN
of_IN
B_NNP
lymphocytes_NNS
(_-LRB-
B_NN
cells_NNS
)_-RRB-
._.
Preparation_NN
and_CC
analysis_NN
of_IN
bone_NN
marrow_NN
cells_NNS
from_IN
the_DT
chimeric_JJ
mice_NNS
indicated_VBD
that_IN
the_DT
bone_NN
marrow_NN
is_VBZ
the_DT
effective_JJ
site_NN
for_IN
specific_JJ
depletion_NN
of_IN
the_DT
B-cell_JJ
population_NN
._.
In_IN
fact_NN
,_,
transgenic_JJ
bone_NN
marrow_NN
cells_NNS
cocultured_VBN
with_IN
a_DT
bone_NN
marrow-derived_JJ
stromal_JJ
cell_NN
line_NN
revealed_VBD
an_DT
altered_VBN
B-cell_JJ
maturation_NN
pattern_NN
._.
Identification_NN
and_CC
cloning_NN
of_IN
TCF-1_NNP
,_,
a_DT
T_NNP
lymphocyte-specific_JJ
transcription_NN
factor_NN
containing_VBG
a_DT
sequence-specific_JJ
HMG_NNP
box_NN
._.
CD3-epsilon_JJ
expression_NN
is_VBZ
controlled_VBN
by_IN
a_DT
downstream_NN
T_NNP
lymphocyte-specific_JJ
enhancer_NN
element_NN
._.
We_PRP
report_VBP
the_DT
identification_NN
of_IN
a_DT
T_NNP
cell-specific_JJ
transcription_NN
factor_NN
,_,
TCF-1_NNP
,_,
binding_NN
to_TO
this_DT
element_NN
._.
The_DT
multimerized_JJ
recognition_NN
motif_NN
of_IN
TCF-1_NNP
constituted_VBD
a_DT
T_NNP
cell-specific_JJ
enhancer_NN
._.
Subsequent_JJ
cloning_NN
of_IN
TCF-1_NNP
identified_VBD
three_CD
splice_NN
alternatives_NNS
._.
TCF-1_NN
contained_VBD
a_DT
single_JJ
DNA-binding_JJ
HMG_NNP
box_NN
most_RBS
closely_RB
related_VBN
to_TO
similar_JJ
boxes_NNS
in_IN
the_DT
putative_JJ
mammalian_JJ
sex-determining_NN
gene_NN
SRY_NN
and_CC
in_IN
the_DT
Schizosaccharomyces_NNP
pombe_NN
Mc_NNP
mating_VBG
type_NN
gene_NN
._.
TCF-1_JJ
mRNA_NN
was_VBD
expressed_VBN
uniquely_RB
in_IN
T_NNP
lymphocytes_NNS
._.
Upon_IN
cotransfection_NN
into_IN
non-T_JJ
cells_NNS
,_,
TCF-1_NNP
could_MD
transactivate_VB
through_IN
its_PRP$
cognate_JJ
motif_NN
._.
These_DT
results_NNS
identify_VBP
TCF-1_JJ
as_IN
a_DT
T_NNP
cell-specific_JJ
transcription_NN
factor_NN
,_,
which_WDT
might_MD
play_VB
a_DT
role_NN
in_IN
the_DT
establishment_NN
of_IN
the_DT
mature_JJ
T_NNP
cell_NN
phenotype_NN
._.
Nuclear_NNP
factor_NN
kappa_NN
B_NNP
activates_VBZ
proenkephalin_RB
transcription_NN
in_IN
T_NNP
lymphocytes_NNS
._.
Upon_IN
activation_NN
,_,
T_NNP
lymphocytes_NNS
accumulate_VBP
high_JJ
levels_NNS
of_IN
the_DT
neuropeptide_NN
enkephalin_NN
which_WDT
correlate_VBP
with_IN
high_JJ
levels_NNS
of_IN
proenkephalin_NN
mRNA_NN
in_IN
the_DT
cells_NNS
._.
Here_RB
we_PRP
investigated_VBD
the_DT
transcriptional_JJ
basis_NN
for_IN
these_DT
changes_NNS
._.
The_DT
proenkephalin_NN
promoter_NN
contains_VBZ
a_DT
sequence_NN
GGGGACGTCCCC_NNP
,_,
named_VBN
B2_NN
,_,
which_WDT
is_VBZ
similar_JJ
to_TO
the_DT
kappa_NN
B_NNP
sequence_NN
GGGGACTTTCC_NNP
,_,
the_DT
binding_JJ
site_NN
of_IN
the_DT
transcription_NN
factor_NN
nuclear_JJ
factor_NN
(_-LRB-
NF_NNP
)_-RRB-
-kappa_NNP
B_NNP
._.
Activation_NN
of_IN
T_NNP
lymphocytes_NNS
induces_VBZ
an_DT
NF-kappa_NNP
B-like_NNP
binding_NN
activity_NN
to_TO
the_DT
B2_JJ
site_NN
,_,
concomitant_JJ
with_IN
activation_NN
of_IN
the_DT
proenkephalin_NN
promoter_NN
._.
Mutations_NNS
at_IN
the_DT
B2_JJ
site_NN
abolish_VB
this_DT
transcriptional_JJ
activation_NN
._.
The_DT
purified_VBN
homodimer_NN
(_-LRB-
two_CD
p50s_NNS
)_-RRB-
of_IN
the_DT
DNA-binding_JJ
subunit_NN
of_IN
NF-kappa_NNP
B_NNP
binds_VBZ
the_DT
B2_JJ
site_NN
of_IN
proenkephalin_VBG
relatively_RB
better_JJR
than_IN
does_VBZ
the_DT
heterotetramer_NN
(_-LRB-
two_CD
p65s_NNS
plus_CC
two_CD
p50s_NNS
)_-RRB-
form_NN
of_IN
the_DT
factor_NN
._.
Thus_RB
,_,
it_PRP
appears_VBZ
that_IN
the_DT
T-cell-specific_JJ
activation_NN
of_IN
the_DT
proenkephalin_NN
promoter_NN
is_VBZ
mediated_VBN
by_IN
NF-kappa_NNP
B_NNP
._.
However_RB
,_,
as_IN
NF-kappa_NNP
B_NNP
is_VBZ
ubiquitous_JJ
and_CC
the_DT
transcriptional_JJ
activation_NN
through_IN
the_DT
B2_JJ
site_NN
is_VBZ
T_NNP
cell_NN
specific_NN
,_,
yet_RB
another_DT
T-cell-specific_JJ
factor_NN
which_WDT
synergizes_VBZ
with_IN
NF-kappa_NNP
B_NNP
should_MD
be_VB
considered_VBN
._.
Expression_NN
of_IN
c-jun_NN
,_,
jun_NN
B_NNP
and_CC
jun_NN
D_NNP
proto-oncogenes_NNS
in_IN
human_JJ
peripheral-blood_NN
granulocytes_NNS
._.
We_PRP
have_VBP
found_VBN
that_IN
purified_VBN
human_JJ
peripheral-blood_NN
granulocytes_NNS
express_VBP
constitutively_RB
significant_JJ
levels_NNS
of_IN
proto-oncogenes_NNS
c-jun_JJ
,_,
jun_NN
B_NNP
and_CC
jun_NN
D_NNP
mRNA_NN
._.
Upon_IN
functional_JJ
activation_NN
of_IN
granulocytes_NNS
by_IN
4_CD
beta-phorbol_JJ
12-myristate_JJ
13-acetate_JJ
(_-LRB-
PMA_NNP
)_-RRB-
,_,
the_DT
levels_NNS
of_IN
c-jun_NN
,_,
jun_NN
B_NNP
and_CC
jun_NN
D_NN
transcripts_NNS
were_VBD
increased_VBN
._.
The_DT
three_CD
jun_NN
genes_NNS
showed_VBD
a_DT
similar_JJ
time_NN
course_NN
in_IN
their_PRP$
induction_NN
by_IN
PMA_NNP
,_,
maximal_JJ
mRNA_NN
levels_NNS
being_VBG
reached_VBN
after_IN
60_CD
min_NN
of_IN
induction_NN
._.
These_DT
results_NNS
suggest_VBP
that_IN
expression_NN
of_IN
c-jun_NN
,_,
jun_NN
B_NNP
and_CC
jun_NN
D_NNP
genes_NNS
might_MD
be_VB
involved_VBN
in_IN
terminal_NN
granulocyte_NN
differentiation_NN
or_CC
in_IN
regulating_JJ
granulocyte_NN
functionality_NN
._.
Platelet-activating_NN
factor_NN
induces_VBZ
phospholipid_JJ
turnover_NN
,_,
calcium_NN
flux_NN
,_,
arachidonic_JJ
acid_NN
liberation_NN
,_,
eicosanoid_JJ
generation_NN
,_,
and_CC
oncogene_NNP
expression_NN
in_IN
a_DT
human_NN
B_NNP
cell_NN
line_NN
._.
Platelet-activating_NN
factor_NN
is_VBZ
a_DT
potent_JJ
mediator_NN
of_IN
the_DT
inflammatory_JJ
response_NN
._.
Studies_NNS
of_IN
the_DT
actions_NNS
of_IN
platelet-activating_JJ
factor_NN
have_VBP
centered_VBN
mainly_RB
around_IN
neutrophils_NNS
,_,
monocytes_NNS
,_,
and_CC
platelets_NNS
._.
In_IN
this_DT
report_NN
we_PRP
begin_VBP
to_TO
uncover_VB
the_DT
influence_NN
of_IN
platelet-activating_NN
factor_NN
on_IN
B_NNP
lymphocytes_NNS
._.
Employing_VBG
the_DT
EBV-transformed_JJ
human_NN
B_NNP
cell_NN
line_NN
SKW6.4_NNP
,_,
we_PRP
demonstrate_VBP
that_DT
platelet-activating_NN
factor_NN
significantly_RB
alters_IN
membrane_NN
phospholipid_JJ
metabolism_NN
indicated_VBN
by_IN
the_DT
incorporation_NN
of_IN
32P_JJ
into_IN
phosphatidylcholine_NN
,_,
phosphatidylinositol_NN
,_,
and_CC
phosphatidic_JJ
acid_NN
but_CC
not_RB
significantly_RB
into_IN
phosphatidylethanolamine_NN
at_IN
concentrations_NNS
ranging_VBG
from_IN
10(-9)_JJ
to_TO
10(-6)_JJ
M_NNP
._.
The_DT
inactive_JJ
precursor_NN
,_,
lyso-platelet-activating_JJ
factor_NN
,_,
at_IN
a_DT
concentration_NN
as_RB
high_JJ
as_IN
10(-7)_JJ
M_NNP
had_VBD
no_DT
effect_NN
on_IN
any_DT
of_IN
the_DT
membrane_NN
phospholipids_NNS
._.
We_PRP
also_RB
show_VBP
that_DT
platelet-activating_NN
factor_NN
from_IN
10(-12)_JJ
to_TO
10(-6)_JJ
M_NNP
induced_VBD
rapid_JJ
and_CC
significant_JJ
elevation_NN
in_IN
intracellular_JJ
calcium_NN
levels_NNS
,_,
whereas_IN
lyso-platelet-activating_JJ
factor_NN
was_VBD
again_RB
ineffective_JJ
._.
We_PRP
further_RB
demonstrate_VBP
the_DT
impact_NN
of_IN
platelet-activating_VBG
factor_NN
binding_NN
to_TO
B_NNP
cells_NNS
by_IN
measuring_VBG
platelet-activating_NN
factor_NN
induced_VBD
arachidonic_JJ
acid_NN
release_NN
and_CC
5-hydroxyeicosatetraenoic_JJ
acid_NN
production_NN
._.
Moreover_RB
,_,
platelet-activating_NN
factor_NN
was_VBD
capable_JJ
of_IN
inducing_VBG
transcription_NN
of_IN
the_DT
nuclear_JJ
proto-oncogenes_NNS
c-fos_NNS
and_CC
c-jun_NN
._.
Finally_RB
we_PRP
explored_VBD
the_DT
possible_JJ
role_NN
of_IN
5-hydroxyeicosatetraenoic_JJ
acid_NN
as_IN
a_DT
regulator_NN
of_IN
arachidonic_JJ
acid_NN
liberation_NN
demonstrating_NN
that_IN
endogenous_JJ
5-lipoxygenase_JJ
activity_NN
modulates_NNS
platelet-activating_NN
factor_NN
induced_VBD
arachidonic_JJ
acid_NN
release_NN
perhaps_RB
acting_VBG
at_IN
the_DT
level_NN
of_IN
phospholipase_NN
A2_NN
._.
In_IN
summary_NN
,_,
platelet-activating_NN
factor_NN
is_VBZ
shown_VBN
here_RB
to_TO
have_VB
a_DT
direct_JJ
and_CC
profound_JJ
effect_NN
on_IN
a_DT
pure_JJ
B_NNP
cell_NN
line_NN
._.
A_DT
novel_NN
HIV-1_NN
isolate_VBP
containing_VBG
alterations_NNS
affecting_VBG
the_DT
NF-kappa_NNP
B_NNP
element_NN
._.
Three_CD
molecular_JJ
clones_NNS
of_IN
HIV-1_NN
,_,
derived_VBN
from_IN
a_DT
single_JJ
isolate_NN
(_-LRB-
AL1_NNP
)_-RRB-
,_,
exhibited_VBD
distinct_JJ
replicative_NN
and_CC
cytopathic_JJ
properties_NNS
during_IN
propagation_NN
in_IN
a_DT
human_JJ
T_NNP
cell_NN
line_NN
._.
The_DT
phenotypic_JJ
differences_NNS
observed_VBN
were_VBD
attributable_JJ
,_,
in_IN
large_JJ
part_NN
,_,
to_TO
changes_NNS
affecting_VBG
the_DT
viral_JJ
LTR_NNP
._.
Nucleotide_NNP
sequence_NN
and_CC
PCR_NN
analyses_NNS
demonstrated_VBD
the_DT
presence_NN
of_IN
novel_JJ
duplications_NNS
or_CC
deletions_NNS
involving_VBG
the_DT
NF-kappa_NNP
B_NNP
motif_NN
._.
These_DT
changes_NNS
in_IN
the_DT
enhancer_NN
element_NN
were_VBD
identified_VBN
in_IN
the_DT
original_JJ
AL1_NNP
virus_NN
stock_NN
._.
Subcloning_VBG
of_IN
the_DT
variant_JJ
NF-kappa_NNP
B_NNP
segments_NNS
into_IN
LTR-driven_JJ
CAT_JJ
expression_NN
vectors_NNS
confirmed_VBD
a_DT
correlation_NN
between_IN
promoter_NN
activity_NN
and_CC
replicative/cytopathic_JJ
capacity_NN
._.
1,25-Dihydroxyvitamin_CD
D3_NN
receptor_NN
RNA_NNP
:_:
expression_NN
in_IN
hematopoietic_JJ
cells_NNS
._.
1,25-Dihydroxyvitamin_CD
D3_NNS
(_-LRB-
1,25(OH)2D3_CD
)_-RRB-
induces_VBZ
differentiation_JJ
and_CC
inhibits_VBZ
proliferation_NN
of_IN
myeloid_JJ
leukemic_JJ
cells_NNS
from_IN
various_JJ
lines_NNS
and_CC
patients_NNS
;_:
these_DT
effects_NNS
are_VBP
probably_RB
mediated_VBN
through_IN
the_DT
1,25(OH)2D3_CD
receptor_NN
._.
Little_NNP
is_VBZ
known_VBN
of_IN
expression_NN
of_IN
1,25(OH)2D3_CD
receptor_NN
RNA_NNP
in_IN
hematopoietic_JJ
cells_NNS
._.
We_PRP
examined_VBD
the_DT
expression_NN
and_CC
modulation_NN
of_IN
expression_NN
of_IN
1,25(OH)2D3_CD
receptor_NN
RNA_NNP
in_IN
various_JJ
proliferating_NN
and_CC
nonproliferating_JJ
hematopoietic_JJ
cells_NNS
._.
Constitutive_JJ
expression_NN
of_IN
1,25(OH)2D3_CD
receptor_NN
RNA_NNP
was_VBD
detected_VBN
in_IN
various_JJ
kinds_NNS
of_IN
hematopoietic_JJ
cells_NNS
,_,
including_VBG
macrophages_NNS
and_CC
activated_JJ
T_NNP
lymphocytes_NNS
,_,
as_RB
well_RB
as_IN
in_IN
cell_NN
lines_NNS
KG-1_.
(_-LRB-
myeloblasts_NNS
)_-RRB-
,_,
HL-60_FW
(_-LRB-
promyelocytes_NNS
)_-RRB-
,_,
ML-3_JJ
(_-LRB-
myelomonoblasts_NNS
)_-RRB-
,_,
U937_UH
,_,
THP-1_DT
(_-LRB-
monoblasts_NNS
)_-RRB-
,_,
K562_FW
(_-LRB-
erythroblasts_NNS
)_-RRB-
,_,
and_CC
S-LB1_JJ
(_-LRB-
HTLV-1-transfected_JJ
T_NN
lymphocytes_NNS
)_-RRB-
._.
Receptor_NN
transcripts_NNS
were_VBD
4.6_CD
kilobases_NNS
(_-LRB-
kb_NN
)_-RRB-
,_,
and_CC
no_DT
variant_JJ
sizes_NNS
were_VBD
observed_VBN
._.
All_DT
cell_NN
lines_NNS
examined_VBN
in_IN
this_DT
group_NN
also_RB
expressed_VBD
1,25(OH)2D3_CD
receptors_NNS
._.
Most_JJS
B_NNP
lymphocyte_NN
lines_NNS
expressed_VBN
negligible_JJ
levels_NNS
of_IN
1,25(OH)2D3_CD
receptor_NN
RNA_NNP
and_CC
protein_NN
;_:
however_RB
;_:
analysis_NN
of_IN
a_DT
lymphoid/myeloid_JJ
somatic_JJ
hybrid_NN
suggested_VBD
that_IN
suppression_NN
of_IN
expression_NN
of_IN
1,25(OH)2D3_CD
receptor_NN
RNA_NN
in_IN
B_NNP
lymphocytes_NNS
may_MD
be_VB
a_DT
dominant_JJ
characteristic_NN
._.
HL-60_JJ
cells_NNS
were_VBD
cultured_VBN
with_IN
10(-7)_JJ
mol/L_NN
1,25(OH)2D3_CD
for_IN
24_CD
to_TO
72_CD
hours_NNS
,_,
and_CC
levels_NNS
of_IN
expression_NN
of_IN
1,25(OH)2D3_CD
receptor_NN
and_CC
its_PRP$
RNA_NNP
were_VBD
examined_VBN
._.
Levels_NNP
of_IN
RNA_NNP
coding_NN
for_IN
the_DT
receptor_NN
were_VBD
not_RB
modulated_VBN
by_IN
exposure_NN
to_TO
high_JJ
levels_NNS
of_IN
ligand_NN
._.
Levels_NNP
of_IN
occupied_JJ
1,25(OH)2D3_CD
receptor_NN
protein_NN
increased_VBN
in_IN
these_DT
HL-60_JJ
cells_NNS
;_:
but_CC
the_DT
total_JJ
number_NN
of_IN
1,25(OH)2D3_CD
receptors_NNS
decreased_VBD
about_IN
50_CD
%_NN
at_IN
24_CD
hours_NNS
and_CC
returned_VBD
toward_IN
normal_JJ
at_IN
72_CD
hours_NNS
._.
Steady-state_NNP
levels_NNS
of_IN
1,25(OH)2D3_CD
receptor_NN
RNA_NNP
were_VBD
not_RB
affected_VBN
by_IN
terminal_JJ
differentiation_NN
of_IN
HL-60_NNP
toward_IN
either_DT
granulocytes_NNS
or_CC
macrophages_NNS
._.
Nondividing_VBG
macrophages_NNS
from_IN
normal_JJ
individuals_NNS
also_RB
expressed_VBD
1,25(OH)2D3_CD
receptor_NN
RNA_NNP
._.
In_IN
contrast_NN
,_,
nondividing_JJ
peripheral_JJ
blood_NN
lymphocytes_NNS
from_IN
normal_JJ
individuals_NNS
did_VBD
not_RB
express_VB
1,25(OH)2D3_CD
receptor_NN
RNA_NNP
;_:
with_IN
stimulation_NN
of_IN
proliferation_NN
of_IN
these_DT
cells_NNS
,_,
accumulation_NN
of_IN
1,25(OH)2D3_CD
receptor_NN
RNA_NNP
increased_VBD
markedly_RB
._.
Half-life_NN
(_-LRB-
t1/2_NN
)_-RRB-
of_IN
1,25(OH)2D3_CD
receptor_NN
RNA_NNP
in_IN
T_NNP
lymphocytes_NNS
was_VBD
short_JJ
(_-LRB-
1_CD
hour_NN
)_-RRB-
as_IN
determined_VBN
by_IN
measuring_VBG
decay_NN
of_IN
the_DT
message_NN
after_IN
addition_NN
of_IN
actinomycin_NN
D_NNP
._.
Consistent_NN
with_IN
this_DT
short_JJ
t1/2_NN
,_,
accumulation_NN
of_IN
1,25(OH)2D3_CD
receptor_NN
RNA_NNP
increased_VBD
in_IN
cells_NNS
as_IN
their_PRP$
protein_NN
synthesis_NN
was_VBD
inhibited_VBN
._.
Further_JJ
studies_NNS
are_VBP
required_VBN
to_TO
understand_VB
the_DT
physiologic_JJ
role_NN
of_IN
1,25(OH)2D3_CD
receptors_NNS
in_IN
myeloid_JJ
cells_NNS
and_CC
proliferating_VBG
T_NNP
lymphocytes_NNS
._.
Kappa_NNP
B_NNP
binding_JJ
proteins_NNS
are_VBP
constitutively_RB
expressed_VBN
in_IN
an_DT
IL-2_JJ
autocrine_NN
human_NN
T_NNP
cell_NN
line_NN
._.
The_DT
IL-2_NN
and_CC
the_DT
IL-2-R_NNP
alpha_NN
genes_NNS
are_VBP
both_DT
expressed_VBN
transiently_RB
in_IN
normal_JJ
T_NNP
lymphocytes_NNS
after_IN
Ag_NNP
or_CC
mitogen_NN
activation_NN
._.
In_IN
contrast_NN
,_,
the_DT
human_JJ
T_NNP
cell_NN
line_NN
,_,
IARC_NNP
301_CD
,_,
expresses_VBZ
these_DT
two_CD
genes_NNS
constitutively_RB
and_CC
we_PRP
have_VBP
previously_RB
demonstrated_VBN
that_IN
its_PRP$
growth_NN
depends_VBZ
on_IN
the_DT
autocrine_NN
production_NN
of_IN
this_DT
T_NNP
cell_NN
growth_NN
factor_NN
and_CC
high_JJ
affinity_NN
IL-2R_NN
._.
To_TO
dissect_VB
the_DT
molecular_JJ
basis_NN
for_IN
the_DT
unusual_JJ
persistent_JJ
expression_NN
of_IN
the_DT
IL-2_JJ
and_CC
IL-2-R_JJ
alpha_NN
genes_NNS
in_IN
these_DT
IARC_NNP
301_CD
T_NNP
cells_NNS
,_,
we_PRP
have_VBP
analyzed_VBN
the_DT
interactions_NNS
of_IN
constitutively_NN
expressed_VBN
nuclear_JJ
proteins_NNS
with_IN
the_DT
5'_JJ
flanking_NN
regions_NNS
of_IN
the_DT
IL-2_NN
and_CC
IL-2-R_DT
alpha_NN
genes_NNS
using_VBG
both_DT
DNase_NNP
I_PRP
footprinting_VBG
and_CC
gel_NNP
retardation_NN
techniques_NNS
._.
We_PRP
have_VBP
found_VBN
that_IN
a_DT
region_NN
in_IN
both_DT
genes_NNS
(_-LRB-
-276_CC
to_TO
-250_VB
for_IN
IL-2-R_JJ
alpha_NN
and_CC
-203_JJ
to_TO
-183_VB
for_IN
IL-2_NN
)_-RRB-
,_,
which_WDT
corresponds_VBZ
to_TO
a_DT
kappa_NN
B_NNP
enhancer_NN
element_NN
,_,
is_VBZ
specifically_RB
protected_VBN
by_IN
nuclear_JJ
proteins_NNS
from_IN
IARC_NNP
301_CD
._.
In_IN
agreement_NN
with_IN
this_DT
finding_NN
,_,
both_CC
the_DT
IL-2_JJ
and_CC
IL-2-R_JJ
alpha_NN
promoters_NNS
are_VBP
active_JJ
in_IN
transient_NN
transfection_NN
assays_VBZ
in_IN
IARC_NNP
301_CD
cells_NNS
._.
In_IN
contrast_NN
,_,
mutation_NN
of_IN
the_DT
kappa_NN
B_NNP
enhancer_NN
results_NNS
in_IN
markedly_NN
attenuated_VBD
activities_NNS
of_IN
both_DT
promoters_NNS
._.
Two_CD
proteins_NNS
binding_VBG
the_DT
kappa_NN
B_NNP
sequence_NN
,_,
NF-kappa_NNP
B_NNP
and_CC
KBF1_NNP
,_,
are_VBP
constitutively_RB
expressed_VBN
in_IN
IARC_NNP
301_CD
nuclei_NNS
and_CC
induced_VBN
by_IN
PMA_NNP
and_CC
PHA_NNP
in_IN
Jurkat_NNP
._.
They_PRP
bind_VBP
to_TO
the_DT
kappa_NN
B_NNP
motifs_NNS
with_IN
different_JJ
relative_JJ
affinities_NNS
that_WDT
may_MD
reflect_VB
their_PRP$
different_JJ
contribution_NN
in_IN
the_DT
expression_NN
of_IN
various_JJ
promoters_NNS
._.
The_DT
functional_JJ
domains_NNS
of_IN
the_DT
murine_NN
Thy-1_DT
gene_NN
promoter_NN
._.
The_DT
Thy-1_JJ
gene_NN
promoter_NN
resembles_VBZ
a_DT
"_``
housekeeping_NN
"_''
promoter_NN
in_IN
that_WDT
it_PRP
is_VBZ
located_VBN
within_IN
a_DT
methylation-free_JJ
island_NN
,_,
lacks_VBZ
a_DT
canonical_JJ
TATA_NNP
box_NN
,_,
and_CC
displays_NNS
heterogeneity_NN
in_IN
the_DT
5'-end_JJ
termini_NN
of_IN
the_DT
mRNA_NN
._.
Using_VBG
transgenic_JJ
mice_NNS
,_,
we_PRP
show_VBP
that_IN
this_DT
promoter_NN
does_VBZ
not_RB
confer_VB
any_DT
tissue_NN
specificity_NN
and_CC
is_VBZ
active_JJ
only_RB
in_IN
a_DT
position-dependent_JJ
manner_NN
._.
It_PRP
can_MD
only_RB
be_VB
activated_VBN
in_IN
a_DT
tissue-specific_JJ
manner_NN
by_IN
elements_NNS
that_WDT
lie_VBP
downstream_NN
of_IN
the_DT
initiation_NN
site_NN
._.
We_PRP
have_VBP
analyzed_VBN
the_DT
functional_JJ
domains_NNS
of_IN
the_DT
minimal_JJ
Thy-1_NN
promoter_NN
and_CC
show_NN
that_IN
the_DT
dominant_JJ
promoter_NN
elements_NNS
consist_VBP
of_IN
multiple_JJ
binding_NN
sites_NNS
for_IN
the_DT
transcription_NN
factor_NN
Sp1_NNP
,_,
an_DT
inverted_JJ
CCAAT_NN
box_NN
,_,
and_CC
sequences_NNS
proximal_JJ
to_TO
the_DT
transcription_NN
start_NN
site_NN
._.
DNase_NN
I_PRP
and_CC
gel_NNP
mobility_NN
shift_NN
assays_VBZ
show_VB
the_DT
binding_NN
of_IN
a_DT
number_NN
of_IN
nuclear_JJ
factors_NNS
to_TO
these_DT
elements_NNS
,_,
including_VBG
Sp1_NNP
and_CC
CP1_NNP
._.
Our_PRP$
results_NNS
show_VBP
that_IN
the_DT
structure_NN
of_IN
this_DT
promoter_NN
only_RB
permits_VBZ
productive_JJ
interactions_NNS
of_IN
the_DT
two_CD
transcription_NN
factors_NNS
Sp1_NNP
and_CC
CP1_NNP
with_IN
the_DT
basal_NN
transcription_NN
machinery_NN
in_IN
the_DT
presence_NN
of_IN
enhancer_NN
sequences_NNS
._.
Comparison_NNP
of_IN
constitutive_JJ
and_CC
inducible_JJ
transcriptional_JJ
enhancement_NN
mediated_VBN
by_IN
kappa_NN
B-related_JJ
sequences_NNS
:_:
modulation_NN
of_IN
activity_NN
in_IN
B_NNP
cells_NNS
by_IN
human_JJ
T-cell_NN
leukemia_NN
virus_NN
type_NN
I_PRP
tax_NN
gene_NN
._.
The_DT
kappa_NN
B_NN
sequence_NN
(_-LRB-
GGGACTTTCC_NNP
)_-RRB-
binds_VBZ
a_DT
factor_NN
,_,
NF-kappa_NNP
B_NNP
,_,
that_WDT
is_VBZ
constitutively_RB
found_VBN
in_IN
its_PRP$
functional_JJ
,_,
DNA_NN
binding_NN
form_NN
only_RB
in_IN
B_NNP
lymphocytes_NNS
._.
A_DT
factor_NN
with_IN
apparently_RB
indistinguishable_JJ
sequence_NN
specificity_NN
can_MD
be_VB
induced_VBN
in_IN
many_JJ
other_JJ
cell_NN
types_NNS
,_,
where_WRB
it_PRP
is_VBZ
used_VBN
to_TO
regulate_VB
inducible_JJ
gene_NN
expression_NN
._.
For_IN
example_NN
,_,
kappa_VB
B-related_JJ
sequences_NNS
have_VBP
been_VBN
shown_VBN
to_TO
be_VB
important_JJ
for_IN
the_DT
transcription_NN
of_IN
a_DT
few_JJ
inducible_JJ
genes_NNS
,_,
such_JJ
as_IN
the_DT
interleukin_NN
2_CD
receptor_NN
alpha-chain_NN
gene_NN
and_CC
the_DT
beta-interferon_JJ
gene_NN
._.
However_RB
,_,
these_DT
genes_NNS
are_VBP
not_RB
constitutively_RB
active_JJ
in_IN
B_NNP
lymphocytes_NNS
,_,
suggesting_VBG
that_IN
other_JJ
regulatory_JJ
mechanisms_NNS
must_MD
play_VB
a_DT
role_NN
in_IN
determining_VBG
the_DT
patterns_NNS
of_IN
expression_NN
._.
We_PRP
have_VBP
investigated_VBN
the_DT
constitutive_JJ
and_CC
inducible_JJ
transcriptional_JJ
activity_NN
mediated_VBN
by_IN
five_CD
kappa_NN
B-related_JJ
sequence_NN
elements_NNS
in_IN
two_CD
different_JJ
cell_NN
types_NNS
._.
We_PRP
show_VBP
that_IN
in_IN
S194_NNP
plasma_NN
cells_NNS
the_DT
activity_NN
of_IN
each_DT
element_NN
correlates_VBZ
well_RB
with_IN
the_DT
relative_JJ
affinity_NN
of_IN
B-cell-derived_JJ
NF-kappa_NNP
B_NNP
for_IN
that_DT
element_NN
._.
This_DT
leads_VBZ
to_TO
significantly_RB
lower_JJR
transcription_NN
enhancement_NN
by_IN
sites_NNS
derived_VBN
from_IN
the_DT
interleukin_NN
2_CD
receptor_NN
or_CC
T-cell_NN
receptor_NN
genes_NNS
in_IN
S194_NNP
cells_NNS
._.
However_RB
,_,
in_IN
either_DT
EL-4_NN
(_-LRB-
T_NNP
)_-RRB-
cells_NNS
or_CC
S194_CD
cells_NNS
,_,
both_DT
lower-affinity_JJ
sites_NNS
can_MD
be_VB
significantly_RB
induced_VBN
by_IN
the_DT
tax_NN
gene_NN
product_NN
of_IN
human_JJ
T-cell_NN
leukemia_NN
virus_NN
type_NN
I_PRP
,_,
showing_VBG
that_IN
NF-kappa_NNP
B_NNP
activity_NN
can_MD
be_VB
modulated_VBN
even_RB
in_IN
a_DT
B-cell_JJ
line_NN
that_WDT
constitutively_RB
expresses_VBZ
this_DT
Isolation_NNP
of_IN
a_DT
rel-related_JJ
human_JJ
cDNA_NN
that_IN
potentially_RB
encodes_VBZ
the_DT
65-kD_JJ
subunit_NN
of_IN
NF-kappa_NNP
B_NNP
(_-LRB-
published_VBN
erratum_NN
appears_VBZ
in_IN
Science_NNP
1991_CD
Oct_NNP
4_CD
;_:
254_CD
(_-LRB-
5028_CD
)_-RRB-
:_:
11_CD
)_-RRB-
A_DT
DNA_NN
probe_NN
that_IN
spanned_VBD
a_DT
domain_NN
conserved_VBN
among_IN
the_DT
proto-oncogene_NN
c-rel_NN
,_,
the_DT
Drosophila_NNP
morphogen_NN
dorsal_NN
,_,
and_CC
the_DT
p50_NN
DNA_NN
binding_NN
subunit_NN
of_IN
NF-kappa_NNP
B_NNP
was_VBD
generated_VBN
from_IN
Jurkat_NNP
T_NNP
cell_NN
complementary_JJ
DNA_NN
with_IN
the_DT
polymerase_NN
chain_NN
reaction_NN
(_-LRB-
PCR_NN
)_-RRB-
and_CC
degenerate_JJ
oligonucleotides_NNS
._.
This_DT
probe_NN
was_VBD
used_VBN
to_TO
identify_VB
a_DT
rel-related_JJ
complementary_JJ
DNA_NN
that_WDT
hybridized_VBD
to_TO
a_DT
2.6-kilobase_JJ
messenger_NN
RNA_IN
present_JJ
in_IN
human_JJ
T_NNP
and_CC
B_NNP
lymphocytes_NNS
._.
In_IN
vitro_NN
transcription_NN
and_CC
translation_NN
of_IN
the_DT
complementary_JJ
DNA_NN
resulted_VBN
in_IN
the_DT
synthesis_NN
of_IN
a_DT
protein_NN
with_IN
an_DT
apparent_JJ
molecular_JJ
size_NN
of_IN
65_CD
kilodaltons_NNS
(_-LRB-
kD_NN
)_-RRB-
._.
The_DT
translated_VBN
protein_NN
showed_VBD
weak_JJ
DNA_NNP
binding_NN
with_IN
a_DT
specificity_NN
for_IN
the_DT
kappa_NN
B_NNP
binding_NN
motif_NN
._.
This_DT
protein-DNA_NN
complex_JJ
comigrated_VBN
with_IN
the_DT
complex_JJ
obtained_VBN
with_IN
the_DT
purified_VBN
human_JJ
p65_IN
NF-kappa_NNP
B_NNP
subunit_NN
and_CC
binding_NN
was_VBD
inhibited_VBN
by_IN
I_PRP
kappa_VBD
B-alpha_NNP
and_CC
-beta_JJ
proteins_NNS
._.
In_IN
addition_NN
,_,
the_DT
65-kD_JJ
protein_NN
associated_VBN
with_IN
the_DT
p50_NN
subunit_NN
of_IN
NF-kappa_NNP
B_NNP
and_CC
the_DT
kappa_NN
B_NNP
probe_NN
to_TO
form_VB
a_DT
complex_JJ
with_IN
the_DT
same_JJ
electrophoretic_JJ
mobility_NN
as_IN
the_DT
NF-kappa_NNP
B-DNA_NNP
complex_NN
._.
Therefore_CC
the_DT
rel-related_JJ
65-kD_JJ
protein_NN
may_MD
represent_VB
the_DT
p65_VBG
subunit_NN
of_IN
the_DT
active_JJ
NF-kappa_NNP
B_NNP
transcription_NN
factor_NN
complex_NN
._.
Lymphocyte_NNP
glucocorticoid_NN
receptor_NN
number_NN
in_IN
posttraumatic_JJ
stress_NN
disorder_NN
._.
OBJECTIVE_VBP
:_:
The_DT
authors_NNS
'_POS
objective_NN
was_VBD
to_TO
investigate_VB
the_DT
possibility_NN
that_IN
glucocorticoid_NN
receptor_NN
changes_NNS
may_MD
be_VB
involved_VBN
in_IN
the_DT
dysregulation_NN
of_IN
the_DT
hypothalamic-pituitary-adrenal_JJ
(_-LRB-
HPA_NN
)_-RRB-
axis_NN
in_IN
posttraumatic_JJ
stress_NN
disorder_NN
(_-LRB-
PTSD_NN
)_-RRB-
._.
METHOD_NNS
:_:
They_PRP
measured_VBD
the_DT
number_NN
of_IN
lymphocyte_NN
cytosolic_JJ
glucocorticoid_NN
receptors_NNS
and_CC
plasma_NN
cortisol_NN
concentrations_NNS
in_IN
15_CD
consecutively_RB
admitted_VBN
male_JJ
combat_NN
Vietnam_NNP
veterans_NNS
with_IN
PTSD_NNP
and_CC
in_IN
a_DT
normal_JJ
comparison_NN
group_NN
of_IN
11_CD
subjects_NNS
._.
RESULTS_NNS
:_:
Both_DT
the_DT
patients_NNS
and_CC
the_DT
normal_JJ
comparison_NN
subjects_NNS
showed_VBD
a_DT
morning-to-afternoon_NN
decline_NN
in_IN
glucocorticoid_NN
receptor_NN
concentrations_NNS
,_,
paralleling_VBG
the_DT
normal_JJ
diurnal_JJ
decline_NN
in_IN
cortisol_JJ
levels_NNS
._.
The_DT
number_NN
of_IN
glucocorticoid_JJ
receptors_NNS
was_VBD
63_CD
%_NN
greater_JJR
in_IN
the_DT
morning_NN
and_CC
26_CD
%_NN
greater_JJR
in_IN
the_DT
afternoon_NN
in_IN
the_DT
patients_NNS
with_IN
PTSD_NNP
than_IN
in_IN
the_DT
normal_JJ
subjects_NNS
._.
No_DT
group_NN
differences_NNS
in_IN
cortisol_JJ
levels_NNS
were_VBD
observed_VBN
,_,
nor_CC
were_VBD
glucocorticoid_JJ
receptor_NN
number_NN
and_CC
cortisol_JJ
levels_NNS
correlated_VBN
._.
The_DT
number_NN
of_IN
morning_NN
glucocorticoid_NN
receptors_NNS
was_VBD
positively_RB
correlated_JJ
with_IN
symptoms_NNS
of_IN
PTSD_NNP
and_CC
anxiety_NN
._.
CONCLUSIONS_NNS
:_:
These_DT
results_NNS
provide_VBP
further_JJ
evidence_NN
for_IN
a_DT
dysregulation_NN
of_IN
the_DT
HPA_NNP
axis_NN
in_IN
PTSD_NNP
._.
The_DT
finding_VBG
that_IN
patients_NNS
with_IN
PTSD_NNP
had_VBD
a_DT
substantially_RB
greater_JJR
number_NN
of_IN
lymphocyte_NN
glucocorticoid_NN
receptors_NNS
than_IN
normal_JJ
comparison_NN
subjects_NNS
is_VBZ
consistent_JJ
with_IN
the_DT
authors_NNS
'_POS
previous_JJ
observations_NNS
of_IN
low_JJ
24-hour_JJ
urinary_JJ
cortisol_NN
excretion_NN
in_IN
subjects_NNS
with_IN
PTSD_NNP
._.
Furthermore_RB
,_,
the_DT
receptor_NN
changes_NNS
observed_VBN
are_VBP
opposite_JJ
of_IN
those_DT
reported_VBN
in_IN
major_JJ
depressive_JJ
disorder_NN
._.
The_DT
present_JJ
data_NNS
,_,
along_IN
with_IN
other_JJ
findings_NNS
of_IN
HPA_NNP
abnormalities_NNS
in_IN
PTSD_NNP
,_,
support_NN
the_DT
possibility_NN
of_IN
a_DT
greater_JJR
negative_JJ
feedback_NN
sensitivity_NN
at_IN
one_CD
or_CC
more_JJR
levels_NNS
of_IN
the_DT
HPA_NNP
axis_NN
._.
A_DT
thymus-specific_JJ
member_NN
of_IN
the_DT
HMG_NNP
protein_NN
family_NN
regulates_VBZ
the_DT
human_JJ
T_NNP
cell_NN
receptor_NN
C_NNP
alpha_NN
enhancer_NN
._.
The_DT
human_JJ
T_NNP
cell-specific_JJ
transcription_NN
factor_NN
TCF-1_NN
alpha_NN
plays_VBZ
a_DT
key_JJ
role_NN
in_IN
the_DT
tissue-specific_JJ
activation_NN
of_IN
the_DT
T_NNP
cell_NN
receptor_NN
(_-LRB-
TCR_NNP
)_-RRB-
C_NNP
alpha_NN
enhancer_NN
and_CC
binds_NNS
to_TO
pyrimidine-rich_JJ
elements_NNS
(_-LRB-
5'-PyCTTTG-3'_''
)_-RRB-
present_NN
in_IN
a_DT
variety_NN
of_IN
other_JJ
T_NNP
cell-specific_JJ
control_NN
regions_NNS
._.
Using_VBG
amino_JJ
acid_NN
sequence_NN
information_NN
derived_VBN
from_IN
the_DT
DNA_NNP
affinity-purified_JJ
protein_NN
,_,
we_PRP
have_VBP
now_RB
isolated_VBN
cDNA_NN
clones_NNS
encoding_VBG
TCF-1_JJ
alpha_NN
._.
The_DT
TCF-1_NNP
alpha_NN
cDNA_NN
contains_VBZ
a_DT
single_JJ
68-amino-acid_JJ
domain_NN
that_WDT
is_VBZ
homologous_JJ
to_TO
a_DT
region_NN
conserved_VBN
among_IN
high-mobility_JJ
group_NN
(_-LRB-
HMG_NNP
)_-RRB-
and_CC
nonhistone_NN
chromosomal_JJ
proteins_NNS
._.
Expression_NN
of_IN
full-length_JJ
and_CC
mutant_JJ
cDNA_NN
clones_NNS
in_IN
bacteria_NNS
reveal_VBP
that_IN
the_DT
single_JJ
HMG_NNP
motif_NN
,_,
which_WDT
is_VBZ
predicted_VBN
to_TO
contain_VB
two_CD
extended_JJ
alpha-helical_JJ
segments_NNS
,_,
is_VBZ
sufficient_JJ
to_TO
direct_VB
the_DT
sequence-specific_JJ
binding_NN
of_IN
TCF-1_NNP
alpha_NN
to_TO
DNA_NNP
._.
Northern_JJ
blot_NN
experiments_NNS
demonstrate_VBP
further_RB
that_IN
TCF-1_DT
alpha_NN
mRNA_NN
is_VBZ
highly_RB
tissue_NN
specific_JJ
,_,
found_VBN
primarily_RB
in_IN
the_DT
thymus_NN
or_CC
T_NNP
cell_NN
lines_NNS
._.
The_DT
immature_JJ
CEM_NNP
T_NNP
cell_NN
line_NN
expresses_VBZ
relatively_RB
low_JJ
levels_NNS
of_IN
TCF-1_NN
alpha_NN
mRNA_NN
,_,
which_WDT
are_VBP
increased_VBN
upon_IN
activation_NN
of_IN
these_DT
cells_NNS
by_IN
phorbol_JJ
esters_NNS
._.
Interestingly_RB
,_,
the_DT
cloned_JJ
TCF-1_NN
alpha_NN
protein_NN
is_VBZ
a_DT
potent_JJ
transcriptional_JJ
activator_NN
of_IN
the_DT
human_JJ
TCR_NNP
alpha_NN
enhancer_NN
in_IN
nonlymphoid_JJ
cell_NN
lines_NNS
,_,
whereas_IN
the_DT
activity_NN
of_IN
the_DT
endogenous_JJ
protein_NN
in_IN
T_NNP
cell_NN
lines_NNS
is_VBZ
strongly_RB
dependent_JJ
on_IN
an_DT
additional_JJ
T_NNP
cell-specific_JJ
protein_NN
that_IN
interacts_NNS
with_IN
the_DT
core_NN
enhancer_NN
._.
TCF-1_JJ
alpha_NN
is_VBZ
currently_RB
unique_JJ
among_IN
the_DT
newly_RB
emerging_VBG
family_NN
of_IN
DNA-binding_JJ
regulatory_JJ
proteins_NNS
that_WDT
share_VBP
the_DT
HMG_NNP
motif_NN
in_IN
that_IN
it_PRP
is_VBZ
a_DT
highly_RB
tissue-specific_JJ
RNA_NNP
polymerase_NN
II_NNP
transcription_NN
factor_NN
._.
Immune_NNP
response_NN
of_IN
peripheral_JJ
blood_NN
mononuclear_NN
cells_NNS
to_TO
HBx-antigen_JJ
of_IN
hepatitis_NN
B_NNP
virus_NN
._.
The_DT
hepatitis_NN
B_NNP
virus_NN
genome_NN
encodes_VBZ
a_DT
transcriptional_JJ
transactivator_NN
protein_NN
designated_VBN
HBxAg_NNP
._.
We_PRP
have_VBP
investigated_VBN
whether_IN
this_DT
antigen_NN
is_VBZ
a_DT
target_NN
structure_NN
for_IN
human_JJ
T-lymphocytes_NNS
._.
Using_VBG
recombinant_JJ
HBxAg_NNP
protein_NN
,_,
we_PRP
found_VBD
HBxAg-specific_JJ
stimulation_NN
of_IN
peripheral_JJ
blood_NN
mononuclear_NN
cells_NNS
in_IN
patients_NNS
with_IN
acute_JJ
hepatitis_NN
B_NNP
virus_NN
infection_NN
(_-LRB-
6_CD
of_IN
6_CD
)_-RRB-
and_CC
chronic_JJ
hepatitis_NN
B_NNP
virus_NN
infection_NN
(_-LRB-
6_CD
of_IN
17_CD
)_-RRB-
but_CC
not_RB
in_IN
healthy_JJ
individuals_NNS
._.
With_IN
HBxAg-specific_JJ
synthetic_JJ
polypeptides_NNS
,_,
several_JJ
T-cell_NN
epitopes_NNS
were_VBD
identified_VBN
._.
Most_RBS
were_VBD
located_VBN
in_IN
the_DT
carboxyterminal_JJ
half_NN
of_IN
the_DT
HBxAg_NNP
protein_NN
._.
Five_CD
T-cell_NN
clones_NNS
specific_JJ
for_IN
a_DT
T-cell_JJ
epitope_NN
located_VBN
at_IN
the_DT
carboxyterminal_JJ
region_NN
of_IN
HBxAg_NNP
were_VBD
established_VBN
and_CC
found_VBN
to_TO
belong_VB
to_TO
the_DT
CD2/CD4-positive_JJ
,_,
CD8-negative_JJ
subtype_NN
._.
These_DT
data_NNS
establish_VBP
for_IN
the_DT
first_JJ
time_NN
HBxAg_NNP
as_IN
an_DT
antigen_NN
in_IN
the_DT
cellular_JJ
immune_JJ
response_NN
._.
A_DT
study_NN
on_IN
the_DT
circadian_JJ
rhythm_NN
of_IN
glucocorticoid_NN
receptor_NN
._.
Circadian_JJ
rhythm_NN
in_IN
glucocorticoid_NN
receptor_NN
(_-LRB-
GR_CD
)_-RRB-
was_VBD
studied_VBN
in_IN
the_DT
rat_NN
liver_NN
and_CC
human_JJ
peripheral_NN
leukocytes_NNS
._.
For_IN
rats_NNS
exposed_VBN
to_TO
a_DT
natural_JJ
environmental_JJ
photic_JJ
cycle_NN
or_CC
a_DT
12L_JJ
:_:
12D_JJ
artificial_JJ
light_JJ
regime_NN
,_,
peak_JJ
values_NNS
of_IN
hepatic_JJ
GR_CD
were_VBD
detected_VBN
between_IN
23:00_CD
and_CC
02:00_CD
h_NN
._.
Except_IN
for_IN
a_DT
4-hour_JJ
advancement_NN
of_IN
the_DT
peak_NN
,_,
a_DT
similar_JJ
circadian_JJ
rhythm_NN
of_IN
hepatic_JJ
GR_CD
was_VBD
detected_VBN
in_IN
rats_NNS
reared_VBD
under_IN
a_DT
reversed_JJ
lighting_NN
regimen_NNS
(_-LRB-
12D_CD
:_:
12L_CD
;_:
lights_NNS
on_IN
between_IN
18:30_CD
and_CC
06:30_CD
h_NN
)_-RRB-
._.
In_IN
human_JJ
leukocytes_NNS
,_,
the_DT
peak_JJ
value_NN
of_IN
GR_CD
was_VBD
found_VBN
to_TO
parallel_VB
that_DT
of_IN
plasma_NN
cortisol_NN
with_IN
high_JJ
and_CC
low_JJ
values_NNS
detected_VBN
at_IN
04:00-08:00_CD
h_NN
and_CC
23:00-24:00_CD
h_NN
,_,
respectively_RB
._.
In_IN
patients_NNS
suffering_VBG
from_IN
Cushing_NNP
's_POS
syndrome_NN
,_,
the_DT
circadian_JJ
rhythm_NN
of_IN
plasma_NN
cortisol_NN
either_CC
disappeared_VBD
or_CC
was_VBD
inverted_VBN
while_IN
that_DT
of_IN
GR_NNP
did_VBD
not_RB
significantly_RB
deviate_VB
from_IN
the_DT
normal_JJ
subjects_NNS
._.
For_IN
apoplexic_JJ
patients_NNS
with_IN
lesions_NNS
localized_VBN
to_TO
the_DT
base_NN
of_IN
the_DT
brain_NN
as_IN
indicated_VBN
by_IN
computerized_JJ
tomography_NN
,_,
the_DT
diurnal_JJ
variation_NN
of_IN
GR_CD
was_VBD
abolished_VBN
._.
Conversely_RB
,_,
diurnal_JJ
rhythmicity_NN
persisted_VBD
in_IN
apoplexy_JJ
patients_NNS
whose_WP$
lesions_NNS
were_VBD
in_IN
the_DT
cerebral_JJ
cortex_NN
._.
Thus_RB
,_,
we_PRP
postulated_VBD
that_IN
the_DT
circadian_JJ
modification_NN
of_IN
GR_CD
was_VBD
independent_JJ
of_IN
the_DT
diurnal_JJ
fluctuations_NNS
in_IN
plasma_NN
cortisol_NN
level_NN
or_CC
the_DT
circadian_JJ
variations_NNS
in_IN
environmental_JJ
lighting_NN
and_CC
that_IN
the_DT
rhythmicity_NN
might_MD
be_VB
regulated_VBN
by_IN
the_DT
'_''
circadian_NN
pacemaker_NN
'_POS
located_VBN
in_IN
the_DT
human_NN
basal_NN
brain_NN
._.
These_DT
diurnal_JJ
variations_NNS
in_IN
GR_NNP
might_MD
serve_VB
to_TO
coordinate_VB
the_DT
reactivity_NN
of_IN
the_DT
target_NN
cells_NNS
to_TO
cortisol_VB
because_IN
the_DT
diurnal_JJ
rhythms_NNS
of_IN
a_DT
GR-mediated_JJ
response_NN
,_,
the_DT
fractional_JJ
inhibition_NN
of_IN
chemotactic_NN
migration_NN
rate_NN
of_IN
polymorphonuclear_NN
leukocytes_NNS
by_IN
cortisol_NN
,_,
were_VBD
found_VBN
to_TO
be_VB
synchronous_JJ
with_IN
those_DT
of_IN
GR_CD
._.
Multiple_NNP
Oct2_NNP
isoforms_NNS
are_VBP
generated_VBN
by_IN
alternative_JJ
splicing_NN
._.
The_DT
interaction_NN
of_IN
the_DT
Oct2_NNP
transcription_NN
factor_NN
with_IN
the_DT
cognate_NN
octamer_NN
motif_NN
ATGCAAAT_NN
is_VBZ
a_DT
critical_JJ
determinant_NN
of_IN
the_DT
lymphoid-specific_JJ
expression_NN
of_IN
immunoglobulin_NN
genes_NNS
._.
Ectopic_JJ
expression_NN
of_IN
cloned_JJ
Oct2_NNP
cDNA_NN
was_VBD
shown_VBN
to_TO
be_VB
sufficient_JJ
to_TO
reconstitute_VB
at_IN
least_JJS
some_DT
aspects_NNS
of_IN
this_DT
regulation_NN
in_IN
non-lymphoid_JJ
cells_NNS
._.
We_PRP
describe_VBP
the_DT
isolation_NN
and_CC
characterization_NN
of_IN
multiple_JJ
cDNAs_NNS
encoding_VBG
mouse_NN
Oct2_NNP
from_IN
a_DT
mature_JJ
B-cell_NN
line_NN
and_CC
we_PRP
show_VBP
that_IN
a_DT
variety_NN
of_IN
isoforms_NNS
of_IN
this_DT
transcription_NN
factor_NN
is_VBZ
generated_VBN
from_IN
a_DT
single_JJ
gene_NN
by_IN
an_DT
alternative_NN
splicing_NN
mechanism_NN
._.
All_PDT
the_DT
isoforms_NNS
retain_VBP
the_DT
previously_RB
characterized_VBN
POU-domain_JJ
and_CC
are_VBP
therefore_RB
able_JJ
to_TO
bind_NN
to_TO
the_DT
octamer_NN
motif_NN
._.
Different_JJ
amounts_NNS
of_IN
the_DT
various_JJ
isoforms_NNS
are_VBP
present_JJ
within_IN
the_DT
same_JJ
B-cell_NN
regardless_RB
of_IN
the_DT
developmental_JJ
stage_NN
of_IN
B-cell_JJ
differentiation_NN
and_CC
at_IN
least_JJS
some_DT
of_IN
the_DT
isoforms_NNS
are_VBP
conserved_VBN
between_IN
mouse_NN
and_CC
humans_NNS
._.
In_IN
cotransfection_NN
experiments_NNS
we_PRP
show_VBP
that_IN
all_PDT
the_DT
isoforms_NNS
are_VBP
able_JJ
to_TO
activate_VB
an_DT
octamer_NN
containing_VBG
promoter_NN
element_NN
in_IN
fibroblasts_NNS
revealing_VBG
an_DT
unexpected_JJ
functional_JJ
redundancy_NN
._.
Finally_RB
,_,
we_PRP
show_VBP
that_IN
one_CD
of_IN
the_DT
isoforms_NNS
encodes_VBZ
the_DT
previously_RB
described_VBN
lymphoid-specific_JJ
Oct2B_NNP
protein_NN
which_WDT
has_VBZ
been_VBN
suggested_VBN
to_TO
be_VB
involved_VBN
in_IN
the_DT
function_NN
of_IN
the_DT
octamer_NN
motif_NN
in_IN
the_DT
context_NN
of_IN
the_DT
immunoglobulin_NN
heavy-chain_NN
(_-LRB-
IgH_NNP
)_-RRB-
enhancer_NN
._.
Murine_NNP
and_CC
human_JJ
T-lymphocyte_JJ
GATA-3_JJ
factors_NNS
mediate_JJ
transcription_NN
through_IN
a_DT
cis-regulatory_JJ
element_NN
within_IN
the_DT
human_JJ
T-cell_NN
receptor_NN
delta_NN
gene_NN
enhancer_NN
._.
A_DT
family_NN
of_IN
transcriptional_JJ
activators_NNS
has_VBZ
recently_RB
been_VBN
identified_VBN
in_IN
chickens_NNS
;_:
these_DT
transcriptional_JJ
activators_NNS
recognize_VBP
a_DT
common_JJ
consensus_NN
motif_NN
(_-LRB-
WGATAR_NN
)_-RRB-
through_IN
a_DT
conserved_VBN
C4_IN
zinc_NN
finger_NN
DNA-binding_JJ
domain_NN
._.
One_CD
of_IN
the_DT
members_NNS
of_IN
this_DT
multigene_NN
family_NN
,_,
cGATA-3_JJ
,_,
is_VBZ
most_RBS
abundantly_RB
expressed_VBN
in_IN
the_DT
T-lymphocyte_JJ
cell_NN
lineage_NN
._.
Analysis_NN
of_IN
human_JJ
and_CC
murine_JJ
GATA-3_JJ
factors_NNS
shows_VBZ
a_DT
striking_JJ
degree_NN
of_IN
amino_JJ
acid_NN
sequence_NN
identity_NN
and_CC
similar_JJ
patterns_NNS
of_IN
tissue_NN
specificity_NN
of_IN
expression_NN
in_IN
these_DT
three_CD
organisms_NNS
._.
The_DT
murine_NN
and_CC
human_JJ
factors_NNS
are_VBP
abundantly_RB
expressed_VBN
in_IN
a_DT
variety_NN
of_IN
human_JJ
and_CC
murine_JJ
T-cell_NN
lines_NNS
and_CC
can_MD
activate_VB
transcription_NN
through_IN
a_DT
tissue-specific_JJ
GATA-binding_JJ
site_NN
identified_VBN
within_IN
the_DT
human_JJ
T-cell_NN
receptor_NN
delta_NN
gene_NN
enhancer_NN
._.
We_PRP
infer_VBP
that_IN
the_DT
murine_NN
and_CC
human_JJ
GATA-3_JJ
proteins_NNS
play_VBP
a_DT
central_JJ
and_CC
highly_RB
conserved_VBN
role_NN
in_IN
vertebrate_JJ
T-cell-specific_JJ
transcriptional_JJ
regulation_NN
._.
Processing_NNP
of_IN
the_DT
precursor_NN
of_IN
NF-kappa_NNP
B_NNP
by_IN
the_DT
HIV-1_NN
protease_NN
during_IN
acute_JJ
infection_NN
._.
Transcription_NN
of_IN
the_DT
human_JJ
immunodeficiency_NN
virus_NN
type-1_NN
(_-LRB-
HIV-1_NN
)_-RRB-
genome_NN
is_VBZ
regulated_VBN
in_IN
part_NN
by_IN
cellular_JJ
factors_NNS
and_CC
is_VBZ
stimulated_VBN
by_IN
activation_NN
of_IN
latently_RB
infected_JJ
T_NNP
cells_NNS
._.
T-cell_NN
activation_NN
also_RB
correlates_VBZ
with_IN
the_DT
induction_NN
of_IN
the_DT
factor_NN
NF-kappa_NNP
B_NNP
which_WDT
binds_VBZ
to_TO
two_CD
adjacent_JJ
sites_NNS
in_IN
the_DT
HIV-1_JJ
long_JJ
terminal_NN
repeat_NN
._.
This_DT
factor_NN
consists_VBZ
of_IN
two_CD
DNA-binding_JJ
subunits_NNS
of_IN
relative_JJ
molecular_JJ
mass_NN
50,000_CD
(_-LRB-
50K_NN
)_-RRB-
associated_VBN
with_IN
two_CD
65K_JJ
subunits_NNS
._.
It_PRP
is_VBZ
located_VBN
in_IN
the_DT
nucleus_JJ
in_IN
mature_JJ
B_NNP
cells_NNS
,_,
but_CC
is_VBZ
present_JJ
in_IN
other_JJ
cell_NN
types_NNS
as_IN
an_DT
inactive_JJ
cytoplasmic_JJ
complex_NN
._.
External_JJ
stimuli_NNS
,_,
including_VBG
those_DT
that_WDT
activate_VBP
T_NNP
cells_NNS
,_,
result_NN
in_IN
nuclear_JJ
translocation_NN
of_IN
active_JJ
NF-kappa_NNP
B_NNP
._.
The_DT
cloning_NN
of_IN
the_DT
complementary_JJ
DNA_NN
for_IN
the_DT
50K_JJ
subunit_NN
helped_VBD
to_TO
identify_VB
an_DT
exclusively_RB
cytoplasmic_JJ
105K_JJ
precursor_NN
(_-LRB-
p105_NN
)_-RRB-
(_-LRB-
V.B._NNP
,_,
P.K._NNP
and_CC
A.I._NNP
,_,
manuscript_NN
submitted_VBD
)_-RRB-
._.
The_DT
expression_NN
of_IN
active_JJ
NF-kappa_NNP
B_NNP
might_MD
therefore_RB
also_RB
be_VB
regulated_VBN
by_IN
the_DT
extent_NN
of_IN
processing_NN
of_IN
p105_NN
._.
Because_IN
HIV-1_NNP
requires_VBZ
active_JJ
NF-kappa_NNP
B_NNP
for_IN
efficient_JJ
transcription_NN
,_,
we_PRP
tested_VBD
the_DT
effect_NN
of_IN
HIV-1_PRP$
infection_NN
on_IN
the_DT
processing_NN
of_IN
the_DT
human_JJ
105K_CD
precursor_NN
._.
We_PRP
show_VBP
here_RB
that_IN
the_DT
HIV-1_NN
protease_NN
can_MD
process_VB
p105_VB
and_CC
increases_NNS
levels_NNS
of_IN
active_JJ
nuclear_JJ
NF-kappa_NNP
B_NNP
complex_NN
._.
Vitamin_NN
D_NN
receptor_NN
expression_NN
in_IN
human_JJ
lymphocytes_NNS
._.
Signal_NNP
requirements_NNS
and_CC
characterization_NN
by_IN
western_JJ
blots_NNS
and_CC
DNA_NNP
sequencing_NN
._.
The_DT
signals_NNS
controlling_VBG
the_DT
expression_NN
of_IN
the_DT
receptor_NN
protein_NN
for_IN
1_CD
alpha,25-dihydroxyvitamin_NN
D3_CD
in_IN
normal_JJ
human_JJ
lymphocytes_NNS
and_CC
the_DT
relationship_NN
of_IN
this_DT
protein_NN
to_TO
the_DT
classical_JJ
vitamin_NN
D_NN
receptor_NN
were_VBD
examined_VBN
._.
Lymphocytes_NNS
activated_VBN
with_IN
the_DT
OKT3_JJ
antibody_NN
to_TO
the_DT
T-cell_NN
antigen_NN
receptor_NN
expressed_VBD
fewer_JJR
binding_NN
sites_NNS
as_IN
compared_VBN
to_TO
lymphocytes_NNS
that_WDT
were_VBD
activated_VBN
by_IN
the_DT
polyclonal_JJ
activator_NN
phytohemagglutinin_NN
(_-LRB-
PHA_NNP
)_-RRB-
._.
However_RB
,_,
combination_NN
of_IN
OKT3_JJ
and_CC
phorbol_JJ
myristate_NN
acetate_NN
produced_VBD
a_DT
concentration_NN
of_IN
binding_VBG
sites_NNS
similar_JJ
to_TO
the_DT
PHA-activated_JJ
cells_NNS
._.
The_DT
receptor_NN
from_IN
OKT3_JJ
and_CC
OKT3_JJ
+_NN
phorbol_NN
myristate_NN
acetate-activated_JJ
lymphocytes_NNS
exhibited_VBD
decreased_VBN
binding_NN
to_TO
DNA-cellulose_JJ
compared_VBN
to_TO
PHA-activated_JJ
lymphocytes_NNS
._.
In_IN
lymphocytes_NNS
activated_VBN
either_RB
by_IN
PHA_NNP
or_CC
OKT3_CD
(_-LRB-
but_CC
not_RB
in_IN
resting_VBG
cells_NNS
)_-RRB-
,_,
a_DT
50-kDa_JJ
species_NN
cross-reacting_NN
with_IN
a_DT
monoclonal_JJ
antibody_NN
against_IN
the_DT
intestinal_JJ
vitamin_NN
D_NN
receptor_NN
was_VBD
detected_VBN
._.
Finally_RB
,_,
RNA_NNP
from_IN
activated_JJ
lymphocytes_NNS
was_VBD
amplified_VBN
by_IN
polymerase_NN
chain_NN
reaction_NN
using_VBG
oligonucleotide_JJ
primers_NNS
flanking_VBG
the_DT
196_CD
base_NN
pair_NN
long_JJ
region_NN
encoding_VBG
the_DT
DNA-binding_JJ
domain_NN
of_IN
the_DT
human_JJ
intestinal_NN
receptor_NN
._.
The_DT
amplified_JJ
product_NN
showed_VBD
an_DT
identical_JJ
nucleotide_JJ
sequence_NN
to_TO
the_DT
DNA-binding_JJ
domain_NN
of_IN
the_DT
human_JJ
intestinal_NN
receptor_NN
._.
These_DT
findings_NNS
suggest_VBP
that_IN
expression_NN
of_IN
the_DT
1,25-(OH)2D3_CD
receptor_NN
in_IN
lymphocytes_NNS
is_VBZ
triggered_VBN
by_IN
distinct_JJ
and_CC
contingent_JJ
signals_NNS
,_,
and_CC
that_IN
the_DT
protein_NN
and_CC
the_DT
mRNA_NN
encoding_NN
it_PRP
are_VBP
identical_JJ
to_TO
the_DT
classical_JJ
vitamin_NN
D_NN
receptor_NN
._.
Cloning_NNP
of_IN
murine_NN
TCF-1_NN
,_,
a_DT
T_NNP
cell-specific_JJ
transcription_NN
factor_NN
interacting_VBG
with_IN
functional_JJ
motifs_NNS
in_IN
the_DT
CD3-epsilon_NNP
and_CC
T_NNP
cell_NN
receptor_NN
alpha_NN
enhancers_NNS
._.
CD3-epsilon_NNP
gene_NN
expression_NN
is_VBZ
confined_VBN
to_TO
the_DT
T_NNP
cell_NN
lineage_NN
._.
We_PRP
have_VBP
recently_RB
identified_VBN
and_CC
cloned_VBD
a_DT
human_JJ
transcription_NN
factor_NN
,_,
TCF-1_NNP
,_,
that_IN
binds_NNS
to_TO
a_DT
functional_JJ
element_NN
in_IN
the_DT
T_NNP
lymphocyte-specific_JJ
enhancer_NN
of_IN
CD3-epsilon_NNP
._.
In_IN
a_DT
panel_NN
of_IN
human_JJ
cell_NN
lines_NNS
,_,
TCF-1_JJ
expression_NN
was_VBD
restricted_VBN
to_TO
T_NNP
lineage_NN
cells_NNS
._.
TCF-1_NN
belonged_VBD
to_TO
a_DT
novel_JJ
family_NN
of_IN
genes_NNS
that_WDT
contain_VBP
the_DT
so-called_JJ
high_JJ
mobility_NN
group_NN
1_CD
(_-LRB-
HMG_NN
)_-RRB-
box_NN
._.
Here_RB
we_PRP
report_VBP
the_DT
cloning_NN
of_IN
murine_NN
TCF-1_NN
._.
Two_CD
splice_NN
alternatives_NNS
were_VBD
identified_VBN
that_WDT
were_VBD
not_RB
previously_RB
observed_VBN
in_IN
human_JJ
TCF-1_NN
._.
Murine_NNP
and_CC
human_JJ
TCF-1_NN
displayed_VBD
a_DT
95.5_CD
%_NN
overall_JJ
amino_IN
acid_NN
homology_NN
._.
Recombinant_NNP
murine_NN
and_CC
human_JJ
TCF-1_NN
recognized_VBD
the_DT
same_JJ
sequence_NN
motif_NN
in_IN
the_DT
CD3-epsilon_NNP
enhancer_NN
as_IN
judged_VBN
by_IN
gel_JJ
retardation_NN
and_CC
methylation_NN
interference_NN
assays_VBZ
._.
With_IN
the_DT
murine_NN
cDNA_NN
clones_NNS
several_JJ
aspects_NNS
of_IN
TCF-1_NNP
were_VBD
analyzed_VBN
._.
First_RB
,_,
deletion_NN
analysis_NN
revealed_VBN
that_IN
a_DT
region_NN
of_IN
TCF-1_NN
containing_VBG
the_DT
HMG_NNP
box_NN
was_VBD
sufficient_JJ
for_IN
sequence-specific_JJ
binding_NN
._.
Second_JJ
,_,
by_IN
high_JJ
stringency_NN
Northern_JJ
blotting_NN
and_CC
in_IN
situ_FW
hybridization_NN
,_,
TCF-1_JJ
expression_NN
was_VBD
shown_VBN
to_TO
be_VB
confined_VBN
to_TO
the_DT
thymus_NN
and_CC
to_TO
the_DT
T_NNP
cell_NN
areas_NNS
of_IN
the_DT
spleen_NN
._.
Third_NNP
,_,
TCF-1_NNP
bound_VBD
specifically_RB
to_TO
a_DT
functional_JJ
T_NNP
cell-specific_JJ
element_NN
in_IN
the_DT
T_NNP
cell_NN
receptor_NN
alpha_NN
(_-LRB-
TCR-alpha_NNP
)_-RRB-
enhancer_NN
._.
The_DT
T_NNP
lineage-specific_JJ
expression_NN
and_CC
the_DT
affinity_NN
for_IN
functional_JJ
motifs_NNS
in_IN
the_DT
TCR-alpha_NNP
and_CC
CD3-epsilon_NN
enhancers_NNS
imply_VBP
an_DT
important_JJ
role_NN
for_IN
TCF-1_NNP
in_IN
the_DT
establishment_NN
of_IN
the_DT
mature_JJ
T_NNP
cell_NN
phenotype_NN
._.
HIV_NNP
enhancer_NN
activity_NN
perpetuated_VBN
by_IN
NF-kappa_NNP
B_NNP
induction_NN
on_IN
infection_NN
of_IN
monocytes_NNS
(_-LRB-
see_VB
comments_NNS
)_-RRB-
Permissiveness_NN
to_TO
replication_NN
of_IN
human_JJ
immunodeficiency_NN
virus_NN
(_-LRB-
HIV_NNP
)_-RRB-
differs_VBZ
in_IN
T_NNP
lymphocytes_NNS
and_CC
macrophages_NNS
._.
In_IN
T_NNP
cells_NNS
,_,
HIV_NNP
transcription_NN
is_VBZ
poorly_RB
detected_VBN
in_IN
vivo_NN
._.
Cloned_VBN
,_,
normal_JJ
T_NNP
lymphocytes_NNS
show_VBP
very_RB
little_JJ
,_,
if_IN
any_DT
,_,
basal_JJ
activity_NN
of_IN
the_DT
HIV_NNP
enhancer_NN
and_CC
low_JJ
nuclear_JJ
expression_NN
of_IN
NF-kappa_NNP
B_NNP
,_,
a_DT
potent_JJ
transcriptional_JJ
activator_NN
of_IN
the_DT
HIV_NNP
enhancer_NN
._.
In_IN
contrast_NN
,_,
fixed_VBN
tissue_NN
macrophages_NNS
express_VBP
detectable_JJ
HIV_NNP
proteins_NNS
,_,
indicating_VBG
permanent_JJ
virus_NN
transcription_NN
._.
One_CD
explanation_NN
for_IN
the_DT
perpetuation_NN
of_IN
virus_NN
infection_NN
in_IN
macrophages_NNS
could_MD
be_VB
sustained_VBN
nuclear_JJ
NF-kappa_NNP
B_NNP
expression_NN
._.
However_RB
,_,
the_DT
U937_NNP
monocytic_JJ
cell_NN
line_NN
,_,
which_WDT
is_VBZ
fully_RB
permissive_JJ
to_TO
HIV_NNP
replication_NN
,_,
is_VBZ
known_VBN
to_TO
express_VB
only_RB
low_JJ
levels_NNS
of_IN
nuclear_JJ
NF-kappa_NNP
B_NNP
._.
We_PRP
show_VBP
here_RB
that_IN
chronic_NN
HIV_NN
infection_NN
results_NNS
in_IN
both_DT
induction_NN
of_IN
a_DT
nuclear_JJ
factor_NN
with_IN
antigenic_JJ
properties_NNS
indistinguishable_JJ
from_IN
those_DT
of_IN
NF-kappa_NNP
B_NNP
and_CC
permanently_RB
increased_VBN
HIV_NNP
enhancer_NN
activity_NN
._.
This_DT
phenomenon_NN
,_,
which_WDT
is_VBZ
independent_JJ
of_IN
tumour_NN
necrosis_NN
factor_NN
,_,
is_VBZ
associated_VBN
with_IN
HIV_NNP
replication_NN
,_,
and_CC
is_VBZ
thus_RB
likely_JJ
to_TO
explain_VB
at_IN
least_JJS
in_IN
part_NN
the_DT
perpetuation_NN
of_IN
HIV_NNP
infection_NN
in_IN
monocytes_NNS
._.
Role_NNP
for_IN
the_DT
Epstein-Barr_NNP
virus_NN
nuclear_JJ
antigen_NN
2_CD
in_IN
viral_NN
promoter_NN
switching_VBG
during_IN
initial_JJ
stages_NNS
of_IN
infection_NN
._.
During_IN
latent_JJ
Epstein-Barr_NNP
virus_NN
(_-LRB-
EBV_NN
)_-RRB-
infection_NN
of_IN
human_JJ
B_NNP
lymphocytes_NNS
,_,
six_CD
viral_JJ
nuclear_JJ
antigen_NN
(_-LRB-
EBNAs_NN
)_-RRB-
are_VBP
expressed_VBN
from_IN
long_RB
primary_JJ
transcripts_NNS
by_IN
means_NNS
of_IN
alternative_JJ
splicing_NN
and_CC
alternative_JJ
polyadenylylation_NN
sites_NNS
._.
These_DT
transcripts_NNS
initiate_VBP
from_IN
one_CD
of_IN
two_CD
promoters_NNS
,_,
Cp_NNP
or_CC
Wp_NNP
,_,
that_WDT
function_VBP
in_IN
a_DT
mutually_RB
exclusive_JJ
fashion_NN
._.
Wp_NNP
is_VBZ
exclusively_RB
utilized_VBN
during_IN
the_DT
initial_JJ
stages_NNS
of_IN
infection_NN
of_IN
primary_JJ
B_NNP
lymphocytes_NNS
,_,
followed_VBN
by_IN
a_DT
switch_NN
to_TO
Cp_NNP
usage_NN
._.
These_DT
studies_NNS
have_VBP
been_VBN
extended_VBN
to_TO
show_VB
that_IN
(_-LRB-
i_NN
)_-RRB-
a_DT
mutant_JJ
EBV_NNP
strain_NN
lacking_VBG
the_DT
gene_NN
encoding_VBG
EBNA_NNP
2_CD
fails_VBZ
to_TO
switch_VB
from_IN
Wp_NNP
to_TO
Cp_VB
usage_NN
in_IN
primary_JJ
B_NNP
lymphocytes_NNS
,_,
although_IN
the_DT
virus_NN
contains_VBZ
a_DT
functional_JJ
Cp_NN
;_:
(_-LRB-
ii_NNS
)_-RRB-
a_DT
region_NN
from_IN
-429_PRP$
to_TO
-245_DT
base_NN
pairs_NNS
upstream_RB
of_IN
Cp_NNP
is_VBZ
essential_JJ
for_IN
Cp_NNP
activity_NN
in_IN
B_NNP
lymphocytes_NNS
,_,
but_CC
only_RB
in_IN
the_DT
context_NN
of_IN
upstream_RB
and_CC
downstream_RB
sequences_NNS
;_:
(_-LRB-
iii_NN
)_-RRB-
this_DT
region_NN
contains_VBZ
an_DT
EBNA_NNP
2-dependent_JJ
enhancer_NN
;_:
and_CC
(_-LRB-
iv_NN
)_-RRB-
DNase_NN
I_PRP
protection_NN
employing_VBG
nuclear_JJ
extracts_NNS
from_IN
B_NNP
and_CC
T_NNP
lymphocytes_NNS
revealed_VBD
a_DT
B-cell-specific_JJ
footprint_NN
in_IN
the_DT
region_NN
of_IN
the_DT
EBNA_NNP
2-dependent_JJ
enhancer_NN
._.
These_DT
results_NNS
support_VBP
a_DT
model_NN
for_IN
viral_JJ
promoter_NN
switching_VBG
during_IN
the_DT
initial_JJ
stages_NNS
of_IN
infection_NN
in_IN
which_WDT
Wp_NNP
activity_NN
leads_VBZ
to_TO
the_DT
expression_NN
of_IN
EBNA_NNP
2_CD
,_,
followed_VBN
by_IN
activation_NN
of_IN
Cp_NNP
through_IN
the_DT
EBNA_NNP
2-dependent_JJ
enhancer_NN
._.
Glucocorticoid_NNP
receptor_NN
characteristics_NNS
in_IN
monocytes_NNS
of_IN
patients_NNS
with_IN
corticosteroid-resistant_JJ
bronchial_JJ
asthma_NN
._.
The_DT
mechanism_NN
of_IN
corticosteroid_JJ
resistance_NN
in_IN
bronchial_JJ
asthma_NN
has_VBZ
been_VBN
studied_VBN
by_IN
determining_VBG
the_DT
rank_NN
order_NN
of_IN
potency_NN
for_IN
different_JJ
corticosteroids_NNS
in_IN
inhibiting_VBG
the_DT
generation_NN
of_IN
a_DT
3_CD
kD_NN
molecule_NN
from_IN
peripheral_JJ
blood_NN
monocytes_NNS
isolated_VBN
from_IN
corticosteroid-sensitive_JJ
(_-LRB-
CS_NNP
)_-RRB-
and_CC
corticosteroid-resistant_JJ
(_-LRB-
CR_VBD
)_-RRB-
asthmatic_JJ
subjects_NNS
,_,
which_WDT
augments_VBD
leukotriene_NN
B4_CC
(_-LRB-
LTB4_NN
)_-RRB-
generation_NN
by_IN
human_JJ
neutrophils_NNS
(_-LRB-
PMN_NNP
)_-RRB-
stimulated_VBN
by_IN
calcium_NN
ionophore_NN
._.
In_IN
addition_NN
,_,
binding_JJ
studies_NNS
with_IN
(_-LRB-
3H_NN
)_-RRB-
dexamethasone_NN
have_VBP
been_VBN
performed_VBN
to_TO
determine_VB
the_DT
dissociation_NN
constant_JJ
(_-LRB-
Kd_NN
)_-RRB-
and_CC
receptor_NN
numbers_NNS
(_-LRB-
Ro_NNP
)_-RRB-
in_IN
the_DT
monocytes_NNS
of_IN
these_DT
two_CD
groups_NNS
of_IN
subjects_NNS
._.
The_DT
concentration_NN
of_IN
corticosteroid_JJ
producing_VBG
50_CD
%_NN
inhibition_NN
(_-LRB-
IC50_NN
)_-RRB-
was_VBD
600_CD
nM_JJ
,_,
70_CD
nM_NNS
,_,
and_CC
0.5_CD
nM_NNS
for_IN
hydrocortisone_NN
,_,
methylprednisolone_NN
,_,
and_CC
dexamethasone_NN
,_,
respectively_RB
,_,
in_IN
monocytes_NNS
from_IN
CS_NNP
individuals_NNS
._.
There_EX
was_VBD
only_RB
weak_JJ
inhibition_NN
of_IN
the_DT
generation_NN
of_IN
enhancing_VBG
activity_NN
by_IN
the_DT
corticosteroids_NNS
in_IN
the_DT
CR_NNP
asthmatic_JJ
individuals_NNS
._.
The_DT
dexamethasone_NN
Kd_NNP
was_VBD
2.45_CD
+/-_,
0.58_CD
nM_NNS
(_-LRB-
mean_NN
+/-_,
SEM_NNP
,_,
n_NN
=_SYM
6_CD
)_-RRB-
in_IN
the_DT
CS_NNP
group_NN
and_CC
1.6_CD
+/-_,
0.35_CD
nM_NNS
(_-LRB-
mean_NN
+/-_,
SEM_NNP
,_,
n_NN
=_SYM
6_CD
)_-RRB-
in_IN
the_DT
CR_NNP
group_NN
of_IN
patients_NNS
(_-LRB-
p_NN
=_SYM
0.14_CD
)_-RRB-
._.
The_DT
Ro_NNP
in_IN
the_DT
CS_NNP
group_NN
was_VBD
3,605_CD
+/-_,
984_CD
binding_NN
sites_NNS
per_IN
nucleus_FW
(_-LRB-
mean_NN
+/-_,
SEM_NNP
,_,
n_NN
=_SYM
6_CD
)_-RRB-
and_CC
4,757_CD
+/-_,
692_CD
binding_NN
sites_NNS
per_IN
nucleus_FW
(_-LRB-
mean_NN
+/-_,
SEM_NNP
,_,
n_NN
=_SYM
6_CD
)_-RRB-
in_IN
the_DT
CR_NNP
group_NN
(_-LRB-
p_NN
=_SYM
0.23_CD
)_-RRB-
._.
These_DT
findings_NNS
indicate_VBP
that_IN
corticosteroid_JJ
resistance_NN
in_IN
bronchial_JJ
asthma_NN
can_MD
not_RB
be_VB
explained_VBN
by_IN
abnormalities_NNS
in_IN
corticosteroid_NN
receptor_NN
characteristics_NNS
._.
Tissue-specific_JJ
expression_NN
of_IN
the_DT
platelet_NN
GPIIb_NNP
gene_NN
._.
One_CD
of_IN
the_DT
major_JJ
objectives_NNS
in_IN
the_DT
study_NN
of_IN
thrombogenesis_NN
is_VBZ
to_TO
determine_VB
the_DT
mechanisms_NNS
by_IN
which_WDT
a_DT
hematopoietic_JJ
progenitor_NN
is_VBZ
activated_VBN
and_CC
committed_VBN
to_TO
the_DT
megakaryocytic_JJ
lineage_NN
._.
Recent_JJ
development_NN
of_IN
primary_JJ
cultures_NNS
of_IN
human_JJ
megakaryocytes_NNS
and_CC
the_DT
molecular_JJ
cloning_NN
of_IN
genes_NNS
that_WDT
are_VBP
specific_JJ
to_TO
this_DT
lineage_NN
offer_NN
the_DT
possibility_NN
of_IN
getting_VBG
some_DT
insights_NNS
into_IN
the_DT
genetic_JJ
mechanisms_NNS
that_WDT
control_VBP
megakaryocytopoiesis_NN
._.
One_CD
gene_NN
of_IN
interest_NN
is_VBZ
the_DT
glycoprotein_NN
IIb_NN
(_-LRB-
GPIIb_NNP
)_-RRB-
gene_NN
;_:
GPIIb_NNP
,_,
the_DT
alpha_NN
subunit_NN
of_IN
the_DT
platelet_NN
cytoadhesin_NN
GPIIb-IIIa_NNP
,_,
is_VBZ
produced_VBN
in_IN
megakaryocytes_NNS
at_IN
an_DT
early_JJ
stage_NN
of_IN
the_DT
differentiation_NN
,_,
whereas_IN
the_DT
other_JJ
subunit_NN
of_IN
this_DT
complex_JJ
,_,
GPIIIa_NNP
,_,
is_VBZ
expressed_VBN
in_IN
other_JJ
cells_NNS
._.
For_IN
these_DT
reasons_NNS
,_,
the_DT
5'-flanking_JJ
region_NN
of_IN
the_DT
GPIIb_NNP
gene_NN
was_VBD
used_VBN
to_TO
identify_VB
the_DT
regions_NNS
that_IN
interact_NN
with_IN
DNA-binding_JJ
nuclear_JJ
factors_NNS
._.
A_DT
fragment_NN
extending_VBG
from_IN
-643_JJ
to_TO
+33_CD
is_VBZ
capable_JJ
of_IN
controlling_VBG
the_DT
tissue-specific_JJ
expression_NN
of_IN
the_DT
CAT_NNP
gene_NN
in_IN
transfection_NN
experiments_NNS
._.
Within_IN
this_DT
region_NN
,_,
we_PRP
have_VBP
identified_VBN
several_JJ
sequences_NNS
that_WDT
are_VBP
implicated_VBN
in_IN
DNA_NNP
protein_NN
interactions_NNS
as_IN
shown_VBN
in_IN
DNAse_NN
I_PRP
footprints_VBD
and_CC
gel_NNP
mobility_NN
shift_NN
assays_VBZ
._.
One_CD
region_NN
,_,
centered_VBN
at_IN
-54_NNP
,_,
is_VBZ
similar_JJ
to_TO
a_DT
nuclear_JJ
factor_NN
E1-binding_JJ
site_NN
,_,
and_CC
a_DT
region_NN
located_VBN
at_IN
position_NN
-233_:
contains_VBZ
a_DT
CCAAT_NN
motif_NN
._.
Two_CD
domains_NNS
centered_VBN
at_IN
positions_NNS
-345_.
and_CC
-540_JJ
,_,
respectively_RB
,_,
bind_VBP
proteins_NNS
that_WDT
are_VBP
present_JJ
in_IN
megakaryocytic_JJ
cells_NNS
and_CC
nonrelated_JJ
cells_NNS
as_RB
well_RB
._.
Finally_RB
,_,
two_CD
other_JJ
domains_NNS
,_,
located_VBN
at_IN
positions_NNS
-460_JJ
and_CC
-510_JJ
,_,
interact_JJ
with_IN
proteins_NNS
that_WDT
are_VBP
only_RB
present_JJ
in_IN
megakaryocytic_JJ
cells_NNS
._.
In_IN
addition_NN
,_,
deletion_NN
of_IN
the_DT
region_NN
containing_VBG
these_DT
two_CD
domains_NNS
results_NNS
in_IN
a_DT
significant_JJ
decrease_NN
of_IN
the_DT
promoter_NN
activity_NN
._.
It_PRP
is_VBZ
very_RB
likely_JJ
that_IN
these_DT
domains_NNS
bind_VBP
megakaryocyte-specific_JJ
nuclear_JJ
proteins_NNS
acting_VBG
as_IN
positive_JJ
transcription_NN
factors_NNS
._.
Inhibition_NN
of_IN
protein_NN
phosphatases_NNS
by_IN
okadaic_JJ
acid_NN
induces_VBZ
AP1_NNP
in_IN
human_JJ
T_NNP
cells_NNS
._.
To_TO
examine_VB
the_DT
role_NN
of_IN
protein_NN
phosphatases_NNS
in_IN
T_NNP
cell_NN
activation_NN
,_,
Jurkat_NNP
cells_NNS
were_VBD
treated_VBN
with_IN
okadaic_JJ
acid_NN
,_,
an_DT
inhibitor_NN
of_IN
type_NN
1_CD
and_CC
2A_CD
phosphatases_NNS
,_,
and_CC
nuclear_JJ
extracts_NNS
were_VBD
examined_VBN
for_IN
the_DT
presence_NN
of_IN
AP1_NNP
as_IN
a_DT
measure_NN
of_IN
early_JJ
T_NNP
cell_NN
activation_NN
._.
Okadaic_JJ
acid_NN
was_VBD
found_VBN
to_TO
be_VB
a_DT
potent_JJ
inducer_NN
of_IN
AP1_NNP
._.
In_IN
contrast_NN
to_TO
phorbol_VB
esters_NNS
such_JJ
as_IN
phorbol_NN
myristate_NN
acetate_NN
(_-LRB-
PMA_NNP
)_-RRB-
,_,
the_DT
induction_NN
of_IN
AP1_NNP
by_IN
okadaic_JJ
acid_NN
occurs_VBZ
predominantly_RB
by_IN
transcriptional_JJ
activation_NN
of_IN
the_DT
jun_NN
and_CC
fos_JJ
family_NN
of_IN
proto-oncogenes_NNS
._.
Surprisingly_RB
,_,
while_IN
the_DT
addition_NN
of_IN
phytohemagglutinin_NN
further_RB
enhanced_VBD
the_DT
induction_NN
of_IN
AP1_NNP
,_,
the_DT
addition_NN
of_IN
PMA_NNP
inhibited_VBD
it_PRP
._.
Okadaic_JJ
acid_NN
treatment_NN
was_VBD
found_VBN
to_TO
dramatically_RB
increase_VB
mRNA_NNS
transcripts_NNS
of_IN
the_DT
jun_NN
family_NN
of_IN
proto-oncogenes_NNS
including_VBG
c-jun_NN
,_,
junD_NN
,_,
and_CC
junB_NN
and_CC
to_TO
a_DT
lesser_JJR
extent_NN
the_DT
fos_JJ
family_NN
including_VBG
c-fos_JJ
and_CC
fra-1_JJ
._.
By_IN
comparison_NN
,_,
PMA_NNP
is_VBZ
a_DT
very_RB
inefficient_JJ
inducer_NN
of_IN
the_DT
jun_NN
gene_NN
family_NN
in_IN
Jurkat_NNP
cells_NNS
._.
Similar_JJ
to_TO
its_PRP$
effect_NN
on_IN
the_DT
induction_NN
of_IN
AP1_NNP
by_IN
okadaic_JJ
acid_NN
,_,
PMA_NNP
inhibits_VBZ
the_DT
induction_NN
of_IN
c-jun_JJ
mRNA_NN
by_IN
okadaic_JJ
acid_NN
._.
Transfection_NN
of_IN
c-jun_JJ
promoter_NN
constructs_NNS
confirmed_VBD
the_DT
marked_JJ
difference_NN
between_IN
PMA_NNP
and_CC
okadaic_JJ
acid_NN
in_IN
inducing_NN
c-jun_NN
transcription_NN
._.
The_DT
induction_NN
of_IN
AP1_NNP
by_IN
okadaic_JJ
acid_NN
suggests_VBZ
that_IN
protein_NN
phosphatases_NNS
1_CD
and_CC
2A_CD
(_-LRB-
PP1_NNP
and_CC
PP2A_NNP
)_-RRB-
may_MD
be_VB
involved_VBN
in_IN
T_NNP
cell_NN
activation_NN
as_IN
important_JJ
negative_JJ
regulators_NNS
of_IN
the_DT
transcription_NN
factor_NN
AP1_NNP
._.
Demonstration_NN
of_IN
estrogen_NN
and_CC
progesterone_NN
receptors_NNS
as_RB
well_RB
as_IN
Ki-67_NNP
and_CC
p-145_DT
antigens_NNS
in_IN
single_JJ
tumor_NN
cells_NNS
from_IN
blood_NN
and_CC
pleural_JJ
effusions_NNS
using_VBG
a_DT
slide_NN
assay_NN
._.
We_PRP
describe_VBP
a_DT
slide_NN
assay_NN
that_WDT
allows_VBZ
the_DT
demonstration_NN
of_IN
antigens_NNS
localized_VBN
in_IN
the_DT
nucleus_JJ
from_IN
isolated_VBN
white_JJ
blood_NN
cells_NNS
as_RB
well_RB
as_IN
from_IN
single_JJ
tumor_NN
cells_NNS
derived_VBN
from_IN
malignant_JJ
effusions_NNS
._.
With_IN
the_DT
antibodies_NNS
Ki-67_.
and_CC
anti-p-145_JJ
an_DT
increased_VBN
rate_NN
of_IN
nuclear_JJ
and_CC
nucleolar_JJ
staining_NN
resulted_VBD
in_IN
cells_NNS
from_IN
highly_RB
malignant_JJ
lymphomas_NNS
._.
An_DT
almost_RB
identical_JJ
reaction_NN
was_VBD
obtained_VBN
when_WRB
tumor_NN
cells_NNS
from_IN
malignant_JJ
effusions_NNS
were_VBD
tested_VBN
._.
Cells_NNP
isolated_VBD
from_IN
the_DT
blood_NN
of_IN
patients_NNS
with_IN
leukemic_JJ
spread_NN
of_IN
lymphomas_NNS
of_IN
low_JJ
malignancy_NN
yielded_VBD
a_DT
weak_JJ
staining_NN
comparable_JJ
to_TO
that_DT
of_IN
normal_JJ
mesothelial_NN
cells_NNS
from_IN
non-tumorous_JJ
cavity_NN
fluids_NNS
._.
The_DT
detection_NN
of_IN
estrogen_NN
and_CC
progesterone_NN
receptors_NNS
(_-LRB-
ER_NNP
and_CC
PR_NNP
)_-RRB-
localized_VBN
in_IN
the_DT
cell_NN
nucleus_NN
can_MD
be_VB
achieved_VBN
by_IN
the_DT
same_JJ
assay_NN
._.
The_DT
reaction_NN
is_VBZ
enhanced_VBN
by_IN
incubation_NN
of_IN
the_DT
tumor_NN
cells_NNS
for_IN
30_CD
min_NN
at_IN
37_CD
degrees_NNS
C_NN
prior_JJ
to_TO
fixation_NN
._.
Pleural_JJ
effusions_NNS
from_IN
20_CD
patients_NNS
with_IN
breast_NN
cancer_NN
were_VBD
tested_VBN
._.
ER_NNP
was_VBD
positive_JJ
in_IN
13_CD
and_CC
PR_NNP
was_VBD
positive_JJ
in_IN
12_CD
of_IN
the_DT
20_CD
samples_NNS
._.
In_IN
5_CD
cases_NNS
there_EX
was_VBD
a_DT
divergent_JJ
reaction_NN
with_IN
ER_NNP
and_CC
PR_NNP
antibody_NN
._.
The_DT
hormone_NN
receptors_NNS
of_IN
the_DT
primary_JJ
tumor_NN
were_VBD
known_VBN
in_IN
15_CD
(_-LRB-
ER_NN
)_-RRB-
and_CC
14_CD
(_-LRB-
PR_NN
)_-RRB-
patients_NNS
,_,
respectively_RB
._.
In_IN
each_DT
cohort_NN
there_EX
was_VBD
only_RB
one_CD
case_NN
with_IN
a_DT
negative_JJ
reaction_NN
of_IN
the_DT
primary_JJ
tumor_NN
and_CC
a_DT
positive_JJ
reaction_NN
with_IN
the_DT
isolated_JJ
tumor_NN
cells_NNS
from_IN
the_DT
pleural_JJ
effusions_NNS
._.
These_DT
results_NNS
indicate_VBP
that_IN
the_DT
demonstration_NN
of_IN
hormone_NN
receptor_NN
proteins_VBZ
in_IN
cells_NNS
from_IN
malignant_JJ
effusions_NNS
is_VBZ
possible_JJ
and_CC
that_IN
there_EX
is_VBZ
a_DT
correlation_NN
with_IN
the_DT
status_NN
of_IN
the_DT
primary_JJ
site_NN
of_IN
cancer_NN
._.
Transforming_VBG
growth_NN
factor-beta_NN
suppresses_NNS
human_JJ
B_NNP
lymphocyte_NN
Ig_NN
production_NN
by_IN
inhibiting_VBG
synthesis_NN
and_CC
the_DT
switch_NN
from_IN
the_DT
membrane_NN
form_NN
to_TO
the_DT
secreted_VBN
form_NN
of_IN
Ig_NNP
mRNA_NN
._.
Transforming_VBG
growth_NN
factor-beta_NN
(_-LRB-
TGF-beta_NN
)_-RRB-
inhibits_VBZ
B_NNP
cell_NN
Ig_NNP
secretion_NN
and_CC
reduces_VBZ
B_NNP
cell_NN
membrane_NN
Ig_NNP
expression_NN
._.
The_DT
addition_NN
of_IN
TGF-beta_JJ
to_TO
human_JJ
B_NNP
lymphocyte_NN
cultures_NNS
stimulated_VBN
with_IN
Staphylococcus_NNP
aureus_NN
Cowan_NNP
strain_NN
I_PRP
and_CC
IL-2_NNP
completely_RB
inhibited_VBD
B_NNP
cell_NN
Ig_NN
secretion_NN
(_-LRB-
greater_JJR
than_IN
90_CD
%_NN
)_-RRB-
and_CC
decreased_VBD
B_NNP
cell_NN
surface_NN
IgM_NNP
,_,
IgD_NNP
,_,
kappa_NN
L_NNP
chain_NN
,_,
and_CC
lambda_NN
L_NNP
chain_NN
expression_NN
._.
In_IN
contrast_NN
,_,
TGF-beta_NNP
had_VBD
only_RB
minimal_JJ
effects_NNS
on_IN
two_CD
other_JJ
B_NNP
cell_NN
membrane_NN
proteins_VBZ
,_,
HLA-DR_NNP
and_CC
CD20_NNP
._.
Internal_NNP
labeling_NN
with_IN
(35S)methionine_NNP
and_CC
immunoprecipitation_NN
with_IN
anti-IgM_JJ
,_,
anti-kappa_JJ
,_,
and_CC
anti-lambda_DT
antibodies_NNS
revealed_VBD
a_DT
striking_JJ
reduction_NN
in_IN
kappa_NN
L_NNP
chain_NN
in_IN
the_DT
presence_NN
of_IN
TGF-beta_NNP
._.
A_DT
less_JJR
pronounced_VBN
reduction_NN
in_IN
lambda_NN
L_NNP
chain_NN
and_CC
microH_NN
chain_NN
was_VBD
also_RB
noted_VBN
._.
Northern_JJ
blot_NN
analysis_NN
of_IN
RNA_NNP
purified_VBN
from_IN
B_NNP
cells_NNS
treated_VBN
with_IN
TGF-beta_NNP
for_IN
varying_VBG
time_NN
intervals_NNS
revealed_VBD
a_DT
significant_JJ
decrease_NN
in_IN
steady_JJ
state_NN
kappa_NN
and_CC
lambda_NN
L_NNP
chain_NN
mRNA_NN
levels_NNS
._.
Furthermore_RB
,_,
a_DT
significant_JJ
decrease_NN
in_IN
the_DT
switch_NN
from_IN
the_DT
membrane_NN
forms_NNS
of_IN
mu_NN
and_CC
gamma_NN
to_TO
their_PRP$
respective_JJ
secreted_JJ
forms_NNS
was_VBD
noted_VBN
in_IN
the_DT
presence_NN
of_IN
TGF-beta_NNP
._.
Nuclear_NNP
run-on_JJ
experiments_NNS
demonstrated_VBD
decreased_VBN
transcription_NN
of_IN
kappa_NN
L_NNP
chain_NN
._.
The_DT
effects_NNS
of_IN
TGF-beta_NNP
on_IN
two_CD
transcriptional_JJ
regulatory_JJ
factors_NNS
,_,
Oct-2_NNP
and_CC
nuclear_JJ
factor_NN
(_-LRB-
NF_NNP
)_-RRB-
kappa_NN
B_NNP
,_,
known_VBN
to_TO
be_VB
important_JJ
in_IN
Ig_NNP
gene_NN
transcription_NN
were_VBD
examined_VBN
._.
Oct-2_NNP
mRNA_NN
levels_NNS
and_CC
both_DT
Oct-2_NNP
and_CC
NF-kappa_NNP
B_NNP
proteins_VBZ
in_IN
nuclear_JJ
extracts_NNS
were_VBD
not_RB
altered_VBN
by_IN
treatment_NN
with_IN
TGF-beta_NNP
._.
In_IN
contrast_NN
,_,
levels_NNS
of_IN
the_DT
transcriptional_JJ
factor_NN
AP-1_NN
,_,
which_WDT
is_VBZ
not_RB
known_VBN
to_TO
be_VB
important_JJ
in_IN
B_NNP
cell_NN
Ig_NN
production_NN
,_,
were_VBD
reduced_VBN
by_IN
TGF-beta_NNP
._.
These_DT
findings_NNS
demonstrate_VBP
that_IN
TGF-beta_NNP
decreases_VBZ
B_NNP
lymphocyte_NN
Ig_NNP
secretion_NN
by_IN
inhibiting_VBG
the_DT
synthesis_NN
of_IN
Ig_NNP
mRNA_NNS
and_CC
inhibiting_VBG
the_DT
switch_NN
from_IN
the_DT
membrane_NN
form_NN
to_TO
the_DT
secreted_JJ
forms_NNS
of_IN
mu_NN
and_CC
gamma_NN
mRNA_NN
._.
The_DT
mechanism_NN
by_IN
which_WDT
TGF-beta_NNP
inhibits_VBZ
Ig_NNP
chain_NN
synthesis_NN
is_VBZ
unclear_JJ
although_IN
it_PRP
does_VBZ
not_RB
involve_VB
inhibition_NN
of_IN
the_DT
binding_NN
of_IN
NF-kappa_NNP
B_NNP
or_CC
Oct-2_NNP
to_TO
their_PRP$
respective_JJ
target_NN
sequences_NNS
._.
Differentiation-associated_JJ
expression_NN
of_IN
the_DT
Epstein-Barr_NNP
virus_NN
BZLF1_IN
transactivator_NN
protein_NN
in_IN
oral_JJ
hairy_JJ
leukoplakia_NN
._.
The_DT
BZLF1_JJ
protein_NN
of_IN
Epstein-Barr_NNP
virus_NN
(_-LRB-
EBV_NN
)_-RRB-
is_VBZ
a_DT
key_JJ
immediate-early_JJ
protein_NN
which_WDT
has_VBZ
been_VBN
shown_VBN
to_TO
disrupt_VB
virus_NN
latency_RB
in_IN
EBV-infected_JJ
B_NNP
cells_NNS
._.
We_PRP
have_VBP
generated_VBN
a_DT
monoclonal_JJ
antibody_NN
,_,
BZ1_NNP
,_,
to_TO
BZLF1_NNP
which_WDT
reacts_VBZ
in_IN
immunohistology_NN
,_,
immunoblotting_VBG
,_,
and_CC
immunoprecipitation_NN
and_CC
which_WDT
recognizes_VBZ
both_DT
the_DT
active_JJ
,_,
dimeric_JJ
form_NN
and_CC
the_DT
inactive_JJ
,_,
monomeric_JJ
form_NN
of_IN
the_DT
protein_NN
._.
Biopsies_NNS
of_IN
oral_JJ
hairy_JJ
leukoplakia_NN
,_,
an_DT
AIDS-associated_JJ
lesion_NN
characterized_VBN
by_IN
high-level_JJ
EBV_NNP
replication_NN
,_,
were_VBD
examined_VBN
by_IN
immunohistochemistry_NN
using_VBG
the_DT
BZ1_NNP
monoclonal_JJ
antibody_NN
._.
A_DT
differentiation-associated_JJ
pattern_NN
of_IN
BZLF1_NNP
expression_NN
was_VBD
observed_VBN
,_,
BZ1_IN
reacting_VBG
with_IN
nuclei_JJ
of_IN
the_DT
upper_JJ
spinous_JJ
layer_NN
of_IN
the_DT
lesion_NN
._.
This_DT
finding_NN
suggests_VBZ
that_IN
the_DT
BZLF1_NNP
promoter_NN
may_MD
be_VB
regulated_VBN
by_IN
the_DT
degree_NN
of_IN
squamous_JJ
differentiation_NN
._.
A_DT
comparison_NN
of_IN
in_IN
situ_FW
hybridization_NN
to_TO
EBV_NNP
DNA_NNP
and_CC
viral_JJ
capsid_NN
antigen_NN
staining_VBG
with_IN
BZ1_NNP
reactivity_NN
suggested_VBD
that_IN
BZLF1_NNP
expression_NN
precedes_VBZ
rampant_JJ
virus_NN
replication_NN
._.
The_DT
inability_NN
to_TO
detect_VB
EBV_NN
in_IN
the_DT
lower_JJR
epithelial_NN
layers_NNS
of_IN
oral_JJ
hairy_JJ
leukoplakia_NN
raises_VBZ
questions_NNS
concerning_VBG
the_DT
nature_NN
of_IN
EBV_NNP
latency_,
and_CC
persistence_NN
in_IN
stratified_JJ
squamous_JJ
epithelium_NN
._.
Transactivation_NN
of_IN
the_DT
human_JJ
immunodeficiency_NN
virus_NN
promoter_NN
by_IN
human_JJ
herpesvirus_NN
6_CD
(_-LRB-
HHV-6_NN
)_-RRB-
strains_NNS
GS_NNP
and_CC
Z-29_NNP
in_IN
primary_JJ
human_JJ
T_NNP
lymphocytes_NNS
and_CC
identification_NN
of_IN
transactivating_VBG
HHV-6_NN
(_-LRB-
GS_NNP
)_-RRB-
gene_NN
fragments_NNS
._.
Human_JJ
herpesvirus_NN
6_CD
(_-LRB-
HHV-6_NN
)_-RRB-
can_MD
activate_VB
the_DT
human_JJ
immunodeficiency_NN
virus_NN
(_-LRB-
HIV_NNP
)_-RRB-
promoter_NN
and_CC
accelerate_VB
cytopathic_JJ
effects_NNS
in_IN
HIV-infected_PRP$
human_JJ
T_NNP
cells_NNS
._.
This_DT
study_NN
examines_VBZ
the_DT
regions_NNS
of_IN
the_DT
HIV_NNP
promoter_NN
required_VBN
for_IN
HHV-6_NNP
transactivation_NN
in_IN
a_DT
heterogeneous_JJ
population_NN
of_IN
primary_JJ
human_JJ
T_NNP
lymphocytes_NNS
with_IN
or_CC
without_IN
antigenic_JJ
stimulation_NN
._.
Two_CD
different_JJ
strains_NNS
of_IN
HHV-6_NN
,_,
GS_NNP
and_CC
Z29_NNP
,_,
transactivated_VBD
the_DT
HIV_NNP
promoter_NN
._.
The_DT
GS_NNP
strain_NN
transactivated_VBD
the_DT
promoter_NN
in_IN
both_DT
stimulated_VBN
and_CC
resting_VBG
T_NNP
cells_NNS
,_,
while_IN
the_DT
Z29_NNP
strain_NN
increased_VBD
HIV_PRP$
promoter_NN
activity_NN
only_RB
in_IN
stimulated_VBN
T_NNP
cells_NNS
._.
Three_CD
DNA_NN
clones_NNS
containing_VBG
HHV-6_NNP
(_-LRB-
GS_NNS
)_-RRB-
genomic_JJ
fragments_NNS
transactivated_VBD
the_DT
HIV_NNP
promoter_NN
in_IN
cotransfected_JJ
T_NNP
cells_NNS
._.
A_DT
21.4-kb_JJ
DNA_NNP
clone_NN
,_,
pZVB70_NN
,_,
showed_VBD
the_DT
highest_JJS
transactivating_NN
ability_NN
,_,
while_IN
two_CD
other_JJ
DNA_NN
fragments_NNS
,_,
pZVB10_VBG
(_-LRB-
6.2_CD
kb_NN
)_-RRB-
and_CC
pZVH14_NN
(_-LRB-
8.7_CD
kb_NN
)_-RRB-
,_,
showed_VBD
lower_JJR
activity_NN
._.
One_CD
of_IN
these_DT
clones_NNS
,_,
pZVH14_NNS
,_,
activated_VBN
the_DT
HIV_NNP
promoter_NN
construct_VB
containing_VBG
a_DT
mutation_NN
in_IN
the_DT
NF_NNP
kappa_NN
B_NNP
site_NN
._.
However_RB
,_,
this_DT
mutated_JJ
NF_NNP
kappa_NN
B_NNP
promoter_NN
was_VBD
not_RB
transactivated_VBN
during_IN
HHV-6_NNP
(_-LRB-
GS_NNS
)_-RRB-
infection_NN
or_CC
after_IN
cotransfection_NN
with_IN
pZVB70_NN
or_CC
pZVB10_NN
._.
These_DT
data_NNS
indicate_VBP
that_IN
the_DT
NF_NNP
kappa_NN
B_NNP
sites_NNS
of_IN
the_DT
HIV_NNP
promoter_NN
are_VBP
essential_JJ
for_IN
its_PRP$
transactivation_NN
during_IN
HHV-6_NNP
(_-LRB-
GS_NNS
)_-RRB-
infection_NN
._.
By_IN
increasing_VBG
HIV_PRP$
promoter_NN
activity_NN
in_IN
primary_JJ
T_NNP
lymphocytes_NNS
,_,
HHV-6_NNP
may_MD
consequently_RB
increase_VB
HIV_NNP
replication_NN
,_,
leading_VBG
to_TO
an_DT
increase_NN
in_IN
the_DT
cytopathic_JJ
effect_NN
on_IN
coinfected_JJ
human_JJ
T_NNP
cells_NNS
._.
The_DT
rhombotin_NN
family_NN
of_IN
cysteine-rich_JJ
LIM-domain_JJ
oncogenes_NNS
:_:
distinct_JJ
members_NNS
are_VBP
involved_VBN
in_IN
T-cell_DT
translocations_NNS
to_TO
human_JJ
chromosomes_NNS
11p15_VBD
and_CC
11p13_CD
._.
A_DT
chromosomal_NN
translocation_NN
in_IN
a_DT
T-cell_NN
leukemia_NN
involving_VBG
the_DT
short_JJ
arm_NN
of_IN
human_JJ
chromosome_NN
11_CD
at_IN
band_NN
11p15_CD
disrupts_NNS
the_DT
rhombotin_NN
gene_NN
._.
This_DT
gene_NN
encodes_VBZ
a_DT
protein_NN
with_IN
duplicated_JJ
cysteine-rich_JJ
regions_NNS
called_VBD
LIM_NNP
domains_VBZ
,_,
which_WDT
show_VBP
homology_NN
to_TO
zinc-binding_JJ
proteins_NNS
and_CC
to_TO
iron-sulfur_NN
centers_NNS
of_IN
ferredoxins_NNS
._.
Two_CD
homologues_NNS
of_IN
the_DT
rhombotin_NNP
gene_NN
have_VBP
now_RB
been_VBN
isolated_VBN
._.
One_CD
of_IN
these_DT
,_,
designated_VBN
Rhom-2_NNP
,_,
is_VBZ
located_VBN
on_IN
human_JJ
chromosome_NN
11_CD
at_IN
band_NN
11p13_CD
,_,
where_WRB
a_DT
cluster_NN
of_IN
T-cell_NN
leukemia-specific_JJ
translocations_NNS
occur_VBP
;_:
all_DT
translocation_NN
breakpoints_NNS
at_IN
11p13_CD
are_VBP
upstream_RB
of_IN
the_DT
Rhom-2_NNP
gene_NN
._.
Human_NNP
and_CC
mouse_NN
Rhom-2_NN
are_VBP
highly_RB
conserved_VBN
and_CC
,_,
like_IN
rhombotin_NN
,_,
encode_JJ
two_CD
tandem_NN
cysteine-rich_JJ
LIM_NNP
domains_NNS
._.
Rhom-2_JJ
mRNA_NN
is_VBZ
expressed_VBN
in_IN
early_RB
mouse_NN
development_NN
in_IN
central_JJ
nervous_JJ
system_NN
,_,
lung_NN
,_,
kidney_NN
,_,
liver_NN
,_,
and_CC
spleen_JJ
but_CC
only_RB
very_RB
low_JJ
levels_NNS
occur_VBP
in_IN
thymus_NN
._.
The_DT
other_JJ
gene_NN
,_,
designated_VBN
Rhom-3_NN
,_,
is_VBZ
not_RB
on_IN
chromosome_NN
11_CD
but_CC
also_RB
retains_VBZ
homology_NN
to_TO
the_DT
LIM_NNP
domain_NN
of_IN
rhombotin_NN
._.
Since_IN
the_DT
Rhom-2_NNP
gene_NN
is_VBZ
such_JJ
a_DT
common_JJ
site_NN
of_IN
chromosomal_JJ
damage_NN
in_IN
T-cell_NN
tumors_NNS
,_,
the_DT
consistency_NN
of_IN
translocations_NNS
near_IN
the_DT
rhombotin_NNP
gene_NN
was_VBD
further_RB
examined_VBN
._.
A_DT
second_JJ
translocation_NN
adjacent_JJ
to_TO
rhombotin_NNP
was_VBD
found_VBN
and_CC
at_IN
the_DT
same_JJ
position_NN
as_IN
in_IN
the_DT
previous_JJ
example_NN
._.
Therefore_RB
,_,
chromosome_NN
bands_NNS
11p15_WP
(_-LRB-
rhombotin_NN
)_-RRB-
and_CC
11p13_CD
(_-LRB-
Rhom-2_NN
)_-RRB-
are_VBP
consistent_JJ
sites_NNS
of_IN
chromosome_NN
translocation_NN
in_IN
T-cell_DT
leukemia_NN
,_,
with_IN
the_DT
11p15_CD
target_NN
more_JJR
rarely_RB
involved_VBN
._.
The_DT
results_NNS
define_VB
the_DT
rhombotin_NNP
gene_NN
family_NN
as_IN
a_DT
class_NN
of_IN
T-cell_DT
oncogenes_NNS
with_IN
duplicated_JJ
cysteine-rich_JJ
LIM_NNP
domains_NNS
._.
The_DT
human_JJ
myelomonocytic_JJ
cell_NN
line_NN
U-937_CC
as_IN
a_DT
model_NN
for_IN
studying_VBG
alterations_NNS
in_IN
steroid-induced_JJ
monokine_NN
gene_NN
expression_NN
:_:
marked_VBN
enhancement_NN
of_IN
lipopolysaccharide-stimulated_JJ
interleukin-1_JJ
beta_NN
messenger_NN
RNA_IN
levels_NNS
by_IN
1,25-dihydroxyvitamin_CD
D3_CD
._.
The_DT
active_JJ
metabolite_NN
of_IN
vitamin_NN
D_NNP
,_,
1,25-dihydroxyvitamin_CD
D3_NNS
(_-LRB-
1,25-(OH)2D3_CD
)_-RRB-
,_,
is_VBZ
a_DT
potent_JJ
regulator_NN
of_IN
human_JJ
monocyte/macrophage_NN
function_NN
in_IN
vitro_NN
._.
To_TO
establish_VB
a_DT
model_NN
for_IN
1,25-(OH)2D3_CD
regulation_NN
of_IN
human_JJ
monocyte_NN
monokine_NN
synthesis_NN
,_,
three_CD
human_JJ
cell_NN
lines_NNS
(_-LRB-
U-937_UH
,_,
THP-1_NNP
,_,
and_CC
HL-60_CD
)_-RRB-
were_VBD
examined_VBN
for_IN
:_:
1_LS
)_-RRB-
the_DT
presence_NN
of_IN
functional_JJ
1,25-(OH)2D3_CD
receptors_NNS
;_:
2_CD
)_-RRB-
the_DT
accumulation_NN
of_IN
interleukin-1_JJ
beta_NN
(_-LRB-
IL-1_JJ
beta_NN
)_-RRB-
mRNA_NN
and_CC
IL-1_DT
beta_JJ
protein_NN
in_IN
response_NN
to_TO
lipopolysaccharide_NN
(_-LRB-
LPS_NNP
)_-RRB-
;_:
and_CC
3_CD
)_-RRB-
the_DT
regulation_NN
of_IN
this_DT
response_NN
by_IN
1,25-(OH)2D3_CD
._.
All_DT
three_CD
cell_NN
lines_NNS
expressed_VBN
vitamin_NN
D_NN
receptor_NN
and_CC
had_VBD
increased_VBN
levels_NNS
of_IN
IL-1_DT
beta_JJ
mRNA_NN
in_IN
response_NN
to_TO
LPS_NNP
._.
Preincubation_NNP
of_IN
cells_NNS
with_IN
1,25-(OH)2D3_CD
augmented_JJ
IL-1_NN
beta_NN
mRNA_NN
levels_NNS
only_RB
in_IN
U-937_JJ
and_CC
HL-60_JJ
cells_NNS
._.
From_IN
these_DT
data_NNS
,_,
and_CC
taking_VBG
into_IN
consideration_NN
their_PRP$
state_NN
of_IN
differentiation_NN
and_CC
relative_JJ
ease_NN
of_IN
culture_NN
,_,
U-937_DT
was_VBD
chosen_VBN
over_IN
HL-60_NNP
and_CC
THP-1_NNP
as_IN
the_DT
cell_NN
line_NN
we_PRP
further_RB
characterized_VBD
._.
In_IN
U-937_JJ
cells_NNS
,_,
optimum_JJ
time_NN
and_CC
dose_NN
of_IN
pretreatment_NN
with_IN
1,25-(OH)2D3_CD
were_VBD
determined_VBN
to_TO
be_VB
12-24_CD
h_NN
at_IN
a_DT
receptor_NN
saturating_VBG
concentration_NN
of_IN
1,25-(OH)2D3_CD
(_-LRB-
10_CD
nM_NN
)_-RRB-
._.
Preincubation_NNP
of_IN
cells_NNS
with_IN
1,25-(OH)2D3_CD
had_VBD
no_DT
effect_NN
on_IN
the_DT
time_NN
course_NN
of_IN
IL-1_DT
beta_JJ
mRNA_JJ
appearance_NN
in_IN
response_NN
to_TO
LPS_NNP
._.
However_RB
,_,
exposure_NN
of_IN
U-937_JJ
cells_NNS
to_TO
1,25-(OH)2D3_CD
increased_VBN
by_IN
200_CD
%_NN
the_DT
level_NN
of_IN
IL-1_DT
beta_JJ
mRNA_NN
detected_VBN
and_CC
decreased_VBN
by_IN
three_CD
orders_NNS
of_IN
magnitude_NN
the_DT
concentration_NN
of_IN
LPS_NNP
required_VBD
to_TO
achieve_VB
steady_JJ
state_NN
mRNA_NNS
levels_NNS
equivalent_JJ
to_TO
those_DT
observed_VBN
in_IN
U-937_JJ
cells_NNS
not_RB
preincubated_VBN
with_IN
the_DT
hormone.2+o_NN
Cortivazol_NNP
mediated_JJ
induction_NN
of_IN
glucocorticoid_NN
receptor_NN
messenger_NN
ribonucleic_JJ
acid_NN
in_IN
wild-type_JJ
and_CC
dexamethasone-resistant_JJ
human_JJ
leukemic_NN
(_-LRB-
CEM_NNP
)_-RRB-
cells_NNS
._.
Cortivazol_NNP
is_VBZ
a_DT
phenylpyrazolo_NN
glucocorticoid_NN
of_IN
high_JJ
potency_NN
and_CC
unusual_JJ
structure_NN
._.
In_IN
both_DT
wild-type_JJ
and_CC
highly_RB
dexamethasone_NN
(_-LRB-
dex_NN
)_-RRB-
-resistant_JJ
clones_NNS
of_IN
the_DT
human_JJ
leukemic_JJ
cell_NN
line_NN
CEM_NNP
,_,
exposure_NN
to_TO
cortivazol_VB
leads_NNS
to_TO
cell_NN
death_NN
._.
It_PRP
has_VBZ
been_VBN
shown_VBN
recently_RB
that_IN
in_IN
wild-type_JJ
CEM_NNP
cells_NNS
but_CC
not_RB
in_IN
a_DT
dex-resistant_JJ
,_,
glucocorticoid_JJ
receptor_NN
(_-LRB-
GR_CD
)_-RRB-
-defective_JJ
clone_NN
ICR-27_NN
TK-3_NN
,_,
dex_NN
induces_VBZ
GR_CD
mRNA_NN
._.
To_TO
test_VB
the_DT
hypothesis_NN
that_IN
cortivazol_JJ
acts_NNS
in_IN
dex-resistant_JJ
cells_NNS
by_IN
making_VBG
use_NN
of_IN
the_DT
residual_JJ
GR_CD
found_VBD
there_RB
,_,
wild-type_JJ
and_CC
dex-resistant_JJ
clones_NNS
were_VBD
treated_VBN
with_IN
various_JJ
concentrations_NNS
of_IN
cortivazol_NN
and_CC
induction_NN
of_IN
GR_CD
mRNA_NN
was_VBD
studied_VBN
._.
Cortivazol_NNP
significantly_RB
induced_VBD
GR_CD
mRNA_NN
in_IN
the_DT
normal_JJ
CEM-C7_NNS
as_RB
well_RB
as_IN
in_IN
two_CD
classes_NNS
of_IN
dex-resistant_JJ
clones_NNS
,_,
although_IN
the_DT
dex-resistant_JJ
clones_NNS
needed_VBN
at_IN
least_JJS
10_CD
times_NNS
more_JJR
cortivazol_NN
than_IN
the_DT
normal_JJ
cells_NNS
for_IN
significant_JJ
GR_CD
mRNA_NN
induction_NN
._.
Increased_VBN
levels_NNS
of_IN
GR_CD
mRNA_NN
were_VBD
noticed_VBN
as_RB
early_RB
as_IN
3_CD
h_NN
after_IN
treatment_NN
._.
A_DT
general_JJ
correlation_NN
between_IN
induction_NN
of_IN
GR_CD
mRNA_NN
and_CC
lysis_NN
of_IN
the_DT
normal_JJ
and_CC
dex-resistant_JJ
cells_NNS
was_VBD
found_VBN
._.
Positive_JJ
induction_NN
of_IN
GR_CD
mRNA_NN
might_MD
be_VB
one_CD
of_IN
the_DT
earliest_JJS
crucial_JJ
steps_NNS
in_IN
the_DT
lysis_NN
of_IN
normal_JJ
and_CC
dex-resistant_JJ
CEM_NNP
cells_NNS
,_,
or_CC
might_MD
serve_VB
as_IN
a_DT
marker_NN
for_IN
the_DT
process_NN
._.
However_RB
,_,
the_DT
lysis_NN
pathway_NN
in_IN
the_DT
dex-resistant_JJ
cells_NNS
is_VBZ
defective_JJ
in_IN
that_DT
dex-resistant_JJ
clones_NNS
needed_VBN
significantly_RB
more_RBR
cortivazol_JJ
than_IN
the_DT
normal_JJ
cells_NNS
for_IN
lysis_NN
of_IN
the_DT
cells_NNS
._.
Expression_NN
of_IN
1,25(OH)2D3_CD
receptors_NNS
on_IN
alveolar_JJ
lymphocytes_NNS
from_IN
patients_NNS
with_IN
pulmonary_JJ
granulomatous_JJ
diseases_NNS
._.
1,25(OH)2D3_CD
is_VBZ
known_VBN
to_TO
be_VB
produced_VBN
at_IN
sites_NNS
of_IN
granulomatous_JJ
reactions_NNS
._.
In_IN
order_NN
to_TO
characterize_VB
the_DT
cell_NN
types_NNS
that_WDT
are_VBP
targets_NNS
for_IN
this_DT
immunoregulatory_NN
hormone_NN
,_,
we_PRP
have_VBP
evaluated_VBN
the_DT
expression_NN
of_IN
1,25(OH)2D3_CD
receptors_NNS
on_IN
peripheral_JJ
blood_NN
T-lymphocytes_NNS
and_CC
those_DT
recovered_VBN
from_IN
the_DT
lung_NN
by_IN
bronchoalveolar_JJ
lavage_NN
from_IN
patients_NNS
with_IN
pulmonary_JJ
granulomatous_JJ
diseases_NNS
(_-LRB-
tuberculosis_NN
and_CC
sarcoidosis_NN
)_-RRB-
and_CC
from_IN
normal_JJ
control_NN
subjects_NNS
using_VBG
combined_VBN
autoradiographic_JJ
and_CC
immunohistochemical_JJ
techniques_NNS
._.
Lavage_NN
T-lymphocytes_NNS
from_IN
patients_NNS
with_IN
tuberculosis_NN
or_CC
with_IN
sarcoidosis_NN
,_,
but_CC
not_RB
those_DT
from_IN
normal_JJ
control_NN
subjects_NNS
,_,
expressed_VBN
1,25(OH)2D3_CD
receptors_NNS
as_IN
demonstrated_VBN
by_IN
binding_NN
of_IN
(3H)1,25(OH)2D3_NNP
,_,
which_WDT
was_VBD
inhibited_VBN
by_IN
the_DT
presence_NN
of_IN
excess_JJ
unlabeled_JJ
1,25(OH)2D3_CD
,_,
but_CC
not_RB
by_IN
the_DT
presence_NN
of_IN
unlabeled_JJ
25(OH)D3_CD
(_-LRB-
receptor-positive_JJ
lymphocytes_NNS
:_:
sarcoidosis_NN
,_,
20_CD
+/-_CD
12_CD
%_NN
;_:
tuberculosis_NN
,_,
31_CD
+/-_,
17_CD
%_NN
)_-RRB-
._.
In_IN
contrast_NN
,_,
blood_NN
lymphocytes_NNS
from_IN
patients_NNS
with_IN
granulomatous_JJ
diseases_NNS
did_VBD
not_RB
express_VB
detectable_JJ
1,25(OH)2D3_CD
receptors_NNS
._.
The_DT
percentage_NN
of_IN
lavage_JJ
T-lymphocytes_NNS
expressing_VBG
1,25(OH)2D3_CD
receptors_NNS
was_VBD
significantly_RB
greater_JJR
for_IN
patients_NNS
with_IN
tuberculosis_NN
presenting_VBG
with_IN
isolated_JJ
hilar_JJ
adenopathy_NN
than_IN
for_IN
patients_NNS
with_IN
pulmonary_JJ
infiltrates_NNS
and/or_CC
cavities_NNS
._.
1,25(OH)2D3_CD
receptors_NNS
were_VBD
expressed_VBN
to_TO
a_DT
greater_JJR
extent_NN
on_IN
CD8+_NNP
T-lymphocytes_NNS
than_IN
on_IN
CD4+_NNP
T-lymphocytes_NNS
in_IN
sarcoidosis_NN
,_,
whereas_IN
a_DT
greater_JJR
proportion_NN
of_IN
CD4+_JJ
than_IN
of_IN
CD8+_NNP
T-lymphocytes_NNS
from_IN
patients_NNS
with_IN
tuberculosis_NN
were_VBD
receptor-positive_JJ
._.
These_DT
findings_NNS
support_VBP
the_DT
conclusion_NN
that_IN
the_DT
interaction_NN
of_IN
1,25(OH)2D3_CD
with_IN
its_PRP$
receptor_NN
on_IN
T-lymphocytes_NNS
may_MD
play_VB
an_DT
important_JJ
role_NN
in_IN
the_DT
regulation_NN
of_IN
granulomatous_JJ
reactions_NNS
,_,
but_CC
because_IN
these_DT
receptors_NNS
are_VBP
expressed_VBN
on_IN
different_JJ
lymphocyte_NN
populations_NNS
,_,
the_DT
net_JJ
effect_NN
of_IN
this_DT
potent_JJ
immunoregulatory_JJ
molecule_NN
is_VBZ
likely_JJ
different_JJ
in_IN
sarcoidosis_NN
and_CC
tuberculosis_NN
._.
Inhibition_NN
of_IN
transcription_NN
factors_NNS
belonging_VBG
to_TO
the_DT
rel/NF-kappa_NN
B_NNP
family_NN
by_IN
a_DT
transdominant_NN
negative_JJ
mutant_NN
._.
The_DT
KBF1_NNP
factor_NN
,_,
which_WDT
binds_VBZ
to_TO
the_DT
enhancer_NN
A_DT
located_VBN
in_IN
the_DT
promoter_NN
of_IN
the_DT
mouse_NN
MHC_NNP
class_NN
I_PRP
gene_NN
H-2Kb_JJ
,_,
is_VBZ
indistinguishable_JJ
from_IN
the_DT
p50_NN
DNA_NN
binding_NN
subunit_NN
of_IN
the_DT
transcription_NN
factor_NN
NF-kappa_NNP
B_NNP
,_,
which_WDT
regulates_VBZ
a_DT
series_NN
of_IN
genes_NNS
involved_VBN
in_IN
immune_JJ
and_CC
inflammatory_JJ
responses_NNS
._.
The_DT
KBF1/p50_NNP
factor_NN
binds_NNS
as_IN
a_DT
homodimer_NN
but_CC
can_MD
also_RB
form_VB
heterodimers_NNS
with_IN
the_DT
products_NNS
of_IN
other_JJ
members_NNS
of_IN
the_DT
same_JJ
family_NN
,_,
like_IN
the_DT
c-rel_NN
and_CC
v-rel_NN
(_-LRB-
proto_NN
)_-RRB-
oncogenes_NNS
._.
The_DT
dimerization_NN
domain_NN
of_IN
KBF1/p50_NNP
is_VBZ
contained_VBN
between_IN
amino_IN
acids_NNS
201_CD
and_CC
367_CD
._.
A_DT
mutant_NN
of_IN
KBF1/p50_DT
(_-LRB-
delta_JJ
SP_NNP
)_-RRB-
,_,
unable_JJ
to_TO
bind_NN
to_TO
DNA_NNP
but_CC
able_JJ
to_TO
form_VB
homo-_NNS
or_CC
heterodimers_NNS
,_,
has_VBZ
been_VBN
constructed_VBN
._.
This_DT
protein_NN
reduces_VBZ
or_CC
abolishes_VBZ
in_IN
vitro_NN
the_DT
DNA_NNP
binding_NN
activity_NN
of_IN
wild-type_JJ
proteins_NNS
of_IN
the_DT
same_JJ
family_NN
(_-LRB-
KBF1/p50_NNP
,_,
c-_.
and_CC
v-rel_JJ
)_-RRB-
._.
This_DT
mutant_NN
also_RB
functions_VBZ
in_IN
vivo_NN
as_IN
a_DT
trans-acting_JJ
dominant_JJ
negative_JJ
regulator_NN
:_:
the_DT
transcriptional_JJ
inducibility_NN
of_IN
the_DT
HIV_NN
long_RB
terminal_JJ
repeat_NN
(_-LRB-
which_WDT
contains_VBZ
two_CD
potential_JJ
NF-kappa_NNP
B_NNP
binding_NN
sites_NNS
)_-RRB-
by_IN
phorbol_NN
ester_NN
(_-LRB-
PMA_NNP
)_-RRB-
is_VBZ
inhibited_VBN
when_WRB
it_PRP
is_VBZ
co-transfected_VBN
into_IN
CD4+_NNP
T_NNP
cells_NNS
with_IN
the_DT
delta_NN
SP_NNP
mutant_NN
._.
Similarly_RB
the_DT
basal_NN
as_RB
well_RB
as_IN
TNF_NNP
or_CC
IL1-induced_JJ
activity_NN
of_IN
the_DT
MHC_NNP
class_NN
I_PRP
H-2Kb_JJ
promoter_NN
can_MD
be_VB
inhibited_VBN
by_IN
this_DT
mutant_JJ
in_IN
two_CD
different_JJ
cell_NN
lines_NNS
._.
These_DT
results_NNS
constitute_VBP
the_DT
first_JJ
formal_JJ
demonstration_NN
that_IN
these_DT
genes_NNS
are_VBP
regulated_VBN
by_IN
members_NNS
of_IN
the_DT
rel/NF-kappa_NN
B_NNP
family_NN
._.
Human_JJ
erythroid_NN
5-aminolevulinate_JJ
synthase_NN
:_:
promoter_NN
analysis_NN
and_CC
identification_NN
of_IN
an_DT
iron-responsive_JJ
element_NN
in_IN
the_DT
mRNA_NN
._.
5-Aminolevulinate_JJ
synthase_NN
(_-LRB-
ALAS_NNP
)_-RRB-
catalyzes_VBZ
the_DT
first_JJ
step_NN
of_IN
the_DT
heme_NN
biosynthetic_JJ
pathway_NN
._.
cDNA_NN
clones_NNS
for_IN
the_DT
human_JJ
erythroid_NN
ALAS_NNP
isozyme_,
were_VBD
isolated_VBN
from_IN
a_DT
fetal_NN
liver_NN
library_NN
._.
It_PRP
can_MD
be_VB
deduced_VBN
that_IN
the_DT
erythroid_JJ
ALAS_NNP
precursor_NN
protein_NN
has_VBZ
a_DT
molecular_JJ
weight_NN
of_IN
64.6_CD
kd_NN
,_,
and_CC
is_VBZ
similar_JJ
in_IN
size_NN
to_TO
the_DT
previously_RB
isolated_VBN
human_JJ
housekeeping_NN
ALAS_NNP
precursor_NN
of_IN
molecular_JJ
weight_NN
70.6_CD
kd_NN
._.
The_DT
mature_JJ
mitochondrial_JJ
forms_NNS
of_IN
the_DT
erythroid_NN
and_CC
housekeeping_NN
ALAS_NNP
isozymes_NNS
are_VBP
predicted_VBN
to_TO
have_VB
molecular_JJ
weights_NNS
of_IN
59.5_CD
kd_NN
and_CC
64.6_CD
kd_NN
,_,
respectively_RB
._.
The_DT
two_CD
isozymes_NNS
show_VBP
little_JJ
amino_JJ
acid_NN
identity_NN
in_IN
their_PRP$
N-terminal_JJ
signal_NN
sequences_NNS
but_CC
have_VBP
considerable_JJ
sequence_NN
identity_NN
in_IN
the_DT
C-terminal_JJ
two-thirds_NNS
of_IN
their_PRP$
proteins_NNS
._.
An_DT
analysis_NN
of_IN
the_DT
immediate_JJ
promoter_NN
of_IN
the_DT
human_JJ
erythroid_NN
ALAS_NNP
gene_NN
revealed_VBD
several_JJ
putative_JJ
erythroid-specific_JJ
cis-acting_JJ
elements_NNS
including_VBG
both_DT
a_DT
GATA-1_NN
and_CC
an_DT
NF-E2_NNP
binding_NN
site_NN
._.
An_DT
iron-responsive_JJ
element_NN
(_-LRB-
IRE_NNP
)_-RRB-
motif_NN
has_VBZ
been_VBN
identified_VBN
in_IN
the_DT
5'-untranslated_JJ
region_NN
of_IN
the_DT
human_JJ
erythroid_NN
ALAS_NNP
mRNA_NN
,_,
but_CC
is_VBZ
not_RB
present_JJ
in_IN
the_DT
housekeeping_NN
ALAS_NNP
mRNA_NN
._.
Gel_NNP
retardation_NN
experiments_NNS
established_VBN
that_IN
this_DT
IRE_NNP
motif_NN
formed_VBD
a_DT
protein-RNA_NN
complex_NN
with_IN
cytosolic_JJ
extracts_NNS
from_IN
human_JJ
K562_NN
cells_NNS
and_CC
this_DT
binding_NN
was_VBD
strongly_RB
competed_VBN
with_IN
IRE_NNP
transcripts_NNS
from_IN
ferritin_NN
or_CC
transferrin_NN
receptor_NN
mRNAs_NNS
._.
A_DT
transcript_NN
of_IN
the_DT
ALAS_NNP
IRE_NNP
,_,
mutated_VBN
in_IN
the_DT
conserved_JJ
loop_NN
of_IN
the_DT
IRE_NNP
,_,
did_VBD
not_RB
readily_RB
form_VB
this_DT
protein-RNA_NN
complex_NN
._.
These_DT
results_NNS
suggest_VBP
that_IN
the_DT
IRE_NNP
motif_NN
in_IN
the_DT
ALAS_NNP
mRNA_NN
is_VBZ
functional_JJ
and_CC
imply_VBP
that_IN
translation_NN
of_IN
the_DT
mRNA_NN
is_VBZ
controlled_VBN
by_IN
cellular_JJ
iron_NN
availability_NN
during_IN
erythropoiesis_NN
._.
Human_JJ
tumor_NN
necrosis_NN
factor_NN
alpha_NN
gene_NN
regulation_NN
in_IN
phorbol_NN
ester_NN
stimulated_VBD
T_NNP
and_CC
B_NNP
cell_NN
lines_NNS
._.
The_DT
minimal_JJ
region_NN
of_IN
the_DT
human_JJ
tumor_NN
necrosis_NN
factor_NN
alpha_NN
(_-LRB-
TNF-alpha_NNP
)_-RRB-
gene_NN
promoter_NN
necessary_JJ
for_IN
its_PRP$
transcriptional_JJ
induction_NN
by_IN
phorbol_NN
esters_NNS
(_-LRB-
PMA_NNP
)_-RRB-
in_IN
human_JJ
T_NNP
and_CC
B_NNP
lymphocyte_NN
cell_NN
lines_NNS
has_VBZ
been_VBN
localized_VBN
between_IN
-52_NNP
and_CC
+89_CD
nucleotides_NNS
(_-LRB-
nt_NN
)_-RRB-
relative_JJ
to_TO
the_DT
gene_NN
's_POS
transcriptional_JJ
start_NN
site_NN
._.
Comparison_NN
of_IN
these_DT
sequences_NNS
to_TO
those_DT
required_VBN
to_TO
mediate_VB
virus_NN
or_CC
lipopolysaccharide_NN
(_-LRB-
LPS_NNP
)_-RRB-
induction_NN
of_IN
the_DT
gene_NN
reveal_VBP
significant_JJ
differences_NNS
,_,
and_CC
thus_RB
,_,
the_DT
sequence_NN
requirements_NNS
for_IN
PMA_NNP
induction_NN
are_VBP
distinct_JJ
from_IN
those_DT
that_IN
mediate_JJ
induction_NN
by_IN
virus_NN
or_CC
LPS_NNP
._.
Although_IN
three_CD
sites_NNS
in_IN
the_DT
TNF-alpha_NN
promoter_NN
(_-LRB-
kappa_FW
1_CD
,_,
kappa_NN
2_CD
,_,
and_CC
kappa_NN
3_CD
)_-RRB-
specifically_RB
bind_VBP
the_DT
transcription_NN
factor_NN
NF-kappa_NNP
B_NNP
in_IN
lymphoid_JJ
nuclear_JJ
extracts_NNS
,_,
TNF-alpha_NNP
mRNA_NN
induction_NN
by_IN
PMA_NNP
does_VBZ
not_RB
correlate_VB
with_IN
NF-kappa_NNP
B_NNP
binding_NN
activities_NNS
displayed_VBN
by_IN
different_JJ
T_NNP
and_CC
B_NNP
cell_NN
lines_NNS
._.
Moreover_RB
,_,
kappa_VB
1_CD
-_:
kappa_NN
3_CD
can_MD
each_DT
be_VB
deleted_VBN
from_IN
the_DT
TNF-alpha_NNP
promoter_NN
with_IN
little_JJ
effect_NN
on_IN
the_DT
gene_NN
's_POS
inducibility_NN
by_IN
PMA_NNP
._.
Therefore_RB
,_,
TNF-alpha_NNP
mRNA_NN
induction_NN
by_IN
PMA_NNP
,_,
like_IN
its_PRP$
induction_NN
by_IN
virus_NN
and_CC
LPS_NNP
,_,
is_VBZ
not_RB
primarily_RB
mediated_VBN
by_IN
NF-kappa_NNP
B_NNP
,_,
but_CC
rather_RB
is_VBZ
mediated_VBN
through_IN
other_JJ
sequences_NNS
and_CC
protein_NN
factors_NNS
._.
Surprisingly_RB
,_,
multimers_NNS
of_IN
kappa_NN
1_CD
-_:
kappa_NN
3_CD
can_MD
confer_VB
PMA_NNP
inducibility_NN
on_IN
a_DT
heterologous_JJ
promoter_NN
in_IN
a_DT
B_NNP
(_-LRB-
Raji_NNP
)_-RRB-
,_,
but_CC
not_RB
a_DT
T_NNP
(_-LRB-
HUT78_NN
)_-RRB-
cell_NN
line_NN
._.
However_RB
they_PRP
are_VBP
not_RB
functional_JJ
on_IN
a_DT
truncated_JJ
TNF-alpha_NNP
promoter_NN
,_,
indicating_VBG
that_IN
promoter_NN
context_NN
and_CC
cell_NN
type_NN
specificity_NN
influence_NN
the_DT
PMA_NNP
inducible_JJ
function_NN
of_IN
these_DT
NF-kappa_NNP
B_NNP
binding_NN
sites_NNS
._.
Towards_IN
a_DT
molecular_JJ
understanding_NN
of_IN
T-cell_JJ
differentiation_NN
._.
Lymphoid_NNP
differentiation_NN
is_VBZ
one_CD
of_IN
the_DT
best_JJS
studied_VBN
examples_NNS
of_IN
mammalian_JJ
development_NN
._.
Here_RB
Hans_NNP
Clevers_NNP
and_CC
Michael_NNP
Owen_NNP
describe_VBP
how_WRB
the_DT
cloning_NN
of_IN
the_DT
genes_NNS
that_WDT
encode_VBP
T-cell-specific_JJ
membrane_NN
proteins_VBZ
allows_VBZ
the_DT
identification_NN
of_IN
transcription_NN
factors_NNS
that_WDT
control_VBP
the_DT
expression_NN
of_IN
these_DT
T-cell_JJ
genes_NNS
._.
Such_JJ
transcription_NN
factors_NNS
play_VBP
a_DT
key_JJ
role_NN
in_IN
the_DT
development_NN
of_IN
the_DT
mature_JJ
T-cell_NN
phenotype_NN
by_IN
functioning_VBG
as_IN
'_POS
master_NN
regulators_NNS
of_IN
T-cell_DT
differentiation_NN
'_''
._.
Regulation_NN
of_IN
jun_NN
and_CC
fos_JJ
gene_NN
expression_NN
in_IN
human_JJ
monocytes_NNS
by_IN
the_DT
macrophage_NN
colony-stimulating_JJ
factor_NN
._.
The_DT
macrophage_NN
colony-stimulating_NN
factor_NN
(_-LRB-
M-CSF_NNP
)_-RRB-
is_VBZ
required_VBN
for_IN
the_DT
growth_NN
and_CC
differentiation_NN
of_IN
mononuclear_JJ
phagocytes_NNS
._.
However_RB
,_,
the_DT
signaling_VBG
events_NNS
responsible_JJ
for_IN
these_DT
effects_NNS
remain_VBP
unclear_JJ
._.
The_DT
present_JJ
studies_NNS
have_VBP
examined_VBN
the_DT
effects_NNS
of_IN
M-CSF_NNP
on_IN
potential_JJ
signaling_NN
pathways_NNS
involving_VBG
expression_NN
of_IN
the_DT
jun_NN
and_CC
fos_JJ
early_JJ
response_NN
genes_NNS
._.
Low_NNP
levels_NNS
of_IN
c-jun_NN
transcripts_NNS
were_VBD
detectable_JJ
in_IN
resting_VBG
human_JJ
peripheral_NN
blood_NN
monocytes_NNS
._.
Treatment_NNP
of_IN
these_DT
cells_NNS
with_IN
10(3)_JJ
units/ml_NN
human_NN
recombinant_NN
M-CSF_NNP
was_VBD
associated_VBN
with_IN
rapid_JJ
and_CC
transient_JJ
increases_NNS
in_IN
c-jun_JJ
mRNA_NN
levels_NNS
._.
Nuclear_NNP
run-on_JJ
assays_.
and_CC
mRNA_JJ
stability_NN
studies_NNS
demonstrated_VBD
that_IN
M-CSF_NNP
regulates_VBZ
c-jun_JJ
expression_NN
by_IN
both_DT
an_DT
increase_NN
in_IN
transcription_NN
rate_NN
and_CC
a_DT
prolongation_NN
in_IN
the_DT
half-life_NN
of_IN
c-jun_JJ
transcripts_NNS
._.
M-CSF_NNP
treatment_NN
was_VBD
also_RB
associated_VBN
with_IN
a_DT
rapid_JJ
induction_NN
of_IN
the_DT
jun-B_NNP
gene_NN
,_,
although_IN
expression_NN
of_IN
this_DT
gene_NN
was_VBD
prolonged_VBN
compared_VBN
to_TO
that_DT
of_IN
c-jun_NN
._.
We_PRP
further_RB
demonstrate_VBP
that_IN
M-CSF_NNP
increases_VBZ
c-fos_JJ
mRNA_NN
levels_NNS
in_IN
human_JJ
monocytes_NNS
through_IN
control_NN
at_IN
both_DT
the_DT
transcriptional_JJ
and_CC
posttranscriptional_JJ
levels_NNS
._.
Maximal_NNP
induction_NN
of_IN
the_DT
c-fos_JJ
gene_NN
was_VBD
followed_VBN
by_IN
that_IN
for_IN
the_DT
fos-B_JJ
gene_NN
._.
Moreover_RB
,_,
M-CSF-induced_JJ
expression_NN
of_IN
the_DT
fos-related_JJ
gene_NN
,_,
fra-1_CD
,_,
was_VBD
delayed_VBN
compared_VBN
to_TO
that_DT
for_IN
both_DT
c-fos_NNS
and_CC
fos-B_NN
._.
Taken_VBN
together_RB
,_,
the_DT
results_NNS
indicate_VBP
that_IN
M-CSF_NNP
treatment_NN
is_VBZ
associated_VBN
with_IN
differential_JJ
activation_NN
of_IN
multiple_JJ
members_NNS
of_IN
the_DT
jun/fos_NNS
family_NN
and_CC
that_DT
expression_NN
of_IN
these_DT
genes_NNS
could_MD
contribute_VB
to_TO
nuclear_JJ
signaling_NN
mechanisms_NNS
that_IN
regulate_VB
a_DT
specific_JJ
program_NN
of_IN
monocyte_NN
differentiation_NN
._.
Cloning_NNP
of_IN
a_DT
human_JJ
homeobox_NN
gene_NN
that_WDT
resembles_VBZ
a_DT
diverged_JJ
Drosophila_NNP
homeobox_NN
gene_NN
and_CC
is_VBZ
expressed_VBN
in_IN
activated_VBN
lymphocytes_NNS
._.
A_DT
new_JJ
homeobox_NN
gene_NN
,_,
HB24_NNP
,_,
has_VBZ
been_VBN
isolated_VBN
from_IN
a_DT
human_JJ
B-lymphocyte_NNP
cDNA_NN
library_NN
._.
Northern_JJ
blot_NN
analysis_NN
of_IN
polyadenylated_VBN
RNA_NNP
purified_VBN
from_IN
activated_JJ
human_JJ
B_NN
cells_NNS
revealed_VBD
a_DT
single_JJ
mRNA_NN
transcript_NN
of_IN
approximately_RB
2.3_CD
kb_NN
._.
Two_CD
cDNA_NNS
clones_NNS
were_VBD
sequenced_VBN
and_CC
provided_VBN
2,250_CD
nucleotides_NNS
(_-LRB-
nt_NN
)_-RRB-
of_IN
DNA_NNP
sequence_NN
information_NN
._.
There_EX
is_VBZ
a_DT
single_JJ
methionine_NN
codon-initiated_VBD
open_JJ
reading_NN
frame_NN
of_IN
1,458_CD
nt_NN
in_IN
frame_NN
with_IN
a_DT
homeobox_NN
and_CC
a_DT
CAX_NNP
repeat_NN
,_,
and_CC
the_DT
open_JJ
reading_NN
frame_NN
is_VBZ
predicted_VBN
to_TO
encode_VB
a_DT
protein_NN
of_IN
51,659_CD
daltons_NNS
._.
When_WRB
the_DT
homeodomain_NN
from_IN
HB24_NNP
was_VBD
compared_VBN
to_TO
known_VBN
mammalian_JJ
and_CC
Drosophila_NNP
homeodomains_NNS
it_PRP
was_VBD
found_VBN
to_TO
be_VB
only_RB
moderately_RB
conserved_VBN
,_,
but_CC
when_WRB
it_PRP
was_VBD
compared_VBN
to_TO
a_DT
highly_RB
diverged_VBN
Drosophila_NNP
homeodomain_NN
,_,
H2.0_NNP
,_,
it_PRP
was_VBD
found_VBN
to_TO
be_VB
80_CD
%_NN
identical_JJ
._.
The_DT
HB24_NNP
mRNA_NN
was_VBD
absent_JJ
or_CC
present_JJ
at_IN
low_JJ
levels_NNS
in_IN
normal_JJ
B_NNP
and_CC
T_NNP
lymphocytes_NNS
;_:
however_RB
,_,
with_IN
the_DT
appropriate_JJ
activation_NN
signal_NN
HB24_IN
mRNA_NN
was_VBD
induced_VBN
within_IN
several_JJ
hours_NNS
even_RB
in_IN
the_DT
presence_NN
of_IN
cycloheximide_NN
._.
Characterization_NNP
of_IN
HB24_NNP
expression_NN
in_IN
lymphoid_JJ
and_CC
select_JJ
developing_VBG
tissues_NNS
was_VBD
performed_VBN
by_IN
in_IN
situ_FW
hybridization_NN
._.
Positive_JJ
hybridization_NN
was_VBD
found_VBN
in_IN
thymus_NN
,_,
tonsil_NN
,_,
bone_NN
marrow_NN
,_,
developing_VBG
vessels_NNS
,_,
and_CC
in_IN
fetal_NN
brain_NN
._.
HB24_PRP
is_VBZ
likely_JJ
to_TO
have_VB
an_DT
important_JJ
role_NN
in_IN
lymphocytes_NNS
as_RB
well_RB
as_IN
in_IN
certain_JJ
developing_VBG
tissues_NNS
._.
Severe_JJ
5-fluorouracil_JJ
toxicity_NN
secondary_JJ
to_TO
dihydropyrimidine_VB
dehydrogenase_JJ
deficiency_NN
._.
A_DT
potentially_RB
more_RBR
common_JJ
pharmacogenetic_JJ
syndrome_NN
._.
This_DT
study_NN
describes_VBZ
the_DT
inheritance_NN
of_IN
a_DT
defect_NN
in_IN
pyrimidine_NN
catabolism_NN
and_CC
its_PRP$
association_NN
with_IN
drug-induced_JJ
toxicity_NN
in_IN
a_DT
patient_NN
receiving_VBG
5-fluorouracil_FW
(_-LRB-
FUra_NN
)_-RRB-
as_IN
adjuvant_JJ
chemotherapy_NN
for_IN
breast_NN
carcinoma_NN
._.
The_DT
study_NN
population_NN
included_VBD
the_DT
affected_JJ
patient_NN
(_-LRB-
proband_NN
)_-RRB-
,_,
nine_CD
of_IN
her_PRP$
blood_NN
relatives_NNS
,_,
and_CC
seven_CD
healthy_JJ
volunteers_NNS
._.
The_DT
activity_NN
of_IN
dihydropyrimidine_NN
dehydrogenase_NN
(_-LRB-
DPD_NNP
)_-RRB-
,_,
the_DT
initial_JJ
enzyme_NN
of_IN
pyrimidine_NN
(_-LRB-
and_CC
FUra_NNP
)_-RRB-
catabolism_NN
,_,
in_IN
peripheral_JJ
blood_NN
mononuclear_NN
cells_NNS
was_VBD
measured_VBN
in_IN
each_DT
subject_NN
by_IN
a_DT
specific_JJ
radiometric_JJ
assay_NN
using_VBG
FUra_NNP
as_IN
the_DT
substrate_NN
._.
The_DT
proband_NN
had_VBD
no_DT
detectable_JJ
DPD_NNP
activity_NN
._.
When_WRB
enzyme_JJ
levels_NNS
in_IN
the_DT
proband_NN
and_CC
relatives_NNS
were_VBD
compared_VBN
with_IN
that_DT
in_IN
controls_NNS
,_,
an_DT
autosomal_JJ
recessive_JJ
pattern_NN
of_IN
inheritance_NN
was_VBD
demonstrated_VBN
._.
This_DT
is_VBZ
the_DT
third_JJ
patient_NN
with_IN
severe_JJ
FUra_NNP
toxicity_NN
secondary_JJ
to_TO
an_DT
alteration_NN
in_IN
pyrimidine_NN
catabolism_NN
and_CC
the_DT
second_JJ
from_IN
our_PRP$
clinic_NN
population_NN
suggesting_VBG
that_IN
the_DT
frequency_NN
of_IN
this_DT
genetic_JJ
defect_NN
may_MD
be_VB
greater_JJR
than_IN
previously_RB
thought_VBN
._.
Monitoring_NNP
DPD_NNP
activity_NN
may_MD
be_VB
important_JJ
in_IN
the_DT
management_NN
of_IN
patients_NNS
experiencing_VBG
severe_JJ
toxicity_NN
secondary_JJ
to_TO
FUra_NNP
chemotherapy_NN
._.
Characterization_NNP
of_IN
an_DT
immediate-early_JJ
gene_NN
induced_VBN
in_IN
adherent_NN
monocytes_NNS
that_IN
encodes_NNS
I_PRP
kappa_VBD
B-like_JJ
activity_NN
._.
We_PRP
have_VBP
cloned_VBN
a_DT
group_NN
of_IN
cDNAs_NNS
representing_VBG
mRNAs_NNS
that_WDT
are_VBP
rapidly_RB
induced_VBN
following_VBG
adherence_NN
of_IN
human_JJ
monocytes_NNS
._.
One_CD
of_IN
the_DT
induced_JJ
transcripts_NNS
(_-LRB-
MAD-3_NN
)_-RRB-
encodes_VBZ
a_DT
protein_NN
of_IN
317_CD
amino_IN
acids_NNS
with_IN
one_CD
domain_NN
containing_VBG
five_CD
tandem_NN
repeats_NNS
of_IN
the_DT
cdc10/ankyrin_NN
motif_NN
,_,
which_WDT
is_VBZ
60_CD
%_NN
similar_JJ
(_-LRB-
46_CD
%_NN
identical_JJ
)_-RRB-
to_TO
the_DT
ankyrin_NN
repeat_NN
region_NN
of_IN
the_DT
precursor_NN
of_IN
NF-kappa_NNP
B/KBF1_NNP
p50_NN
._.
The_DT
C-terminus_NN
has_VBZ
a_DT
putative_JJ
protein_NN
kinase_NN
C_NNP
phosphorylation_NN
site_NN
._.
In_IN
vitro_NN
translated_VBN
MAD-3_JJ
protein_NN
was_VBD
found_VBN
to_TO
specifically_RB
inhibit_VB
the_DT
DNA-binding_JJ
activity_NN
of_IN
the_DT
p50/p65_NN
NF-kappa_NNP
B_NNP
complex_NN
but_CC
not_RB
that_IN
of_IN
the_DT
p50/p50_NN
KBF1_IN
factor_NN
or_CC
of_IN
other_JJ
DNA-binding_JJ
proteins_NNS
._.
The_DT
MAD-3_JJ
cDNA_NN
encodes_VBZ
an_DT
I_PRP
kappa_VBD
B-like_JJ
protein_NN
that_WDT
is_VBZ
likely_JJ
to_TO
be_VB
involved_VBN
in_IN
regulation_NN
of_IN
transcriptional_JJ
responses_NNS
to_TO
NF-kappa_NNP
B_NNP
,_,
including_VBG
adhesion-dependent_JJ
pathways_NNS
of_IN
monocyte_NN
activation_NN
._.
Reactive_JJ
oxygen_NN
intermediates_NNS
as_IN
apparently_RB
widely_RB
used_VBN
messengers_NNS
in_IN
the_DT
activation_NN
of_IN
the_DT
NF-kappa_NNP
B_NNP
transcription_NN
factor_NN
and_CC
HIV-1_NN
._.
Hydrogen_JJ
peroxide_NN
and_CC
oxygen_NN
radicals_NNS
are_VBP
agents_NNS
commonly_RB
produced_VBN
during_IN
inflammatory_JJ
processes_NNS
._.
In_IN
this_DT
study_NN
,_,
we_PRP
show_VBP
that_IN
micromolar_JJ
concentrations_NNS
of_IN
H2O2_NNP
can_MD
induce_VB
the_DT
expression_NN
and_CC
replication_NN
of_IN
HIV-1_NN
in_IN
a_DT
human_JJ
T_NNP
cell_NN
line_NN
._.
The_DT
effect_NN
is_VBZ
mediated_VBN
by_IN
the_DT
NF-kappa_NNP
B_NNP
transcription_NN
factor_NN
which_WDT
is_VBZ
potently_RB
and_CC
rapidly_RB
activated_VBN
by_IN
an_DT
H2O2_JJ
treatment_NN
of_IN
cells_NNS
from_IN
its_PRP$
inactive_JJ
cytoplasmic_JJ
form_NN
._.
N-acetyl-L-cysteine_NN
(_-LRB-
NP_NNP
)_-RRB-
,_,
a_DT
well_RB
characterized_VBN
antioxidant_NN
which_WDT
counteracts_VBZ
the_DT
effects_NNS
of_IN
reactive_NN
oxygen_NN
intermediates_NNS
(_-LRB-
ROI_NN
)_-RRB-
in_IN
living_VBG
cells_NNS
,_,
prevented_VBD
the_DT
activation_NN
of_IN
NF-kappa_NNP
B_NNP
by_IN
H2O2_NNP
._.
NP_NNP
and_CC
other_JJ
thiol_NN
compounds_NNS
also_RB
blocked_VBD
the_DT
activation_NN
of_IN
NF-kappa_NNP
B_NNP
by_IN
cycloheximide_NN
,_,
double-stranded_JJ
RNA_NNP
,_,
calcium_NN
ionophore_NN
,_,
TNF-alpha_NNP
,_,
active_JJ
phorbol_NN
ester_NN
,_,
interleukin-1_NN
,_,
lipopolysaccharide_NN
and_CC
lectin_NN
._.
This_DT
suggests_VBZ
that_IN
diverse_JJ
agents_NNS
thought_VBD
to_TO
activate_VB
NF-kappa_NNP
B_NNP
by_IN
distinct_JJ
intracellular_JJ
pathways_NNS
might_MD
all_DT
act_VB
through_IN
a_DT
common_JJ
mechanism_NN
involving_VBG
the_DT
synthesis_NN
of_IN
ROI_NNP
._.
ROI_NNP
appear_VB
to_TO
serve_VB
as_IN
messengers_NNS
mediating_VBG
directly_RB
or_CC
indirectly_RB
the_DT
release_NN
of_IN
the_DT
inhibitory_JJ
subunit_NN
I_PRP
kappa_VBD
B_NNP
from_IN
NF-kappa_NNP
B_NNP
._.
HTLV-1_JJ
Tax_NNP
induces_VBZ
expression_NN
of_IN
various_JJ
immediate_JJ
early_JJ
serum_NN
responsive_JJ
genes_NNS
._.
Human_JJ
T-cell_NN
leukemia_NN
virus_NN
type_NN
1_CD
(_-LRB-
HTLV-1_NN
)_-RRB-
is_VBZ
an_DT
etiological_JJ
agent_NN
of_IN
adult_NN
T-cell_NN
leukemia_NN
(_-LRB-
ATL_NNP
)_-RRB-
._.
We_PRP
showed_VBD
here_RB
by_IN
mobility-shift_JJ
assay_NN
that_IN
T-cell_NN
lines_NNS
transformed_VBN
with_IN
the_DT
virus_NN
contained_VBD
high_JJ
levels_NNS
of_IN
AP-1_NN
activities_NNS
._.
Consistent_NN
with_IN
this_DT
result_NN
,_,
these_DT
cell_NN
lines_NNS
expressed_VBD
increased_VBN
levels_NNS
of_IN
mRNAs_NNS
encoding_VBG
the_DT
AP-1_JJ
proteins_NNS
,_,
c-Fos_NNS
,_,
Fra-1_NNP
,_,
c-Jun_NN
,_,
JunB_NNP
,_,
and_CC
JunD_NNP
._.
Previously_RB
,_,
transcription_NN
of_IN
the_DT
c-fos_JJ
gene_NN
has_VBZ
been_VBN
reported_VBN
to_TO
be_VB
transactivated_VBN
by_IN
the_DT
viral_JJ
transcription_NN
factor_NN
,_,
Tax1_NNP
._.
By_IN
using_VBG
the_DT
human_JJ
T-cell_NN
line_NN
(_-LRB-
JPX-9_NNP
)_-RRB-
,_,
in_IN
which_WDT
expression_NN
of_IN
the_DT
Tax1_NNP
is_VBZ
inducible_JJ
,_,
we_PRP
showed_VBD
that_IN
expression_NN
of_IN
mRNAs_NNS
for_IN
Fra-1_NNP
,_,
c-Jun_JJ
,_,
and_CC
JunD_NNP
was_VBD
also_RB
transactivated_VBN
by_IN
Tax1_NNP
._.
Moreover_RB
,_,
Tax1_NNP
activated_VBD
expression_NN
of_IN
two_CD
other_JJ
transcription_NN
factors_NNS
having_VBG
zinc_NN
finger_NN
motifs_NNS
,_,
Egr-1_JJ
and_CC
Egr-2_JJ
,_,
in_IN
the_DT
same_JJ
cells_NNS
._.
The_DT
Tax1-inducible_JJ
transcription_NN
factors_NNS
identified_VBN
here_RB
are_VBP
encoded_VBN
by_IN
the_DT
members_NNS
of_IN
immediate_JJ
early_JJ
genes_NNS
under_IN
the_DT
control_NN
of_IN
growth_NN
signals_NNS
._.
Thus_RB
,_,
Tax1_NNP
was_VBD
suggested_VBN
to_TO
replace_VB
growth_NN
signals_NNS
,_,
at_IN
least_JJS
in_IN
part_NN
,_,
by_IN
this_DT
mechanism_NN
._.
Contribution_NNP
of_IN
NF-kappa_NNP
B_NNP
and_CC
Sp1_NNP
binding_NN
motifs_NNS
to_TO
the_DT
replicative_JJ
capacity_NN
of_IN
human_JJ
immunodeficiency_NN
virus_NN
type_NN
1_CD
:_:
distinct_JJ
patterns_NNS
of_IN
viral_JJ
growth_NN
are_VBP
determined_VBN
by_IN
T-cell_DT
types_NNS
._.
Starting_VBG
with_IN
a_DT
replication-incompetent_JJ
molecular_JJ
clone_NN
of_IN
human_JJ
immunodeficiency_NN
virus_NN
type_NN
1_CD
,_,
lacking_VBG
all_PDT
the_DT
NF-kappa_NNP
B_NNP
and_CC
Sp1_NNP
binding_NN
sites_NNS
present_JJ
in_IN
the_DT
native_JJ
long_JJ
terminal_NN
repeat_NN
(_-LRB-
LTR_NNP
)_-RRB-
,_,
proviruses_VBZ
containing_VBG
reconstructed_VBN
LTRs_NNS
with_IN
individual_JJ
or_CC
combinations_NNS
of_IN
NF-kappa_NNP
B_NNP
and_CC
Sp1_NNP
elements_NNS
were_VBD
generated_VBN
and_CC
evaluated_VBN
for_IN
their_PRP$
capacity_NN
to_TO
produce_VB
virus_NN
progeny_NN
following_VBG
transfection-cocultivation_NN
._.
Virus_NNP
stocks_NNS
obtained_VBD
from_IN
these_DT
experiments_NNS
exhibited_VBD
a_DT
continuum_NN
of_IN
replicative_JJ
capacities_NNS
in_IN
different_JJ
human_JJ
T-cell_NN
types_NNS
depending_VBG
on_IN
which_WDT
element_NN
(_-LRB-
s_PRP
)_-RRB-
was_VBD
present_JJ
in_IN
the_DT
LTR_NNP
._.
For_IN
example_NN
,_,
in_IN
experiments_NNS
involving_VBG
proviral_JJ
clones_NNS
with_IN
LTRs_NNS
containing_VBG
one_CD
or_CC
two_CD
NF-kappa_NNP
B_NNP
elements_NNS
(_-LRB-
and_CC
no_DT
Sp1_NNP
binding_NN
sites_NNS
)_-RRB-
,_,
a_DT
hierarchy_NN
of_IN
cellular_JJ
permissivity_NN
to_TO
virus_NN
replication_NN
(_-LRB-
peripheral_JJ
blood_NN
lymphocytes_NNS
=_SYM
MT4_IN
greater_JJR
than_IN
H9_PRP
greater_JJR
than_IN
CEM_NNP
greater_JJR
than_IN
Jurkat_NNP
)_-RRB-
was_VBD
observed_VBN
._.
Of_IN
note_NN
was_VBD
the_DT
associated_JJ
emergence_NN
of_IN
second-site_JJ
LTR_NNP
revertants_NNS
which_WDT
involved_VBD
an_DT
alteration_NN
of_IN
the_DT
TATA_NNP
box_NN
._.
These_DT
results_NNS
suggest_VBP
that_IN
the_DT
human_JJ
immunodeficiency_NN
virus_NN
type_NN
1_CD
LTR_NNP
possesses_NNS
functional_JJ
redundancy_NN
which_WDT
ensures_VBZ
virus_NN
replication_NN
in_IN
different_JJ
T-cell_NN
types_NNS
and_CC
is_VBZ
capable_JJ
of_IN
changing_VBG
depending_VBG
on_IN
the_DT
particular_JJ
combination_NN
of_IN
transcriptional_JJ
factors_NNS
present_JJ
._.
Enhancement_NN
of_IN
human_JJ
immunodeficiency_NN
virus_NN
1_CD
replication_NN
in_IN
monocytes_NNS
by_IN
1,25-dihydroxycholecalciferol_CD
._.
Human_JJ
immunodeficiency_NN
virus_NN
(_-LRB-
HIV_NN
)_-RRB-
expression_NN
and_CC
replication_NN
are_VBP
under_IN
tight_JJ
regulatory_JJ
control_NN
._.
We_PRP
demonstrate_VBP
that_IN
1,25-dihydroxycholecalciferol_JJ
(_-LRB-
1,25-(OH)2D3_CD
)_-RRB-
enhances_VBZ
the_DT
replication_NN
of_IN
monocyte-_NNS
and_CC
lymphocyte-tropic_JJ
strains_NNS
of_IN
HIV-1_PRP$
up_RB
to_TO
10,000-fold_JJ
in_IN
monocyte_NN
cell_NN
lines_NNS
,_,
peripheral_JJ
blood_NN
monocytes_NNS
,_,
and_CC
unfractionated_JJ
peripheral_JJ
blood_NN
mononuclear_NN
cells_NNS
._.
1,25(OH)2D3_CD
is_VBZ
therefore_RB
one_CD
of_IN
the_DT
most_RBS
potent_JJ
regulators_NNS
of_IN
HIV-1_NNP
replication_NN
described_VBD
to_TO
date_NN
._.
Precursors_NNS
of_IN
1,25(OH)2D3_CD
enhance_VB
HIV-1_PRP$
replication_NN
in_IN
proportion_NN
to_TO
their_PRP$
affinity_NN
for_IN
the_DT
1,25(OH)2D3_CD
intracellular_JJ
receptor_NN
,_,
suggesting_VBG
that_IN
1,25(OH)2D3_CD
influences_VBZ
HIV-1_PRP$
replication_NN
by_IN
mechanisms_NNS
involving_VBG
this_DT
receptor_NN
._.
These_DT
studies_NNS
may_MD
have_VB
important_JJ
implications_NNS
for_IN
the_DT
design_NN
of_IN
effective_JJ
therapy_NN
of_IN
HIV-1_PRP$
infection_NN
._.
Inhibition_NN
of_IN
HIV-1_PRP$
replication_NN
and_CC
NF-kappa_NNP
B_NNP
activity_NN
by_IN
cysteine_NN
and_CC
cysteine_NN
derivatives_NNS
._.
HIV-1_JJ
proviral_JJ
DNA_NN
contains_VBZ
two_CD
binding_JJ
sites_NNS
for_IN
the_DT
transcription_NN
factor_NN
NF-kappa_NNP
B_NNP
._.
HIV-1-infected_JJ
individuals_NNS
have_VBP
,_,
on_IN
average_NN
,_,
abnormally_RB
high_JJ
levels_NNS
of_IN
tumour_NN
necrosis_NN
factor_NN
alpha_NN
(_-LRB-
TNF_NN
alpha_NN
)_-RRB-
and_CC
abnormally_RB
low_JJ
plasma_NN
cysteine_NN
levels_NNS
._.
We_PRP
therefore_RB
investigated_VBD
the_DT
effects_NNS
of_IN
cysteine_NN
and_CC
related_JJ
thiols_NNS
on_IN
HIV-1_PRP$
replication_NN
and_CC
NF-kappa_NNP
B_NNP
expression_NN
._.
The_DT
experiments_NNS
in_IN
this_DT
report_NN
show_NN
that_IN
cysteine_NN
or_CC
N-acetylcysteine_NN
(_-LRB-
NP_NNP
)_-RRB-
raise_VBP
the_DT
intracellular_JJ
glutathione_NN
(_-LRB-
GSH_NNP
)_-RRB-
level_NN
and_CC
inhibit_VB
HIV-1_PRP$
replication_NN
in_IN
persistently_RB
infected_JJ
Molt-4_NNP
and_CC
U937_NNP
cells_NNS
._.
However_RB
,_,
inhibition_NN
of_IN
HIV-1_PRP$
replication_NN
appears_VBZ
not_RB
to_TO
be_VB
directly_RB
correlated_VBN
with_IN
GSH_NNP
levels_NNS
._.
Cysteine_NNP
and_CC
NP_NNP
also_RB
inhibit_VBP
NF-kappa_NNP
B_NNP
activity_NN
as_RB
determined_VBN
by_IN
electrophoretic_JJ
mobility_NN
shift_NN
assays_VBZ
and_CC
chloramphenicol_NN
acetyl-transferase_NN
(_-LRB-
CAT_NN
)_-RRB-
gene_NN
expression_NN
under_IN
control_NN
of_IN
NF-kappa_NNP
B_NNP
binding_NN
sites_NNS
in_IN
uninfected_JJ
cells_NNS
._.
This_DT
suggests_VBZ
that_IN
the_DT
cysteine_NN
deficiency_NN
in_IN
HIV-1-infected_PRP$
individuals_NNS
may_MD
cause_VB
an_DT
over-expression_NN
of_IN
NF-kappa_NNP
B-dependent_NNP
genes_NNS
and_CC
enhance_VB
HIV-1_PRP$
replication_NN
._.
NP_NNP
may_MD
be_VB
considered_VBN
for_IN
the_DT
treatment_NN
of_IN
HIV-1-infected_PRP$
individuals_NNS
._.
Glucocorticoid_JJ
receptors_NNS
in_IN
systemic_JJ
lupus_NN
erythematosus_NN
._.
Glucocorticosteroids_NNS
remain_VBP
the_DT
major_JJ
treatment_NN
modality_NN
for_IN
systemic_JJ
lupus_NN
erythematosus_NN
(_-LRB-
SLE_NNP
)_-RRB-
,_,
but_CC
their_PRP$
mechanism_NN
of_IN
action_NN
is_VBZ
unclear_JJ
._.
Over_IN
the_DT
past_JJ
decade_NN
it_PRP
has_VBZ
become_VBN
clear_JJ
that_IN
glucocorticosteroid_NN
receptors_NNS
play_VBP
a_DT
significant_JJ
role_NN
in_IN
the_DT
mechanism_NN
of_IN
glucocorticosteroid_JJ
action_NN
._.
We_PRP
studied_VBD
glucocorticosteroid_NN
receptor_NN
density_NN
and_CC
affinity_NN
on_IN
peripheral_JJ
blood_NN
mononuclear_NN
cells_NNS
by_IN
the_DT
glucocorticosteroid_NN
binding_NN
assay_NN
in_IN
33_CD
patients_NNS
with_IN
SLE_NNP
who_WP
had_VBD
taken_VBN
no_DT
glucocorticosteroid_NN
for_IN
the_DT
previous_JJ
6_CD
months_NNS
and_CC
in_IN
32_CD
healthy_JJ
controls_NNS
._.
Patients_NNS
'_POS
disease_NN
activity_NN
was_VBD
measured_VBN
by_IN
the_DT
SLE_NNP
Disease_NNP
Activity_NNP
Index_NNP
(_-LRB-
SLEDAI_NN
)_-RRB-
._.
Glucocorticosteroid_NNP
receptors_NNS
on_IN
leukocytes_NNS
of_IN
patients_NNS
with_IN
SLE_NNP
were_VBD
significantly_RB
higher_JJR
than_IN
in_IN
healthy_JJ
controls_NNS
(_-LRB-
4419_CD
+/-_:
306_CD
vs_IN
3369_CD
+/-_,
196_CD
,_,
p_RB
less_JJR
than_IN
0.005_CD
)_-RRB-
._.
The_DT
binding_NN
affinity_NN
was_VBD
not_RB
different_JJ
between_IN
patients_NNS
and_CC
controls_NNS
._.
There_EX
was_VBD
no_DT
correlation_NN
between_IN
glucocorticosteroid_NN
receptor_NN
number_NN
and_CC
SLE_JJ
disease_NN
activity_NN
._.
(_-LRB-
Changes_NNS
in_IN
leucocytic_JJ
estrogen_NN
receptor_NN
levels_NNS
in_IN
patients_NNS
with_IN
gynecomastia_NNP
)_-RRB-
The_DT
number_NN
of_IN
estrogen_NN
receptor_NN
(_-LRB-
ER_NNP
)_-RRB-
in_IN
human_JJ
peripheral_NN
leucocytes_NNS
in_IN
13_CD
men_NNS
with_IN
gynecomastia_NN
were_VBD
measured_VBN
by_IN
radioligand_NN
binding_NN
method_NN
._.
The_DT
results_NNS
were_VBD
compared_VBN
with_IN
those_DT
of_IN
13_CD
sex-_NNS
and_CC
age-matched_DT
healthy_JJ
subjects_NNS
._.
It_PRP
was_VBD
found_VBN
that_IN
the_DT
number_NN
of_IN
ER_NNP
in_IN
leucocytes_NNS
was_VBD
significantly_RB
increased_VBN
in_IN
gynecomastia_NN
(_-LRB-
Rs_NNS
of_IN
leucocytes_NNS
were_VBD
1054_CD
+/-_,
254_CD
sites/cell_NN
)_-RRB-
._.
It_PRP
suggested_VBD
that_DT
increase_NN
of_IN
ER_NNP
levels_NNS
play_VBP
an_DT
important_JJ
role_NN
in_IN
the_DT
pathogenesis_NN
of_IN
gynecomastia_NN
._.
(_-LRB-
Changes_NNS
in_IN
levels_NNS
of_IN
leucocytic_JJ
estrogen_NN
receptor_NN
in_IN
patients_NNS
with_IN
menopausal_JJ
type_NN
II_NNP
diabetes_NN
and_CC
its_PRP$
significance_NN
)_-RRB-
The_DT
number_NN
of_IN
estrogen_NN
receptors_NNS
(_-LRB-
ER_NN
)_-RRB-
in_IN
human_JJ
peripheral_NN
leucocytes_NNS
in_IN
12_CD
women_NNS
with_IN
menopausal_JJ
type_NN
II_NNP
diabetes_NN
was_VBD
measured_VBN
with_IN
radio-ligand_NN
binding_NN
method_NN
._.
The_DT
results_NNS
were_VBD
compared_VBN
with_IN
those_DT
of_IN
12_CD
menopausal_JJ
women_NNS
without_IN
diabetes_NN
and_CC
12_CD
normal_JJ
women_NNS
of_IN
childbearing_NN
age_NN
._.
It_PRP
was_VBD
found_VBN
that_IN
the_DT
number_NN
of_IN
ER_NNP
in_IN
the_DT
patients_NNS
was_VBD
significantly_RB
decreased_VBN
._.
Our_PRP$
data_NNS
indicate_VBP
that_IN
decrease_NN
of_IN
ER_NNP
level_NN
in_IN
leukocytes_NNS
may_MD
be_VB
related_VBN
to_TO
the_DT
pathogenesis_NN
of_IN
type_NN
II_NNP
diabetes_NN
in_IN
menopausal_JJ
period_NN
._.
Lymphocyte_NNP
glucocorticoid_NN
receptor_NN
binding_NN
during_IN
depression_NN
and_CC
after_IN
clinical_JJ
recovery_NN
._.
Lymphocyte_NNP
glucocorticoid_NN
receptor_NN
binding_NN
parameters_NNS
were_VBD
studied_VBN
in_IN
15_CD
severely_RB
depressed_JJ
patients_NNS
during_IN
depression_NN
and_CC
after_IN
clinical_JJ
recovery_NN
,_,
and_CC
in_IN
15_CD
healthy_JJ
controls_NNS
._.
There_EX
was_VBD
no_DT
difference_NN
in_IN
glucocorticoid_NN
receptor_NN
number_NN
or_CC
affinity_NN
between_IN
depressed_JJ
patients_NNS
and_CC
recovered_VBD
or_CC
control_NN
subjects_NNS
._.
Afternoon_IN
ACTH_NNP
and_CC
cortisol_JJ
concentrations_NNS
did_VBD
not_RB
differ_VB
significantly_RB
between_IN
the_DT
three_CD
groups_NNS
._.
No_DT
relationship_NN
could_MD
be_VB
established_VBN
between_IN
glucocorticoid_NN
receptor_NN
binding_NN
and_CC
antidepressant_JJ
medication_NN
._.
These_DT
data_NNS
support_VBP
the_DT
view_NN
of_IN
an_DT
impaired_VBN
ligand-induced_JJ
plasticity_NN
of_IN
glucocorticoid_NN
receptor_NN
regulation_NN
rather_RB
than_IN
the_DT
hypothesis_NN
of_IN
decreased_VBN
glucocorticoid_NN
receptor_NN
numbers_NNS
during_IN
depression_NN
._.
Nuclear_JJ
association_NN
of_IN
a_DT
T-cell_JJ
transcription_NN
factor_NN
blocked_VBN
by_IN
FK-506_NNP
and_CC
cyclosporin_NN
A_DT
(_-LRB-
see_VB
comments_NNS
)_-RRB-
Cyclosporin_NNP
A_NNP
and_CC
FK506_NNP
inhibit_VBP
T-_NNS
and_CC
B-cell_JJ
activation_NN
and_CC
other_JJ
processes_NNS
essential_JJ
to_TO
an_DT
effective_JJ
immune_JJ
response_NN
._.
In_IN
T_NNP
lymphocytes_NNS
these_DT
drugs_NNS
disrupt_VB
an_DT
unknown_JJ
step_NN
in_IN
the_DT
transmission_NN
of_IN
signals_NNS
from_IN
the_DT
T-cell_NN
antigen_NN
receptor_NN
to_TO
cytokine_VB
genes_NNS
that_WDT
coordinate_VB
the_DT
immune_JJ
response_NN
._.
The_DT
putative_JJ
intracellular_JJ
receptors_NNS
for_IN
FK506_NNP
and_CC
cyclosporin_NN
are_VBP
cis-trans_NNS
prolyl_JJ
isomerases_NNS
._.
Binding_NNP
of_IN
the_DT
drug_NN
inhibits_VBZ
isomerase_JJ
activity_NN
,_,
but_CC
studies_NNS
with_IN
other_JJ
prolyl_NN
isomerase_NN
inhibitors_NNS
and_CC
analysis_NN
of_IN
cyclosporin-resistant_JJ
mutants_NNS
in_IN
yeast_NN
suggest_VBP
that_IN
the_DT
effects_NNS
of_IN
the_DT
drug_NN
result_NN
from_IN
the_DT
formation_NN
of_IN
an_DT
inhibitory_JJ
complex_NN
between_IN
the_DT
drug_NN
and_CC
isomerase_NN
,_,
and_CC
not_RB
from_IN
inhibition_NN
of_IN
isomerase_NN
activity_NN
._.
A_DT
transcription_NN
factor_NN
,_,
NF-AT_NNP
,_,
which_WDT
is_VBZ
essential_JJ
for_IN
early_RB
T-cell_JJ
gene_NN
activation_NN
,_,
seems_VBZ
to_TO
be_VB
a_DT
specific_JJ
target_NN
of_IN
cyclosporin_NN
A_DT
and_CC
FK506_NNP
action_NN
because_IN
transcription_NN
directed_VBN
by_IN
this_DT
protein_NN
is_VBZ
blocked_VBN
in_IN
T_NNP
cells_NNS
treated_VBN
with_IN
these_DT
drugs_NNS
,_,
with_IN
little_JJ
or_CC
no_DT
effect_NN
on_IN
other_JJ
transcription_NN
factors_NNS
such_JJ
as_IN
AP-1_NNP
and_CC
NF-kappa_NNP
B_NNP
._.
Here_RB
we_PRP
demonstrate_VBP
that_IN
NF-AT_NNP
is_VBZ
formed_VBN
when_WRB
a_DT
signal_NN
from_IN
the_DT
antigen_NN
receptor_NN
induces_VBZ
a_DT
pre-existing_JJ
cytoplasmic_JJ
subunit_NN
to_TO
translocate_VB
to_TO
the_DT
nucleus_NN
and_CC
combine_VB
with_IN
a_DT
newly_RB
synthesized_VBN
nuclear_JJ
subunit_NN
of_IN
NF-AT_NN
._.
FK506_NNP
and_CC
cyclosporin_NN
A_DT
block_NN
translocation_NN
of_IN
the_DT
cytoplasmic_JJ
component_NN
without_IN
affecting_VBG
synthesis_NN
of_IN
the_DT
nuclear_JJ
subunit_NN
._.
Regulation_NN
of_IN
M-CSF_NNP
expression_NN
by_IN
M-CSF_NNP
:_:
role_NN
of_IN
protein_NN
kinase_NN
C_NNP
and_CC
transcription_NN
factor_NN
NF_NNP
kappa_NN
B_NNP
._.
Macrophage-colony-stimulating_JJ
factor_NN
(_-LRB-
M-CSF_NNP
)_-RRB-
,_,
also_RB
referred_VBD
to_TO
as_IN
CSF-1_NN
,_,
regulates_VBZ
the_DT
survival_NN
,_,
growth_NN
,_,
differentiation_NN
and_CC
functional_JJ
activity_NN
of_IN
monocytes_NNS
by_IN
binding_NN
to_TO
a_DT
single_JJ
class_NN
of_IN
high-affinity_JJ
cell_NN
surface_NN
receptors_NNS
,_,
known_VBN
to_TO
be_VB
the_DT
product_NN
of_IN
the_DT
c-fms_NNS
protooncogene_NN
._.
The_DT
detection_NN
of_IN
both_DT
M-CSF_NNP
and_CC
c-fms_NNS
expression_NN
by_IN
cells_NNS
of_IN
the_DT
monocyte_NN
lineage_NN
has_VBZ
suggested_VBN
that_IN
M-CSF_NNP
may_MD
act_VB
by_IN
an_DT
autocrine_NN
mechanism_NN
._.
Interestingly_RB
,_,
it_PRP
has_VBZ
been_VBN
shown_VBN
that_IN
M-CSF_NNP
can_MD
induce_VB
the_DT
expression_NN
of_IN
its_PRP$
own_JJ
gene_NN
._.
Although_IN
sensitivity_NN
to_TO
M-CSF_NNP
can_MD
be_VB
modulated_VBN
by_IN
regulation_NN
of_IN
receptor_NN
expression_NN
and_CC
function_NN
,_,
M-CSF_NNP
responsiveness_NN
is_VBZ
largely_RB
determined_VBN
at_IN
a_DT
postreceptor_NN
level_NN
._.
To_TO
date_NN
,_,
little_RB
is_VBZ
known_VBN
about_IN
the_DT
intracellular_JJ
pathway_NN
of_IN
M-CSF_NNP
signal_NN
transduction_NN
._.
We_PRP
have_VBP
therefore_RB
investigated_VBN
the_DT
changes_NNS
in_IN
protein_NN
kinase_NN
C_NNP
(_-LRB-
PKC_NNP
)_-RRB-
activity_NN
upon_IN
exposure_NN
of_IN
monocytes_NNS
to_TO
M-CSF_NNP
._.
We_PRP
show_VBP
that_IN
M-CSF_NNP
activates_NNS
and_CC
translocates_NNS
PKC_RB
._.
Inhibition_NN
of_IN
PKC_NNP
by_IN
the_DT
isoquinoline_NN
derivative_JJ
H7_IN
abolishes_NNS
induction_NN
of_IN
M-CSF_NNP
by_IN
M-CSF_NNP
._.
Furthermore_RB
,_,
activation_NN
of_IN
PKC_NNP
was_VBD
pertussis-toxin-sensitive_JJ
and_CC
was_VBD
associated_VBN
with_IN
the_DT
detection_NN
of_IN
an_DT
NF_NNP
kappa_NN
B_NNP
protein_NN
in_IN
nuclear_JJ
extracts_NNS
of_IN
M-CSF-induced_JJ
blood_NN
monocytes_NNS
but_CC
not_RB
in_IN
monocytes_NNS
exposed_VBN
to_TO
medium_NN
treatment_NN
only_RB
._.
The_DT
results_NNS
suggest_VBP
that_IN
M-CSF_NNP
induction_NN
of_IN
M-CSF_NNP
involves_VBZ
G_NNP
proteins_VBZ
,_,
PKC_NNP
and_CC
NF_NNP
kappa_NN
B_NNP
._.
NF-kappa_NNP
B_NNP
activation_NN
by_IN
tumor_NN
necrosis_NN
factor_NN
alpha_NN
in_IN
the_DT
Jurkat_NNP
T_NNP
cell_NN
line_NN
is_VBZ
independent_JJ
of_IN
protein_NN
kinase_NN
A_DT
,_,
protein_NN
kinase_NN
C_NNP
,_,
and_CC
Ca(2+)-regulated_JJ
kinases_NNS
._.
NF-kappa_NNP
B_NNP
is_VBZ
a_DT
DNA-binding_JJ
regulatory_JJ
factor_NN
able_JJ
to_TO
control_VB
transcription_NN
of_IN
a_DT
number_NN
of_IN
genes_NNS
,_,
including_VBG
human_JJ
immunodeficiency_NN
virus_NN
(_-LRB-
HIV_NNP
)_-RRB-
genes_NNS
._.
In_IN
T_NNP
cells_NNS
,_,
NF-kappa_NNP
B_NNP
is_VBZ
activated_VBN
upon_IN
cellular_JJ
treatment_NN
by_IN
phorbol_NN
esters_NNS
and_CC
the_DT
cytokine_NN
tumor_NN
necrosis_NN
factor_NN
alpha_NN
(_-LRB-
TNF_NN
alpha_NN
)_-RRB-
._.
In_IN
the_DT
present_JJ
work_NN
,_,
we_PRP
investigated_VBD
the_DT
molecular_JJ
events_NNS
leading_VBG
to_TO
NF-kappa_NNP
B_NNP
activation_NN
by_IN
TNF_NNP
alpha_NN
in_IN
a_DT
human_JJ
T_NNP
cell_NN
line_NN
(_-LRB-
Jurkat_NN
)_-RRB-
and_CC
its_PRP$
subclone_NN
JCT6_NNP
,_,
which_WDT
presents_VBZ
a_DT
deficiency_NN
in_IN
the_DT
PKA_NNP
transduction_NN
pathway_NN
._.
We_PRP
found_VBD
that_IN
in_IN
both_DT
cell_NN
lines_NNS
,_,
both_DT
phorbol_NN
ester_NN
and_CC
TNF_NNP
alpha_NN
were_VBD
able_JJ
to_TO
activate_VB
NF-kappa_NNP
B_NNP
._.
Phorbol_NNP
activation_NN
was_VBD
positively_RB
modulated_VBN
by_IN
Ca2+_NNP
influx_NN
while_IN
TNF_NNP
alpha_NN
activation_NN
was_VBD
not_RB
._.
Furthermore_RB
,_,
while_IN
PMA_NNP
activation_NN
was_VBD
inhibited_VBN
by_IN
the_DT
PKC_NNP
inhibitor_NN
staurosporin_NN
,_,
the_DT
TNF_NNP
alpha_NN
effect_NN
was_VBD
unchanged_JJ
._.
TNF_NNP
alpha_NN
did_VBD
not_RB
activate_JJ
cAMP_JJ
production_NN
and_CC
its_PRP$
signal_NN
was_VBD
not_RB
modulated_VBN
by_IN
cAMP_JJ
activators_NNS
._.
Moreover_RB
,_,
cAMP_IN
activators_NNS
did_VBD
not_RB
activate_JJ
NF-kappa_NNP
B_NNP
in_IN
Jurkat_NNP
cells_NNS
._.
Thus_RB
,_,
TNF_NNP
alpha-induced_CC
NF-kappa_NNP
B_NNP
activation_NN
was_VBD
found_VBN
to_TO
be_VB
mediated_VBN
by_IN
none_NN
of_IN
the_DT
major_JJ
signal-mediating_NN
kinases_NNS
such_JJ
as_IN
protein_NN
kinase_NN
C_NNP
(_-LRB-
PKC_NNP
)_-RRB-
,_,
protein_NN
kinase_NN
A_DT
,_,
or_CC
Ca(2+)-regulated_JJ
kinases_NNS
._.
Furthermore_RB
,_,
we_PRP
found_VBD
that_IN
cytoplasmic_JJ
acidification_NN
facilitated_VBD
NF-kappa_NNP
B_NNP
activation_NN
by_IN
both_DT
TNF_NNP
alpha_NN
and_CC
PKC_NNP
,_,
by_IN
a_DT
mechanism_NN
that_WDT
increases_VBZ
NF-kappa_NNP
B/I_CC
kappa_VB
B_NNP
dissociation_NN
without_IN
affecting_VBG
the_DT
NF-kappa_NNP
B_NNP
translocation_NN
step_NN
._.
NF-kappa_NNP
B_NNP
activity_NN
in_IN
T_NNP
cells_NNS
stably_RB
expressing_VBG
the_DT
Tax_NNP
protein_NN
of_IN
human_JJ
T_NNP
cell_NN
lymphotropic_NN
virus_NN
type_NN
I_PRP
._.
The_DT
effect_NN
of_IN
constitutive_JJ
Tax_NNP
expression_NN
on_IN
the_DT
interaction_NN
of_IN
NF-kappa_NNP
B_NNP
with_IN
its_PRP$
recognition_NN
sequence_NN
and_CC
on_IN
NF-kappa_NNP
B-dependent_NNP
gene_NN
expression_NN
was_VBD
examined_VBN
in_IN
T_NNP
lymphoid_VBD
Jurkat_NNP
cell_NN
lines_NNS
(_-LRB-
19D_CD
and_CC
9J_NNP
)_-RRB-
stably_RB
transformed_VBN
with_IN
a_DT
Tax_NNP
expression_NN
vector_NN
._.
Tax_NNP
expressing_VBG
T_NNP
cell_NN
lines_NNS
contained_VBD
a_DT
constitutive_JJ
level_NN
of_IN
NF-kappa_NNP
B_NNP
binding_NN
activity_NN
,_,
detectable_JJ
by_IN
mobility_NN
shift_NN
assay_NN
and_CC
uv_NN
cross-linking_NN
using_VBG
a_DT
palindromic_JJ
NF-kappa_NNP
B_NNP
probe_NN
homologous_RB
to_TO
the_DT
interferon_NN
beta_NN
PRDII_NNP
site_NN
._.
In_IN
Jurkat_NNP
and_CC
NC2.10_NNP
induction_NN
with_IN
phorbol_NN
esters_NNS
resulted_VBD
in_IN
the_DT
appearance_NN
of_IN
new_JJ
DNA_NNP
binding_JJ
proteins_NNS
of_IN
85_CD
,_,
75_CD
,_,
and_CC
54_CD
kDa_NNS
,_,
whereas_IN
in_IN
Tax_NNP
expressing_VBG
cells_NNS
the_DT
85-kDa_JJ
protein_NN
and_CC
a_DT
92-kDa_JJ
DNA_NN
binding_JJ
protein_NN
were_VBD
constitutively_RB
induced_VBN
._.
Expression_NN
of_IN
Tax_NNP
protein_NN
in_IN
19D_JJ
and_CC
9J_JJ
resulted_VBD
in_IN
transcription_NN
of_IN
the_DT
endogenous_JJ
NF-kappa_NNP
B-dependent_NNP
granulocyte-macrophage_JJ
colony_NN
stimulating_VBG
factor_NN
gene_NN
and_CC
increased_VBD
basal_NN
level_NN
expression_NN
of_IN
transfected_VBN
NF-kappa_NNP
B-regulated_JJ
promoters_NNS
._.
Nonetheless_RB
transcription_NN
of_IN
both_DT
the_DT
endogenous_JJ
and_CC
the_DT
transfected_JJ
gene_NN
was_VBD
inducible_JJ
by_IN
PMA_NNP
treatment_NN
._.
Tax_NNP
expression_NN
in_IN
Jurkat_NNP
T_NNP
cells_NNS
may_MD
alter_VB
the_DT
stoichiometry_NN
of_IN
NF-kappa_NNP
B_NNP
DNA_NNP
binding_JJ
proteins_NNS
and_CC
thus_RB
change_VB
the_DT
expression_NN
of_IN
NF-kappa_NNP
B-regulated_JJ
promoters_NNS
._.
Regulation_NN
of_IN
glucocorticoid_JJ
receptors_NNS
in_IN
human_JJ
mononuclear_NN
cells_NNS
:_:
effects_NNS
of_IN
glucocorticoid_JJ
treatment_NN
,_,
Cushing_NNP
's_POS
disease_NN
and_CC
ketoconazole_NN
._.
Glucocorticoid_JJ
receptors_NNS
(_-LRB-
GcR_NN
)_-RRB-
were_VBD
determined_VBN
by_IN
a_DT
whole_JJ
cell_NN
assay_NN
in_IN
human_JJ
mononulear_NN
leukocytes_NNS
(_-LRB-
hMNL_NN
)_-RRB-
from_IN
control_NN
subjects_NNS
,_,
patients_NNS
receiving_VBG
glucocorticoid_JJ
therapy_NN
for_IN
systemic_JJ
diseases_NNS
and_CC
Cushing_NN
's_POS
disease_NN
patients_NNS
with_IN
or_CC
without_IN
ketoconazole_JJ
therapy_NN
._.
Prolonged_JJ
corticosteroid_NN
treatment_NN
resulted_VBD
in_IN
down-regulation_NN
of_IN
GcR_NNP
,_,
while_IN
the_DT
mean_JJ
level_NN
of_IN
GcR_NNP
in_IN
Cushing_NNP
's_POS
disease_NN
was_VBD
normal_JJ
._.
In_IN
this_DT
group_NN
,_,
however_RB
,_,
receptor_NN
levels_NNS
and_CC
morning_NN
plasma_NN
cortisol_NN
values_NNS
showed_VBD
a_DT
negative_JJ
correlation_NN
,_,
indicating_VBG
a_DT
subtle_JJ
down-regulatory_JJ
effect_NN
._.
Furthermore_RB
,_,
GcR_NNP
were_VBD
unaltered_JJ
after_IN
these_DT
patients_NNS
received_VBD
ketoconazole_JJ
,_,
in_IN
spite_NN
of_IN
a_DT
marked_VBN
reduction_NN
in_IN
morning_NN
plasma_NN
cortisol_NN
and_CC
urinary_JJ
free_JJ
cortisol_NN
._.
We_PRP
also_RB
observed_VBD
that_IN
ketoconazole_NN
was_VBD
a_DT
weak_JJ
competitor_NN
of_IN
GcR_NNP
in_IN
intact_JJ
cells_NNS
,_,
although_IN
it_PRP
significantly_RB
inhibited_VBD
(3H)_NNP
dexamethasone_NN
binding_NN
in_IN
cytosolic_JJ
preparations_NNS
from_IN
rat_NN
tissues_NNS
._.
The_DT
results_NNS
suggested_VBD
that_IN
GcR_NNP
in_IN
hMNL_NN
are_VBP
down-regulated_JJ
by_IN
synthetic_JJ
steroids_NNS
given_VBN
in_IN
vivo_NN
,_,
but_CC
they_PRP
showed_VBD
very_RB
mild_JJ
down-regulation_NN
in_IN
hypercortisolemic_JJ
patients_NNS
suffering_VBG
from_IN
Cushing_NNP
's_POS
disease_NN
._.
Finally_RB
,_,
we_PRP
did_VBD
not_RB
observed_VBN
either_CC
up-regulation_JJ
or_CC
antagonism_NN
of_IN
GcR_NNP
by_IN
ketoconazole_NN
treatment_NN
,_,
at_IN
the_DT
time_NN
that_IN
cortisol_JJ
levels_NNS
of_IN
patients_NNS
with_IN
Cushing_NNP
's_POS
disease_NN
were_VBD
reduced_VBN
._.
This_DT
indicates_VBZ
that_IN
the_DT
beneficial_JJ
effects_NNS
of_IN
ketoconazole_NN
in_IN
Cushing_NNP
's_POS
disease_NN
are_VBP
due_JJ
to_TO
adrenal_JJ
cortisol_NN
suppression_NN
and_CC
not_RB
to_TO
interaction_NN
with_IN
GcR_NNP
of_IN
target_NN
cells_NNS
,_,
and_CC
that_IN
the_DT
process_NN
of_IN
GcR_NNP
regulation_NN
in_IN
hMNL_NN
is_VBZ
a_DT
complex_JJ
phenomenon_NN
awaiting_VBG
further_JJ
elucidation_NN
._.
Glucocorticoid_JJ
receptors_NNS
in_IN
lymphocytes_NNS
in_IN
anorexia_DT
nervosa_NN
._.
OBJECTIVE_VBP
:_:
The_DT
aim_NN
was_VBD
to_TO
explore_VB
the_DT
down-regulation_NN
of_IN
the_DT
glucocorticoid_JJ
receptors_NNS
during_IN
hypercortisolaemia_NN
in_IN
anorexia_DT
nervosa_NN
._.
DESIGN_NNP
:_:
Urine_NNP
and_CC
plasma_NN
samples_NNS
were_VBD
obtained_VBN
for_IN
cortisol_JJ
determination_NN
and_CC
blood_NN
lymphocytes_NNS
were_VBD
isolated_VBN
for_IN
receptor_NN
binding_NN
studies_NNS
._.
PATIENTS_NNS
:_:
Sixteen_CD
anorexic_DT
patients_NNS
,_,
aged_VBN
16-27_CD
years_NNS
,_,
with_IN
a_DT
mean_JJ
+/-_NNP
SEM_NNP
body_NN
mass_NN
index_NN
of_IN
14.2_CD
+/-_CD
2.0_CD
(_-LRB-
ranging_VBG
from_IN
11.1_CD
to_TO
17.4_CD
)_-RRB-
,_,
and_CC
15_CD
normal_JJ
women_NNS
were_VBD
studied_VBN
._.
Six_CD
patients_NNS
were_VBD
reinvestigated_VBN
after_IN
a_DT
significant_JJ
weight_NN
gain_NN
._.
MEASUREMENTS_NNS
:_:
The_DT
binding_JJ
capacity_NN
and_CC
affinity_NN
of_IN
the_DT
glucocorticoid_JJ
receptors_NNS
were_VBD
measured_VBN
with_IN
dexamethasone_NN
as_IN
ligand_NN
on_IN
lymphocytes_NNS
._.
RESULTS_NNS
:_:
In_IN
patients_NNS
,_,
both_DT
total_JJ
and_CC
free_JJ
plasma_NN
cortisol_NN
concentrations_NNS
were_VBD
higher_JJR
than_IN
in_IN
the_DT
normal_JJ
women_NNS
,_,
as_IN
was_VBD
their_PRP$
urinary_JJ
free_JJ
cortisol_NN
;_:
the_DT
number_NN
of_IN
glucocorticoid_JJ
receptors_NNS
per_IN
cell_NN
(_-LRB-
Ro_NNP
)_-RRB-
and_CC
the_DT
binding_NN
affinity_NN
(_-LRB-
Kd_NNP
)_-RRB-
for_IN
dexamethasone_NN
were_VBD
,_,
however_RB
,_,
not_RB
significantly_RB
different_JJ
(_-LRB-
Ro_NNP
:_:
7687_CD
+/-_,
1750_CD
vs_IN
7347_CD
+/-_,
1285_CD
sites/cell_NN
;_:
Kd_NNP
:_:
7.7_CD
+/-_CD
2.4_CD
vs_IN
7.4_CD
+/-_,
1.7_CD
nM_NNS
at_IN
24_CD
degrees_NNS
C_NN
)_-RRB-
._.
After_IN
weight_NN
gain_NN
(_-LRB-
14_CD
+/-_,
2_CD
to_TO
16_CD
+/-_,
2_CD
kg/m2_NN
)_-RRB-
,_,
receptor_NN
numbers_NNS
were_VBD
8421_CD
+/-_CD
2126_CD
(_-LRB-
pre_NN
)_-RRB-
and_CC
9011_CD
+/-_CD
500_CD
(_-LRB-
post_NN
)_-RRB-
sites/cell_NN
,_,
which_WDT
are_VBP
not_RB
significantly_RB
different_JJ
(_-LRB-
P_NNP
greater_JJR
than_IN
0.2_CD
)_-RRB-
;_:
the_DT
Kd_NNP
was_VBD
unchanged_JJ
(_-LRB-
9.3_CD
+/-_:
2.6_CD
vs_NN
9.2_CD
+/-_,
2.4_CD
nM_NNS
)_-RRB-
._.
CONCLUSIONS_NNS
Hypercortisolaemia_NNP
does_VBZ
not_RB
down-regulate_JJ
the_DT
lymphocyte_NN
glucocorticoid_NN
receptors_NNS
in_IN
anorexia_DT
nervosa_NN
and_CC
a_DT
post-receptor_NN
defect_NN
might_MD
be_VB
involved_VBN
in_IN
peripheral_JJ
tissue_NN
resistance_NN
to_TO
the_DT
effects_NNS
of_IN
glucocorticoid_JJ
hormones_NNS
in_IN
undernutrition_NN
._.
Tumor_NN
necrosis_NN
factor-alpha_NN
mRNA_NN
accumulation_NN
in_IN
human_JJ
myelomonocytic_JJ
cell_NN
lines_NNS
._.
Role_NNP
of_IN
transcriptional_JJ
regulation_NN
by_IN
DNA_NNP
sequence_NN
motifs_NNS
and_CC
mRNA_NN
stabilization_NN
._.
The_DT
cytokine_NN
TNF_NNP
mediates_VBZ
many_JJ
of_IN
the_DT
pathologic_NN
signs_NNS
of_IN
cachexia_NN
,_,
inflammation_NN
,_,
and_CC
sepsis_NN
._.
The_DT
current_JJ
work_NN
describes_VBZ
the_DT
regulation_NN
of_IN
TNF_NNP
in_IN
human_JJ
myelomonocytic_JJ
cell_NN
lines_NNS
after_IN
PMA_NNP
stimulation_NN
._.
The_DT
cell_NN
lines_NNS
exhibit_VBP
a_DT
low_JJ
level_NN
of_IN
constitutive_JJ
TNF_NNP
mRNA_NN
expression_NN
._.
Within_IN
2_CD
to_TO
4_CD
h_NN
of_IN
PMA_NNP
exposure_NN
,_,
steady_JJ
state_NN
levels_NNS
of_IN
TNF_NNP
mRNA_NNS
are_VBP
markedly_RB
elevated_VBN
in_IN
all_DT
myelomonocytic_JJ
cell_NN
lines_NNS
studied_VBN
._.
This_DT
rise_NN
is_VBZ
due_JJ
to_TO
increased_VBN
mRNA_NN
stability_NN
,_,
which_WDT
increased_VBD
by_IN
almost_RB
twofold_JJ
,_,
and_CC
to_TO
an_DT
overall_JJ
increase_NN
in_IN
transcription_NN
,_,
which_WDT
rises_VBZ
by_IN
more_JJR
than_IN
sixfold_RB
._.
At_IN
the_DT
level_NN
of_IN
the_DT
genomic_JJ
TNF_NNP
gene_NN
,_,
a_DT
DNase_NN
I_PRP
hypersensitive_VBP
site_NN
is_VBZ
detected_VBN
within_IN
the_DT
TNF_NNP
promoter_NN
between_IN
-200_CD
to_TO
-100_CD
bp_NN
relative_JJ
to_TO
the_DT
transcription_NN
initiation_NN
site_NN
._.
Although_IN
absent_JJ
in_IN
nonexpressing_NN
erythroleukemia_NN
cell_NN
lines_NNS
,_,
the_DT
DNase_NN
I_PRP
site_NN
is_VBZ
present_JJ
in_IN
uninduced_JJ
myelomonocytic_JJ
cell_NN
lines_NNS
and_CC
is_VBZ
not_RB
changed_VBN
after_IN
PMA_NNP
induction_NN
._.
The_DT
PMA_NNP
induction_NN
of_IN
c-fos_JJ
mRNA_NNS
correlated_VBN
well_RB
with_IN
TNF_NNP
gene_NN
induction_NN
;_:
expression_NN
of_IN
genes_NNS
encoding_VBG
other_JJ
proteins_NNS
in_IN
the_DT
AP-1_NN
complex_NN
(_-LRB-
junB_NN
and_CC
junD_NN
)_-RRB-
were_VBD
also_RB
induced_VBN
by_IN
PMA_NNP
._.
The_DT
nuclear_JJ
extracts_NNS
from_IN
resting_VBG
and_CC
induced_VBN
ML-1_JJ
cells_NNS
contain_VBP
proteins_NNS
binding_JJ
specifically_RB
to_TO
the_DT
AP-1_NN
,_,
AP-2_NNP
,_,
and_CC
NF_NNP
kappa_NN
B_NNP
sequence_NN
located_VBN
within_IN
the_DT
TNF_NNP
promoter_NN
._.
PMA_NNP
induction_NN
increases_VBZ
the_DT
level_NN
of_IN
a_DT
number_NN
of_IN
specific_JJ
binding_NN
complexes_NNS
relative_JJ
to_TO
the_DT
resting_VBG
cells_NNS
._.
The_DT
regulatory_JJ
mechanisms_NNS
of_IN
the_DT
human_NN
and_CC
murine_NN
TNF_NN
genes_NNS
are_VBP
discussed_VBN
._.
USF-related_JJ
transcription_NN
factor_NN
,_,
HIV-TF1_NNP
,_,
stimulates_NNS
transcription_NN
of_IN
human_JJ
immunodeficiency_NN
virus-1_NN
._.
The_DT
transcription_NN
factor_NN
HIV-TF1_NNP
,_,
which_WDT
binds_VBZ
to_TO
a_DT
region_NN
about_IN
60_CD
bp_NN
upstream_RB
from_IN
the_DT
enhancer_NN
of_IN
the_DT
human_JJ
immunodeficiency_NN
virus-1_NN
(_-LRB-
HIV-1_NN
)_-RRB-
,_,
was_VBD
purified_VBN
from_IN
human_JJ
B_NNP
cells_NNS
._.
HIV-TF1_NNP
had_VBD
a_DT
molecular_JJ
weight_NN
of_IN
39,000_CD
._.
Binding_NNP
of_IN
HIV-TF1_NNP
to_TO
the_DT
HIV_NN
long_RB
terminal_JJ
repeat_NN
(_-LRB-
LTR_NNP
)_-RRB-
activated_VBN
transcription_NN
from_IN
the_DT
HIV_NNP
promoter_NN
in_IN
vitro_NN
._.
The_DT
HIV-TF1-binding_JJ
site_NN
in_IN
HIV_NNP
LTR_NNP
was_VBD
similar_JJ
to_TO
the_DT
site_NN
recognized_VBN
by_IN
upstream_RB
stimulatory_JJ
factor_NN
(_-LRB-
USF_NNP
)_-RRB-
in_IN
the_DT
adenovirus_JJ
major_JJ
late_JJ
promoter_NN
._.
DNA-binding_JJ
properties_NNS
of_IN
HIV-TF1_NNP
suggested_VBD
that_IN
HIV-TF1_NNP
might_MD
be_VB
identical_JJ
or_CC
related_VBN
to_TO
USF_NNP
._.
Interestingly_RB
,_,
treatment_NN
of_IN
purified_VBN
HIV-TF1_PRP$
by_IN
phosphatase_NN
greatly_RB
reduced_VBD
its_PRP$
DNA-binding_JJ
activity_NN
,_,
suggesting_VBG
that_IN
phosphorylation_NN
of_IN
HIV-TF1_NNP
was_VBD
essential_JJ
for_IN
DNA_NNP
binding_NN
._.
The_DT
disruption_NN
of_IN
HIV-TF1-binding_PRP$
site_NN
induced_VBN
a_DT
60_CD
%_NN
decrease_NN
in_IN
the_DT
level_NN
of_IN
transcription_NN
from_IN
the_DT
HIV_NNP
promoter_NN
in_IN
vivo_NN
._.
These_DT
results_NNS
suggest_VBP
that_IN
HIV-TF1_NNP
is_VBZ
involved_VBN
in_IN
transcriptional_JJ
regulation_NN
of_IN
HIV-1_NN
._.
The_DT
effect_NN
of_IN
toremifene_JJ
therapy_NN
on_IN
serum_NN
immunoglobulin_NN
levels_NNS
in_IN
breast_NN
cancer_NN
._.
Estrogens_NNS
and_CC
anti-estrogens_NNS
enhance_VB
the_DT
number_NN
of_IN
immunoglobulin_NN
(_-LRB-
Ig_NNP
)_-RRB-
-secreting_JJ
cells_NNS
in_IN
pokeweed_NN
mitogen_NN
(_-LRB-
PWM_NNP
)_-RRB-
-stimulated_:
lymphocyte_JJ
cultures_NNS
._.
Lymphocytes_NNS
from_IN
patients_NNS
who_WP
have_VBP
received_VBN
anti-estrogen_JJ
therapy_NN
show_NN
similar_JJ
enhancement_NN
of_IN
Ig-secreting_JJ
cells_NNS
after_IN
PWM_NNP
stimulation_NN
._.
In_IN
this_DT
study_NN
the_DT
effect_NN
of_IN
anti-estrogen_NN
(_-LRB-
toremifene_NN
)_-RRB-
therapy_NN
on_IN
serum_NN
immunoglobulin_NN
(_-LRB-
IgA_NNP
,_,
IgM_NNP
,_,
IgG_NNP
)_-RRB-
levels_NNS
in_IN
breast_NN
cancer_NN
patients_NNS
was_VBD
investigated_VBN
._.
Serum_NNP
Ig_NNP
levels_NNS
were_VBD
followed_VBN
up_IN
to_TO
two_CD
years_NNS
after_IN
or_CC
during_IN
the_DT
therapy_NN
._.
An_DT
unexpected_JJ
finding_NN
was_VBD
that_IN
the_DT
Ig_NNP
levels_NNS
decreased_VBD
during_IN
the_DT
follow-up_JJ
period_NN
._.
This_DT
decrease_NN
was_VBD
seen_VBN
in_IN
patients_NNS
who_WP
responded_VBD
to_TO
the_DT
therapy_NN
as_RB
well_RB
as_IN
in_IN
those_DT
who_WP
did_VBD
not_RB
._.
HIV1_PRP$
infection_NN
of_IN
human_JJ
monocytes_NNS
and_CC
macrophages_NNS
promotes_NNS
induction_NN
or_CC
translocation_NN
of_IN
NF-KB-related_JJ
factors_NNS
._.
In_IN
1991_CD
,_,
we_PRP
demonstrated_VBD
,_,
using_VBG
electrophoretic_JJ
mobility_NN
shift_NN
assays_VBZ
,_,
that_IN
3_CD
different_JJ
factors_NNS
(_-LRB-
termed_VBN
B1_NNP
,_,
B2_JJ
and_CC
B3_JJ
)_-RRB-
with_IN
affinity_NN
for_IN
the_DT
KB-enhancer_NNP
target_NN
sequence_NN
were_VBD
specifically_RB
detected_VBN
in_IN
nuclear_JJ
extracts_NNS
from_IN
HIV1-infected_PRP$
monocytes_NNS
and_CC
macrophages_NNS
._.
The_DT
B2_JJ
factor_NN
was_VBD
induced_VBN
in_IN
the_DT
nuclei_NNS
of_IN
these_DT
cells_NNS
only_RB
upon_IN
HIV1_PRP$
infection_NN
._.
The_DT
B3_JJ
factor_NN
was_VBD
only_RB
slightly_RB
evident_JJ
in_IN
nuclei_JJ
of_IN
uninfected_JJ
cells_NNS
but_CC
was_VBD
readily_RB
detectable_JJ
in_IN
nuclei_NNS
of_IN
infected_JJ
monocytes_NNS
._.
Its_PRP$
expression_NN
remained_VBD
very_RB
low_JJ
in_IN
nuclei_NNS
of_IN
HIV1-infected_PRP$
macrophages_NNS
._.
In_IN
this_DT
paper_NN
,_,
we_PRP
demonstrate_VBP
that_IN
the_DT
B2_JJ
factor_NN
is_VBZ
expressed_VBN
in_IN
the_DT
cytosol_NN
of_IN
monocytes_NNS
and_CC
macrophages_NNS
as_IN
a_DT
DNA-binding_JJ
protein_NN
,_,
indicating_VBG
that_IN
it_PRP
is_VBZ
not_RB
associated_VBN
with_IN
an_DT
inhibitor_NN
(_-LRB-
IKB_NN
)_-RRB-
._.
This_DT
factor_NN
remained_VBD
clustered_VBN
in_IN
the_DT
cytosol_NN
and_CC
was_VBD
translocated_VBN
to_TO
the_DT
nuclei_NNS
only_RB
after_IN
HIV1_PRP$
infection_NN
._.
The_DT
B3_JJ
factor_NN
is_VBZ
detected_VBN
in_IN
the_DT
cytosol_NN
only_RB
when_WRB
cells_NNS
are_VBP
HIV1-infected_JJ
._.
The_DT
role_NN
of_IN
HIV1_PRP$
infection_NN
in_IN
the_DT
expression_NN
and_CC
the_DT
translocation_NN
of_IN
these_DT
factors_NNS
is_VBZ
discussed_VBN
._.
Induction_NN
of_IN
NF-kappa_NNP
B_NNP
during_IN
monocyte_NN
differentiation_NN
is_VBZ
associated_VBN
with_IN
activation_NN
of_IN
HIV-gene_NNP
expression_NN
._.
Cells_NNP
of_IN
the_DT
monocyte-macrophage_NN
lineage_NN
are_VBP
important_JJ
targets_NNS
of_IN
HIV_NNP
infection_NN
._.
We_PRP
report_VBP
here_RB
that_IN
the_DT
phenotypic_JJ
differentiation_NN
of_IN
monocyte_NN
cell_NN
lines_NNS
induced_VBN
by_IN
phorbol_NN
esters_NNS
or_CC
tumour_NN
necrosis_NN
factor_NN
alpha_NN
(_-LRB-
TNF_NN
alpha_NN
)_-RRB-
is_VBZ
associated_VBN
with_IN
expression_NN
of_IN
nuclear_JJ
factor_NN
kappa_NN
B_NNP
(_-LRB-
NF-kappa_NN
B_NNP
)_-RRB-
._.
In_IN
parallel_JJ
with_IN
such_JJ
differentiation_NN
,_,
HIV_NNP
transcription_NN
,_,
monitored_VBD
using_VBG
an_DT
HIV_NN
long_JJ
terminal_NN
repeat_NN
reporter_NN
gene_NN
construct_VB
,_,
is_VBZ
activated_VBN
in_IN
such_JJ
cells_NNS
under_IN
the_DT
influence_NN
of_IN
enhanced_JJ
NF-kappa_NNP
B_NNP
expression_NN
._.
Also_RB
,_,
in_IN
a_DT
promonocyte_JJ
cell_NN
line_NN
chronically_RB
infected_VBD
with_IN
HIV_NNP
,_,
NF-kappa_NNP
B_NNP
expression_NN
and_CC
HIV_NNP
transcription_NN
were_VBD
enhanced_VBN
on_IN
stimulation_NN
with_IN
phorbol_NN
ester_NN
or_CC
TNF_NNP
alpha_NN
._.
Thus_RB
,_,
stimulation_NN
of_IN
monocyte_NN
cell_NN
lines_NNS
by_IN
phorbol_NN
esters_NNS
or_CC
TNF_NNP
alpha_NN
induces_VBZ
cell_NN
differentiation_NN
and_CC
activates_NNS
HIV_NNP
transcription_NN
._.
Such_JJ
a_DT
process_NN
may_MD
have_VB
fundamental_JJ
implications_NNS
in_IN
AIDS_NNP
pathogenesis_NN
in_IN
vivo_JJ
and_CC
may_MD
be_VB
important_JJ
in_IN
disease_NN
progression_NN
induced_VBN
by_IN
opportunistic_JJ
infections_NNS
directly_RB
or_CC
indirectly_RB
involving_VBG
macrophages_NNS
._.
A_DT
nuclear_JJ
factor_NN
NF-GM2_.
that_WDT
interacts_VBZ
with_IN
a_DT
regulatory_JJ
region_NN
of_IN
the_DT
GM-CSF_NNP
gene_NN
essential_JJ
for_IN
its_PRP$
induction_NN
in_IN
responses_NNS
to_TO
T-cell_JJ
activation_NN
:_:
purification_NN
from_IN
human_JJ
T-cell_NN
leukemia_NN
line_NN
Jurkat_NNP
cells_NNS
and_CC
similarity_NN
to_TO
NF-kappa_NNP
B_NNP
._.
Activation_NN
of_IN
T_NNP
cells_NNS
by_IN
antigen_JJ
,_,
lectin_NN
,_,
or_CC
a_DT
combination_NN
of_IN
phorbol-12-myristate_NN
acetate_NN
(_-LRB-
PMA_NNP
)_-RRB-
and_CC
calcium_NN
ionophore_NN
(_-LRB-
A23187_CC
)_-RRB-
leads_VBZ
to_TO
the_DT
induction_NN
of_IN
genes_NNS
for_IN
a_DT
set_NN
of_IN
lymphokines_NNS
,_,
including_VBG
granulocyte-macrophage_JJ
colony-stimulating_JJ
factor_NN
(_-LRB-
GM-CSF_NNP
)_-RRB-
._.
We_PRP
demonstrated_VBD
in_IN
earlier_JJR
studies_NNS
that_IN
the_DT
upstream_JJ
region_NN
of_IN
the_DT
mouse_NN
GM-CSF_NNP
promoter_NN
at_IN
positions_NNS
between_IN
-95_NN
and_CC
-73_DT
is_VBZ
essential_JJ
for_IN
transcriptional_JJ
activation_NN
in_IN
response_NN
to_TO
PMA/A23187_CD
._.
This_DT
region_NN
contains_VBZ
two_CD
DNA-binding_JJ
motifs_NNS
,_,
GM2_NNP
and_CC
GC-box_NNP
._.
The_DT
GM2_JJ
sequence_NN
(_-LRB-
GGTAGTTCCC_NNP
)_-RRB-
is_VBZ
recognized_VBN
by_IN
an_DT
inducible_JJ
factor_NN
NF-GM2_:
;_:
the_DT
other_JJ
(_-LRB-
CCGCCC_NN
)_-RRB-
by_IN
constitutive_JJ
factors_NNS
A1_JJ
,_,
A2_NNP
,_,
and_CC
B_NNP
._.
To_TO
elucidate_VB
the_DT
mechanism_NN
of_IN
GM-CSF_NNP
gene_NN
activation_NN
,_,
we_PRP
have_VBP
purified_VBN
the_DT
inducible_JJ
factor_NN
NF-GM2_NN
from_IN
the_DT
nuclear_JJ
extract_VB
of_IN
stimulated_VBN
Jurkat_NNP
cells_NNS
on_IN
the_DT
basis_NN
of_IN
specific_JJ
DNA-binding_JJ
activity_NN
._.
The_DT
purified_VBN
NF-GM2_NNP
consists_VBZ
of_IN
50_CD
(_-LRB-
p50_NN
)_-RRB-
and_CC
65_CD
kDa_NNS
(_-LRB-
p65_NN
)_-RRB-
polypeptides_NNS
and_CC
has_VBZ
a_DT
binding_NN
activity_NN
specific_JJ
for_IN
both_DT
the_DT
GM-CSF_NNP
and_CC
immunoglobulin_NN
kappa_FW
(_-LRB-
GGAAAGTCCC_NN
)_-RRB-
enhancers_NNS
._.
Electrophoretically_RB
purified_VBN
p50_NN
alone_RB
can_MD
form_VB
a_DT
protein-DNA_NN
complex_NN
,_,
but_CC
in_IN
the_DT
mixture_NN
,_,
p50_VBD
associates_NNS
preferentially_RB
with_IN
p65_VBG
to_TO
form_VB
the_DT
NF-GM2_NNP
complex_NN
._.
In_IN
addition_NN
,_,
p65_PRP
gave_VBD
per_IN
se_NN
,_,
with_IN
low_JJ
affinity_NN
,_,
a_DT
protein-DNA_NN
complex_NN
that_IN
migrated_VBN
more_RBR
slowly_RB
than_IN
native_JJ
NF-GM2_NNP
complex_NN
._.
Furthermore_RB
,_,
an_DT
antiserum_NN
against_IN
KBF1_NNP
(_-LRB-
identical_JJ
to_TO
50_CD
kDa_NN
NF-kappa_NNP
B_NNP
protein_NN
)_-RRB-
reacted_VBD
with_IN
the_DT
p50_NN
of_IN
NF-GM2_NNP
,_,
indicating_VBG
that_IN
the_DT
NF-GM2_JJ
polypeptide_NN
can_MD
not_RB
be_VB
immunologically_RB
differentiated_JJ
from_IN
the_DT
50_CD
kDa_NN
subunit_NN
of_IN
NF-kappa_NNP
B_NNP
._.
The_DT
purified_VBN
NF-GM2_NNP
activated_VBN
in_IN
vitro_NN
transcription_NN
from_IN
the_DT
kappa_NN
B_NNP
enhancer_NN
,_,
while_IN
it_PRP
failed_VBD
to_TO
stimulate_VB
transcription_NN
from_IN
the_DT
GM-CSF_NNP
promoter_NN
harboring_VBG
the_DT
GM2_NNP
sequence_NN
._.
This_DT
suggests_VBZ
that_IN
the_DT
activation_NN
mechanism_NN
of_IN
the_DT
GM-CSF_NNP
gene_NN
through_IN
the_DT
GM2/GC-box_JJ
sequence_NN
is_VBZ
different_JJ
from_IN
that_DT
of_IN
genes_NNS
carrying_VBG
the_DT
kappa_NN
B_NNP
enhancer_NN
alone_RB
._.
Glucocorticoid_JJ
receptors_NNS
in_IN
normal_JJ
leukocytes_NNS
:_:
effects_NNS
of_IN
age_NN
,_,
gender_NN
,_,
season_NN
,_,
and_CC
plasma_NN
cortisol_NN
concentrations_NNS
._.
We_PRP
measured_VBD
glucocorticoid_JJ
receptors_NNS
(_-LRB-
GR_CD
)_-RRB-
in_IN
mononuclear_NN
leukocytes_NNS
(_-LRB-
MNL_NNS
)_-RRB-
isolated_VBN
from_IN
peripheral_JJ
blood_NN
of_IN
145_CD
apparently_RB
healthy_JJ
volunteers_NNS
(_-LRB-
86_CD
men_NNS
and_CC
59_CD
women_NNS
)_-RRB-
._.
An_DT
age-related_JJ
decrease_NN
in_IN
the_DT
number_NN
of_IN
GR_CD
was_VBD
suggested_VBN
between_IN
subjects_NNS
younger_JJR
than_IN
20_CD
years_NNS
and_CC
elderly_JJ
subjects_NNS
;_:
there_EX
was_VBD
no_DT
apparent_JJ
seasonal_JJ
variation_NN
in_IN
GR_CD
._.
Gender_NNP
difference_NN
in_IN
the_DT
number_NN
of_IN
GR_NNP
was_VBD
not_RB
significant_JJ
,_,
although_IN
women_NNS
showed_VBD
slightly_RB
fewer_JJR
GR_CD
._.
Eight_CD
patients_NNS
with_IN
dermatomyositis/polymyositis_NN
were_VBD
examined_VBN
to_TO
determine_VB
whether_IN
the_DT
number_NN
of_IN
GR_CD
in_IN
MNL_NNP
could_MD
be_VB
down-regulated_JJ
by_IN
their_PRP$
cognate_JJ
ligands_NNS
._.
The_DT
number_NN
of_IN
GR_CD
in_IN
MNL_NNP
from_IN
these_DT
patients_NNS
was_VBD
significantly_RB
decreased_VBN
one_CD
month_NN
after_IN
the_DT
initiation_NN
of_IN
prednisolone_JJ
therapy_NN
._.
However_RB
,_,
in_IN
normal_JJ
subjects_NNS
,_,
the_DT
GR_CD
in_IN
MNL_NNP
did_VBD
not_RB
demonstrate_VB
circadian_NN
variation_NN
,_,
in_IN
contrast_NN
to_TO
concentrations_NNS
of_IN
plasma_NN
cortisol_NN
._.
Anti-CD2_JJ
receptor_NN
antibodies_NNS
activate_VBP
the_DT
HIV_NN
long_RB
terminal_JJ
repeat_NN
in_IN
T_NNP
lymphocytes_NNS
._.
The_DT
CD2_NNP
T_NNP
lymphocyte_NN
glycoprotein_NN
surface_NN
molecule_NN
mediates_VBZ
both_DT
cell_NN
to_TO
cell_NN
adhesion_NN
and_CC
T_NNP
cell_NN
activation_NN
,_,
two_CD
processes_NNS
that_WDT
are_VBP
involved_VBN
in_IN
the_DT
spread_NN
of_IN
HIV_NNP
infection_NN
._.
Treatment_NNP
of_IN
chronically_RB
HIV-infected_JJ
PBMC_NNP
with_IN
anti-CD2_DT
mAb_NN
has_VBZ
been_VBN
shown_VBN
to_TO
induce_VB
the_DT
expression_NN
of_IN
infectious_JJ
virus_NN
from_IN
these_DT
cultures_NNS
._.
In_IN
this_DT
study_NN
we_PRP
investigated_VBD
the_DT
mechanisms_NNS
whereby_WRB
anti-CD2_JJ
antibodies_NNS
stimulate_VB
viral_JJ
production_NN
._.
We_PRP
demonstrate_VBP
that_IN
treatment_NN
of_IN
transiently_VBG
transfected_VBN
T_NNP
lymphocytes_NNS
with_IN
anti-CD2_JJ
antibodies_NNS
results_NNS
in_IN
activation_NN
of_IN
the_DT
HIV_NN
long_RB
terminal_JJ
repeat_NN
._.
Furthermore_RB
,_,
CAT_NNP
assays_VBZ
using_VBG
mutated_JJ
HIV_NN
long_JJ
terminal_NN
repeat-CAT_NN
constructs_NNS
and_CC
gel_JJ
shift_NN
assays_RB
demonstrate_VBP
that_IN
this_DT
activation_NN
is_VBZ
dependent_JJ
on_IN
the_DT
NF-kappa_NNP
B_NNP
enhancer_NN
._.
These_DT
studies_NNS
suggest_VBP
that_IN
interaction_NN
of_IN
CD2_NNP
with_IN
its_PRP$
natural_JJ
ligand_NN
,_,
LFA-3_JJ
,_,
may_MD
play_VB
a_DT
role_NN
in_IN
regulation_NN
of_IN
HIV_NNP
expression_NN
._.
Nuclear_NNP
transcription_NN
factors_NNS
that_WDT
bind_VBP
to_TO
elements_NNS
of_IN
the_DT
IL-2_NN
promoter_NN
._.
Induction_NN
requirements_NNS
in_IN
primary_JJ
human_JJ
T_NNP
cells_NNS
._.
Prior_RB
studies_NNS
have_VBP
identified_VBN
several_JJ
elements_NNS
that_WDT
contribute_VBP
to_TO
the_DT
activity_NN
of_IN
the_DT
IL-2_NN
promoter_NN
in_IN
the_DT
stimulated_VBN
T_NNP
cell_NN
line_NN
,_,
Jurkat_NNP
._.
The_DT
sites_NNS
and_CC
their_PRP$
corresponding_JJ
nuclear_JJ
binding_JJ
factors_NNS
include_VBP
:_:
NF-kappa_NNP
B_NNP
,_,
AP-1_NNP
,_,
AP-3_NNP
,_,
OCT-1_NNP
,_,
and_CC
NF-AT_NNP
._.
The_DT
latter_JJ
"_``
nuclear_JJ
factor_NN
for_IN
activated_JJ
T_NNP
cells_NNS
"_``
likely_JJ
contributes_NNS
to_TO
the_DT
tissue_NN
specificity_NN
of_IN
IL-2_DT
gene_NN
expression_NN
._.
Using_VBG
electrophoretic_JJ
mobility_NN
shift_NN
assays_VBZ
,_,
we_PRP
have_VBP
studied_VBN
these_DT
transcription_NN
factors_NNS
in_IN
primary_JJ
T_NNP
cells_NNS
from_IN
human_JJ
blood_NN
to_TO
verify_VB
their_PRP$
presence_NN
in_IN
a_DT
physiologic_NN
setting_NN
and_CC
to_TO
identify_VB
the_DT
signals_NNS
that_WDT
stimulate_VB
factor_NN
activity_NN
._.
All_DT
factors_NNS
are_VBP
induced_VBN
in_IN
the_DT
nuclei_NNS
of_IN
T_NNP
cells_NNS
upon_IN
activation_NN
with_IN
mitogens_NNS
but_CC
not_RB
with_IN
exogenous_JJ
IL-2_JJ
growth_NN
factor_NN
._.
However_RB
,_,
the_DT
signaling_NN
requirements_NNS
and_CC
sensitivity_NN
to_TO
protein_NN
synthesis_NN
inhibitors_NNS
differ_VBP
considerably_RB
._.
Only_RB
the_DT
activities_NNS
for_IN
NF-AT_NNP
and_CC
AP-1_NNP
sites_NNS
require_VBP
two_CD
signals_NNS
for_IN
optimal_JJ
induction_NN
,_,
i.e._NN
,_,
PMA_NNP
plus_CC
either_DT
lectin_NN
or_CC
antibody_NN
to_TO
the_DT
CD3_NNP
or_CC
CD28_DT
surface_NN
molecules_NNS
._.
Other_JJ
factors_NNS
are_VBP
induced_VBN
by_IN
lectin_NN
,_,
antibody_NN
,_,
and/or_CC
PMA_NNP
alone_RB
._.
After_IN
appropriate_JJ
stimulation_NN
,_,
both_DT
NF-AT_NNP
and_CC
AP-1_NNP
are_VBP
peculiarly_RB
sensitive_JJ
to_TO
the_DT
protein_NN
synthesis_NN
inhibitor_NN
anisomycin_NN
._.
Our_PRP$
data_NNS
correlate_VBP
the_DT
activity_NN
of_IN
NF-AT_NNP
and_CC
AP-1_NNP
in_IN
gel_NNP
shift_NN
assays_VBZ
with_IN
the_DT
two_CD
signals_NNS
requirements_NNS
for_IN
IL-2_DT
gene_NN
expression_NN
._.
An_DT
erythroid_VBN
specific_JJ
enhancer_VBG
upstream_RB
to_TO
the_DT
gene_NN
encoding_VBG
the_DT
cell-type_JJ
specific_JJ
transcription_NN
factor_NN
GATA-1_NN
._.
The_DT
transcription_NN
factor_NN
GATA-1_NN
is_VBZ
expressed_VBN
in_IN
a_DT
subset_NN
of_IN
hemopoietic_JJ
cells_NNS
,_,
where_WRB
it_PRP
mediates_VBZ
the_DT
cell-type_NN
specific_JJ
expression_NN
of_IN
several_JJ
genes_NNS
._.
We_PRP
have_VBP
cloned_VBN
the_DT
mouse_NN
and_CC
human_NN
GATA-1_NN
genes_NNS
._.
A_DT
region_NN
upstream_RB
to_TO
the_DT
first_JJ
exon_NN
,_,
and_CC
highly_RB
conserved_VBN
between_IN
mouse_NN
and_CC
man_NN
,_,
acts_VBZ
as_IN
an_DT
erythroid_JJ
specific_JJ
enhancer_NN
in_IN
transient_NN
assays_VBZ
,_,
if_IN
linked_VBN
to_TO
the_DT
GATA-1_NN
or_CC
to_TO
the_DT
SV40_NN
promoter_NN
._.
The_DT
activity_NN
of_IN
the_DT
enhancer_NN
is_VBZ
almost_RB
completely_RB
dependent_JJ
on_IN
the_DT
integrity_NN
of_IN
a_DT
dimeric_JJ
GATA-1_JJ
binding_NN
site_NN
._.
Demonstration_NN
of_IN
a_DT
1,25-dihydroxyvitamin_CD
D3-responsive_JJ
protein_NN
in_IN
human_JJ
lymphocytes_NNS
:_:
immunologic_NN
crossreactivity_NN
and_CC
inverse_NN
regulation_NN
with_IN
the_DT
vitamin_NN
D_NN
receptor_NN
._.
Using_VBG
Western_JJ
blot_NN
analysis_NN
with_IN
a_DT
monoclonal_JJ
antibody_NN
recognizing_VBG
a_DT
17-amino_JJ
acid_NN
epitope_NN
of_IN
the_DT
1,25-dihydroxyvitamin_CD
D3_NNS
(_-LRB-
1,25(OH)2D3_CD
)_-RRB-
receptor_NN
,_,
we_PRP
have_VBP
detected_VBN
two_CD
crossreacting_JJ
proteins_NNS
in_IN
activated_JJ
normal_JJ
human_JJ
lymphocytes_NNS
._.
The_DT
smaller_JJR
of_IN
the_DT
two_CD
proteins_NNS
(_-LRB-
50_CD
kDa_NN
)_-RRB-
was_VBD
indistinguishable_JJ
from_IN
the_DT
classical_JJ
1,25(OH)2D3_CD
receptor_NN
and_CC
,_,
similar_JJ
to_TO
the_DT
classical_JJ
1,25(OH)2D3_CD
receptor_NN
,_,
was_VBD
upregulated_VBN
in_IN
a_DT
dose-dependent_JJ
fashion_NN
by_IN
1,25(OH)2D3_CD
._.
The_DT
larger_JJR
crossreacting_JJ
protein_NN
exhibited_VBD
an_DT
electrophoretic_JJ
mobility_NN
of_IN
80_CD
kDa_NN
,_,
was_VBD
localized_VBN
in_IN
the_DT
cell_NN
cytosol_NN
,_,
and_CC
appeared_VBD
to_TO
be_VB
specific_JJ
for_IN
activated_JJ
lymphocytes_NNS
since_IN
it_PRP
was_VBD
not_RB
detected_VBN
in_IN
several_JJ
other_JJ
human_JJ
cells_NNS
including_VBG
monocytes_NNS
._.
More_RBR
strikingly_RB
,_,
the_DT
80-kDa_JJ
protein_NN
was_VBD
downregulated_JJ
in_IN
a_DT
dose-dependent_JJ
fashion_NN
by_IN
1,25(OH)2D3_CD
;_:
this_DT
effect_NN
was_VBD
independent_JJ
of_IN
the_DT
mode_NN
of_IN
lymphocyte_NN
activation_NN
and_CC
specific_JJ
for_IN
the_DT
1,25(OH)2D3_CD
metabolite_NN
of_IN
vitamin_NN
D3_NNS
._.
However_RB
,_,
two_CD
potent_JJ
immunosuppressive_JJ
agents_NNS
,_,
glucocorticoids_NNS
and_CC
cyclosporin_NN
A_DT
,_,
also_RB
inhibited_VBD
the_DT
80-kDa_JJ
protein_NN
._.
T-helper-cell_NN
determinants_NNS
in_IN
protein_NN
antigens_NNS
are_VBP
preferentially_RB
located_VBN
in_IN
cysteine-rich_JJ
antigen_JJ
segments_NNS
resistant_JJ
to_TO
proteolytic_JJ
cleavage_NN
by_IN
cathepsin_NN
B_NNP
,_,
L_NNP
,_,
and_CC
D_NNP
._.
We_PRP
report_VBP
on_IN
a_DT
computer_NN
algorithm_NN
capable_JJ
of_IN
predicting_VBG
the_DT
location_NN
of_IN
T-helper-cell_NN
epitopes_NNS
in_IN
protein_NN
antigen_NN
(_-LRB-
Ag_NNP
)_-RRB-
by_IN
analysing_VBG
the_DT
Ag_NNP
amino_IN
acid_NN
sequence_NN
._.
The_DT
algorithm_NN
was_VBD
constructed_VBN
with_IN
the_DT
aim_NN
of_IN
identifying_VBG
segments_NNS
in_IN
Ag_NNP
which_WDT
are_VBP
resistant_JJ
to_TO
proteolytic_JJ
degradation_NN
by_IN
the_DT
enzymes_NNS
cathepsin_NN
B_NNP
,_,
L_NNP
,_,
and_CC
D_NNP
._.
These_DT
are_VBP
prominent_JJ
enzymes_NNS
in_IN
the_DT
endocytic_JJ
pathway_NN
through_IN
which_WDT
soluble_JJ
protein_NN
Ag_RB
enter_VBP
APC_NNP
,_,
and_CC
resistant_JJ
segments_NNS
in_IN
Ag_NNP
may_MD
,_,
therefore_RB
,_,
be_VB
expected_VBN
to_TO
contain_VB
more_JJR
T-cell_NN
determinants_NNS
than_IN
susceptible_JJ
segments_NNS
._.
From_IN
information_NN
available_JJ
in_IN
the_DT
literature_NN
on_IN
the_DT
substrate_JJ
specificity_NN
of_IN
the_DT
three_CD
enzymes_NNS
,_,
it_PRP
is_VBZ
clear_JJ
that_IN
a_DT
cysteine_NN
is_VBZ
not_RB
accepted_VBN
in_IN
any_DT
of_IN
the_DT
S2_NNP
,_,
S1_NNP
,_,
S1'_NNP
,_,
and_CC
S2'_JJ
subsites_NNS
of_IN
cathepsin_NN
B_NNP
and_CC
L_NNP
,_,
and_CC
not_RB
in_IN
the_DT
S1_NNP
and_CC
S1'_NNP
subsites_NNS
of_IN
cathepsin_NN
D_NNP
._.
Moreover_RB
,_,
we_PRP
have_VBP
noticed_VBN
that_IN
cysteine-containing_JJ
T-cell_NN
determinants_NNS
in_IN
a_DT
number_NN
of_IN
protein_NN
Ag_NNP
are_VBP
particularly_RB
rich_JJ
in_IN
the_DT
amino_NN
acids_NNS
alanine_JJR
,_,
glycine_NN
,_,
lysine_NN
,_,
leucine_NN
,_,
serine_NN
,_,
threonine_CD
,_,
and_CC
valine_NN
._.
By_IN
searching_VBG
protein_NN
Ag_NNP
for_IN
clusters_NNS
of_IN
amino_NN
acids_NNS
containing_VBG
cysteine_NN
and_CC
two_CD
of_IN
the_DT
other_JJ
amino_NN
acids_NNS
we_PRP
were_VBD
able_JJ
to_TO
predict_VB
17_CD
out_IN
of_IN
23_CD
empirically_RB
known_VBN
T-cell_NN
determinants_NNS
in_IN
the_DT
Ag_NNP
with_IN
a_DT
relatively_RB
low_JJ
number_NN
of_IN
false_JJ
(_-LRB-
positive_JJ
)_-RRB-
predictions_NNS
._.
Furthermore_RB
,_,
we_PRP
present_VBP
a_DT
new_JJ
principle_NN
for_IN
searching_VBG
Ag_NNP
for_IN
potential_JJ
amphipatic_JJ
alpha-helical_JJ
protein_NN
segments_NNS
._.
Such_JJ
segments_NNS
accord_VBP
well_RB
with_IN
empirically_RB
known_VBN
T-cell_NN
determinants_NNS
and_CC
our_PRP$
algorithm_NN
produces_VBZ
a_DT
lower_JJR
number_NN
of_IN
false_JJ
positive_JJ
predictions_NNS
than_IN
the_DT
principle_NN
based_VBN
on_IN
discrete_JJ
Fourier_NNP
transformations_NNS
previously_RB
described_VBN
._.
A_DT
human_JJ
putative_NN
lymphocyte_NN
G0/G1_IN
switch_NN
gene_NN
containing_VBG
a_DT
CpG-rich_JJ
island_NN
encodes_VBZ
a_DT
small_JJ
basic_JJ
protein_NN
with_IN
the_DT
potential_JJ
to_TO
be_VB
phosphorylated_VBN
._.
Genes_NNP
actively_RB
involved_VBD
in_IN
the_DT
G0/G1_JJ
switch_NN
(_-LRB-
G0S_JJ
genes_NNS
)_-RRB-
may_MD
be_VB
differentially_RB
expressed_VBN
during_IN
the_DT
lectin-induced_JJ
switch_NN
of_IN
lymphocytes_NNS
from_IN
the_DT
G0_NNP
to_TO
the_DT
G1_NNP
phases_NNS
of_IN
the_DT
cell_NN
cycle_NN
._.
This_DT
paper_NN
presents_VBZ
studies_NNS
of_IN
G0S2_NNP
,_,
a_DT
member_NN
of_IN
a_DT
set_NN
of_IN
putative_JJ
G0S_NNP
genes_NNS
,_,
for_IN
which_WDT
cDNAs_NNS
were_VBD
cloned_VBN
and_CC
selected_VBN
on_IN
the_DT
basis_NN
of_IN
differential_JJ
cDNA_NN
hybridization_NN
._.
G0S2_IN
mRNA_NN
increases_NNS
transiently_RB
within_IN
1-2_JJ
hr_NN
of_IN
the_DT
addition_NN
of_IN
lectin_NN
or_CC
cycloheximide_NN
to_TO
cultured_JJ
blood_NN
mononuclear_NN
cells_NNS
._.
Comparison_NNP
of_IN
a_DT
nearly_RB
full-length_JJ
cDNA_NN
sequence_NN
with_IN
the_DT
corresponding_JJ
genomic_JJ
sequence_NN
reveals_VBZ
one_CD
small_JJ
intron_NN
and_CC
an_DT
open_JJ
reading_NN
frame_NN
in_IN
the_DT
second_JJ
exon_NN
._.
The_DT
derived_VBD
103-amino-acid_JJ
basic_JJ
protein_NN
has_VBZ
two_CD
potential_JJ
alpha-helical_JJ
domains_NNS
separated_VBN
by_IN
a_DT
hydrophobic_JJ
region_NN
with_IN
the_DT
potential_JJ
to_TO
generate_VB
turns_NNS
and_CC
assume_VB
a_DT
beta-sheet_NN
conformation_NN
._.
Consistent_NNP
with_IN
involvement_NN
in_IN
the_DT
G0/G1_NNP
switch_NN
,_,
the_DT
protein_NN
contains_VBZ
potential_JJ
sites_NNS
for_IN
phosphorylation_NN
by_IN
protein_NN
kinase_NN
C_NNP
and_CC
casein_NN
kinase_NN
II_NNP
._.
The_DT
gene_NN
contains_VBZ
a_DT
CpG-rich_JJ
island_NN
suggesting_VBG
expression_NN
in_IN
the_DT
germ_NN
line_NN
._.
An_DT
upstream_JJ
segment_NN
contains_VBZ
tandem_NN
dinucleotide_NN
repeats_VBZ
(CT)19/(CA)16_CD
._.
There_EX
is_VBZ
a_DT
suitably_RB
located_VBN
TATA_NNP
box_NN
,_,
but_CC
potential_JJ
sites_NNS
for_IN
CCAAT-box_JJ
binding_JJ
factors_NNS
are_VBP
far_RB
upstream_RB
,_,
embedded_VBN
in_IN
a_DT
42-nucleotide_JJ
repeat_NN
element_NN
._.
Potential_JJ
sites_NNS
for_IN
transcription_NN
factors_NNS
AP1_NNP
,_,
AP2_NNP
,_,
and_CC
AP3_NNP
are_VBP
consistent_JJ
with_IN
rapid_JJ
transcriptional_JJ
activation_NN
in_IN
response_NN
to_TO
inducing_VBG
agents_NNS
._.
Synergism_NNP
between_IN
two_CD
distinct_JJ
elements_NNS
of_IN
the_DT
HTLV-I_JJ
enhancer_NN
during_IN
activation_NN
by_IN
the_DT
trans-activator_NN
of_IN
HTLV-I_NNP
._.
We_PRP
have_VBP
conducted_VBN
functional_JJ
studies_NNS
of_IN
the_DT
enhancer_NN
elements_NNS
of_IN
human_NN
T-cell_NN
leukemia_NN
virus_NN
type_NN
I_PRP
(_-LRB-
HTLV-I_JJ
)_-RRB-
using_VBG
the_DT
human_JJ
T-cell_NN
lines_NNS
Jurkat_NNP
and_CC
MOLT_NNP
4_CD
,_,
which_WDT
are_VBP
negative_JJ
for_IN
HTLV-I_NNP
,_,
and_CC
MT-2_NNP
and_CC
TL-Mor_NNP
,_,
which_WDT
carry_VBP
the_DT
proviral_JJ
genome_NN
of_IN
HTLV-I_NNP
._.
Two_CD
distinct_JJ
elements_NNS
have_VBP
been_VBN
implicated_VBN
in_IN
function_NN
of_IN
the_DT
HTLV-I_JJ
enhancer_NN
._.
One_CD
is_VBZ
the_DT
21-base-pair_JJ
(_-LRB-
bp_NN
)_-RRB-
core_NN
element_NN
that_WDT
is_VBZ
responsible_JJ
for_IN
trans-activation_NN
by_IN
the_DT
HTLV-I_JJ
trans-activator_NN
p40tax_NN
and_CC
that_DT
has_VBZ
the_DT
ability_NN
to_TO
bind_NN
to_TO
cyclic-AMP_JJ
responsive_JJ
element_NN
binding_NN
factor_NN
(_-LRB-
CREB_NNP
)_-RRB-
-like_JJ
factor_NN
(_-LRB-
s_PRP
)_-RRB-
._.
The_DT
other_JJ
is_VBZ
a_DT
region_NN
interposed_VBN
between_IN
the_DT
21-bp_JJ
elements_NNS
._.
In_IN
this_DT
study_NN
we_PRP
demonstrate_VBP
that_IN
a_DT
subfragment_NN
(_-LRB-
C26_NNP
)_-RRB-
in_IN
the_DT
region_NN
between_IN
the_DT
21-bp_JJ
elements_NNS
is_VBZ
involved_VBN
in_IN
trans-activation_NN
by_IN
p40tax_NN
,_,
possibly_RB
through_IN
binding_NN
to_TO
an_DT
NF-kappa_NNP
B-like_JJ
nuclear_JJ
factor_NN
or_CC
factors_NNS
._.
Formation_NN
of_IN
the_DT
protein-DNA_NN
complex_NN
with_IN
the_DT
C26_NNP
subfragment_NN
was_VBD
positively_RB
affected_VBN
by_IN
p40tax_NN
._.
The_DT
C26_NNP
element_NN
conferred_VBD
partial_JJ
responsiveness_NN
to_TO
p40tax_VB
when_WRB
linked_VBN
to_TO
one_CD
copy_NN
of_IN
the_DT
21-bp_JJ
element_NN
that_IN
,_,
by_IN
itself_PRP
,_,
showed_VBD
little_JJ
activation_NN
in_IN
response_NN
to_TO
p40tax_NN
._.
However_RB
,_,
the_DT
C26_NNP
element_NN
alone_RB
,_,
even_RB
when_WRB
repeated_VBN
,_,
could_MD
not_RB
be_VB
activated_VBN
by_IN
p40tax_NN
,_,
unlike_IN
other_JJ
NF-kappa_NNP
B-binding_NNP
elements_NNS
._.
In_IN
contrast_NN
,_,
the_DT
C26_NNP
element_NN
itself_PRP
was_VBD
profoundly_RB
activated_VBN
upon_IN
stimulation_NN
with_IN
12-O-tetradecanoylphorbol-13-acetate_JJ
._.
These_DT
findings_NNS
therefore_RB
suggest_VBP
that_IN
the_DT
HTLV-I_JJ
enhancer_NN
contains_VBZ
multiple_JJ
functional_JJ
elements_NNS
,_,
including_VBG
binding_JJ
sites_NNS
for_IN
at_IN
least_JJS
CREB-_NNP
and_CC
NF-kappa_NNP
B-like_NNP
factors_NNS
,_,
which_WDT
synergistically_RB
cooperate_VBP
in_IN
activation_NN
of_IN
the_DT
HTLV-I_JJ
enhancer_NN
in_IN
response_NN
to_TO
p40tax_NN
._.
Our_PRP$
results_NNS
also_RB
demonstrate_VBP
that_IN
TPA-dependent_NNP
activation_NN
of_IN
the_DT
HTLV-I_JJ
enhancer_NN
may_MD
be_VB
mediated_VBN
through_IN
the_DT
C26_NNP
element_NN
._.
v-erbA_JJ
overexpression_NN
is_VBZ
required_VBN
to_TO
extinguish_VB
c-erbA_JJ
function_NN
in_IN
erythroid_JJ
cell_NN
differentiation_NN
and_CC
regulation_NN
of_IN
the_DT
erbA_NN
target_NN
gene_NN
CAII_NNP
._.
The_DT
v-erbA_JJ
oncoprotein_NN
represents_VBZ
a_DT
retrovirus-transduced_JJ
oncogenic_JJ
version_NN
of_IN
the_DT
thyroid_NN
hormone_NN
(_-LRB-
T3/T4_DT
)_-RRB-
receptor_NN
c-erbA_NNS
(_-LRB-
type_NN
alpha_NN
)_-RRB-
._.
It_PRP
contributes_VBZ
to_TO
virus-induced_JJ
erythroleukemia_NN
by_IN
efficiently_RB
arresting_VBG
differentiation_NN
of_IN
red_JJ
cell_NN
progenitors_NNS
and_CC
by_IN
suppressing_VBG
transcription_NN
of_IN
erythrocyte-specific_JJ
genes_NNS
._.
Here_RB
,_,
we_PRP
show_VBP
that_IN
v-erbA_JJ
and_CC
c-erbA_JJ
bind_NN
directly_RB
to_TO
sequences_NNS
within_IN
the_DT
promoter_NN
of_IN
the_DT
erythrocyte-specific_JJ
carbonic_JJ
anhydrase_NN
II_NNP
(_-LRB-
CAII_NN
)_-RRB-
,_,
a_DT
gene_NN
whose_WP$
transcription_NN
is_VBZ
efficiently_RB
suppressed_VBN
by_IN
v-erbA_NN
._.
This_DT
erbA-binding_JJ
site_NN
confers_VBZ
thyroid_DT
hormone_NN
responsiveness_NN
to_TO
a_DT
heterologous_JJ
promoter_NN
in_IN
transient_JJ
expression_NN
experiments_NNS
and_CC
is_VBZ
a_DT
target_NN
for_IN
efficient_JJ
down-regulation_NN
of_IN
CAII_NNP
transcription_NN
by_IN
the_DT
v-erbA_JJ
oncoprotein_NNP
._.
In_IN
stably_RB
transformed_VBN
erythroblasts_NNS
coexpressing_VBG
the_DT
v-erbA_JJ
oncoprotein_NN
and_CC
the_DT
c-erbA/T3_JJ
receptor_NN
at_IN
an_DT
approximately_RB
equimolar_JJ
ratio_NN
,_,
c-erbA_JJ
activity_NN
is_VBZ
dominant_JJ
over_IN
v-erbA_NN
._.
T3_DT
efficiently_RB
induced_VBN
erythroid_JJ
differentiation_NN
in_IN
these_DT
cells_NNS
,_,
thus_RB
overcoming_VBG
the_DT
v-erbA-mediated_JJ
differentiation_NN
arrest_NN
._.
Likewise_RB
,_,
T3_DT
activated_VBN
CAII_NNP
transcription_NN
as_RB
well_RB
as_IN
transient_JJ
expression_NN
of_IN
a_DT
T3-responsive_JJ
reporter_NN
gene_NN
containing_VBG
the_DT
CAII-specific_JJ
erbA-binding_JJ
site_NN
._.
The_DT
c-erbA-dependent_JJ
activation_NN
of_IN
this_DT
CAII_JJ
reporter_NN
construct_VB
could_MD
only_RB
be_VB
suppressed_VBN
by_IN
very_RB
high_JJ
amounts_NNS
of_IN
v-erbA_NN
._.
Our_PRP$
results_NNS
suggest_VBP
that_IN
overexpression_NN
of_IN
v-erbA_NN
is_VBZ
required_VBN
for_IN
its_PRP$
function_NN
as_IN
an_DT
oncoprotein_NN
._.
Inhibition_NN
of_IN
phorbol_NN
ester-induced_VBN
monocytic_JJ
differentiation_NN
by_IN
dexamethasone_NN
is_VBZ
associated_VBN
with_IN
down-regulation_NN
of_IN
c-fos_JJ
and_CC
c-jun_JJ
(_-LRB-
AP-1_NN
)_-RRB-
._.
Previous_JJ
studies_NNS
have_VBP
shown_VBN
that_IN
treatment_NN
of_IN
human_JJ
myeloid_JJ
leukemia_NN
cells_NNS
with_IN
12-O-tetradecanoylphorbol-13-acetate_JJ
(_-LRB-
TPA_NNP
)_-RRB-
is_VBZ
associated_VBN
with_IN
induction_NN
of_IN
monocytic_JJ
differentiation_NN
and_CC
expression_NN
of_IN
the_DT
c-jun_JJ
and_CC
c-fos_JJ
early_JJ
response_NN
genes_NNS
._.
The_DT
present_JJ
work_NN
demonstrates_VBZ
that_IN
the_DT
glucocorticoid_JJ
dexamethasone_NN
inhibits_VBZ
TPA-induced_JJ
increases_NNS
in_IN
c-jun_JJ
and_CC
c-fos_JJ
mRNA_NN
levels_NNS
in_IN
U-937_DT
leukemia_NN
cells_NNS
._.
These_DT
findings_NNS
were_VBD
associated_VBN
with_IN
a_DT
block_NN
in_IN
appearance_NN
of_IN
the_DT
monocytic_JJ
phenotype_NN
,_,
including_VBG
inhibition_NN
of_IN
TPA-induced_JJ
increases_NNS
in_IN
lamin_NN
A_DT
,_,
lamin_NN
C_NNP
,_,
and_CC
vimentin_NN
transcripts_NNS
._.
Other_JJ
studies_NNS
have_VBP
demonstrated_VBN
that_IN
TPA-induced_JJ
monocytic_JJ
differentiation_NN
and_CC
expression_NN
of_IN
the_DT
c-jun_NN
and_CC
c-fos_JJ
genes_NNS
in_IN
myeloid_JJ
leukemia_NN
cells_NNS
are_VBP
regulated_VBN
by_IN
protein_NN
kinase_NN
C_NNP
(_-LRB-
PKC_NNP
)_-RRB-
._.
The_DT
finding_NN
that_IN
dexamethasone_NN
has_VBZ
no_DT
effect_NN
on_IN
TPA-induced_NNP
activation_NN
of_IN
PKC_NNP
suggests_VBZ
that_IN
this_DT
glucocorticoid_JJ
inhibits_NNS
signals_NNS
downstream_RB
or_CC
parallel_VB
to_TO
this_DT
enzyme_NN
._.
Nuclear_NNP
run-on_NN
assays_RB
demonstrate_VBP
that_IN
:_:
(_-LRB-
1_CD
)_-RRB-
induction_NN
of_IN
c-jun_JJ
and_CC
c-fos_JJ
expression_NN
by_IN
TPA_NNP
is_VBZ
regulated_VBN
by_IN
transcriptional_JJ
mechanisms_NNS
,_,
(_-LRB-
2_CD
)_-RRB-
TPA-induced_DT
expression_NN
of_IN
c-jun_JJ
and_CC
c-fos_JJ
does_VBZ
not_RB
require_VB
protein_NN
synthesis_NN
,_,
and_CC
(_-LRB-
3_CD
)_-RRB-
TPA-induced_JJ
expression_NN
of_IN
both_DT
genes_NNS
is_VBZ
inhibited_VBN
at_IN
the_DT
transcriptional_JJ
level_NN
by_IN
dexamethasone_NN
._.
To_TO
further_RBR
define_VB
the_DT
effects_NNS
of_IN
dexamethasone_NN
at_IN
the_DT
molecular_JJ
level_NN
,_,
we_PRP
prepared_VBD
a_DT
series_NN
of_IN
deleted_VBN
c-jun_NN
promoter_NN
fragments_NNS
linked_VBN
to_TO
the_DT
chloramphenicol_NN
acetyltransferase_NN
(_-LRB-
CAT_NN
)_-RRB-
gene_NN
._.
Increases_NNS
in_IN
CAT_NN
activity_NN
during_IN
transient_JJ
expression_NN
of_IN
these_DT
constructs_NNS
in_IN
TPA-treated_JJ
U-937_JJ
cells_NNS
could_MD
be_VB
assigned_VBN
to_TO
the_DT
region_NN
(_-LRB-
-97_NN
to_TO
-20_DT
)_-RRB-
of_IN
the_DT
promoter_NN
that_WDT
contains_VBZ
the_DT
AP-1_NN
binding_NN
site_NN
._.
This_DT
induction_NN
of_IN
CAT_NN
activity_NN
was_VBD
sensitive_JJ
to_TO
dexamethasone_NN
._.
These_DT
findings_NNS
suggest_VBP
that_IN
dexamethasone_NN
down-regulates_NNS
TPA-induced_JJ
transcription_NN
of_IN
the_DT
c-jun_JJ
gene_NN
during_IN
monocytic_JJ
differentiation_NN
by_IN
inhibiting_VBG
activation_NN
of_IN
the_DT
AP-1_NNP
site_NN
._.
Charybdotoxin-sensitive_JJ
,_,
Ca(2+)-dependent_JJ
membrane_NN
potential_JJ
changes_NNS
are_VBP
not_RB
involved_VBN
in_IN
human_JJ
T_NNP
or_CC
B_NNP
cell_NN
activation_NN
and_CC
proliferation_NN
._.
The_DT
involvement_NN
of_IN
ion_NN
channels_NNS
in_IN
B_NNP
and_CC
T_NNP
lymphocyte_NN
activation_NN
is_VBZ
supported_VBN
by_IN
many_JJ
reports_NNS
of_IN
changes_NNS
in_IN
ion_NN
fluxes_NNS
and_CC
membrane_NN
potential_NN
after_IN
mitogen_NN
binding_NN
._.
Human_NNP
T_NNP
and_CC
B_NNP
lymphocytes_NNS
demonstrate_VBP
an_DT
early_JJ
and_CC
transient_JJ
hyperpolarization_NN
after_IN
ligand_NN
binding_NN
._.
Inasmuch_RB
as_IN
the_DT
change_NN
in_IN
membrane_NN
potential_NN
is_VBZ
dependent_JJ
on_IN
elevation_NN
of_IN
free_JJ
cytosolic_JJ
calcium_NN
,_,
the_DT
hyperpolarization_NN
is_VBZ
presumably_RB
through_IN
opening_NN
of_IN
Ca(2+)-stimulated_JJ
K+_NNP
channels_NNS
._.
We_PRP
have_VBP
used_VBN
charybdotoxin_NN
,_,
a_DT
known_VBN
inhibitor_NN
of_IN
Ca(2+)-dependent_JJ
K+_NNP
channels_NNS
,_,
to_TO
study_VB
the_DT
role_NN
of_IN
these_DT
channels_NNS
in_IN
lymphocyte_NN
activation_NN
and_CC
mitogenesis_NN
._.
We_PRP
demonstrate_VBP
that_IN
charybdotoxin_NN
inhibits_VBZ
the_DT
ligand-induced_JJ
transient_NN
membrane_NN
hyperpolarization_NN
in_IN
B_NNP
and_CC
T_NNP
cells_NNS
in_IN
a_DT
dose-dependent_JJ
fashion_NN
,_,
without_IN
affecting_VBG
changes_NNS
in_IN
cytosolic_JJ
Ca2+_NNP
._.
However_RB
,_,
blockade_NN
of_IN
the_DT
Ca(2+)-activated_JJ
K+_NNP
channel_NN
is_VBZ
not_RB
associated_VBN
with_IN
changes_NNS
in_IN
cell-cycle_NN
gene_NN
activation_NN
,_,
IL-2_JJ
production_NN
,_,
IL-2R_JJ
expression_NN
or_CC
B_NNP
and_CC
T_NNP
cell_NN
mitogenesis_NN
._.
These_DT
results_NNS
imply_VBP
that_IN
membrane_NN
potential_JJ
changes_NNS
secondary_JJ
to_TO
the_DT
ligand-dependent_JJ
opening_NN
of_IN
Ca(2+)-activated_JJ
K+_NNP
channels_NNS
are_VBP
not_RB
involved_VBN
in_IN
B_NNP
and_CC
T_NNP
lymphocyte_NN
activation_NN
and_CC
mitogenesis_NN
._.
Evaluation_NN
of_IN
the_DT
role_NN
of_IN
ligand_NN
and_CC
thermal_JJ
activation_NN
of_IN
specific_JJ
DNA_NN
binding_NN
by_IN
in_IN
vitro_NN
synthesized_VBN
human_JJ
glucocorticoid_NN
receptor_NN
._.
We_PRP
have_VBP
used_VBN
a_DT
DNA-binding/immunoprecipitation_NN
assay_NN
to_TO
analyze_VB
the_DT
capacity_NN
of_IN
human_JJ
glucocorticoid_NN
receptor_NN
(_-LRB-
hGR_NN
)_-RRB-
,_,
generated_VBD
in_IN
rabbit_NN
reticulocyte_NN
lysates_NNS
,_,
to_TO
bind_NN
DNA_NN
._.
In_IN
vitro_NN
translated_VBN
hGR_NN
was_VBD
indistinguishable_JJ
from_IN
native_JJ
hGR_NN
,_,
as_IN
determined_VBN
by_IN
migration_NN
on_IN
sodium_NN
dodecyl_NN
sulfate-polyacrylamide_JJ
gels_NNS
,_,
sedimentation_NN
on_IN
sucrose_NN
density_NN
gradients_NNS
,_,
and_CC
reactivity_NN
with_IN
antipeptide_JJ
antibodies_NNS
generated_VBD
against_IN
hGR_NN
._.
In_IN
addition_NN
,_,
cell-free_JJ
synthesized_JJ
hGR_NN
was_VBD
capable_JJ
of_IN
specific_JJ
binding_NN
to_TO
glucocorticoid_VB
response_NN
element_NN
(_-LRB-
GRE_NNP
)_-RRB-
-containing_JJ
DNA_NN
fragments_NNS
._.
Using_VBG
this_DT
assay_NN
system_NN
,_,
we_PRP
have_VBP
evaluated_VBN
the_DT
contributions_NNS
of_IN
ligand_NN
binding_NN
and_CC
heat_NN
activation_NN
to_TO
DNA_NNP
binding_NN
by_IN
these_DT
glucocorticoid_JJ
receptors_NNS
._.
In_IN
vitro_NN
translated_VBN
hGR_NN
was_VBD
capable_JJ
of_IN
selective_JJ
DNA_NN
binding_NN
even_RB
in_IN
the_DT
absence_NN
of_IN
glucocorticoid_NN
._.
Treatment_NNP
with_IN
dexamethasone_NN
or_CC
the_DT
antiglucocorticoid_JJ
RU486_NNP
had_VBD
no_DT
additional_JJ
effect_NN
on_IN
the_DT
DNA-binding_JJ
capacity_NN
when_WRB
receptor_NN
preparations_NNS
were_VBD
maintained_VBN
at_IN
0_CD
C_NNP
(_-LRB-
no_NN
activation_NN
)_-RRB-
._.
In_IN
contrast_NN
,_,
addition_NN
of_IN
either_DT
ligand_NN
or_CC
antagonist_NN
in_IN
combination_NN
with_IN
a_DT
heat_NN
activation_NN
step_NN
promoted_VBN
DNA_NNP
binding_NN
by_IN
approximately_RB
3-fold_JJ
over_IN
that_DT
of_IN
heat-activated_JJ
unliganded_JJ
receptors_NNS
._.
Agonist_NNP
(_-LRB-
dexamethasone_NN
)_-RRB-
was_VBD
slightly_RB
more_RBR
effective_JJ
in_IN
supporting_VBG
specific_JJ
DNA_NN
binding_NN
than_IN
antagonist_NN
(_-LRB-
RU486_NNP
)_-RRB-
._.
DNA_NN
binding_NN
by_IN
in_IN
vitro_NN
synthesized_VBN
GR_CD
was_VBD
blocked_VBN
by_IN
the_DT
addition_NN
of_IN
sodium_NN
molybdate_NN
to_TO
the_DT
receptor_NN
preparations_NNS
before_IN
steroid_NN
addition_NN
and_CC
thermal_JJ
activation_NN
._.
Addition_NN
of_IN
KCl_NN
resulted_VBD
in_IN
less_JJR
DNA_NN
binding_NN
either_CC
due_JJ
to_TO
blockage_NN
of_IN
DNA-receptor_NN
complex_NN
formation_NN
or_CC
disruption_NN
of_IN
the_DT
complexes_NNS
._.
The_DT
specificity_NN
of_IN
DNA_NNP
binding_NN
by_IN
cell-free_JJ
synthesized_JJ
hGR_NN
was_VBD
analyzed_VBN
further_RB
by_IN
examining_VBG
the_DT
abilities_NNS
of_IN
various_JJ
DNAs_NNP
to_TO
compete_VB
for_IN
binding_NN
to_TO
a_DT
naturally_RB
occurring_VBG
GRE_NNP
found_VBD
in_IN
the_DT
mouse_NN
mammary_NN
tumor_NN
virus-long_JJ
terminal_NN
repeat_NN
._.
Oligonucleotides_NNS
containing_VBG
the_DT
consensus_NN
GRE_NNP
were_VBD
the_DT
most_RBS
efficient_JJ
competitors_NNS
,_,
and_CC
fragments_NNS
containing_VBG
regulatory_JJ
sequences_NNS
from_IN
glucocorticoid-repressible_JJ
genes_NNS
were_VBD
somewhat_RB
competitive_JJ
,_,
whereas_IN
single_JJ
stranded_VBN
oligonucleotides_NNS
were_VBD
unable_JJ
to_TO
compete_VB
for_IN
mouse_NN
mammary_NN
tumor_NN
virus-long_JJ
terminal_JJ
repeat_NN
DNA_NNP
binding_NN
,_,
except_IN
when_WRB
competitor_NN
was_VBD
present_JJ
at_IN
extremely_RB
high_JJ
concentrations_NNS
._.
Together_RB
these_DT
studies_NNS
indicate_VBP
that_IN
hGR_NN
synthesized_VBN
in_IN
rabbit_NN
reticulocyte_NN
lysates_VBZ
displays_NNS
many_JJ
of_IN
the_DT
same_JJ
properties_NNS
,_,
including_VBG
GRE-specific_JJ
DNA_NNP
binding_NN
,_,
observed_VBD
for_IN
glucocorticoid_NN
receptor_NN
present_NN
in_IN
cytosolic_JJ
extracts_NNS
of_IN
mammalian_JJ
cells_NNS
and_CC
tissues_NNS
._.
Similarities_NNS
between_IN
the_DT
effects_NNS
of_IN
dexamethasone_NN
and_CC
RU486_NNP
suggest_VBP
that_IN
the_DT
antiglucocorticoid_JJ
properties_NNS
of_IN
RU486_NNP
do_VBP
not_RB
occur_VB
at_IN
the_DT
level_NN
of_IN
specific_JJ
DNA_NNP
binding_NN
._.
One_CD
base_NN
pair_NN
change_NN
abolishes_VBZ
the_DT
T_NNP
cell-restricted_JJ
activity_NN
of_IN
a_DT
kB-like_JJ
proto-enhancer_NN
element_NN
from_IN
the_DT
interleukin_NN
2_CD
promoter_NN
._.
The_DT
inducible_JJ
,_,
T_NNP
cell-specific_JJ
enhancers_NNS
of_IN
murine_NN
and_CC
human_JJ
Interleukin_NN
2_CD
(_-LRB-
Il-2_NN
)_-RRB-
genes_NNS
contain_VBP
the_DT
kB-like_JJ
sequence_NN
GGGATTTCACC_NNP
as_IN
an_DT
essential_JJ
cis-acting_NN
enhancer_NN
motif_NN
._.
When_WRB
cloned_VBN
in_IN
multiple_JJ
copies_NNS
this_DT
so-called_JJ
TCEd_NNP
(_-LRB-
distal_NN
T_NNP
cell_NN
element_NN
)_-RRB-
acts_VBZ
as_IN
an_DT
inducible_JJ
proto-enhancer_NN
element_NN
in_IN
E14_NNP
T_NNP
lymphoma_NN
cells_NNS
,_,
but_CC
not_RB
in_IN
HeLa_NNP
cells_NNS
._.
In_IN
extracts_NNS
of_IN
induced_JJ
,_,
Il-2_JJ
secreting_NN
El4_.
cells_NNS
three_CD
individual_JJ
protein_NN
factors_NNS
bind_VBP
to_TO
TCEd_NNP
DNA_NNP
._.
The_DT
binding_NN
of_IN
the_DT
most_RBS
prominent_JJ
factor_NN
,_,
named_VBN
TCF-1_NN
(_-LRB-
T_NNP
cell_NN
factor_NN
1_CD
)_-RRB-
,_,
is_VBZ
correlated_VBN
with_IN
the_DT
proto-enhancer_NN
activity_NN
of_IN
TCEd_NNP
._.
TCF-1_NNP
consists_VBZ
of_IN
two_CD
polypeptides_NNS
of_IN
about_IN
50_CD
kD_NN
and_CC
105_CD
kD_NN
;_:
the_DT
former_JJ
seems_VBZ
to_TO
be_VB
related_VBN
to_TO
the_DT
50_CD
kD_NN
polypeptide_NN
of_IN
NF-kB_NNP
._.
Purified_VBN
NF-kB_NNP
is_VBZ
also_RB
able_JJ
to_TO
bind_NN
to_TO
the_DT
TCEd_NNP
,_,
but_CC
TCF-1_JJ
binds_NNS
stronger_JJR
than_IN
NF-kB_NNP
to_TO
TCEd_NNP
DNA_NNP
._.
The_DT
conversion_NN
of_IN
the_DT
TCEd_NNP
to_TO
a_DT
'_''
perfect_JJ
'_''
NF-kB_NNP
binding_JJ
site_NN
leads_VBZ
to_TO
a_DT
tighter_JJR
binding_NN
of_IN
NF-kB_NNP
to_TO
TCEd_NNP
DNA_NNP
and_CC
,_,
as_IN
a_DT
functional_JJ
consequence_NN
,_,
to_TO
the_DT
activity_NN
of_IN
the_DT
'_''
converted_VBD
'_''
TCEd_RB
motifs_NNS
in_IN
HeLa_NNP
cells_NNS
._.
Thus_RB
,_,
the_DT
substitution_NN
of_IN
the_DT
underlined_JJ
A_DT
residue_NN
to_TO
a_DT
C_NNP
within_IN
the_DT
GGGATTTCACC_NNP
motif_NN
abolishes_VBZ
its_PRP$
T_NNP
cell-restricted_JJ
activity_NN
and_CC
leads_VBZ
to_TO
its_PRP$
functioning_NN
in_IN
both_DT
El4_NNP
cells_NNS
and_CC
HeLa_NNP
cells_NNS
._.
These_DT
results_NNS
indicate_VBP
that_IN
lymphocyte-specific_JJ
factors_NNS
binding_JJ
to_TO
the_DT
TCEd_NNP
are_VBP
involved_VBN
in_IN
the_DT
control_NN
of_IN
T_NNP
cell_NN
specific-transcription_NN
of_IN
the_DT
Il-2_NNP
gene_NN
._.
Negative_JJ
regulation_NN
of_IN
human_JJ
immunodeficiency_NN
virus_NN
type_NN
1_CD
expression_NN
in_IN
monocytes_NNS
:_:
role_NN
of_IN
the_DT
65-kDa_JJ
plus_CC
50-kDa_JJ
NF-kappa_NNP
B_NNP
dimer_NN
._.
Although_IN
monocytic_JJ
cells_NNS
can_MD
provide_VB
a_DT
reservoir_NN
for_IN
viral_JJ
production_NN
in_IN
vivo_NN
,_,
their_PRP$
regulation_NN
of_IN
human_JJ
immunodeficiency_NN
virus_NN
type_NN
1_CD
(_-LRB-
HIV-1_NN
)_-RRB-
transcription_NN
can_MD
be_VB
either_DT
latent_JJ
,_,
restricted_VBN
,_,
or_CC
productive_JJ
._.
These_DT
differences_NNS
in_IN
gene_NN
expression_NN
have_VBP
not_RB
been_VBN
molecularly_RB
defined_VBN
._.
In_IN
THP-1_JJ
cells_NNS
with_IN
restricted_JJ
HIV_NNP
expression_NN
,_,
there_EX
is_VBZ
an_DT
absence_NN
of_IN
DNA-protein_NNP
binding_NN
complex_NN
formation_NN
with_IN
the_DT
HIV-1_NNP
promoter-enhancer_NN
associated_VBN
with_IN
markedly_RB
less_JJR
viral_JJ
RNA_NN
production_NN
._.
This_DT
absence_NN
of_IN
binding_NN
was_VBD
localized_VBN
to_TO
the_DT
NF-kappa_NNP
B_NNP
region_NN
of_IN
the_DT
HIV-1_NN
enhancer_NN
;_:
the_DT
65-kDa_JJ
plus_CC
50-kDa_JJ
NF-kappa_NNP
B_NNP
heterodimer_NN
was_VBD
preferentially_RB
lost_VBN
._.
Adding_VBG
purified_VBN
NF-kappa_NNP
B_NNP
protein_NN
to_TO
nuclear_JJ
extracts_NNS
from_IN
cells_NNS
with_IN
restricted_JJ
expression_NN
overcomes_RB
this_DT
lack_NN
of_IN
binding_NN
._.
In_IN
addition_NN
,_,
treatment_NN
of_IN
these_DT
nuclear_JJ
extracts_NNS
with_IN
sodium_NN
deoxycholate_NN
restored_VBD
their_PRP$
ability_NN
to_TO
form_VB
the_DT
heterodimer_NN
,_,
suggesting_VBG
the_DT
presence_NN
of_IN
an_DT
inhibitor_NN
of_IN
NF-kappa_NNP
B_NNP
activity_NN
._.
Furthermore_RB
,_,
treatment_NN
of_IN
nuclear_JJ
extracts_NNS
from_IN
these_DT
cells_NNS
that_WDT
had_VBD
restricted_VBN
expression_NN
with_IN
lipopolysaccharide_NN
increased_VBN
viral_JJ
production_NN
and_CC
NF-kappa_NNP
B_NNP
activity_NN
._.
Antiserum_NNP
specific_JJ
for_IN
NF-kappa_NNP
B_NNP
binding_JJ
proteins_NNS
,_,
but_CC
not_RB
c-rel-specific_JJ
antiserum_NN
,_,
disrupted_VBD
heterodimer_RP
complex_JJ
formation_NN
._.
Thus_RB
,_,
both_DT
NF-kappa_NNP
B-binding_NNP
complexes_NNS
are_VBP
needed_VBN
for_IN
optimal_JJ
viral_JJ
transcription_NN
._.
Binding_NNP
of_IN
the_DT
65-kDa_JJ
plus_CC
50-kDa_JJ
heterodimer_NN
to_TO
the_DT
HIV-1_NN
enhancer_NN
can_MD
be_VB
negatively_RB
regulated_VBN
in_IN
monocytes_NNS
,_,
providing_VBG
one_CD
mechanism_NN
restricting_VBG
HIV-1_JJ
gene_NN
expression_NN
._.
Isolation_NNP
of_IN
a_DT
candidate_NN
repressor/activator_NN
,_,
NF-E1_NNP
(_-LRB-
YY-1_NN
,_,
delta_NN
)_-RRB-
,_,
that_WDT
binds_VBZ
to_TO
the_DT
immunoglobulin_NN
kappa_NN
3'_IN
enhancer_NN
and_CC
the_DT
immunoglobulin_NN
heavy-chain_NN
mu_NN
E1_NNP
site_NN
._.
We_PRP
have_VBP
determined_VBN
that_IN
the_DT
developmental_JJ
control_NN
of_IN
immunoglobulin_NN
kappa_NN
3'_JJ
enhancer_NN
(_-LRB-
kappa_NN
E3'_JJ
)_-RRB-
activity_NN
is_VBZ
the_DT
result_NN
of_IN
the_DT
combined_JJ
influence_NN
of_IN
positive-_NNS
and_CC
negative-acting_JJ
elements_NNS
._.
We_PRP
show_VBP
that_IN
a_DT
central_JJ
core_NN
in_IN
the_DT
kappa_NN
E3'_JJ
enhancer_NN
is_VBZ
active_JJ
at_IN
the_DT
pre-B-cell_JJ
stage_NN
but_CC
is_VBZ
repressed_VBN
by_IN
flanking_VBG
negative-acting_JJ
elements_NNS
._.
The_DT
negative-acting_JJ
sequences_NNS
repress_VBG
enhancer_NN
activity_NN
in_IN
a_DT
position-_NNS
and_CC
orientation-independent_JJ
manner_NN
at_IN
the_DT
pre-B-cell_JJ
stage_NN
._.
We_PRP
have_VBP
isolated_VBN
a_DT
human_JJ
cDNA_NN
clone_NN
encoding_VBG
a_DT
zinc_NN
finger_NN
protein_NN
(_-LRB-
NF-E1_JJ
)_-RRB-
that_IN
binds_NNS
to_TO
the_DT
negative-acting_JJ
segment_NN
of_IN
the_DT
kappa_NN
E3'_JJ
enhancer_NN
._.
This_DT
protein_NN
also_RB
binds_VBZ
to_TO
the_DT
immunoglobulin_NN
heavy-chain_NN
enhancer_NN
mu_NN
E1_NNP
site_NN
._.
NF-E1_NNP
is_VBZ
encoded_VBN
by_IN
the_DT
same_JJ
gene_NN
as_IN
the_DT
YY-1_JJ
protein_NN
,_,
which_WDT
binds_VBZ
to_TO
the_DT
adeno-associated_JJ
virus_NN
P5_DT
promoter_NN
._.
NF-E1_NNP
is_VBZ
also_RB
the_DT
human_JJ
homologue_NN
of_IN
the_DT
mouse_NN
delta_JJ
protein_NN
,_,
which_WDT
binds_VBZ
to_TO
ribosomal_JJ
protein_NN
gene_NN
promoters_NNS
._.
The_DT
predicted_VBD
amino_IN
acid_JJ
sequence_NN
of_IN
this_DT
protein_NN
contains_VBZ
features_NNS
characteristic_NN
of_IN
transcriptional_JJ
activators_NNS
as_RB
well_RB
as_IN
transcriptional_JJ
repressors_NNS
._.
Cotransfection_NNP
studies_NNS
with_IN
this_DT
cDNA_NN
indicate_VBP
that_IN
it_PRP
can_MD
repress_VB
basal_JJ
promoter_NN
activity_NN
._.
The_DT
apparent_JJ
dual_JJ
function_NN
of_IN
this_DT
protein_NN
is_VBZ
discussed_VBN
._.
Clone_NNP
pAT_NN
133_CD
identifies_VBZ
a_DT
gene_NN
that_WDT
encodes_VBZ
another_DT
human_JJ
member_NN
of_IN
a_DT
class_NN
of_IN
growth_NN
factor-induced_JJ
genes_NNS
with_IN
almost_RB
identical_JJ
zinc-finger_NN
domains_NNS
._.
We_PRP
report_VBP
the_DT
structure_NN
and_CC
regulation_NN
of_IN
a_DT
gene_NN
represented_VBN
by_IN
clone_NN
pAT_NN
133_CD
,_,
which_WDT
is_VBZ
induced_VBN
upon_IN
transition_NN
from_IN
a_DT
resting_VBG
state_NN
(_-LRB-
G0_NN
)_-RRB-
through_IN
the_DT
early_JJ
phase_NN
of_IN
the_DT
cell_NN
cycle_NN
(_-LRB-
G1_IN
)_-RRB-
._.
The_DT
pAT_NN
133_CD
gene_NN
is_VBZ
immediately_RB
induced_VBN
,_,
with_IN
FOS-like_JJ
kinetics_NNS
,_,
in_IN
human_JJ
T_NNP
cells_NNS
and_CC
in_IN
fibroblasts_NNS
._.
Primary_JJ
structure_NN
analysis_NN
showed_VBN
that_IN
the_DT
encoded_JJ
protein_NN
contains_VBZ
three_CD
tandem_NN
zinc-finger_NN
sequences_NNS
of_IN
the_DT
type_NN
Cys2-Xaa12-His2_NN
._.
This_DT
zinc-finger_JJ
region_NN
,_,
which_WDT
is_VBZ
thought_VBN
to_TO
bind_NN
DNA_NN
in_IN
a_DT
sequence-specific_JJ
manner_NN
,_,
is_VBZ
similar_JJ
(_-LRB-
greater_JJR
than_IN
80_CD
%_NN
on_IN
the_DT
amino_JJ
acid_NN
level_NN
)_-RRB-
to_TO
two_CD
previously_RB
described_VBN
transcription_NN
factors_NNS
pAT_JJ
225/EGR1_CD
and_CC
pAT_JJ
591/EGR2_NNS
._.
Except_IN
for_IN
the_DT
conserved_JJ
zinc-finger_NN
domains_NNS
,_,
the_DT
amino_JJ
acid_NN
sequences_NNS
of_IN
the_DT
three_CD
proteins_NNS
are_VBP
distinct_JJ
._.
This_DT
structural_JJ
similarity_NN
suggests_VBZ
that_IN
the_DT
pAT_NN
133_CD
gene_NN
encodes_VBZ
a_DT
transcription_NN
factor_NN
with_IN
a_DT
specific_JJ
biological_JJ
function_NN
._.
Comparing_VBG
the_DT
regulation_NN
of_IN
these_DT
related_VBN
zinc-finger-encoding_NN
genes_NNS
showed_VBD
coordinate_VB
induction_NN
upon_IN
mitogenic_JJ
stimulation_NN
of_IN
resting_VBG
T_NNP
lymphocytes_NNS
and_CC
of_IN
resting_VBG
fibroblasts_NNS
._.
However_RB
,_,
upon_IN
transition_NN
from_IN
a_DT
proliferating_NN
(_-LRB-
G1_NNP
)_-RRB-
to_TO
a_DT
resting_VBG
state_NN
of_IN
the_DT
cell_NN
cycle_NN
the_DT
three_CD
genes_NNS
were_VBD
differently_RB
regulated_VBN
._.
In_IN
human_JJ
histiocytic_NN
U937_IN
cells_NNS
mRNA_NNS
of_IN
clone_NN
pAT_NN
133_CD
was_VBD
constitutively_RB
expressed_VBN
,_,
whereas_IN
mRNA_NN
of_IN
pAT_NN
225/EGR1_CD
was_VBD
induced_VBN
upon_IN
induction_NN
of_IN
terminal_NN
differentiation_NN
._.
In_IN
contrast_NN
mRNA_NNS
representing_VBG
pAT_JJ
591/EGR2_NNS
was_VBD
not_RB
expressed_VBN
in_IN
these_DT
cells_NNS
._.
This_DT
difference_NN
in_IN
gene_NN
regulation_NN
suggests_VBZ
distinct_JJ
biological_JJ
roles_NNS
in_IN
the_DT
control_NN
of_IN
cell_NN
proliferation_NN
for_IN
the_DT
respective_JJ
proteins_NNS
._.
cAMP-dependent_JJ
regulation_NN
of_IN
proenkephalin_NN
by_IN
JunD_NNP
and_CC
JunB_NNP
:_:
positive_JJ
and_CC
negative_JJ
effects_NNS
of_IN
AP-1_JJ
proteins_NNS
._.
We_PRP
demonstrate_VBP
that_IN
JunD_NNP
,_,
a_DT
component_NN
of_IN
the_DT
AP-1_JJ
transcription_NN
factor_NN
complex_NN
,_,
activates_NNS
transcription_NN
of_IN
the_DT
human_JJ
proenkephalin_NN
gene_NN
in_IN
a_DT
fashion_NN
that_WDT
is_VBZ
completely_RB
dependent_JJ
upon_IN
the_DT
cAMP-dependent_JJ
protein_NN
kinase_NN
,_,
protein_NN
kinase_NN
A_DT
._.
Activation_NN
of_IN
proenkephalin_NN
transcription_NN
by_IN
JunD_NNP
is_VBZ
dependent_JJ
upon_IN
a_DT
previously_RB
characterized_VBN
cAMP-_NNS
,_,
phorbol_NN
ester-_NNS
,_,
and_CC
Ca(2+)-inducible_JJ
enhancer_NN
,_,
and_CC
JunD_NNP
is_VBZ
shown_VBN
to_TO
bind_NN
the_DT
enhancer_NN
as_IN
a_DT
homodimer_NN
._.
Another_DT
component_NN
of_IN
the_DT
AP-1_JJ
transcription_NN
complex_NN
,_,
JunB_NNP
,_,
is_VBZ
shown_VBN
to_TO
inhibit_VB
activation_NN
mediated_VBN
by_IN
JunD_NNP
._.
As_IN
a_DT
homodimer_NN
JunB_NNP
is_VBZ
unable_JJ
to_TO
bind_NN
the_DT
enhancer_NN
;_:
however_RB
in_IN
the_DT
presence_NN
of_IN
c-Fos_JJ
,_,
high-affinity_JJ
binding_NN
is_VBZ
observed_VBN
._.
Furthermore_RB
,_,
JunD_NNP
is_VBZ
shown_VBN
to_TO
activate_VB
transcription_NN
of_IN
genes_NNS
linked_VBN
to_TO
both_DT
cAMP_JJ
and_CC
phorbol_JJ
ester_NN
response_NN
elements_NNS
in_IN
a_DT
protein_NN
kinase_NN
A-dependent_JJ
fashion_NN
,_,
further_JJ
blurring_VBG
the_DT
distinction_NN
between_IN
these_DT
response_NN
elements_NNS
._.
These_DT
results_NNS
demonstrate_VBP
that_IN
the_DT
transcriptional_JJ
activity_NN
of_IN
an_DT
AP-1-related_JJ
protein_NN
is_VBZ
regulated_VBN
by_IN
the_DT
cAMP-dependent_JJ
second-messenger_NN
pathway_NN
and_CC
suggest_VB
that_IN
JunD_NNP
and_CC
other_JJ
AP-1-related_JJ
proteins_NNS
may_MD
play_VB
an_DT
important_JJ
role_NN
in_IN
the_DT
regulation_NN
of_IN
gene_NN
expression_NN
by_IN
cAMP-dependent_JJ
intracellular_JJ
signaling_NN
pathways_NNS
._.
Glucocorticoid_JJ
resistance_NN
in_IN
chronic_JJ
asthma_NN
._.
Glucocorticoid_NNP
pharmacokinetics_NNS
,_,
glucocorticoid_NN
receptor_NN
characteristics_NNS
,_,
and_CC
inhibition_NN
of_IN
peripheral_JJ
blood_NN
T_NNP
cell_NN
proliferation_NN
by_IN
glucocorticoids_NNS
in_IN
vitro_NN
._.
A_DT
total_NN
of_IN
37_CD
chronic_NN
,_,
severe_JJ
,_,
nonsmoking_JJ
asthmatic_JJ
patients_NNS
with_IN
documented_VBN
reversible_JJ
airways_NNS
obstruction_NN
were_VBD
classified_VBN
as_IN
glucocorticoid-sensitive_JJ
or_CC
-resistant_JJ
on_IN
the_DT
basis_NN
of_IN
changes_NNS
in_IN
FEV1_NNP
,_,
FVC_NNP
,_,
and_CC
peak_NN
expiratory_NN
flow_NN
(_-LRB-
PEF_NN
)_-RRB-
after_IN
oral_JJ
prednisolone_NN
._.
The_DT
resistant_JJ
patients_NNS
showed_VBD
no_DT
significant_JJ
improvements_NNS
in_IN
airflow_NN
limitation_NN
._.
Phytohemagglutinin_FW
(_-LRB-
PHA_NN
)_-RRB-
-induced_JJ
proliferation_NN
of_IN
peripheral_JJ
blood_NN
T_NNP
lymphocytes_VBZ
from_IN
the_DT
sensitive_JJ
but_CC
not_RB
the_DT
resistant_JJ
asthmatic_JJ
patients_NNS
was_VBD
significantly_RB
(_-LRB-
p_NN
less_JJR
than_IN
0.01_CD
)_-RRB-
inhibited_VBN
by_IN
dexamethasone_NN
(_-LRB-
10(-7)_JJ
mol/L_NN
)_-RRB-
,_,
reflecting_VBG
a_DT
shift_NN
of_IN
the_DT
dose-response_NN
curve_NN
._.
When_WRB
all_DT
the_DT
asthmatic_JJ
patients_NNS
were_VBD
analyzed_VBN
together_RB
,_,
there_EX
was_VBD
a_DT
significant_JJ
correlation_NN
between_IN
the_DT
degree_NN
of_IN
sensitivity_NN
of_IN
T_NNP
cells_NNS
to_TO
dexamethasone_VB
and_CC
the_DT
clinical_JJ
responsiveness_NN
to_TO
prednisolone_NN
(_-LRB-
p_NN
less_JJR
than_IN
0.01_CD
)_-RRB-
._.
No_DT
differences_NNS
were_VBD
observed_VBN
between_IN
six_CD
of_IN
the_DT
sensitive_JJ
and_CC
resistant_JJ
patients_NNS
in_IN
the_DT
clearance_NN
of_IN
plasma_NN
prednisolone_NN
derived_VBN
from_IN
orally_RB
administered_VBN
prednisone_NN
._.
Peripheral_JJ
blood_NN
mononuclear_NN
cell_NN
glucocorticoid_NN
receptors_NNS
were_VBD
also_RB
characterized_VBN
in_IN
five_CD
sensitive_JJ
and_CC
seven_CD
resistant_JJ
patients_NNS
._.
The_DT
numbers_NNS
and_CC
binding_JJ
affinities_NNS
of_IN
these_DT
receptors_NNS
could_MD
not_RB
account_VB
for_IN
the_DT
observed_JJ
difference_NN
in_IN
the_DT
susceptibility_NN
of_IN
these_DT
cells_NNS
to_TO
functional_JJ
inhibition_NN
by_IN
dexamethasone_NN
in_IN
vitro_NN
._.
These_DT
results_NNS
suggest_VBP
that_IN
clinical_JJ
glucocorticoid_JJ
resistance_NN
in_IN
chronic_JJ
asthma_NN
does_VBZ
not_RB
reflect_VB
abnormal_JJ
glucocorticoid_JJ
clearance_NN
but_CC
may_MD
be_VB
due_JJ
at_IN
least_JJS
partly_RB
to_TO
a_DT
relative_JJ
insensitivity_NN
of_IN
T_NNP
lymphocytes_NNS
to_TO
glucocorticoids_NNS
._.
This_DT
lack_NN
of_IN
sensitivity_NN
is_VBZ
unexplained_JJ
but_CC
is_VBZ
not_RB
attributable_JJ
to_TO
abnormalities_NNS
of_IN
cellular_JJ
glucocorticoid_JJ
receptors_NNS
._.
Regulation_NN
of_IN
interleukin-1_JJ
beta_JJ
production_NN
by_IN
glucocorticoids_NNS
in_IN
human_JJ
monocytes_NNS
:_:
the_DT
mechanism_NN
of_IN
action_NN
depends_VBZ
on_IN
the_DT
activation_NN
signal_NN
._.
Glucocorticoids_NNS
are_VBP
known_VBN
to_TO
downregulate_JJ
interleukin-1_JJ
beta_JJ
production_NN
in_IN
monocytic_JJ
cells_NNS
by_IN
two_CD
different_JJ
mechanims_NNS
:_:
direct_JJ
inhibition_NN
of_IN
the_DT
gene_NN
transcription_NN
and_CC
destabilization_NN
of_IN
the_DT
preformed_JJ
interleukin-1_NN
beta_NN
mRNA_NN
._.
Now_RB
we_PRP
have_VBP
examined_VBN
the_DT
effect_NN
of_IN
the_DT
nature_NN
of_IN
the_DT
monocyte_NN
activating_VBG
signal_NN
on_IN
these_DT
two_CD
inhibitory_JJ
mechanims_NNS
._.
When_WRB
human_JJ
monocytes_NNS
were_VBD
preincubated_VBN
with_IN
dexamethasone_NN
for_IN
1_CD
hour_NN
and_CC
then_RB
stimulated_VBD
either_CC
with_IN
bacterial_JJ
lipopolysaccharide_NN
or_CC
phorbol_NN
myristate_NN
,_,
it_PRP
was_VBD
found_VBN
that_IN
dexamethasone_NN
inhibited_VBD
the_DT
lipopolysaccharide-induced_JJ
interleukin-1_NN
beta_JJ
protein_NN
production_NN
,_,
but_CC
the_DT
phorbol_NN
myristate-induced_JJ
production_NN
was_VBD
increased_VBN
3-10_CD
fold_NN
._.
This_DT
difference_NN
was_VBD
also_RB
seen_VBN
at_IN
the_DT
mRNA_NN
level_NN
._.
When_WRB
dexamethasone_NN
was_VBD
added_VBN
to_TO
the_DT
cultures_NNS
3_CD
hours_NNS
after_IN
the_DT
stimulators_NNS
,_,
it_PRP
clearly_RB
decreased_VBD
the_DT
interleukin-1_NN
beta_NN
mRNA_NN
levels_NNS
regardless_RB
of_IN
the_DT
stimulator_NN
used_VBN
(_-LRB-
although_IN
the_DT
effect_NN
was_VBD
clearly_RB
weaker_JJR
on_IN
the_DT
PMA-induced_JJ
mRNA_NN
)_-RRB-
._.
Thus_RB
these_DT
data_NNS
suggest_VBP
that_IN
the_DT
phorbol_NN
myristate-induced_JJ
signal_NN
(_-LRB-
prolonged_JJ
protein_NN
kinase_NN
C_NNP
activation_NN
?_.
)_-RRB-
can_MD
not_RB
be_VB
inhibited_VBN
by_IN
prior_JJ
incubation_NN
with_IN
dexamethasone_NN
and_CC
it_PRP
also_RB
protects_VBZ
the_DT
induced_JJ
mRNA_NN
for_IN
the_DT
degradative_JJ
action_NN
of_IN
dexamethasone_NN
._.
Identification_NN
of_IN
transcriptional_JJ
suppressor_NN
proteins_NNS
that_WDT
bind_VBP
to_TO
the_DT
negative_JJ
regulatory_JJ
element_NN
of_IN
the_DT
human_JJ
immunodeficiency_NN
virus_NN
type_NN
1_CD
._.
Two_CD
different_JJ
proteins_NNS
which_WDT
independently_RB
bound_VBD
to_TO
neighboring_JJ
sequences_NNS
within_IN
the_DT
negative_JJ
regulatory_JJ
element_NN
(_-LRB-
NRE_NNP
)_-RRB-
of_IN
human_JJ
immunodeficiency_NN
virus_NN
type_NN
1_CD
(_-LRB-
HIV-1_NN
)_-RRB-
were_VBD
detected_VBN
in_IN
the_DT
nuclear_JJ
extract_VB
of_IN
a_DT
virus-infected_JJ
human_JJ
T_NNP
cell_NN
line_NN
._.
One_CD
of_IN
the_DT
factors_NNS
bound_VBD
to_TO
a_DT
novel_NN
dyad_NN
symmetrical_JJ
sequence_NN
._.
This_DT
sequence_NN
is_VBZ
well_RB
conserved_VBN
in_IN
various_JJ
HIV-1_NN
isolates_NNS
and_CC
partial_JJ
homology_NN
was_VBD
found_VBN
with_IN
the_DT
promoter_NN
region_NN
of_IN
the_DT
human_JJ
retinoblastoma_NN
gene_NN
._.
Similar_JJ
DNA_NNP
binding_NN
activity_NN
was_VBD
detected_VBN
in_IN
a_DT
variety_NN
of_IN
virus-uninfected_JJ
human_JJ
T_NNP
cell_NN
lines_NNS
and_CC
HeLa_NNP
cells_NNS
by_IN
means_NNS
of_IN
a_DT
gel_NN
mobility_NN
shift_NN
assay_NN
._.
The_DT
other_JJ
factor_NN
bound_VBN
to_TO
a_DT
putative_JJ
AP-1_NN
recognition_NN
sequence_NN
predicted_VBD
for_IN
the_DT
HIV-1_NN
NRE_RB
._.
However_RB
,_,
this_DT
factor_NN
did_VBD
not_RB
bind_NN
to_TO
a_DT
typical_JJ
AP-1_JJ
site_NN
._.
The_DT
insertion_NN
of_IN
multiple_JJ
copies_NNS
of_IN
the_DT
binding_JJ
site_NN
for_IN
the_DT
former_JJ
or_CC
latter_JJ
factor_NN
into_IN
a_DT
heterologous_JJ
promoter_NN
reduced_VBD
the_DT
promoter_NN
activity_NN
to_TO
one-tenth_JJ
or_CC
one-third_JJ
,_,
respectively_RB
._.
Thus_RB
,_,
each_DT
factor_NN
may_MD
function_VB
as_IN
a_DT
novel_NN
negative_JJ
regulator_NN
of_IN
transcription_NN
._.
Constitutive_JJ
activation_NN
of_IN
NF-kB_NNP
in_IN
human_JJ
thymocytes_NNS
._.
NF-kB_NNP
is_VBZ
a_DT
eukaryotic_JJ
transcription_NN
regulatory_JJ
factor_NN
._.
In_IN
T_NNP
cells_NNS
and_CC
T_NNP
cell_NN
lines_NNS
,_,
NF-kB_NNP
is_VBZ
bound_VBN
to_TO
a_DT
cytoplasmic_JJ
proteic_NN
inhibitor_NN
,_,
the_DT
IkB_NNP
._.
Treatment_NNP
of_IN
T_NNP
cells_NNS
with_IN
mitogens_NNS
(_-LRB-
phorbol_NN
esters_NNS
)_-RRB-
or_CC
cytokines_NNS
(_-LRB-
TNF_NN
alpha_NN
)_-RRB-
induces_VBZ
NF-kB_JJ
nuclear_JJ
translocation_NN
and_CC
the_DT
subsequent_JJ
expression_NN
of_IN
NF-kB_NNP
dependent_JJ
T_NNP
cell_NN
genes_NNS
._.
Here_RB
we_PRP
examined_VBD
the_DT
activation_NN
of_IN
NF-kB_NNP
in_IN
human_JJ
T_NNP
cell_NN
thymic_IN
progenitors_NNS
._.
We_PRP
report_VBP
differences_NNS
in_IN
(Ca2+)i_JJ
requirement_NN
for_IN
NF-kB_NNP
activation_NN
in_IN
thymocytes_NNS
as_IN
compared_VBN
to_TO
mature_VB
T_NNP
cells_NNS
._.
Furthermore_RB
,_,
our_PRP$
results_NNS
indicated_VBD
that_IN
thymocytes_NNS
have_VBP
a_DT
constitutively_RB
active_JJ
form_NN
of_IN
NF-kB_NNP
,_,
suggesting_VBG
that_IN
they_PRP
are_VBP
activated_VBN
in_IN
vivo_NN
._.
The_DT
role_NN
of_IN
jun_NN
and_CC
fos_NNS
gene_NN
family_NN
members_NNS
in_IN
12-O-tetradecanoylphorbol-13-acetate_JJ
induced_JJ
hemopoietic_JJ
differentiation_NN
._.
Terminal_JJ
differentiation_NN
of_IN
the_DT
leukemic_JJ
cell_NN
lines_NNS
U-937_.
and_CC
HL-60_JJ
by_IN
12-O-tetradecanoylphorbol-13-acetate_DT
is_VBZ
accompanied_VBN
by_IN
marked_JJ
changes_NNS
in_IN
gene_NN
expression_NN
._.
In_IN
this_DT
study_NN
,_,
we_PRP
demonstrate_VBP
that_IN
the_DT
expression_NN
of_IN
jun_NN
and_CC
fos_NNS
gene_NN
family_NN
members_NNS
is_VBZ
induced_VBN
with_IN
variable_JJ
kinetics_NNS
during_IN
12-O-tetradecanoylphorbol-13-acetate_JJ
induced_JJ
differentiation_NN
,_,
with_IN
c-jun_JJ
expression_NN
best_RB
paralleling_JJ
differentiation_NN
._.
The_DT
generation_NN
of_IN
AP-1_JJ
complexes_NNS
,_,
as_IN
measured_VBN
by_IN
DNA_NNP
binding_NN
activity_NN
,_,
closely_RB
parallels_NNS
morphological_JJ
differentiation_NN
._.
Furthermore_RB
,_,
the_DT
ability_NN
of_IN
these_DT
complexes_NNS
to_TO
regulate_VB
gene_NN
expression_NN
is_VBZ
demonstrated_VBN
by_IN
increased_JJ
transcription_NN
from_IN
an_DT
AP-1_NNP
driven_JJ
reporter_NN
construct_VB
and_CC
marked_VBN
increases_NNS
in_IN
the_DT
expression_NN
of_IN
endogenous_JJ
AP-1_NN
regulated_VBN
genes_NNS
._.
Differentiation_NNP
assays_VBZ
using_VBG
water_NN
soluble_JJ
phorbol_NN
esters_NNS
reveal_VBP
that_IN
differentiation_NN
becomes_VBZ
irreversible_JJ
soon_RB
after_IN
AP-1_NNP
appears_VBZ
._.
This_DT
tight_JJ
correlation_NN
between_IN
c-jun_JJ
expression_NN
,_,
the_DT
generation_NN
of_IN
AP-1_JJ
activity_NN
,_,
and_CC
differentiation_NN
suggests_VBZ
a_DT
critical_JJ
role_NN
for_IN
this_DT
gene_NN
and_CC
transcriptional_JJ
complex_NN
during_IN
this_DT
process_NN
._.
TCF-1_NN
,_,
a_DT
T_NNP
cell-specific_JJ
transcription_NN
factor_NN
of_IN
the_DT
HMG_NNP
box_NN
family_NN
,_,
interacts_VBZ
with_IN
sequence_NN
motifs_NNS
in_IN
the_DT
TCR_NNP
beta_NN
and_CC
TCR_NNP
delta_NN
enhancers_NNS
._.
We_PRP
have_VBP
recently_RB
identified_VBN
and_CC
cloned_VBN
TCF-1_NN
,_,
a_DT
T_NNP
cell-specific_JJ
transcription_NN
factor_NN
with_IN
specificity_NN
for_IN
the_DT
AACAAAG_NNP
motif_NN
in_IN
the_DT
CD3_NNP
epsilon_NN
enhancer_NN
and_CC
for_IN
the_DT
TTCAAAG_NNP
motif_NN
in_IN
the_DT
TCR_NNP
alpha_NN
enhancer_NN
._.
TCF-1_NN
belongs_VBZ
to_TO
the_DT
family_NN
of_IN
transcription-regulating_JJ
proteins_NNS
which_WDT
share_VBP
a_DT
region_NN
of_IN
homology_NN
termed_VBD
the_DT
HMG-box_NN
._.
Here_RB
,_,
we_PRP
show_VBP
by_IN
gel_NNP
retardation_NN
analysis_NN
that_IN
TCF-1_NN
specifically_RB
recognizes_VBZ
the_DT
T_NNP
beta_NN
5_CD
element_NN
of_IN
the_DT
TCR_NNP
beta_NN
enhancer_NN
and_CC
the_DT
T_NNP
delta_NN
7_CD
element_NN
of_IN
the_DT
TCR_NNP
delta_NN
enhancer_NN
._.
Comparison_NN
of_IN
the_DT
sequences_NNS
of_IN
all_DT
elements_NNS
recognized_VBN
by_IN
TCF-1_NNP
defines_NNS
a_DT
consensus_NN
motif_NN
A/T_NNP
A/T_NNP
C_NNP
A_DT
A/G_NNP
A_NNP
G_NNP
._.
These_DT
observations_NNS
imply_VBP
that_IN
TCF-1_NNP
is_VBZ
involved_VBN
in_IN
the_DT
control_NN
of_IN
several_JJ
T_NNP
cell-specific_JJ
genes_NNS
and_CC
might_MD
thus_RB
play_VB
an_DT
important_JJ
role_NN
in_IN
the_DT
establishment_NN
and_CC
maintenance_NN
of_IN
the_DT
mature_JJ
T_NNP
cell_NN
phenotype_NN
._.
The_DT
cellular_JJ
oncogene_NN
c-myb_NN
can_MD
interact_VB
synergistically_RB
with_IN
the_DT
Epstein-Barr_NNP
virus_NN
BZLF1_CC
transactivator_NN
in_IN
lymphoid_JJ
cells_NNS
._.
Regulation_NN
of_IN
replicative_JJ
functions_NNS
in_IN
the_DT
Epstein-Barr_NNP
virus_NN
(_-LRB-
EBV_NN
)_-RRB-
genome_NN
is_VBZ
mediated_VBN
through_IN
activation_NN
of_IN
a_DT
virally_RB
encoded_VBN
transcription_NN
factor_NN
,_,
Z_NN
(_-LRB-
BZLF1_CC
)_-RRB-
._.
We_PRP
have_VBP
shown_VBN
that_IN
the_DT
Z_NNP
gene_NN
product_NN
,_,
which_WDT
binds_VBZ
to_TO
AP-1_VB
sites_NNS
as_IN
a_DT
homodimer_NN
and_CC
has_VBZ
sequence_NN
similarity_NN
to_TO
c-Fos_NNS
,_,
can_MD
efficiently_RB
activate_VB
the_DT
EBV_NN
early_RB
promoter_NN
,_,
BMRF1_NNP
,_,
in_IN
certain_JJ
cell_NN
types_NNS
(_-LRB-
i.e._NN
,_,
HeLa_NNP
cells_NNS
)_-RRB-
but_CC
not_RB
others_NNS
(_-LRB-
i.e._NN
,_,
Jurkat_NNP
cells_NNS
)_-RRB-
._.
Here_RB
we_PRP
demonstrate_VBP
that_IN
the_DT
c-myb_JJ
proto-oncogene_NN
product_NN
,_,
which_WDT
is_VBZ
itself_PRP
a_DT
DNA-binding_JJ
protein_NN
and_CC
transcriptional_JJ
transactivator_NN
,_,
can_MD
interact_VB
synergistically_RB
with_IN
Z_NN
in_IN
activating_VBG
the_DT
BMRF1_NNP
promoter_NN
in_IN
Jurkat_NNP
cells_NNS
(_-LRB-
a_DT
T-cell_JJ
line_NN
)_-RRB-
or_CC
Raji_NNP
cells_NNS
(_-LRB-
an_DT
EBV-positive_JJ
B-cell_NN
)_-RRB-
,_,
whereas_IN
the_DT
c-myb_JJ
gene_NN
product_NN
by_IN
itself_PRP
has_VBZ
little_JJ
effect_NN
._.
The_DT
simian_JJ
virus_NN
40_CD
early_JJ
promoter_NN
is_VBZ
also_RB
synergistically_RB
activated_VBN
by_IN
the_DT
Z/c-myb_JJ
combination_NN
._.
Synergistic_JJ
transactivation_NN
of_IN
the_DT
BMRF1_NNP
promoter_NN
by_IN
the_DT
Z/c-myb_JJ
combination_NN
appears_VBZ
to_TO
involve_VB
direct_JJ
binding_NN
by_IN
the_DT
Z_NN
protein_NN
but_CC
not_RB
the_DT
c-myb_JJ
protein_NN
._.
A_DT
30-bp_JJ
sequence_NN
in_IN
the_DT
BMRF1_NNP
promoter_NN
which_WDT
contains_VBZ
a_DT
Z_NN
binding_NN
site_NN
(_-LRB-
a_DT
consensus_NN
AP-1_NN
site_NN
)_-RRB-
is_VBZ
sufficient_JJ
to_TO
transfer_VB
high-level_JJ
lymphoid-specific_JJ
responsiveness_NN
to_TO
the_DT
Z/c-myb_JJ
combination_NN
to_TO
a_DT
heterologous_JJ
promoter_NN
._.
That_IN
the_DT
c-myb_JJ
oncogene_NN
product_NN
can_MD
interact_VB
synergistically_RB
with_IN
an_DT
EBV-encoded_JJ
member_NN
of_IN
the_DT
leucine_NN
zipper_NN
protein_NN
family_NN
suggests_VBZ
c-myb_NN
is_VBZ
likely_JJ
to_TO
engage_VB
in_IN
similar_JJ
interactions_NNS
with_IN
cellularly_JJ
encoded_JJ
transcription_NN
factors_NNS
._.
The_DT
29-kDa_JJ
proteins_NNS
phosphorylated_VBN
in_IN
thrombin-activated_DT
human_JJ
platelets_NNS
are_VBP
forms_NNS
of_IN
the_DT
estrogen_NN
receptor-related_JJ
27-kDa_JJ
heat_NN
shock_NN
protein_NN
._.
Thrombin_NNP
plays_VBZ
a_DT
critical_JJ
role_NN
in_IN
platelet_NN
activation_NN
,_,
hemostasis_NN
,_,
and_CC
thrombosis_NN
._.
Cellular_NNP
activation_NN
by_IN
thrombin_DT
leads_NNS
to_TO
the_DT
phosphorylation_NN
of_IN
multiple_JJ
proteins_NNS
,_,
most_JJS
of_IN
which_WDT
are_VBP
unidentified_JJ
._.
We_PRP
have_VBP
characterized_VBN
several_JJ
29-kDa_JJ
proteins_NNS
that_WDT
are_VBP
rapidly_RB
phosphorylated_VBN
following_VBG
exposure_NN
of_IN
intact_JJ
human_JJ
platelets_NNS
to_TO
thrombin_VB
._.
A_DT
murine_NN
monoclonal_JJ
antibody_NN
raised_VBD
to_TO
an_DT
unidentified_JJ
estrogen_NN
receptor-related_JJ
29-kDa_JJ
protein_NN
selectively_RB
recognized_VBD
these_DT
proteins_NNS
as_RB
well_RB
as_IN
a_DT
more_JJR
basic_JJ
,_,
unphosphorylated_JJ
27-kDa_JJ
protein_NN
._.
Cellular_NNP
activation_NN
by_IN
thrombin_DT
led_VBN
to_TO
a_DT
marked_JJ
shift_NN
in_IN
the_DT
proportion_NN
of_IN
protein_NN
from_IN
the_DT
27-kDa_JJ
unphosphorylated_JJ
form_NN
to_TO
the_DT
29-kDa_JJ
phosphoprotein_NN
species_NNS
._.
Using_VBG
this_DT
antibody_NN
,_,
we_PRP
isolated_VBD
and_CC
sequenced_VBD
a_DT
human_JJ
cDNA_NN
clone_NN
encoding_VBG
a_DT
protein_NN
that_WDT
was_VBD
identical_JJ
to_TO
the_DT
mammalian_JJ
27-kDa_JJ
heat_NN
shock_NN
protein_NN
(_-LRB-
HSP27_NN
)_-RRB-
,_,
a_DT
protein_NN
of_IN
uncertain_JJ
function_NN
that_WDT
is_VBZ
known_VBN
to_TO
be_VB
phosphorylated_VBN
to_TO
several_JJ
forms_NNS
and_CC
to_TO
be_VB
transcriptionally_RB
induced_VBN
by_IN
estrogen_NN
._.
The_DT
29-kDa_JJ
proteins_NNS
were_VBD
confirmed_VBN
to_TO
be_VB
phosphorylated_JJ
forms_NNS
of_IN
HSP27_NN
by_IN
immunoprecipitation_NN
studies_NNS
._.
Thus_RB
,_,
the_DT
"_``
estrogen_NN
receptor-related_JJ
protein_NN
"_''
is_VBZ
HSP27_CD
,_,
and_CC
the_DT
three_CD
major_JJ
29-kDa_JJ
proteins_NNS
phosphorylated_VBN
in_IN
thrombin-activated_DT
platelets_NNS
are_VBP
forms_NNS
of_IN
HSP27_NN
._.
These_DT
data_NNS
suggest_VBP
a_DT
role_NN
for_IN
HSP27_NN
in_IN
the_DT
signal_NN
transduction_IN
events_NNS
of_IN
platelet_NN
activation_NN
._.
Characterization_NNP
of_IN
a_DT
cofactor_NN
that_WDT
regulates_VBZ
dimerization_NN
of_IN
a_DT
mammalian_JJ
homeodomain_JJ
protein_NN
._.
Dimerization_NNP
among_IN
transcription_NN
factors_NNS
has_VBZ
become_VBN
a_DT
recurrent_JJ
theme_NN
in_IN
the_DT
regulation_NN
of_IN
eukaryotic_JJ
gene_NN
expression_NN
._.
Hepatocyte_NNP
nuclear_JJ
factor-1_NN
alpha_NN
(_-LRB-
HNF-1_JJ
alpha_NN
)_-RRB-
is_VBZ
a_DT
homeodomain-containing_JJ
protein_NN
that_WDT
functions_VBZ
as_IN
a_DT
dimer_NN
._.
A_DT
dimerization_NN
cofactor_NN
of_IN
HNF-1_JJ
alpha_NN
(_-LRB-
DCoH_NNP
)_-RRB-
was_VBD
identified_VBN
that_IN
displayed_VBN
a_DT
restricted_VBN
tissue_NN
distribution_NN
and_CC
did_VBD
not_RB
bind_NN
to_TO
DNA_NNP
,_,
but_CC
,_,
rather_RB
,_,
selectively_RB
stabilized_VBD
HNF-1_JJ
alpha_NN
dimers_NNS
._.
The_DT
formation_NN
of_IN
a_DT
stable_JJ
tetrameric_JJ
DCoH-HNF-1_NN
alpha_NN
complex_NN
,_,
which_WDT
required_VBD
the_DT
dimerization_NN
domain_NN
of_IN
HNF-1_JJ
alpha_NN
,_,
did_VBD
not_RB
change_VB
the_DT
DNA_NNP
binding_NN
characteristics_NNS
of_IN
HNF-1_JJ
alpha_NN
,_,
but_CC
enhanced_VBD
its_PRP$
transcriptional_JJ
activity_NN
._.
However_RB
,_,
DCoH_NNP
did_VBD
not_RB
confer_VB
transcriptional_JJ
activation_NN
to_TO
the_DT
GAL4_NNP
DNA_NNP
binding_NN
domain_NN
._.
These_DT
results_NNS
indicate_VBP
that_IN
DCoH_NNP
regulates_VBZ
formation_NN
of_IN
transcriptionally_DT
active_JJ
tetrameric_JJ
complexes_NNS
and_CC
may_MD
contribute_VB
to_TO
the_DT
developmental_JJ
specificity_NN
of_IN
the_DT
complex_NN
._.
High_NNP
affinity_NN
aldosterone_NN
binding_NN
to_TO
plasma_NN
membrane_NN
rich_JJ
fractions_NNS
from_IN
mononuclear_JJ
leukocytes_NNS
:_:
is_VBZ
there_RB
a_DT
membrane_NN
receptor_NN
for_IN
mineralocorticoids_NNS
?_.
In_IN
vitro_NN
effects_NNS
of_IN
aldosterone_NN
on_IN
the_DT
intracellular_JJ
concentrations_NNS
of_IN
sodium_NN
,_,
potassium_NN
and_CC
calcium_NN
,_,
cell_NN
volume_NN
and_CC
the_DT
sodium-proton-antiport_NN
have_VBP
been_VBN
described_VBN
in_IN
intact_JJ
human_JJ
mononuclear_NN
leukocytes_NNS
(_-LRB-
HML_NN
)_-RRB-
._.
In_IN
the_DT
present_JJ
paper_NN
,_,
the_DT
binding_NN
of_IN
a_DT
(125I)-labeled_JJ
aldosterone_NN
derivative_NN
to_TO
plasma_NN
membrane_NN
rich_JJ
fractions_NNS
of_IN
HML_NNP
was_VBD
studied_VBN
._.
High_NNP
affinity_NN
binding_NN
of_IN
the_DT
radioligand_NN
with_IN
an_DT
apparent_JJ
Kd_NN
of_IN
approximately_RB
0.1_CD
nM_NN
was_VBD
found_VBN
._.
Aldosterone_NNP
displaced_VBD
the_DT
tracer_NN
at_IN
a_DT
similar_JJ
Kd_NNP
._.
Both_DT
canrenone_NN
and_CC
cortisol_NN
were_VBD
inactive_JJ
as_IN
ligands_NNS
up_IN
to_TO
concentrations_NNS
of_IN
0.1_CD
microM_NNS
._.
The_DT
findings_NNS
are_VBP
the_DT
first_JJ
to_TO
demonstrate_VB
membrane_NN
binding_NN
sites_NNS
with_IN
a_DT
high_JJ
affinity_NN
for_IN
aldosterone_NN
,_,
but_CC
not_RB
for_IN
cortisol_NN
._.
These_DT
data_NNS
are_VBP
perfectly_RB
compatible_JJ
with_IN
major_JJ
properties_NNS
of_IN
steroidal_JJ
effects_NNS
on_IN
the_DT
sodium-proton-antiport_NN
in_IN
HML_NNP
and_CC
thus_RB
very_RB
likely_JJ
represent_VBP
membrane_NN
receptors_NNS
for_IN
aldosterone_NN
._.
Transcription_NN
factor_NN
requirements_NNS
for_IN
U2_DT
snRNA-encoding_JJ
gene_NN
activation_NN
in_IN
B_NNP
lymphoid_NN
cells_NNS
._.
Transcription_NN
of_IN
a_DT
human_NN
U2_IN
small_JJ
nuclear_JJ
RNA_NN
(_-LRB-
snRNA_NN
)_-RRB-
-encoding_JJ
gene_NN
in_IN
HeLa_NNP
cells_NNS
requires_VBZ
a_DT
distal_JJ
enhancer_NN
element_NN
,_,
which_WDT
is_VBZ
composed_VBN
of_IN
one_CD
octamer_NN
motif_NN
(_-LRB-
Oct_NNP
)_-RRB-
and_CC
three_CD
Sp_JJ
1-binding_JJ
sites_NNS
._.
To_TO
study_VB
the_DT
transcription_NN
factor_NN
requirement_NN
in_IN
B-cells_NNS
,_,
different_JJ
U2_IN
enhancer_NN
constructions_NNS
were_VBD
transfected_VBN
into_IN
the_DT
lymphoid_JJ
cell_NN
line_NN
,_,
BJA-B_NNP
._.
The_DT
results_NNS
showed_VBD
that_IN
the_DT
activation_NN
of_IN
U2_DT
snRNA_NN
transcription_NN
in_IN
B-cells_NNP
also_RB
requires_VBZ
an_DT
enhancer_NN
comprising_VBG
both_DT
the_DT
Oct_NNP
and_CC
at_IN
least_JJS
one_CD
Sp_NNP
1-binding_JJ
site_NN
._.
Deletion_NNP
of_IN
all_PDT
the_DT
Sp_NNP
1-binding_JJ
sites_NNS
from_IN
the_DT
enhancer_NN
reduces_VBZ
transcription_NN
by_IN
80-90_CD
%_NN
in_IN
HeLa_NNP
,_,
as_RB
well_RB
as_IN
in_IN
BJA-B_NNP
cells_NNS
,_,
whereas_IN
the_DT
removal_NN
of_IN
the_DT
octamer-binding_JJ
site_NN
reduces_VBZ
transcription_NN
to_TO
levels_NNS
below_IN
detection_NN
in_IN
both_DT
cell_NN
types_NNS
._.
Enhancers_NNS
containing_VBG
a_DT
single_JJ
Oct_NNP
have_VBP
,_,
nevertheless_RB
,_,
the_DT
capacity_NN
to_TO
partially_RB
activate_JJ
U2_IN
snRNA_NN
transcription_NN
in_IN
both_DT
HeLa_NNP
cells_NNS
,_,
in_IN
which_WDT
only_JJ
OTF-1_NN
is_VBZ
expressed_VBN
,_,
and_CC
in_IN
BJA-B_NNP
cells_NNS
in_IN
which_WDT
OTF-2_NNP
is_VBZ
the_DT
predominantly_RB
expressed_VBN
octamer-binding_JJ
factor_NN
._.
The_DT
most_RBS
likely_JJ
interpretation_NN
of_IN
our_PRP$
results_NNS
is_VBZ
that_IN
both_DT
the_DT
ubiquitous_JJ
transcription_NN
factor_NN
,_,
OTF-1_NNP
,_,
and_CC
the_DT
B-cell-specific_JJ
transcription_NN
factor_NN
,_,
OTF-2_JJ
,_,
can_MD
activate_VB
U2_DT
snRNA_NN
transcription_NN
._.
The_DT
results_NNS
also_RB
revealed_VBD
a_DT
similar_JJ
functional_JJ
cooperation_NN
between_IN
the_DT
transcription_NN
factors_NNS
which_WDT
bind_VBP
to_TO
the_DT
Oct_NNP
and_CC
the_DT
adjacent_JJ
Sp_NNP
1-binding_JJ
site_NN
in_IN
BJA-B_NNP
cells_NNS
,_,
as_RB
has_VBZ
been_VBN
observed_VBN
in_IN
HeLa_NNP
cells_NNS
,_,
since_IN
a_DT
template_NN
which_WDT
contains_VBZ
a_DT
weak_JJ
binding_JJ
site_NN
for_IN
OTFs_NNP
expresses_VBZ
wild-type_JJ
levels_NNS
of_IN
U2_DT
snRNA_NN
in_IN
both_DT
cell_NN
types_NNS
when_WRB
the_DT
weak_JJ
octamer-binding_JJ
site_NN
is_VBZ
combined_VBN
with_IN
a_DT
Sp_NNP
1-binding_JJ
site_NN
._.
Cortisol_NNP
receptor_NN
resistance_NN
:_:
the_DT
variability_NN
of_IN
its_PRP$
clinical_JJ
presentation_NN
and_CC
response_NN
to_TO
treatment_NN
._.
Primary_JJ
(_-LRB-
partial_JJ
)_-RRB-
cortisol_NN
receptor_NN
resistance_NN
was_VBD
previously_RB
reported_VBN
in_IN
a_DT
total_NN
of_IN
7_CD
patients_NNS
and_CC
14_CD
asymptomatic_JJ
family_NN
members_NNS
._.
Its_PRP$
occurrence_NN
is_VBZ
considered_VBN
to_TO
be_VB
extremely_RB
rare_JJ
._.
In_IN
the_DT
present_JJ
study_NN
we_PRP
report_VBP
on_IN
6_CD
patients_NNS
(_-LRB-
2_CD
males_NNS
and_CC
4_CD
females_NNS
)_-RRB-
with_IN
the_DT
syndrome_NN
._.
The_DT
first_JJ
male_NN
patient_NN
presented_VBN
with_IN
mild_JJ
hypertension_NN
._.
Hydrochlorothiazide_JJ
therapy_NN
resulted_VBD
in_IN
life-threatening_NN
hypokalemia_NN
._.
The_DT
second_JJ
male_NN
patient_NN
had_VBD
slight_JJ
hypertension_NN
without_IN
hypokalemia_NN
._.
All_DT
four_CD
female_JJ
patients_NNS
presented_VBD
between_IN
the_DT
age_NN
of_IN
20-30_CD
yr_NN
with_IN
acne_NN
,_,
hirsutism_NN
,_,
and_CC
irregular_JJ
menstruations_NNS
._.
Low_NNP
dose_NN
dexamethasone_NN
therapy_NN
(_-LRB-
1-1.5_JJ
mg/day_NN
)_-RRB-
was_VBD
of_IN
clinical_JJ
benefit_NN
in_IN
these_DT
patients_NNS
._.
All_DT
patients_NNS
showed_VBD
insufficient_JJ
suppression_NN
of_IN
serum_NN
cortisol_NN
concentrations_NNS
in_IN
the_DT
overnight_JJ
1-mg_JJ
dexamethasone_NN
test_NN
._.
The_DT
diurnal_JJ
rhythm_NN
of_IN
ACTH_NNP
and_CC
cortisol_NN
was_VBD
intact_JJ
,_,
albeit_IN
at_IN
an_DT
elevated_JJ
level_NN
._.
There_EX
was_VBD
a_DT
normal_JJ
increase_NN
in_IN
ACTH_NNP
,_,
cortisol_NN
,_,
and_CC
GH_NNP
(_-LRB-
except_IN
in_IN
one_CD
obese_JJ
patient_NN
)_-RRB-
in_IN
response_NN
to_TO
insulin-induced_JJ
hypoglycemia_NN
,_,
while_IN
cortisol_JJ
production_NN
was_VBD
elevated_VBN
in_IN
three_CD
patients_NNS
._.
Circulating_VBG
adrenal_JJ
androgen_NN
levels_NNS
were_VBD
increased_VBN
in_IN
all_DT
patients_NNS
._.
Glucocorticoid_JJ
receptors_NNS
were_VBD
investigated_VBN
in_IN
a_DT
whole_JJ
cell_NN
dexamethasone_NN
binding_NN
assay_NN
in_IN
mononuclear_JJ
leukocytes_NNS
._.
In_IN
the_DT
first_JJ
male_JJ
patient_NN
,_,
the_DT
number_NN
of_IN
receptors_NNS
was_VBD
very_RB
low_JJ
,_,
while_IN
the_DT
affinity_NN
was_VBD
lower_JJR
than_IN
that_IN
in_IN
controls_NNS
._.
A_DT
lowered_VBD
affinity_NN
to_TO
dexamethasone_NN
was_VBD
found_VBN
in_IN
one_CD
female_JJ
patient_NN
,_,
while_IN
a_DT
lowered_VBD
number_NN
of_IN
receptors_NNS
was_VBD
found_VBN
in_IN
three_CD
patients_NNS
._.
In_IN
the_DT
second_JJ
male_JJ
patient_NN
,_,
no_DT
abnormalities_NNS
were_VBD
found_VBN
._.
As_IN
a_DT
bioassay_NN
for_IN
glucocorticoid_JJ
action_NN
we_PRP
also_RB
measured_VBD
dexamethasone_NN
suppressibility_NN
of_IN
mitogen-stimulated_JJ
incorporation_NN
of_IN
(3H)thymidine_NNP
in_IN
mononuclear_JJ
leukocytes_NNS
._.
In_IN
the_DT
male_JJ
patient_NN
with_IN
normal_JJ
receptor_NN
status_NN
,_,
dexamethasone_NN
suppressibility_NN
of_IN
(3H)thymidine_NNP
incorporation_NN
was_VBD
significantly_RB
lower_JJR
than_IN
that_DT
in_IN
healthy_JJ
controls_NNS
with_IN
respect_NN
to_TO
both_DT
maximal_JJ
suppression_NN
and_CC
IC50_NN
._.
Partial_JJ
cortisol_NN
receptor_NN
resistance_NN
might_MD
be_VB
less_RBR
rare_JJ
than_IN
previously_RB
thought_VBN
._.
In_IN
the_DT
six_CD
patients_NNS
presented_VBD
,_,
at_IN
least_JJS
three_CD
different_JJ
forms_NNS
can_MD
be_VB
recognized_VBN
._.
Therapy_NNP
with_IN
dexamethasone_NN
was_VBD
successful_JJ
in_IN
female_JJ
patients_NNS
with_IN
acne_JJ
and_CC
hirsutism_NN
,_,
as_IN
the_DT
secondary_JJ
increase_NN
in_IN
the_DT
production_NN
of_IN
adrenal_JJ
androgens_NNS
was_VBD
effectively_RB
controlled_VBN
._.
Kappa_NNP
B-specific_JJ
DNA_NN
binding_JJ
proteins_NNS
are_VBP
differentially_RB
inhibited_VBN
by_IN
enhancer_NN
mutations_NNS
and_CC
biological_JJ
oxidation_NN
._.
Kappa_NNP
B_NNP
(_-LRB-
kappa_NN
B_NN
)_-RRB-
enhancer_NN
binding_JJ
proteins_NNS
isolated_VBN
from_IN
the_DT
nuclei_NNS
of_IN
activated_JJ
human_JJ
T_NNP
cells_NNS
produce_VBP
two_CD
distinct_JJ
nucleoprotein_JJ
complexes_NNS
when_WRB
incubated_VBN
with_IN
the_DT
kappa_NN
B_NNP
element_NN
from_IN
the_DT
interleukin-2_NN
receptor-alpha_NN
(_-LRB-
IL-2R_JJ
alpha_NN
)_-RRB-
gene_NN
._.
These_DT
two_CD
DNA-protein_NNP
complexes_NNS
are_VBP
composed_VBN
of_IN
at_IN
least_JJS
four_CD
host_NN
proteins_NNS
(_-LRB-
p50_NN
,_,
p55_VBD
,_,
p75_VBD
,_,
p85_VBG
)_-RRB-
,_,
each_DT
of_IN
which_WDT
shares_NNS
structural_JJ
similarity_NN
with_IN
the_DT
v-rel_NN
oncogene_IN
product_NN
._.
Nuclear_JJ
expression_NN
of_IN
these_DT
proteins_NNS
is_VBZ
induced_VBN
with_IN
distinctly_RB
biphasic_JJ
kinetics_NNS
following_VBG
phorbol_NN
ester_NN
activation_NN
of_IN
T_NNP
cells_NNS
(_-LRB-
p55/p75_RBR
early_RB
and_CC
p50/p85_VB
late_JJ
)_-RRB-
._.
DNA-protein_NNP
crosslinking_NN
studies_NNS
have_VBP
revealed_VBN
that_IN
the_DT
more_RBR
rapidly_RB
migrating_JJ
B2_NN
complex_NN
contains_VBZ
both_DT
p50_NN
and_CC
p55_VB
while_IN
the_DT
more_RBR
slowly_RB
migrating_JJ
B1_NNP
complex_NN
is_VBZ
composed_VBN
of_IN
p50_NN
,_,
p55_VBD
,_,
p75_VBD
,_,
and_CC
p85_VBD
._.
Site-directed_JJ
mutagenesis_NN
of_IN
the_DT
wild-type_JJ
IL-2R_JJ
alpha_NN
kappa_NN
B_NN
enhancer_NN
(_-LRB-
GGGGAATCTCCC_NNP
)_-RRB-
has_VBZ
revealed_VBN
that_IN
the_DT
binding_NN
of_IN
p50_NN
and_CC
p55_VBD
(_-LRB-
B2_NN
complex_NN
)_-RRB-
is_VBZ
particularly_RB
sensitive_JJ
to_TO
alteration_NN
of_IN
the_DT
5'_JJ
triplet_NN
of_IN
deoxyguanosine_NN
residues_NNS
._.
In_IN
contrast_NN
,_,
formation_NN
of_IN
the_DT
B1_NNP
complex_NN
,_,
reflecting_VBG
the_DT
binding_NN
of_IN
p75_NN
and_CC
p85_VBD
,_,
critically_RB
depends_VBZ
upon_IN
the_DT
more_RBR
3'_JJ
sequences_NNS
of_IN
this_DT
enhancer_NN
element_NN
._.
DNA_NN
binding_NN
by_IN
all_DT
four_CD
of_IN
these_DT
Rel-related_JJ
factors_NNS
is_VBZ
blocked_VBN
by_IN
selective_JJ
chemical_NN
modification_NN
of_IN
lysine_NN
and_CC
arginine_DT
residues_NNS
,_,
suggesting_VBG
that_IN
both_DT
of_IN
these_DT
basic_JJ
amino_NN
acids_NNS
are_VBP
required_VBN
for_IN
binding_NN
to_TO
the_DT
kappa_NN
B_NNP
element_NN
._.
Similarly_RB
,_,
covalent_JJ
modification_NN
of_IN
free_JJ
sulfhydryl_NN
groups_NNS
with_IN
diamide_NN
(_-LRB-
reversible_NN
)_-RRB-
or_CC
N-ethylmaleimide_JJ
(_-LRB-
irreversible_JJ
)_-RRB-
results_NNS
in_IN
a_DT
complete_JJ
loss_NN
of_IN
DNA_NNP
binding_NN
activity_NN
._.
In_IN
contrast_NN
,_,
mild_JJ
oxidation_NN
with_IN
glucose_NN
oxidase_NN
selectively_RB
inhibits_VBZ
p75_.
and_CC
p85_PRP
binding_NN
while_IN
not_RB
blocking_VBG
p50_NN
and_CC
p55_VBD
interactions_NNS
._.
These_DT
findings_NNS
suggest_VBP
that_IN
reduced_VBN
cysteine_NN
thiols_NNS
play_VBP
an_DT
important_JJ
role_NN
in_IN
the_DT
DNA_NNP
binding_NN
activity_NN
of_IN
this_DT
family_NN
of_IN
Rel-related_JJ
transcription_NN
factors_NNS
._.
A_DT
novel_NN
mitogen-inducible_JJ
gene_NN
product_NN
related_VBN
to_TO
p50/p105-NF-kappa_DT
B_NNP
participates_NNS
in_IN
transactivation_NN
through_IN
a_DT
kappa_NN
B_NNP
site_NN
._.
A_DT
Rel-related_JJ
,_,
mitogen-inducible_JJ
,_,
kappa_VB
B-binding_JJ
protein_NN
has_VBZ
been_VBN
cloned_VBN
as_IN
an_DT
immediate-early_JJ
activation_NN
gene_NN
of_IN
human_JJ
peripheral_NN
blood_NN
T_NNP
cells_NNS
._.
The_DT
cDNA_NN
has_VBZ
an_DT
open_JJ
reading_NN
frame_NN
of_IN
900_CD
amino_IN
acids_NNS
capable_JJ
of_IN
encoding_VBG
a_DT
97-kDa_JJ
protein_NN
._.
This_DT
protein_NN
is_VBZ
most_RBS
similar_JJ
to_TO
the_DT
105-kDa_JJ
precursor_NN
polypeptide_NN
of_IN
p50-NF-kappa_NN
B_NNP
._.
Like_IN
the_DT
105-kDa_JJ
precursor_NN
,_,
it_PRP
contains_VBZ
an_DT
amino-terminal_JJ
Rel-related_JJ
domain_NN
of_IN
about_IN
300_CD
amino_IN
acids_NNS
and_CC
a_DT
carboxy-terminal_JJ
domain_NN
containing_VBG
six_CD
full_JJ
cell_NN
cycle_NN
or_CC
ankyrin_IN
repeats_NNS
._.
In_IN
vitro-translated_JJ
proteins_NNS
,_,
truncated_JJ
downstream_NN
of_IN
the_DT
Rel_NNP
domain_NN
and_CC
excluding_VBG
the_DT
repeats_NNS
,_,
bind_NN
kappa_NN
B_NNP
sites_NNS
._.
We_PRP
refer_VBP
to_TO
the_DT
kappa_NN
B-binding_NN
,_,
truncated_JJ
protein_NN
as_IN
p50B_NN
by_IN
analogy_NN
with_IN
p50-NF-kappa_NN
B_NNP
and_CC
to_TO
the_DT
full-length_JJ
protein_NN
as_IN
p97_NN
._.
p50B_NN
is_VBZ
able_JJ
to_TO
form_VB
heteromeric_JJ
kappa_NN
B-binding_JJ
complexes_NNS
with_IN
RelB_NNP
,_,
as_RB
well_RB
as_IN
with_IN
p65_NN
and_CC
p50_NN
,_,
the_DT
two_CD
subunits_NNS
of_IN
NF-kappa_NNP
B_NNP
._.
Transient-transfection_NN
experiments_NNS
in_IN
embryonal_JJ
carcinoma_NN
cells_NNS
demonstrate_VBP
a_DT
functional_JJ
cooperation_NN
between_IN
p50B_NN
and_CC
RelB_NNP
or_CC
p65_VB
in_IN
transactivation_NN
of_IN
a_DT
reporter_NN
plasmid_VBD
dependent_JJ
on_IN
a_DT
kappa_NN
B_NNP
site_NN
._.
The_DT
data_NNS
imply_VBP
the_DT
existence_NN
of_IN
a_DT
complex_JJ
family_NN
of_IN
NF-kappa_NNP
B-like_NNP
transcription_NN
factors_NNS
._.
(_-LRB-
Changes_NNS
in_IN
leucocytic_JJ
estrogen_NN
receptor_NN
levels_NNS
in_IN
patients_NNS
with_IN
climacteric_JJ
syndrome_NN
and_CC
therapeutic_JJ
effect_NN
of_IN
liuwei_JJ
dihuang_JJ
pills_NNS
)_-RRB-
The_DT
numbers_NNS
of_IN
estrogen_NN
receptor_NN
(_-LRB-
ER_NNP
)_-RRB-
in_IN
human_JJ
peripheral_NN
leucocytes_NNS
in_IN
22_CD
women_NNS
with_IN
climacteric_JJ
syndrome_NN
were_VBD
measured_VBN
by_IN
radioligand_NN
method_NN
._.
The_DT
results_NNS
were_VBD
compared_VBN
with_IN
those_DT
of_IN
12_CD
normal_JJ
child-bearing-age_JJ
women_NNS
._.
It_PRP
wat_VBD
found_VBN
that_IN
the_DT
contents_NNS
of_IN
leucocytic_JJ
ER_NNP
in_IN
climacteric_JJ
syndrome_NN
patients_NNS
were_VBD
significantly_RB
lower_JJR
than_IN
normal_JJ
child-bearing-age_JJ
women_NNS
._.
The_DT
authors_NNS
used_VBD
a_DT
Chinese_JJ
prescription_NN
--_:
Liuwei_NNP
Dihuang_NNP
Pills_NNP
(_-LRB-
LDP_NNP
)_-RRB-
to_TO
treat_VB
the_DT
patients_NNS
for_IN
2_CD
months_NNS
._.
The_DT
numbers_NNS
of_IN
leucocytic_JJ
ER_NNP
were_VBD
significantly_RB
increased_VBN
after_IN
treatment_NN
._.
The_DT
data_NNS
indicate_VBP
that_IN
decrease_NN
of_IN
ER_NNP
levels_NNS
in_IN
cell_NN
may_MD
involve_VB
in_IN
the_DT
pathogenesis_NN
of_IN
climacteric_JJ
syndrome_NN
._.
LDP_NNP
not_RB
only_RB
increases_VBZ
plasma_NN
estradiol_NN
levels_NNS
,_,
but_CC
also_RB
increases_VBZ
the_DT
leucocytic_JJ
ER_NNP
levels_NNS
._.
This_DT
may_MD
be_VB
the_DT
basis_NN
of_IN
the_DT
therapeutic_JJ
effect_NN
on_IN
the_DT
disease_NN
._.
A_DT
novel_JJ
primer_NN
extension_NN
method_NN
to_TO
detect_VB
the_DT
number_NN
of_IN
CAG_NNP
repeats_NNS
in_IN
the_DT
androgen_NN
receptor_NN
gene_NN
in_IN
families_NNS
with_IN
X-linked_JJ
spinal_JJ
and_CC
bulbar_NN
muscular_JJ
atrophy_NN
._.
X-linked_JJ
spinal_JJ
and_CC
bulbar_NN
muscular_JJ
atrophy_NN
(_-LRB-
SBMA_NNP
)_-RRB-
,_,
an_DT
adult-onset_JJ
form_NN
of_IN
motor_NN
neuron_NN
disease_NN
,_,
was_VBD
recently_RB
reported_VBN
to_TO
be_VB
caused_VBN
by_IN
amplification_NN
of_IN
the_DT
CAG_NNP
repeats_NNS
in_IN
the_DT
androgen_NN
receptor_NN
gene_NN
._.
We_PRP
report_VBP
here_RB
a_DT
simple_NN
and_CC
rapid_JJ
strategy_NN
to_TO
detect_VB
the_DT
precise_JJ
number_NN
of_IN
the_DT
CAGs_NNP
._.
After_IN
the_DT
DNA_NN
fragment_NN
containing_VBG
the_DT
CAG_NNP
repeats_NNS
is_VBZ
amplified_VBN
by_IN
the_DT
polymerase_NN
chain_NN
reaction_NN
,_,
a_DT
primer_JJ
extension_NN
is_VBZ
carried_VBN
out_RB
;_:
the_DT
extension_NN
of_IN
the_DT
end-labelled_JJ
reverse_NN
primer_NN
adjacent_JJ
to_TO
3'_VB
end_NN
of_IN
CAG_NNP
repeats_NNS
stops_VBZ
at_IN
the_DT
first_JJ
T_NNP
after_IN
CAG_NNP
repeats_NNS
with_IN
the_DT
incorporation_NN
of_IN
dideoxy_JJ
ATP_NNP
in_IN
the_DT
reaction_NN
mixture_NN
._.
The_DT
resultant_NN
primer_NN
products_NNS
are_VBP
analysed_JJ
by_IN
denaturing_VBG
polyacrylamide_NN
gel_NN
electrophoresis_NN
and_CC
autoradiography_NN
._.
This_DT
method_NN
could_MD
be_VB
quite_RB
useful_JJ
to_TO
detect_VB
not_RB
only_RB
CAG_JJ
repeats_NNS
in_IN
SBMA_NNP
but_CC
also_RB
other_JJ
polymorphic_JJ
dinucleotide_NN
and_CC
trinucleotide_NN
repeats_NNS
._.
Activity_NN
of_IN
the_DT
kappa_NN
B_NNP
enhancer_NN
of_IN
the_DT
interleukin-2_NN
receptor_NN
alpha_NN
chain_NN
in_IN
somatic_JJ
cell_NN
hybrids_NNS
is_VBZ
accompanied_VBN
by_IN
the_DT
nuclear_JJ
localization_NN
of_IN
NF-kappa_NNP
B_NNP
._.
The_DT
two_CD
nuclear_JJ
proteins_NNS
NF-kappa_NN
B_NNP
(_-LRB-
consisting_VBG
of_IN
subunits_NNS
p50_.
and_CC
p65_PRP
)_-RRB-
and_CC
the_DT
DNA-binding_JJ
subunit_NN
of_IN
NF-kappa_NNP
B_NNP
(_-LRB-
p50_NN
)_-RRB-
by_IN
itself_PRP
,_,
also_RB
called_VBN
KBF1_NNP
,_,
are_VBP
constitutively_RB
expressed_VBN
and_CC
localized_VBN
in_IN
the_DT
nucleus_NN
of_IN
the_DT
human_JJ
T-cell_NN
line_NN
IARC_NNP
301.5_CD
._.
In_IN
order_NN
to_TO
define_VB
the_DT
roles_NNS
of_IN
these_DT
two_CD
factors_NNS
,_,
which_WDT
bind_VBP
to_TO
the_DT
same_JJ
kappa_NN
B_NNP
enhancers_NNS
,_,
in_IN
transcription_NN
activation_NN
we_PRP
have_VBP
prepared_VBN
somatic_JJ
cell_NN
hybrids_NNS
between_IN
IARC_NNP
301.5_CD
and_CC
a_DT
murine_NN
myeloma_NN
._.
Most_JJS
hybrids_NNS
express_VBP
both_DT
KBF1_NNP
and_CC
NF-kappa_NNP
B_NNP
in_IN
their_PRP$
nuclei_NNS
,_,
but_CC
one_CD
hybrid_JJ
expresses_NNS
only_RB
KBF1_NNP
._.
The_DT
kappa_NN
B_NNP
enhancer_NN
of_IN
the_DT
gene_NN
encoding_VBG
the_DT
interleukin-2_NN
(_-LRB-
IL-2_NN
)_-RRB-
receptor_NN
alpha_NN
chain_NN
(_-LRB-
IL-2R_JJ
alpha_NN
)_-RRB-
is_VBZ
functional_JJ
only_RB
in_IN
the_DT
hybrids_NNS
expressing_VBG
nuclear_JJ
NF-kappa_NNP
B_NNP
._.
These_DT
findings_NNS
show_VBP
that_IN
nuclear_JJ
NF-kappa_NNP
B_NNP
is_VBZ
necessary_JJ
to_TO
activate_VB
the_DT
kappa_NN
B_NNP
enhancer_NN
,_,
while_IN
KBF1_NNP
by_IN
itself_PRP
is_VBZ
not_RB
sufficient_JJ
._.
We_PRP
propose_VBP
that_IN
KBF1_NNP
is_VBZ
a_DT
competitive_JJ
inhibitor_NN
of_IN
NF-kappa_NNP
B_NNP
and_CC
discuss_VB
how_WRB
these_DT
factors_NNS
may_MD
be_VB
involved_VBN
in_IN
the_DT
transient_JJ
expression_NN
of_IN
IL-2_JJ
and_CC
IL-2_JJ
alpha_NN
genes_NNS
during_IN
the_DT
immune_JJ
response_NN
._.
Influence_NN
of_IN
estradiol_NN
and_CC
tamoxifen_VB
on_IN
susceptibility_NN
of_IN
human_JJ
breast_NN
cancer_NN
cell_NN
lines_NNS
to_TO
lysis_VB
by_IN
lymphokine-activated_JJ
killer_NN
cells_NNS
._.
The_DT
design_NN
of_IN
combination_NN
hormonal_JJ
and_CC
immunotherapeutic_JJ
protocols_NNS
for_IN
breast_NN
cancer_NN
patients_NNS
may_MD
be_VB
facilitated_VBN
by_IN
analysis_NN
of_IN
preclinical_JJ
in_IN
vitro_NN
model_NN
systems_NNS
._.
Estrogen_NN
receptor_NN
positive_JJ
(_-LRB-
ER+_NN
:_:
MCF-7_NNP
)_-RRB-
and_CC
negative_JJ
(_-LRB-
ER-_NNP
:_:
MDA-MB-231_JJ
)_-RRB-
human_JJ
breast_NN
cancer_NN
cell_NN
lines_NNS
were_VBD
utilized_VBN
to_TO
evaluate_VB
the_DT
effects_NNS
of_IN
tamoxifen_NNS
(_-LRB-
TAM_NN
)_-RRB-
and_CC
estradiol_NN
(_-LRB-
E2_NN
)_-RRB-
on_IN
modulation_NN
of_IN
breast_NN
cancer_NN
target_NN
susceptibility_NN
to_TO
lysis_NN
by_IN
lymphokine-activated_JJ
killer_NN
(_-LRB-
LAK_NN
)_-RRB-
cells_NNS
._.
E2-stimulated_JJ
ER+_JJ
cells_NNS
were_VBD
more_RBR
susceptible_JJ
to_TO
lysis_NN
by_IN
LAK_NNP
cells_NNS
than_IN
corresponding_JJ
TAM-treated_JJ
or_CC
control_NN
cells_NNS
,_,
while_IN
treatment_NN
of_IN
ER-_NNP
cells_NNS
with_IN
either_DT
E2_NNP
or_CC
TAM_NNP
alone_RB
did_VBD
not_RB
alter_VB
from_IN
control_NN
their_PRP$
susceptibility_NN
to_TO
this_DT
immune-mediated_JJ
lysis_NN
._.
All_DT
ER+_NNP
and_CC
ER-_NNP
cells_NNS
tested_VBN
remained_VBD
sensitive_JJ
after_IN
treatment_NN
with_IN
TAM_NNP
to_TO
lysis_VB
by_IN
LAK_NNP
cells_NNS
._.
In_IN
addition_NN
,_,
an_DT
adenocarcinoma_NN
reactive_NN
human-mouse_NN
chimeric_JJ
monoclonal_JJ
antibody_NN
(_-LRB-
ING-1_NN
)_-RRB-
was_VBD
able_JJ
to_TO
significantly_RB
boost_VB
in_IN
vivo_NN
generated_VBD
LAK_NNP
cell-mediated_JJ
lysis_NN
of_IN
control_NN
,_,
E2-treated_JJ
,_,
and_CC
TAM-treated_JJ
ER+_NNP
and_CC
ER-_NNP
cells_NNS
._.
These_DT
in_IN
vitro_NN
results_NNS
provide_VBP
a_DT
preclinical_JJ
rationale_NN
for_IN
in_IN
vivo_JJ
testing_NN
of_IN
TAM_NNP
,_,
interleukin-2_NN
(_-LRB-
IL-2_NN
)_-RRB-
,_,
and_CC
breast_NN
cancer_NN
reactive_VBP
antibody-dependent_JJ
cellular_JJ
cytotoxicity_NN
facilitating_VBG
antibody_NN
in_IN
patients_NNS
with_IN
refractory_JJ
or_CC
high_JJ
risk_NN
breast_NN
cancer_NN
._.
Glucocorticoid_NNP
receptor_NN
and_CC
inhibition_NN
of_IN
3-O-methyl-D-glucose_JJ
uptake_NN
by_IN
glucocorticoids_NNS
in_IN
peripheral_JJ
blood_NN
leukocytes_NNS
from_IN
normal_JJ
humans_NNS
:_:
correlation_NN
between_IN
receptor_NN
level_NN
and_CC
hormone_NN
effect_NN
in_IN
vitro_NN
._.
We_PRP
have_VBP
measured_VBN
the_DT
glucocorticoid_NN
receptor_NN
concentration_NN
in_IN
mononuclear_JJ
and_CC
polymorphonuclear_JJ
leukocytes_NNS
,_,
both_DT
of_IN
which_WDT
were_VBD
isolated_VBN
from_IN
peripheral_JJ
blood_NN
from_IN
ten_CD
healthy_JJ
male_JJ
volunteers_NNS
._.
In_IN
parallel_RB
,_,
the_DT
inhibitory_JJ
effect_NN
of_IN
dexamethasone_NN
on_IN
3-O-methyl-D-glucose_JJ
uptake_NN
was_VBD
assayed_VBN
in_IN
the_DT
corresponding_JJ
mononuclear_NN
leukocytes_NNS
._.
The_DT
glucocorticoid_NN
receptor_NN
levels_NNS
in_IN
mononuclear_NN
leukocytes_NNS
correlated_VBN
with_IN
those_DT
in_IN
polymorphonuclear_JJ
leukocytes_NNS
,_,
and_CC
there_EX
was_VBD
a_DT
linear_JJ
relationship_NN
between_IN
the_DT
cellular_JJ
glucocorticoid_NN
receptor_NN
levels_NNS
and_CC
glucocorticoid-mediated_JJ
inhibition_NN
of_IN
the_DT
uptake_NN
of_IN
3-O-methyl-D-glucose_JJ
in_IN
mononuclear_JJ
leukocytes_NNS
._.
When_WRB
mononuclear_JJ
leukocytes_NNS
were_VBD
incubated_VBN
in_IN
the_DT
presence_NN
of_IN
8-bromo-cAMP_JJ
,_,
cellular_JJ
glucocorticoid_NN
receptor_NN
levels_NNS
increased_VBN
and_CC
a_DT
more_RBR
pronounced_JJ
inhibitory_JJ
effect_NN
of_IN
dexamethasone_NN
was_VBD
observed_VBN
on_IN
the_DT
transport_NN
of_IN
3-O-methyl-D-glucose_JJ
._.
We_PRP
conclude_VBP
that_IN
the_DT
cellular_JJ
glucocorticoid_NN
receptor_NN
levels_NNS
in_IN
peripheral_JJ
blood_NN
leukocytes_NNS
reflect_VBP
in_IN
vitro_NN
responsiveness_NN
to_TO
glucocorticoids_NNS
in_IN
mononuclear_JJ
leukocytes_NNS
from_IN
healthy_JJ
males_NNS
,_,
and_CC
that_IN
the_DT
individual_JJ
responsiveness_NN
may_MD
alter_VB
upon_IN
changes_NNS
in_IN
the_DT
cellular_JJ
levels_NNS
of_IN
glucocorticoid_NN
receptor_NN
._.
Stimulation_NN
of_IN
interferon_NN
beta_JJ
gene_NN
transcription_NN
in_IN
vitro_NN
by_IN
purified_VBN
NF-kappa_NNP
B_NNP
and_CC
a_DT
novel_NN
TH_IN
protein_NN
._.
The_DT
human_JJ
interferon_NN
beta_NN
(_-LRB-
IFN-beta_NN
)_-RRB-
regulatory_JJ
element_NN
consists_VBZ
of_IN
multiple_JJ
enhanson_NN
domains_NNS
which_WDT
are_VBP
targets_NNS
for_IN
transcription_NN
factors_NNS
involved_VBN
in_IN
inducible_JJ
expression_NN
of_IN
the_DT
promoter_NN
._.
To_TO
further_RBR
characterize_VB
the_DT
protein-DNA_NN
interactions_NNS
mediating_VBG
IFN-beta_NNP
induction_NN
,_,
positive_JJ
regulatory_JJ
domain_NN
(_-LRB-
PRD_NNP
)_-RRB-
II_NNP
binding_JJ
proteins_NNS
were_VBD
purified_VBN
from_IN
phorbol_NN
ester_NN
induced_VBN
Jurkat_NNP
T-cells_NNS
and_CC
from_IN
IFN_NNP
primed_VBN
,_,
cycloheximide/polyinosinic-polycytidylic_JJ
acid_NN
treated_VBD
HeLa_NNP
S3_NNP
cells_NNS
._.
From_IN
HeLa_NNP
cells_NNS
,_,
two_CD
major_JJ
proteins_NNS
of_IN
52_CD
and_CC
45_CD
kilodaltons_NNS
(_-LRB-
kD_NN
)_-RRB-
copurified_VBN
with_IN
DNA_NNP
binding_NN
activity_NN
,_,
whereas_IN
from_IN
T-cells_NNS
,_,
four_CD
proteins_NNS
--_:
a_DT
major_JJ
protein_NN
of_IN
52_CD
kD_NN
and_CC
three_CD
minor_JJ
proteins_NNS
of_IN
82_CD
,_,
67_CD
,_,
and_CC
43-47_CD
kD_NN
--_:
were_VBD
purified_VBN
._.
Also_RB
,_,
an_DT
induction_NN
specific_JJ
DNA_NN
binding_JJ
protein_NN
was_VBD
purified_VBN
from_IN
HeLa_NNP
cells_NNS
that_WDT
interacted_VBD
with_IN
the_DT
(_-LRB-
AAGTGA_NNP
)_-RRB-
4_CD
tetrahexamer_NN
sequence_NN
and_CC
the_DT
PRDI_NNP
domain_NN
._.
This_DT
protein_NN
is_VBZ
immunologically_RB
distinct_JJ
from_IN
IRF-1/ISGF2_NNP
._.
Uninduced_NNP
or_CC
Sendai_NNP
virus_NN
induced_VBD
HeLa_NNP
extracts_NNS
were_VBD
used_VBN
to_TO
examine_VB
transcription_NN
in_IN
vitro_NN
using_VBG
a_DT
series_NN
of_IN
IFN_NNP
beta_NN
promoter_NN
deletions_NNS
._.
Deletions_NNS
upstream_RB
of_IN
the_DT
PRDII_NNP
element_NN
increased_VBD
transcription_NN
in_IN
the_DT
uninduced_JJ
extract_VB
,_,
indicating_VBG
predominantly_RB
negative_JJ
regulation_NN
of_IN
the_DT
promoter_NN
._.
A_DT
2-4-fold_JJ
increase_NN
in_IN
IFN-beta_NNP
promoter_NN
transcription_NN
was_VBD
observed_VBN
in_IN
Sendai_NNP
virus_NN
induced_VBD
extracts_NNS
,_,
and_CC
deletion_NN
of_IN
PRDI_NNP
and_CC
PRDII_NNP
elements_NNS
decreased_VBD
this_DT
induced_JJ
level_NN
of_IN
transcription_NN
._.
When_WRB
purified_VBN
PRDII_NNP
and_CC
tetrahexamer_JJ
binding_JJ
proteins_NNS
were_VBD
added_VBN
to_TO
the_DT
induced_NN
extract_VB
,_,
a_DT
4-fold_JJ
increase_NN
in_IN
transcription_NN
was_VBD
observed_VBN
._.
These_DT
experiments_NNS
demonstrate_VBP
that_IN
it_PRP
is_VBZ
possible_JJ
to_TO
modulate_VB
IFN-beta_JJ
transcription_NN
in_IN
vitro_NN
but_CC
indicate_VBP
that_IN
additional_JJ
proteins_NNS
may_MD
be_VB
required_VBN
to_TO
fully_RB
activate_VB
IFN-beta_JJ
transcription_NN
._.
Structure_JJ
function_NN
analysis_NN
of_IN
vitamin_NN
D_NNP
analogs_NNS
with_IN
C-ring_NN
modifications_NNS
._.
Analogs_NNS
of_IN
1_CD
alpha,25-dihydroxyvitamin_NN
D3_IN
(_-LRB-
1_LS
alpha,25-(OH)_JJ
2D3_CD
)_-RRB-
with_IN
substitutions_NNS
on_IN
C-11_NN
were_VBD
synthesized_VBN
._.
Small_JJ
apolar_JJ
substitutions_NNS
(_-LRB-
11_CD
alpha-methyl_NN
,_,
11_CD
alpha-fluoromethyl_NN
)_-RRB-
did_VBD
not_RB
markedly_RB
decrease_VB
the_DT
affinity_NN
for_IN
the_DT
vitamin_NN
D_NN
receptor_NN
,_,
but_CC
larger_JJR
(_-LRB-
11_CD
alpha-chloromethyl_NN
or_CC
11_CD
alpha-_NNS
or_CC
11_CD
beta-phenyl_NN
)_-RRB-
or_CC
more_JJR
polar_JJ
substitutions_NNS
(_-LRB-
11_CD
alpha-hydroxymethyl_NN
,_,
11_CD
alpha-(2-hydroxyethyl_NN
)_-RRB-
decreased_VBD
the_DT
affinity_NN
to_TO
less_JJR
than_IN
5_CD
%_NN
of_IN
that_DT
of_IN
1_CD
alpha,25-OH)2D3_NN
._.
Their_PRP$
affinity_NN
for_IN
the_DT
vitamin_NN
D-binding_JJ
protein_NN
,_,
however_RB
,_,
increased_VBD
up_RP
to_TO
4-fold_JJ
._.
The_DT
biological_JJ
activity_NN
of_IN
11_CD
alpha-methyl-1_NN
alpha,25-(OH)2D3_NN
closely_RB
resembled_VBD
that_IN
of_IN
the_DT
natural_JJ
hormone_NN
on_IN
normal_JJ
and_CC
leukemic_JJ
cell_NN
proliferation_NN
and_CC
bone_NN
resorption_NN
,_,
whereas_IN
its_PRP$
in_IN
vivo_JJ
effect_NN
on_IN
calcium_NN
metabolism_NN
of_IN
the_DT
rachitic_JJ
chick_NN
was_VBD
about_IN
50_CD
%_NN
of_IN
that_DT
of_IN
1_CD
alpha,25-(OH)2D3_NN
._.
The_DT
11_CD
beta-methyl_NN
analog_NN
had_VBD
a_DT
greater_JJR
than_IN
10-fold_JJ
lower_JJR
activity_NN
._.
The_DT
differentiating_JJ
effects_NNS
of_IN
the_DT
other_JJ
C-11_NN
analogs_NNS
on_IN
human_JJ
promyeloid_JJ
leukemia_NN
cells_NNS
(_-LRB-
HL-60_CD
)_-RRB-
agreed_VBD
well_RB
with_IN
their_PRP$
bone-resorbing_JJ
activity_NN
and_CC
receptor_NN
affinity_NN
,_,
but_CC
they_PRP
demonstrated_VBD
lower_JJR
calcemic_JJ
effects_NNS
in_IN
vivo_NN
._.
Large_JJ
or_CC
polar_JJ
substitutions_NNS
on_IN
C-11_NN
of_IN
1_CD
alpha,25-(OH)2D3_NN
thus_RB
impair_VB
the_DT
binding_NN
of_IN
the_DT
vitamin_NN
D_NN
receptor_NN
but_CC
increase_VB
the_DT
affinity_NN
to_TO
vitamin_NN
D-binding_JJ
protein_NN
._.
The_DT
effects_NNS
of_IN
many_JJ
C-11-substituted_JJ
1_CD
alpha,25-(OH)2D3_JJ
analogs_NNS
on_IN
HL-60_CD
cell_NN
differentiation_NN
exceeded_VBD
their_PRP$
activity_NN
on_IN
calcium_NN
metabolism_NN
._.
Transcriptional_NNP
regulation_NN
during_IN
T-cell_DT
development_NN
:_:
the_DT
alpha_NN
TCR_NNP
gene_NN
as_IN
a_DT
molecular_JJ
model_NN
._.
The_DT
regulation_NN
of_IN
gene_NN
expression_NN
during_IN
lymphocyte_NN
differentiation_NN
is_VBZ
a_DT
complex_JJ
process_NN
involving_VBG
interactions_NNS
between_IN
multiple_JJ
positive_JJ
and_CC
negative_JJ
transcriptional_JJ
regulatory_JJ
elements_NNS
._.
In_IN
this_DT
article_NN
,_,
transcriptional_JJ
regulation_NN
of_IN
the_DT
archetypal_NN
T-cell-specific_JJ
gene_NN
,_,
alpha_NN
TCR_NNP
,_,
is_VBZ
discussed_VBN
._.
Major_JJ
recent_JJ
developments_NNS
,_,
including_VBG
the_DT
identification_NN
of_IN
novel_JJ
families_NNS
of_IN
transcription_NN
factors_NNS
that_WDT
regulate_VB
multiple_JJ
T-cell_NN
genes_NNS
during_IN
thymocyte_JJ
ontogeny_JJ
and_CC
T-cell_JJ
activation_NN
,_,
are_VBP
described_VBN
._.
Cortisol_NNP
resistance_NN
in_IN
acquired_VBN
immunodeficiency_NN
syndrome_NN
._.
This_DT
study_NN
concerns_VBZ
9_CD
iv_NN
drug_NN
abusers_NNS
with_IN
acquired_VBN
immunodeficiency_NN
syndrome_NN
(_-LRB-
AIDS_NNP
)_-RRB-
who_WP
developed_VBD
hypercortisolism_NN
without_IN
the_DT
clinical_JJ
signs_NNS
or_CC
metabolic_JJ
consequences_NNS
of_IN
hypercortisolism_NN
._.
All_DT
patients_NNS
were_VBD
characterized_VBN
by_IN
an_DT
Addisonian_JJ
picture_NN
(_-LRB-
weakness_NN
,_,
weight_NN
loss_NN
,_,
hypotension_NN
,_,
hyponatremia_NN
,_,
and_CC
intense_JJ
mucocutaneous_JJ
melanosis_NN
)_-RRB-
._.
An_DT
acquired_VBN
form_NN
of_IN
peripheral_JJ
resistance_NN
to_TO
glucocorticoids_NNS
was_VBD
suspected_VBN
._.
We_PRP
,_,
therefore_RB
,_,
examined_VBD
glucocorticoid_NN
receptor_NN
characteristics_NNS
on_IN
mononuclear_NN
leukocytes_NNS
by_IN
measuring_VBG
(3H)dexamethasone_NN
binding_NN
and_CC
the_DT
effect_NN
of_IN
dexamethasone_NN
on_IN
(3H)thymidine_NNP
incorporation_NN
,_,
which_WDT
is_VBZ
one_CD
of_IN
the_DT
effects_NNS
of_IN
glucocorticoid_NN
receptor_NN
activation_NN
._.
Glucocorticoid_NNP
receptor_NN
density_NN
was_VBD
increased_VBN
in_IN
AIDS_NNP
patients_NNS
with_IN
an_DT
Addisonian_JJ
picture_NN
(_-LRB-
group_NN
1_CD
;_:
16.2_CD
+/-_CD
9.4_CD
fmol/million_IN
cells_NNS
)_-RRB-
compared_VBN
to_TO
values_NNS
in_IN
12_CD
AIDS_NNP
patients_NNS
without_IN
an_DT
Addisonian_JJ
picture_NN
(_-LRB-
group_NN
2_CD
;_:
6.05_CD
+/-_NNP
2.6_CD
fmol/million_IN
cells_NNS
;_:
P_NNP
less_RBR
than_IN
0.01_CD
)_-RRB-
and_CC
sex-_NNS
and_CC
age-matched_JJ
controls_NNS
(_-LRB-
3.15_CD
+/-_:
2.3_CD
fmol/million_CD
cells_NNS
;_:
P_NNP
less_RBR
than_IN
0.01_CD
)_-RRB-
._.
The_DT
affinity_NN
of_IN
glucocorticoid_JJ
receptors_NNS
(_-LRB-
Kd_NN
)_-RRB-
was_VBD
strikingly_RB
decreased_VBN
(_-LRB-
9.36_CD
+/-_:
3.44_CD
nM_NNS
in_IN
group_NN
1_CD
;_:
3.2_CD
+/-_RB
1.5_CD
nM_NNS
in_IN
group_NN
2_CD
;_:
2.0_CD
+/-_,
0.8_CD
nM_NNS
in_IN
controls_NNS
;_:
P_NNP
less_RBR
than_IN
0.01_CD
)_-RRB-
._.
(3H)Thymidine_JJ
incorporation_NN
was_VBD
decreased_VBN
dose-dependently_RB
by_IN
dexamethasone_NN
in_IN
controls_NNS
and_CC
patients_NNS
;_:
the_DT
effect_NN
was_VBD
significantly_RB
blunted_VBN
(_-LRB-
P_NNP
less_RBR
than_IN
0.05_CD
)_-RRB-
in_IN
group_NN
1_CD
patients_NNS
,_,
which_WDT
suggests_VBZ
that_IN
activation_NN
of_IN
glucocorticoid_NN
receptor_NN
is_VBZ
impaired_VBN
as_IN
a_DT
result_NN
of_IN
the_DT
glucocorticoid_NN
receptor_NN
abnormality_NN
._.
In_IN
conclusion_NN
,_,
AIDS_NNP
patients_NNS
with_IN
hypercortisolism_NN
and_CC
clinical_JJ
features_NNS
of_IN
peripheral_JJ
resistance_NN
to_TO
glucocorticoids_NNS
are_VBP
characterized_VBN
by_IN
abnormal_JJ
glucocorticoid_JJ
receptors_NNS
on_IN
lymphocytes_NNS
._.
Resistance_NN
to_TO
glucocorticoids_NNS
implies_VBZ
a_DT
complex_JJ
change_NN
in_IN
immune-endocrine_JJ
function_NN
,_,
which_WDT
may_MD
be_VB
important_JJ
in_IN
the_DT
course_NN
of_IN
immunodeficiency_NN
syndrome_NN
._.
Induction_NN
of_IN
monocytic_JJ
differentiation_NN
and_CC
NF-kappa_NNP
B-like_NNP
activities_NNS
by_IN
human_JJ
immunodeficiency_NN
virus_NN
1_CD
infection_NN
of_IN
myelomonoblastic_JJ
cells_NNS
._.
The_DT
effects_NNS
of_IN
human_JJ
immunodeficiency_NN
virus_NN
1_CD
(_-LRB-
HIV-1_NN
)_-RRB-
infection_NN
on_IN
cellular_JJ
differentiation_NN
and_CC
NF-kappa_NNP
B_NNP
DNA_NNP
binding_NN
activity_NN
have_VBP
been_VBN
investigated_VBN
in_IN
a_DT
new_JJ
model_NN
of_IN
myeloid_JJ
differentiation_NN
._.
PLB-985_CD
cells_NNS
represent_VBP
a_DT
bipotential_JJ
myelomonoblastic_JJ
cell_NN
population_NN
capable_JJ
of_IN
either_DT
granulocytic_JJ
or_CC
monocytic_JJ
differentiation_NN
after_IN
induction_NN
with_IN
appropriate_JJ
inducers_NNS
._.
By_IN
virtue_NN
of_IN
the_DT
presence_NN
of_IN
CD4_NNP
on_IN
the_DT
cell_NN
surface_NN
,_,
PLB-985_CD
cells_NNS
were_VBD
chronically_RB
infected_VBN
with_IN
HIV-1_PRP$
strain_NN
IIIB_NNP
._.
PLB-IIIB_NNP
cells_NNS
clearly_RB
possessed_VBD
a_DT
more_RBR
monocytic_JJ
phenotype_NN
than_IN
the_DT
parental_JJ
myeloblasts_NNS
,_,
as_IN
determined_VBN
by_IN
differential_JJ
staining_NN
,_,
increased_VBD
expression_NN
of_IN
the_DT
myeloid-specific_JJ
surface_NN
markers_NNS
,_,
and_CC
transcription_NN
of_IN
the_DT
c-fms_NNS
proto-oncogene_NN
._.
NF-kappa_NNP
B_NNP
binding_NN
activity_NN
was_VBD
inducible_JJ
by_IN
tumor_NN
necrosis_NN
factor_NN
and_CC
phorbol_NN
myristate_NN
acetate_NN
in_IN
PLB-985_CD
._.
However_RB
,_,
in_IN
PLB-IIIB_NNP
cells_NNS
,_,
constitutive_JJ
expression_NN
of_IN
a_DT
novel_NN
NF-kappa_NNP
B_NNP
complex_NN
was_VBD
detected_VBN
,_,
composed_VBN
of_IN
proteins_NNS
ranging_VBG
between_IN
70_CD
and_CC
110_CD
kD_NN
._.
These_DT
proteins_NNS
interacted_VBD
specifically_RB
with_IN
the_DT
symmetric_JJ
NF-kappa_NNP
B_NNP
site_NN
from_IN
the_DT
interferon_NN
beta_NN
(_-LRB-
IFN-beta_NN
)_-RRB-
promoter_NN
._.
Mutations_NNS
affecting_VBG
the_DT
5'_JJ
guanine_CD
residues_NNS
of_IN
the_DT
kappa_NN
B_NNP
site_NN
were_VBD
unable_JJ
to_TO
compete_VB
for_IN
these_DT
NF-kappa_JJ
B-related_JJ
proteins_NNS
._.
Inducibility_NN
of_IN
endogenous_JJ
IFN-beta_NNP
and_CC
IFN-alpha_NNP
RNA_NNP
was_VBD
also_RB
increased_VBN
in_IN
PLB-IIIB_NNP
cells_NNS
._.
These_DT
studies_NNS
indicate_VBP
that_IN
HIV-1_PRP$
infection_NN
of_IN
myelomonoblastic_JJ
cells_NNS
may_MD
select_VB
for_IN
a_DT
more_RBR
mature_JJ
monocytic_JJ
phenotype_NN
and_CC
that_DT
unique_JJ
subunit_NN
associations_NNS
of_IN
NF-kappa_NNP
B_NNP
DNA_NNP
binding_JJ
proteins_NNS
may_MD
contribute_VB
to_TO
differential_JJ
NF-kappa_NNP
B-mediated_NNP
gene_NN
expression_NN
._.
The_DT
AP-1_JJ
site_NN
at_IN
-150_DT
bp_NN
,_,
but_CC
not_RB
the_DT
NF-kappa_NNP
B_NNP
site_NN
,_,
is_VBZ
likely_JJ
to_TO
represent_VB
the_DT
major_JJ
target_NN
of_IN
protein_NN
kinase_NN
C_NNP
in_IN
the_DT
interleukin_NN
2_CD
promoter_NN
._.
Stimulation_NN
of_IN
T_NNP
cells_NNS
with_IN
antigen_JJ
results_NNS
in_IN
activation_NN
of_IN
several_JJ
kinases_NNS
,_,
including_VBG
protein_NN
kinase_NN
C_NNP
(_-LRB-
PKC_NNP
)_-RRB-
,_,
that_WDT
may_MD
mediate_VB
the_DT
later_JJ
induction_NN
of_IN
activation-related_JJ
genes_NNS
._.
We_PRP
have_VBP
examined_VBN
the_DT
potential_JJ
role_NN
of_IN
PKC_NNP
in_IN
induction_NN
of_IN
the_DT
interleukin_NN
2_CD
(_-LRB-
IL-2_NN
)_-RRB-
gene_NN
in_IN
T_NNP
cells_NNS
stimulated_VBN
through_IN
the_DT
T_NNP
cell_NN
receptor/CD3_NN
complex_NN
._.
We_PRP
have_VBP
previously_RB
shown_VBN
that_IN
prolonged_JJ
treatment_NN
of_IN
the_DT
untransformed_JJ
T_NNP
cell_NN
clone_NN
Ar-5_.
with_IN
phorbol_NN
esters_NNS
results_NNS
in_IN
downmodulation_NN
of_IN
the_DT
alpha_NN
and_CC
beta_JJ
isozymes_NNS
of_IN
PKC_NNP
,_,
and_CC
abrogates_NNS
induction_NN
of_IN
IL-2_JJ
mRNA_NN
and_CC
protein_NN
._.
Here_RB
we_PRP
show_VBP
that_IN
phorbol_NN
ester_NN
treatment_NN
also_RB
abolishes_VBZ
induction_NN
of_IN
chloramphenicol_NN
acetyltransferase_NN
activity_NN
in_IN
Ar-5_DT
cells_NNS
transfected_VBN
with_IN
a_DT
plasmid_NN
containing_VBG
the_DT
IL-2_JJ
promoter_NN
linked_VBN
to_TO
this_DT
reporter_NN
gene_NN
._.
The_DT
IL-2_JJ
promoter_NN
contains_VBZ
binding_JJ
sites_NNS
for_IN
nuclear_JJ
factors_NNS
including_VBG
NFAT-1_JJ
,_,
Oct_NNP
,_,
NF-kappa_NNP
B_NNP
,_,
and_CC
AP-1_NNP
,_,
which_WDT
are_VBP
all_DT
potentially_RB
sensitive_JJ
to_TO
activation_NN
of_IN
PKC_NNP
._.
We_PRP
show_VBP
that_IN
induction_NN
of_IN
a_DT
trimer_NN
of_IN
the_DT
NFAT_NN
and_CC
Oct_NNP
sites_NNS
is_VBZ
not_RB
sensitive_JJ
to_TO
phorbol_VB
ester_NN
treatment_NN
,_,
and_CC
that_DT
mutations_NNS
in_IN
the_DT
NF-kappa_NNP
B_NNP
site_NN
have_VBP
no_DT
effect_NN
on_IN
inducibility_NN
of_IN
the_DT
IL-2_NN
promoter_NN
._.
In_IN
contrast_NN
,_,
mutations_NNS
in_IN
the_DT
AP-1_JJ
site_NN
located_VBN
at_IN
-150_DT
bp_NN
almost_RB
completely_RB
abrogate_JJ
induction_NN
of_IN
the_DT
IL-2_NN
promoter_NN
,_,
and_CC
appearance_NN
of_IN
an_DT
inducible_JJ
nuclear_JJ
factor_NN
binding_NN
to_TO
this_DT
site_NN
is_VBZ
sensitive_JJ
to_TO
PKC_NNP
depletion_NN
._.
Moreover_RB
,_,
cotransfections_NNS
with_IN
c-fos_JJ
and_CC
c-jun_JJ
expression_NN
plasmids_NNS
markedly_RB
enhance_VB
induction_NN
of_IN
the_DT
IL-2_NN
promoter_NN
in_IN
minimally_RB
stimulated_VBN
T_NNP
cells_NNS
._.
Our_PRP$
results_NNS
indicate_VBP
that_IN
the_DT
AP-1_NN
site_NN
at_IN
-150_DT
bp_NN
represents_VBZ
a_DT
major_JJ
,_,
if_IN
not_RB
the_DT
only_RB
,_,
site_NN
of_IN
PKC_NNP
responsiveness_NN
in_IN
the_DT
IL-2_NN
promoter_NN
._.
Interleukin_NNP
6-induced_JJ
differentiation_NN
of_IN
a_DT
human_NN
B_NNP
cell_NN
line_NN
into_IN
IgM-secreting_JJ
plasma_NN
cells_NNS
is_VBZ
mediated_VBN
by_IN
c-fos_NNS
._.
The_DT
role_NN
of_IN
the_DT
protooncogene_NN
c-fos_NNS
in_IN
interleukin_NN
(_-LRB-
IL_NNP
)_-RRB-
6-induced_VBD
B_NNP
cell_NN
differentiation_NN
was_VBD
assessed_VBN
._.
Treatment_NNP
of_IN
SKW_NNP
6.4_CD
cells_NNS
with_IN
IL_NNP
6_CD
induced_VBD
a_DT
transient_NN
and_CC
early_JJ
stimulation_NN
of_IN
c-fos_JJ
sense_NN
mRNA_NNS
expression_NN
._.
The_DT
effect_NN
appeared_VBD
within_IN
30_CD
min_NN
and_CC
returned_VBD
to_TO
basal_NN
levels_NNS
after_IN
2_CD
h_NN
._.
The_DT
addition_NN
of_IN
antisense_NN
oligonucleotides_NNS
to_TO
c-fos_NNS
significantly_RB
inhibited_VBD
IL_NNP
6-induced_JJ
IgM_NNP
production_NN
by_IN
SKW_JJ
6.4_CD
cells_NNS
(_-LRB-
p_NN
less_JJR
than_IN
0.001_CD
)_-RRB-
,_,
whereas_IN
control_NN
oligonucleotides_NNS
had_VBD
no_DT
inhibitory_JJ
effect_NN
._.
These_DT
results_NNS
indicate_VBP
that_IN
activation_NN
of_IN
c-fos_NNS
is_VBZ
involved_VBN
in_IN
IL_DT
6-induced_JJ
differentiation_NN
of_IN
SKW_JJ
6.4_CD
cells_NNS
into_IN
IgM-secreting_JJ
cells_NNS
._.
Binding_NNP
of_IN
erythroid_NN
and_CC
non-erythroid_JJ
nuclear_JJ
proteins_NNS
to_TO
the_DT
silencer_NN
of_IN
the_DT
human_JJ
epsilon-globin-encoding_NN
gene_NN
._.
To_TO
clarify_VB
the_DT
molecular_JJ
mechanisms_NNS
involved_VBN
in_IN
the_DT
developmental_JJ
control_NN
of_IN
hemoglobin-encoding_NN
genes_NNS
we_PRP
have_VBP
been_VBN
studying_VBG
the_DT
expression_NN
of_IN
these_DT
genes_NNS
in_IN
human_JJ
cells_NNS
in_IN
continuous_JJ
culture_NN
._.
We_PRP
have_VBP
previously_RB
reported_VBN
the_DT
presence_NN
of_IN
a_DT
transcriptional_JJ
control_NN
element_NN
with_IN
the_DT
properties_NNS
of_IN
a_DT
silencer_NN
extending_VBG
from_IN
-392_CD
to_TO
-177_CD
bp_NN
relative_JJ
to_TO
the_DT
cap_NN
site_NN
of_IN
the_DT
human_JJ
epsilon-globin-encoding_NN
gene_NN
(_-LRB-
Cao_FW
et_FW
al._FW
,_,
Proc.Natl.Acad.Sci.USA_NNP
86_CD
(_-LRB-
1989_CD
)_-RRB-
5306-5309_CD
)_-RRB-
._.
We_PRP
also_RB
showed_VBD
that_IN
this_DT
silencer_NN
has_VBZ
stronger_JJR
inhibitory_NN
activity_NN
in_IN
HeLa_NNP
cells_NNS
,_,
as_IN
compared_VBN
to_TO
K562_DT
human_JJ
erythroleukemia_NN
cells_NNS
._.
Using_VBG
deletion_NN
mutants_NNS
and_CC
cis-cloned_JJ
synthetic_JJ
oligodeoxyribonucleotides_NNS
in_IN
transient_JJ
expression_NN
assays_RB
,_,
nucleotide_JJ
sequences_NNS
responsible_JJ
for_IN
this_DT
effect_NN
have_VBP
now_RB
been_VBN
further_RB
delimited_VBN
to_TO
44_CD
bp_NN
located_VBN
from_IN
-294_CD
to_TO
-251_CD
bp_NN
._.
Gel_NNP
electrophoresis_NN
mobility_NN
shift_NN
assays_.
and_CC
DNaseI_JJ
footprinting_NN
assays_RB
demonstrate_VBP
that_IN
these_DT
negative_JJ
regulatory_JJ
sequences_NNS
are_VBP
recognized_VBN
differently_RB
by_IN
proteins_VBZ
present_JJ
in_IN
nuclear_JJ
extracts_NNS
obtained_VBN
from_IN
HeLa_NNP
and_CC
K562_NNP
cells_NNS
._.
Two_CD
binding_JJ
proteins_NNS
are_VBP
detected_VBN
in_IN
K562_NNP
nuclear_JJ
extracts_NNS
,_,
while_IN
only_RB
one_CD
is_VBZ
found_VBN
in_IN
extracts_NNS
from_IN
HeLa_NNP
cells_NNS
._.
Possible_JJ
mechanisms_NNS
by_IN
which_WDT
these_DT
proteins_NNS
may_MD
regulate_VB
transcription_NN
of_IN
the_DT
epsilon-globin-encoding_JJ
gene_NN
in_IN
erythroid_NN
and_CC
non-erythroid_JJ
cells_NNS
are_VBP
discussed_VBN
._.
Gangliosides_NNP
suppress_NN
tumor_NN
necrosis_NN
factor_NN
production_NN
in_IN
human_JJ
monocytes_NNS
._.
Both_DT
normal_JJ
and_CC
malignant_JJ
cells_NNS
contain_VBP
gangliosides_NNS
as_IN
important_JJ
cell_NN
membrane_NN
constituents_NNS
that_IN
,_,
after_IN
being_VBG
shed_VBN
,_,
may_MD
influence_VB
cells_NNS
of_IN
the_DT
immune_JJ
system_NN
._.
We_PRP
have_VBP
studied_VBN
the_DT
impact_NN
of_IN
gangliosides_NNS
on_IN
the_DT
expression_NN
of_IN
TNF_NNP
in_IN
blood_NN
monocytes_NNS
and_CC
in_IN
the_DT
monocytic_JJ
cell_NN
line_NN
Mono_NNP
Mac_NNP
6_CD
._.
Although_IN
under_IN
standard_JJ
culture_NN
conditions_NNS
,_,
bovine_JJ
brain_NN
gangliosides_NNS
(_-LRB-
100_CD
micrograms/ml_NN
)_-RRB-
suppressed_VBN
LPS-stimulated_JJ
TNF_NN
production_NN
5-fold_JJ
in_IN
PBMC_NNP
and_CC
10-fold_JJ
in_IN
Mono_NNP
Mac_NNP
6_CD
cells_NNS
,_,
suppression_NN
was_VBD
more_RBR
efficient_JJ
under_IN
serum-free_JJ
conditions_NNS
._.
Looking_VBG
at_IN
highly_RB
purified_VBN
gangliosides_NNS
,_,
GD3_NNP
,_,
GD1a_NNP
,_,
GM3_NNP
,_,
GM2_NNP
,_,
and_CC
GM1_NNP
were_VBD
all_DT
effective_JJ
in_IN
reducing_VBG
TNF_NN
production_NN
in_IN
PBMC_NNP
,_,
and_CC
in_IN
Mono_NNP
Mac_NNP
6_CD
by_IN
factor_NN
10_CD
to_TO
50_CD
._.
The_DT
suppressive_JJ
activity_NN
was_VBD
lost_VBN
in_IN
molecules_NNS
,_,
lacking_VBG
the_DT
sugar_NN
moiety_NN
or_CC
the_DT
lipid_JJ
moiety_NN
._.
Gangliosides_NNS
appear_VBP
to_TO
act_VB
at_IN
an_DT
early_JJ
step_NN
of_IN
activation_NN
in_IN
that_DT
TNF_NNP
transcripts_NNS
were_VBD
reduced_VBN
and_CC
the_DT
mobilization_NN
of_IN
the_DT
nuclear_JJ
factor_NN
kappa_NN
B_NNP
was_VBD
blocked_VBN
._.
Furthermore_RB
,_,
in_IN
time_NN
kinetics_NNS
,_,
gangliosides_NNS
were_VBD
effective_JJ
for_IN
up_RB
to_TO
30_CD
min_NN
after_IN
addition_NN
of_IN
LPS_NNP
,_,
but_CC
not_RB
thereafter_RB
._.
However_RB
,_,
the_DT
expression_NN
of_IN
the_DT
CD14_NNP
Ag_NNP
,_,
a_DT
receptor_NN
molecule_NN
for_IN
LPS-LPS_NNP
binding_JJ
protein_NN
complexes_NNS
,_,
was_VBD
unaffected_JJ
by_IN
gangliosides_NNS
._.
Finally_RB
,_,
when_WRB
using_VBG
Staphylococcus_NNP
aureus_NN
or_CC
platelet_NN
activating_NN
factor_NN
as_IN
a_DT
stimulus_NN
,_,
gangliosides_NNS
were_VBD
able_JJ
to_TO
suppress_VB
TNF_NNP
production_NN
in_IN
Mono_NNP
Mac_NNP
6_CD
cells_NNS
by_IN
factor_NN
5_CD
to_TO
10_CD
,_,
as_RB
well_RB
._.
On_IN
the_DT
other_JJ
hand_NN
,_,
phorbol_NN
ester-induced_JJ
production_NN
of_IN
O2-_NNP
was_VBD
similar_JJ
in_IN
cells_NNS
treated_VBN
with_IN
and_CC
without_IN
gangliosides_NNS
._.
Taken_VBN
together_RB
,_,
our_PRP$
data_NNS
demonstrate_VBP
that_IN
TNF_NNP
gene_NN
expression_NN
in_IN
monocytes_NNS
induced_VBN
by_IN
different_JJ
types_NNS
of_IN
stimuli_NNS
can_MD
be_VB
blocked_VBN
by_IN
gangliosides_NNS
at_IN
an_DT
early_JJ
step_NN
of_IN
signal_NN
transduction_NN
._.
T_NNP
cell-specific_JJ
negative_JJ
regulation_NN
of_IN
transcription_NN
of_IN
the_DT
human_JJ
cytokine_NN
IL-4_NN
._.
IL-4_NN
secreted_VBN
by_IN
activated_JJ
T_NNP
cells_NNS
is_VBZ
a_DT
pleiotropic_JJ
cytokine_NN
affecting_VBG
growth_NN
and_CC
differentiation_NN
of_IN
diverse_JJ
cell_NN
types_NNS
such_JJ
as_IN
T_NNP
cells_NNS
,_,
B_NNP
cells_NNS
,_,
and_CC
mast_NN
cells_NNS
._.
We_PRP
investigated_VBD
the_DT
upstream_JJ
regulatory_JJ
elements_NNS
of_IN
the_DT
human_JJ
IL-4_NN
promoter_NN
._.
A_DT
novel_NN
T_NNP
cell-specific_JJ
negative_JJ
regulatory_JJ
element_NN
(_-LRB-
NRE_NNP
)_-RRB-
composed_VBN
of_IN
two_CD
protein-binding_JJ
sites_NNS
were_VBD
mapped_VBN
in_IN
the_DT
5'_JJ
flanking_JJ
region_NN
of_IN
the_DT
IL-4_NNP
gene_NN
:_:
-311CTCCCTTCT-303_JJ
(_-LRB-
NRE-I_JJ
)_-RRB-
and_CC
-288CTTTTTGCTT-TGC-300_DT
(_-LRB-
NRE-II_NN
)_-RRB-
._.
A_DT
T_NNP
cell-specific_JJ
protein_NN
Neg-1_NN
and_CC
a_DT
ubiquitous_JJ
protein_NN
Neg-2_JJ
binding_NN
to_TO
NRE-I_NNP
and_CC
NRE-II_NNP
,_,
respectively_RB
,_,
were_VBD
identified_VBN
._.
Furthermore_RB
,_,
a_DT
positive_JJ
regulatory_JJ
element_NN
was_VBD
found_VBN
45_CD
bp_JJ
downstream_NN
of_IN
the_DT
NRE_NNP
._.
The_DT
enhancer_NN
activity_NN
of_IN
the_DT
PRE_JJ
was_VBD
completely_RB
suppressed_VBN
when_WRB
the_DT
NRE_NNP
was_VBD
present_JJ
._.
These_DT
data_NNS
suggest_VBP
that_IN
IL-4_DT
promoter_NN
activity_NN
is_VBZ
normally_RB
down-regulated_JJ
by_IN
an_DT
NRE_NNP
via_IN
repression_NN
of_IN
the_DT
enhancer_NN
positive_JJ
regulatory_JJ
element_NN
._.
These_DT
data_NNS
may_MD
have_VB
implications_NNS
for_IN
the_DT
stringent_JJ
control_NN
of_IN
IL-4_DT
expression_NN
in_IN
T_NNP
cells_NNS
._.
(_-LRB-
Regulatory_NNP
effect_NN
of_IN
insulin_NN
on_IN
glucocorticoid_NN
receptor_NN
in_IN
human_JJ
peripheral_JJ
leukocytes_NNS
)_-RRB-
The_DT
regulatory_JJ
effect_NN
of_IN
insulin_NN
on_IN
the_DT
specific_JJ
binding_JJ
power_NN
of_IN
glucocorticoid_NN
receptor_NN
(_-LRB-
GR_CD
)_-RRB-
of_IN
human_JJ
leukocytes_NNS
was_VBD
assessed_VBN
by_IN
the_DT
unoccupied_JJ
receptor_NN
sites_NNS
capable_JJ
of_IN
combining_VBG
with_IN
(3H)_JJ
labelled_JJ
dexamethasone_NN
measured_VBN
at_IN
3_CD
and_CC
24_CD
h_NN
after_IN
incubation_NN
with_IN
various_JJ
concentrations_NNS
of_IN
insulin_NN
added_VBN
to_TO
the_DT
medium_NN
._.
After_IN
3_CD
h_NN
incubation_IN
the_DT
specific_JJ
binding_NN
power_NN
with_IN
(3H)_JJ
Dex_NNP
was_VBD
decreased_VBN
by_IN
23.3_CD
+/-_,
10.0_CD
,_,
32.2_CD
+/-_,
13.2_CD
and_CC
54.3_CD
+/-_,
9.2_CD
%_NN
(_-LRB-
P_NNP
greater_JJR
than_IN
0.05_CD
,_,
P_NNP
greater_JJR
than_IN
0.05_CD
and_CC
P_NNP
less_RBR
than_IN
0.01_CD
as_IN
compared_VBN
with_IN
the_DT
control_NN
value_NN
of_IN
100_CD
in_IN
the_DT
absence_NN
of_IN
insulin_NN
)_-RRB-
respectively_RB
in_IN
the_DT
presence_NN
of_IN
20_CD
mU/L_NN
(_-LRB-
physiological_JJ
testing_NN
concentration_NN
)_-RRB-
,_,
200_CD
mU/L_NNS
(_-LRB-
physiological_JJ
upper_JJ
limit_NN
)_-RRB-
and_CC
2,000_CD
mU/L_NN
(_-LRB-
pharmacological_JJ
concentration_NN
)_-RRB-
insulin_NN
in_IN
the_DT
incubation_NN
medium_NN
._.
After_IN
24_CD
h_NN
incubation_IN
the_DT
decrease_NN
of_IN
these_DT
values_NNS
increased_VBD
respectively_RB
to_TO
43.5_CD
+/-_,
19.0_CD
,_,
56.1_CD
+/-_,
20.7_CD
and_CC
80.2_CD
+/-_,
15.5_CD
(_-LRB-
P_NNP
less_RBR
than_IN
0.05_CD
,_,
P_NNP
less_JJR
than_IN
0.01_CD
and_CC
P_NNP
less_RBR
than_IN
0.01_CD
compared_VBN
with_IN
control_NN
)_-RRB-
._.
Thus_RB
the_DT
inhibitory_JJ
effect_NN
of_IN
insulin_NN
on_IN
the_DT
GR_CD
binding_JJ
power_NN
is_VBZ
both_DT
dose-_NNS
and_CC
time-dependent_NN
,_,
which_WDT
strongly_RB
suggests_VBZ
that_IN
GR_CD
is_VBZ
tonically_RB
controlled_VBN
by_IN
insulin_NN
concentration_NN
change_NN
under_IN
physiological_JJ
conditions_NNS
._.
Human_JJ
T_NNP
cell_NN
activation_NN
through_IN
the_DT
activation-inducer_NN
molecule/CD69_NN
enhances_VBZ
the_DT
activity_NN
of_IN
transcription_NN
factor_NN
AP-1_NN
._.
The_DT
induction_NN
of_IN
the_DT
AP-1_NN
transcription_NN
factor_NN
has_VBZ
been_VBN
ascribed_VBN
to_TO
the_DT
early_JJ
events_NNS
leading_VBG
to_TO
T_NNP
cell_NN
differentiation_NN
and_CC
activation_NN
._.
We_PRP
have_VBP
studied_VBN
the_DT
regulation_NN
of_IN
AP-1_NN
activity_NN
in_IN
human_JJ
peripheral_NN
blood_NN
T_NNP
lymphocytes_VBZ
stimulated_VBN
through_IN
the_DT
activation_NN
inducer_NN
molecule_NN
(_-LRB-
AIM_NNP
)_-RRB-
/CD69_IN
activation_NN
pathway_NN
._.
Phorbol_JJ
esters_NNS
are_VBP
required_VBN
to_TO
induce_VB
AIM/CD69_DT
cell-surface_NN
expression_NN
as_RB
well_RB
as_IN
for_IN
triggering_VBG
the_DT
proliferation_NN
of_IN
T_NNP
cells_NNS
in_IN
conjunction_NN
with_IN
anti-AIM_JJ
mAb_NN
._.
Mobility_NNP
shift_NN
assays_IN
showed_VBD
that_IN
addition_NN
of_IN
anti-AIM_JJ
mAb_NN
to_TO
PMA-treated_NNP
T_NNP
lymphocytes_VBZ
markedly_RB
enhanced_VBN
the_DT
binding_JJ
activity_NN
of_IN
AP-1_NN
to_TO
its_PRP$
cognate_JJ
sequence_NN
,_,
the_DT
phorbol_NN
ester_NN
response_NN
element_NN
._.
In_IN
contrast_NN
,_,
anti-AIM_JJ
mAb_NN
did_VBD
not_RB
induce_VB
any_DT
change_NN
in_IN
the_DT
binding_JJ
activity_NN
of_IN
NF-kappa_NNP
B_NNP
,_,
a_DT
transcription_NN
factor_NN
whose_WP$
activity_NN
is_VBZ
also_RB
regulated_VBN
by_IN
protein_NN
kinase_NN
C_NNP
._.
The_DT
increase_NN
in_IN
AP-1-binding_JJ
activity_NN
was_VBD
accompanied_VBN
by_IN
the_DT
marked_JJ
stimulation_NN
of_IN
the_DT
transcription_NN
of_IN
c-fos_NNS
but_CC
not_RB
that_IN
of_IN
c-jun_NN
._.
Blockade_NNP
of_IN
the_DT
DNA-binding_JJ
complexes_NNS
with_IN
an_DT
anti-Fos_JJ
mAb_NN
demonstrated_VBD
a_DT
direct_JJ
participation_NN
of_IN
c-Fos_NNS
in_IN
the_DT
AP-1_NN
complexes_NNS
induced_VBN
by_IN
anti-AIM_JJ
mAb_NN
._.
Most_JJS
of_IN
the_DT
AP-1_NN
activity_NN
could_MD
be_VB
eliminated_VBN
when_WRB
the_DT
anti-AIM_JJ
mAb_NN
was_VBD
added_VBN
to_TO
the_DT
culture_NN
medium_NN
in_IN
the_DT
presence_NN
of_IN
cycloheximide_NN
,_,
suggesting_VBG
that_IN
de_FW
novo_FW
protein_NN
synthesis_NN
is_VBZ
crucial_JJ
for_IN
the_DT
induction_NN
of_IN
AP-1-binding_JJ
activity_NN
._.
These_DT
data_NNS
provide_VBP
the_DT
evidence_NN
that_IN
activation_NN
of_IN
human_JJ
peripheral_NN
blood_NN
T_NNP
cells_NNS
through_IN
the_DT
AIM_NNP
activation_NN
pathway_NN
regulate_VB
the_DT
activity_NN
of_IN
AP-1_NN
._.
Therefore_RB
,_,
this_DT
pathway_NN
appears_VBZ
as_IN
a_DT
crucial_JJ
step_NN
in_IN
the_DT
initiation_NN
of_IN
early_JJ
T_NNP
cell_NN
activation_NN
events_NNS
._.
cis-acting_JJ
sequences_NNS
required_VBN
for_IN
inducible_JJ
interleukin-2_JJ
enhancer_NN
function_NN
bind_VBP
a_DT
novel_NN
Ets-related_NNP
protein_NN
,_,
Elf-1_NNP
._.
The_DT
recent_JJ
definition_NN
of_IN
a_DT
consensus_NN
DNA_NN
binding_JJ
sequence_NN
for_IN
the_DT
Ets_NNP
family_NN
of_IN
transcription_NN
factors_NNS
has_VBZ
allowed_VBN
the_DT
identification_NN
of_IN
potential_JJ
Ets_NNP
binding_NN
sites_NNS
in_IN
the_DT
promoters_NNS
and_CC
enhancers_NNS
of_IN
many_JJ
inducible_JJ
T-cell_JJ
genes_NNS
._.
In_IN
the_DT
studies_NNS
described_VBN
in_IN
this_DT
report_NN
,_,
we_PRP
have_VBP
identified_VBN
two_CD
potential_JJ
Ets_NNS
binding_VBG
sites_NNS
,_,
EBS1_NNP
and_CC
EBS2_NNP
,_,
which_WDT
are_VBP
conserved_VBN
in_IN
both_DT
the_DT
human_JJ
and_CC
murine_JJ
interleukin-2_JJ
enhancers_NNS
._.
Within_IN
the_DT
human_JJ
enhancer_NN
,_,
these_DT
two_CD
sites_NNS
are_VBP
located_VBN
within_IN
the_DT
previously_RB
defined_VBN
DNase_NN
I_PRP
footprints_VBD
,_,
NFAT-1_NNP
and_CC
NFIL-2B_NNP
,_,
respectively_RB
._.
Electrophoretic_NNP
mobility_NN
shift_NN
and_CC
methylation_NN
interference_NN
analyses_NNS
demonstrated_VBD
that_IN
EBS1_NNP
and_CC
EBS2_NNP
are_VBP
essential_JJ
for_IN
the_DT
formation_NN
of_IN
the_DT
NFAT-1_NNP
and_CC
NFIL-2B_NNP
nuclear_JJ
protein_NN
complexes_NNS
._.
Furthermore_RB
,_,
in_IN
vitro_NN
mutagenesis_NN
experiments_NNS
demonstrated_VBD
that_IN
inducible_JJ
interleukin-2_JJ
enhancer_NN
function_NN
requires_VBZ
the_DT
presence_NN
of_IN
either_DT
EBS1_NNP
or_CC
EBS2_NNP
._.
Two_CD
well-characterized_JJ
Ets_NNP
family_NN
members_NNS
,_,
Ets-1_JJ
and_CC
Ets-2_JJ
,_,
are_VBP
reciprocally_RB
expressed_VBN
during_IN
T-cell_NNP
activation_NN
._.
Surprisingly_RB
,_,
however_RB
,_,
neither_DT
of_IN
these_DT
proteins_NNS
bound_VBN
in_IN
vitro_NN
to_TO
EBS1_NNP
or_CC
EBS2_NNP
._.
We_PRP
therefore_RB
screened_VBD
a_DT
T-cell_JJ
cDNA_NN
library_NN
under_IN
low-stringency_NN
conditions_NNS
with_IN
a_DT
probe_NN
from_IN
the_DT
DNA_NNP
binding_NN
domain_NN
of_IN
Ets-1_JJ
and_CC
isolated_VBN
a_DT
novel_NN
Ets_NNP
family_NN
member_NN
,_,
Elf-1_NNP
._.
Elf-1_NNP
contains_VBZ
a_DT
DNA_NNP
binding_NN
domain_NN
that_WDT
is_VBZ
nearly_RB
identical_JJ
to_TO
that_DT
of_IN
E74_NNP
,_,
the_DT
ecdysone-inducible_JJ
Drosophila_NNP
transcription_NN
factor_NN
required_VBN
for_IN
metamorphosis_NN
(_-LRB-
hence_RB
the_DT
name_NN
Elf-1_NNP
,_,
for_IN
E74-like_JJ
factor_NN
1_CD
)_-RRB-
._.
Elf-1_JJ
bound_VBN
specifically_RB
to_TO
both_DT
EBS1_NNP
and_CC
EBS2_NNP
in_IN
electrophoretic_JJ
mobility_NN
shift_NN
assays_VBZ
._.
It_PRP
also_RB
bound_VBD
to_TO
the_DT
purine-rich_JJ
CD3R_NNP
element_NN
from_IN
the_DT
human_JJ
immunodeficiency_NN
virus_NN
type_NN
2_CD
long_JJ
terminal_NN
repeat_NN
,_,
which_WDT
is_VBZ
required_VBN
for_IN
inducible_JJ
virus_NN
expression_NN
in_IN
response_NN
to_TO
signalling_VBG
through_IN
the_DT
T-cell_NN
receptor_NN
._.
Taken_VBN
together_RB
,_,
these_DT
results_NNS
demonstrate_VBP
that_IN
multiple_JJ
Ets_NNS
family_NN
members_NNS
with_IN
apparently_RB
distinct_JJ
DNA_NN
binding_NN
specificities_NNS
regulate_VB
differential_JJ
gene_NN
expression_NN
in_IN
resting_VBG
and_CC
activated_VBN
T_NNP
cells_NNS
._.
Mineralocorticoids_NNS
and_CC
mineralocorticoid_JJ
receptors_NNS
in_IN
mononuclear_JJ
leukocytes_NNS
in_IN
patients_NNS
with_IN
pregnancy-induced_JJ
hypertension_NN
._.
To_TO
examine_VB
the_DT
role_NN
of_IN
mineralocorticoids_NNS
in_IN
the_DT
pathophysiology_NN
of_IN
pregnancy-induced_JJ
hypertension_NN
(_-LRB-
PIH_NNP
)_-RRB-
,_,
we_PRP
studied_VBD
plasma_NN
aldosterone_NN
and_CC
18-hydroxycorticosterone_JJ
levels_NNS
in_IN
25_CD
women_NNS
with_IN
PIH_NNP
and_CC
25_CD
normal_JJ
pregnant_JJ
women_NNS
,_,
as_IN
controls_NNS
._.
Furthermore_RB
,_,
we_PRP
evaluated_VBD
the_DT
mineralocorticoid_NN
receptor_NN
(_-LRB-
MR_NNP
)_-RRB-
status_NN
in_IN
mononuclear_NN
leukocytes_NNS
in_IN
the_DT
2_CD
groups_NNS
._.
MR_NNP
count_NN
was_VBD
significantly_RB
(_-LRB-
P_NNP
less_RBR
than_IN
0.0005_CD
)_-RRB-
decreased_VBN
in_IN
the_DT
PIH_NNP
group_NN
(_-LRB-
148_CD
+/-_:
9_CD
binding_JJ
sites/cell_NN
)_-RRB-
compared_VBN
with_IN
the_DT
control_NN
group_NN
(_-LRB-
300_CD
+/-_:
17_CD
binding_NN
sites/cell_NN
;_:
mean_JJ
+/-_,
SEM_NNP
)_-RRB-
._.
Plasma_NNP
aldosterone_NN
in_IN
women_NNS
with_IN
PIH_NNP
was_VBD
281_CD
+/-_,
61_CD
pmol/L_NN
;_:
in_IN
normal_JJ
pregnant_JJ
women_NNS
it_PRP
was_VBD
697_CD
+/-_,
172_CD
pmol/L_NNS
(_-LRB-
P_NNP
less_RBR
than_IN
0.025_CD
)_-RRB-
._.
Plasma_NNP
18-hydroxycorticosterone_CD
was_VBD
also_RB
significantly_RB
(_-LRB-
P_NNP
less_RBR
than_IN
0.025_CD
)_-RRB-
lower_JJR
(_-LRB-
PIH_NNP
,_,
1071_CD
+/-_,
149_CD
pmol/L_NNS
;_:
controls_NNS
,_,
1907_CD
+/-_,
318_CD
pmol/L_NN
)_-RRB-
._.
These_DT
values_NNS
were_VBD
determined_VBN
at_IN
the_DT
onset_NN
of_IN
clinical_JJ
symptoms_NNS
of_IN
PIH_NNP
._.
These_DT
results_NNS
can_MD
not_RB
be_VB
explained_VBN
by_IN
receptor_NN
down-regulation_NN
due_JJ
to_TO
higher_JJR
levels_NNS
of_IN
mineralocorticoids_NNS
in_IN
PIH_NNP
;_:
a_DT
hitherto_NN
unknown_JJ
mineralocorticoid_NN
may_MD
,_,
thus_RB
,_,
be_VB
responsible_JJ
for_IN
the_DT
hypertension_NN
and_CC
altered_VBD
MR_NNP
status_NN
._.
Mineralocorticoid_PRP
effector_NN
mechanism_NN
in_IN
preeclampsia_NN
._.
Mineralocorticoid_PRP
effector_NN
mechanisms_NNS
were_VBD
evaluated_VBN
in_IN
29_CD
patients_NNS
with_IN
preeclampsia_NN
and_CC
in_IN
25_CD
uncomplicated_JJ
pregnancies_NNS
by_IN
measurement_NN
of_IN
plasma_NN
aldosterone_NN
,_,
levels_NNS
of_IN
mineralocorticoid_NN
receptor_NN
(_-LRB-
MR_NNP
)_-RRB-
in_IN
mononuclear_NN
leucocytes_NNS
,_,
and_CC
subtraction_NN
potential_JJ
difference_NN
(_-LRB-
SPD_NNP
;_:
rectal_JJ
minus_CC
oral_JJ
values_NNS
)_-RRB-
._.
Mean_JJ
values_NNS
for_IN
plasma_NN
aldosterone_NN
were_VBD
not_RB
different_JJ
between_IN
the_DT
two_CD
groups_NNS
,_,
but_CC
significant_JJ
differences_NNS
were_VBD
observed_VBN
for_IN
MR_NNP
(_-LRB-
preeclampsia_NN
,_,
81_CD
+/-_,
44_CD
receptors/cell_NN
;_:
controls_NNS
,_,
306_CD
+/-_,
168_CD
)_-RRB-
and_CC
SPD_NNP
(_-LRB-
preeclampsia_NN
,_,
65_CD
+/-_:
7_CD
mV_NN
;_:
controls_NNS
,_,
12_CD
+/-_NNS
5_CD
mV_NN
)_-RRB-
._.
In_IN
six_CD
cases_NNS
we_PRP
determined_VBD
MR_NNP
,_,
plasma_NN
aldosterone_NN
,_,
and_CC
SPD_NNP
in_IN
patients_NNS
with_IN
preeclampsia_NN
before_IN
and_CC
3_CD
months_NNS
after_IN
delivery_NN
._.
MR_NNP
were_VBD
reduced_VBN
before_IN
delivery_NN
(_-LRB-
96_CD
+/-_:
27_CD
receptors/cell_NN
)_-RRB-
,_,
and_CC
SPD_NNP
increased_VBD
(_-LRB-
64_CD
+/-_:
8_CD
mV_NN
)_-RRB-
,_,
with_IN
both_DT
parameters_NNS
normalizing_VBG
after_IN
delivery_NN
(_-LRB-
MR_NNP
,_,
242_CD
+/-_,
79_CD
;_:
SPD_NNP
,_,
14.0_CD
+/-_,
4_CD
mV_NN
)_-RRB-
._.
Aldosterone_NNP
levels_NNS
returned_VBD
to_TO
normal_JJ
nonpregnant_JJ
values_NNS
after_IN
delivery_NN
._.
These_DT
data_NNS
suggest_VBP
an_DT
important_JJ
role_NN
for_IN
abnormalities_NNS
in_IN
mineralocorticoid_JJ
effector_NN
mechanisms_NNS
in_IN
the_DT
etiology_NN
of_IN
preeclampsia_NN
and_CC
could_MD
be_VB
an_DT
useful_JJ
marker_NN
for_IN
diagnosis_NN
._.
A_DT
lymphoid_NN
cell-specific_JJ
nuclear_JJ
factor_NN
containing_VBG
c-Rel-like_JJ
proteins_NNS
preferentially_RB
interacts_VBZ
with_IN
interleukin-6_NN
kappa_NN
B-related_JJ
motifs_NNS
whose_WP$
activities_NNS
are_VBP
repressed_VBN
in_IN
lymphoid_JJ
cells_NNS
._.
The_DT
proto-oncoprotein_NN
c-Rel_NN
is_VBZ
a_DT
member_NN
of_IN
the_DT
nuclear_JJ
factor_NN
kappa_NN
B_NNP
transcription_NN
factor_NN
family_NN
,_,
which_WDT
includes_VBZ
the_DT
p50_NN
and_CC
p65_VBD
subunits_NNS
of_IN
nuclear_JJ
factor_NN
kappa_NN
B_NNP
._.
We_PRP
show_VBP
here_RB
that_IN
c-Rel_JJ
binds_NNS
to_TO
kappa_VB
B_NNP
sites_NNS
as_RB
homodimers_NNS
as_RB
well_RB
as_IN
heterodimers_NNS
with_IN
p50_NN
._.
These_DT
homodimers_NNS
and_CC
heterodimers_NNS
show_VBP
distinct_JJ
DNA-binding_NN
specificities_NNS
and_CC
affinities_NNS
for_IN
various_JJ
kappa_NN
B_NNP
motifs_NNS
._.
In_IN
particular_JJ
,_,
the_DT
c-Rel_JJ
homodimer_NN
has_VBZ
a_DT
high_JJ
affinity_NN
for_IN
interleukin-6_NN
(_-LRB-
IL-6_NN
)_-RRB-
and_CC
beta_JJ
interferon_NN
kappa_NN
B_NNP
sites_NNS
._.
In_IN
spite_NN
of_IN
its_PRP$
association_NN
with_IN
p50_NN
in_IN
vitro_NN
,_,
however_RB
,_,
we_PRP
found_VBD
a_DT
lymphoid_NN
cell-specific_JJ
nuclear_JJ
factor_NN
in_IN
vivo_NN
that_WDT
contains_VBZ
c-Rel_JJ
but_CC
not_RB
p50_VB
epitopes_NNS
;_:
this_DT
factor_NN
,_,
termed_VBN
IL-6_NN
kappa_NN
B_NNP
binding_JJ
factor_NN
II_NNP
,_,
appears_VBZ
to_TO
contain_VB
the_DT
c-Rel_JJ
homodimer_NN
and_CC
preferentially_RB
recognizes_VBZ
several_JJ
IL-6_NN
kappa_NN
B-related_JJ
kappa_NN
B_NNP
motifs_NNS
._.
Although_IN
it_PRP
has_VBZ
been_VBN
previously_RB
shown_VBN
that_IN
the_DT
IL-6_NN
kappa_NN
B_NNP
motif_NN
functions_NNS
as_IN
a_DT
potent_JJ
IL-1/tumor_JJ
necrosis_NN
factor-responsive_JJ
element_NN
in_IN
nonlymphoid_JJ
cells_NNS
,_,
its_PRP$
activity_NN
was_VBD
found_VBN
to_TO
be_VB
repressed_VBN
in_IN
lymphoid_JJ
cells_NNS
such_JJ
as_IN
a_DT
Jurkat_NNP
T-cell_NNP
line_NN
._.
We_PRP
also_RB
present_JJ
evidence_NN
that_IN
IL-6_DT
kappa_NN
B_NNP
binding_JJ
factor_NN
II_NNP
functions_VBZ
as_IN
a_DT
repressor_NN
specific_JJ
for_IN
IL-6_DT
kappa_NN
B-related_JJ
kappa_NN
B_NNP
motifs_NNS
in_IN
lymphoid_JJ
cells_NNS
._.
Modulation_NNP
of_IN
normal_JJ
erythroid_NN
differentiation_NN
by_IN
the_DT
endogenous_JJ
thyroid_NN
hormone_NN
and_CC
retinoic_JJ
acid_NN
receptors_NNS
:_:
a_DT
possible_JJ
target_NN
for_IN
v-erbA_JJ
oncogene_NN
action_NN
._.
The_DT
v-erbA_JJ
oncogene_NN
,_,
a_DT
mutated_JJ
version_NN
of_IN
the_DT
thyroid_NN
hormone_NN
receptor_NN
alpha_NN
(_-LRB-
c-erbA/TR-alpha_NN
)_-RRB-
,_,
inhibits_VBZ
erythroid_JJ
differentiation_NN
and_CC
constitutively_RB
represses_VBZ
transcription_NN
of_IN
certain_JJ
erythrocyte_JJ
genes_NNS
,_,
suggesting_VBG
a_DT
normal_JJ
function_NN
of_IN
the_DT
proto-oncogene_NN
c-erbA_NN
in_IN
erythropoiesis_NN
._.
Here_RB
we_PRP
demonstrate_VBP
that_IN
the_DT
endogenous_JJ
thyroid_NN
hormone_NN
receptor_NN
alpha_NN
(_-LRB-
c-erbA/TR-alpha_NN
)_-RRB-
and_CC
the_DT
closely_RB
related_VBN
retinoic_JJ
acid_NN
receptor_NN
alpha_NN
(_-LRB-
RAR-alpha_NN
)_-RRB-
play_VBP
a_DT
role_NN
in_IN
the_DT
regulation_NN
of_IN
normal_JJ
erythroid_NN
differentiation_NN
._.
Retinoic_JJ
acid_NN
(_-LRB-
RA_NNP
)_-RRB-
distinctly_RB
modulated_VBD
the_DT
erythroid_JJ
differentiation_NN
program_NN
of_IN
normal_JJ
erythroid_NN
progenitors_NNS
and_CC
erythroblasts_NNS
reversibly_RB
transformed_VBN
by_IN
a_DT
conditional_JJ
tyrosine_NN
kinase_NN
oncogene_NN
._.
When_WRB
added_VBN
pulsewise_NN
to_TO
immature_JJ
cells_NNS
,_,
differentiation_NN
was_VBD
accelerated_VBN
while_IN
more_RBR
mature_JJ
cells_NNS
underwent_IN
premature_JJ
cell_NN
death_NN
._.
Thyroid_NNP
hormone_NN
(_-LRB-
T3_DT
)_-RRB-
alone_RB
caused_VBD
similar_JJ
but_CC
weaker_JJR
effects_NNS
._.
Interestingly_RB
,_,
T3_RB
strongly_RB
enhanced_VBD
the_DT
action_NN
of_IN
RA_NNP
,_,
suggesting_VBG
cooperative_JJ
action_NN
of_IN
the_DT
two_CD
receptors_NNS
in_IN
modulating_VBG
erythroid_JJ
differentiation_NN
._.
Expression_NN
of_IN
the_DT
human_JJ
RAR-alpha_NN
in_IN
receptor-negative_JJ
erythroblasts_NNS
conferred_VBN
RA-induced_JJ
regulation_NN
of_IN
differentiation_NN
to_TO
the_DT
otherwise_RB
unresponsive_JJ
cells_NNS
,_,
thus_RB
showing_VBG
that_IN
the_DT
RAR-alpha_NNP
is_VBZ
essential_JJ
for_IN
the_DT
RA_NNP
effect_NN
._.
Likewise_RB
,_,
enhanced_JJ
expression_NN
of_IN
exogenous_JJ
c-erbA/TR-alpha_NN
in_IN
erythroblasts_NNS
rendered_VBD
them_PRP
susceptible_JJ
to_TO
modulation_NN
of_IN
differentiation_NN
by_IN
T3_NNP
,_,
suggesting_VBG
a_DT
similar_JJ
function_NN
of_IN
both_DT
receptors_NNS
._.
Leukotriene_NNP
B4_NNP
stimulates_NNS
c-fos_NNS
and_CC
c-jun_JJ
gene_NN
transcription_NN
and_CC
AP-1_JJ
binding_JJ
activity_NN
in_IN
human_JJ
monocytes_NNS
._.
We_PRP
have_VBP
examined_VBN
the_DT
effect_NN
of_IN
leukotriene_NN
B4_.
(_-LRB-
LTB4_NNP
)_-RRB-
,_,
a_DT
potent_JJ
lipid_JJ
proinflammatory_NN
mediator_NN
,_,
on_IN
the_DT
expression_NN
of_IN
the_DT
proto-oncogenes_NNS
c-jun_NN
and_CC
c-fos_NNS
._.
In_IN
addition_NN
,_,
we_PRP
looked_VBD
at_IN
the_DT
modulation_NN
of_IN
nuclear_JJ
factors_NNS
binding_JJ
specifically_RB
to_TO
the_DT
AP-1_JJ
element_NN
after_IN
LTB4_NNP
stimulation_NN
._.
LTB4_NNP
increased_VBD
the_DT
expression_NN
of_IN
the_DT
c-fos_JJ
gene_NN
in_IN
a_DT
time-_NNS
and_CC
concentration-dependent_JJ
manner_NN
._.
The_DT
c-jun_JJ
mRNA_NN
,_,
which_WDT
is_VBZ
constitutively_RB
expressed_VBN
in_IN
human_NN
peripheral-blood_NN
monocytes_NNS
at_IN
relatively_RB
high_JJ
levels_NNS
,_,
was_VBD
also_RB
slightly_RB
augmented_VBN
by_IN
LTB4_NNP
,_,
although_IN
to_TO
a_DT
much_RB
lower_JJR
extent_NN
than_IN
c-fos_NNS
._.
The_DT
kinetics_NNS
of_IN
expression_NN
of_IN
the_DT
two_CD
genes_NNS
were_VBD
also_RB
slightly_RB
different_JJ
,_,
with_IN
c-fos_JJ
mRNA_NNS
reaching_VBG
a_DT
peak_NN
at_IN
15_CD
min_NN
after_IN
stimulation_NN
and_CC
c-jun_NN
at_IN
30_CD
min_NN
._.
Both_DT
messages_NNS
rapidly_RB
declined_VBD
thereafter_RB
._.
Stability_NN
of_IN
the_DT
c-fos_JJ
and_CC
c-jun_JJ
mRNA_NN
was_VBD
not_RB
affected_VBN
by_IN
LTB4_NNP
,_,
as_IN
assessed_VBN
after_IN
actinomycin_NN
D_NNP
treatment_NN
._.
Nuclear_NNP
transcription_NN
studies_NNS
in_IN
vitro_NN
showed_VBD
that_IN
LTB4_NNP
increased_VBD
the_DT
transcription_NN
of_IN
the_DT
c-fos_JJ
gene_NN
7-fold_JJ
and_CC
the_DT
c-jun_JJ
gene_NN
1.4-fold_JJ
._.
Resting_VBG
monocytes_NNS
contained_VBN
nuclear_JJ
factors_NNS
binding_JJ
to_TO
the_DT
AP-1_JJ
element_NN
,_,
but_CC
stimulation_NN
of_IN
monocytes_NNS
with_IN
LTB4_NNP
induced_VBD
greater_JJR
AP-1-binding_JJ
activity_NN
of_IN
nuclear_JJ
proteins_NNS
._.
These_DT
results_NNS
indicate_VBP
that_IN
LTB4_NNP
may_MD
regulate_VB
the_DT
production_NN
of_IN
different_JJ
cytokines_NNS
by_IN
modulating_VBG
the_DT
yield_NN
and/or_IN
the_DT
function_NN
of_IN
transcription_NN
factors_NNS
such_JJ
as_IN
AP-1-binding_JJ
proto-oncogene_NN
products_NNS
._.
An_DT
11-base-pair_JJ
DNA_NN
sequence_NN
motif_NN
apparently_RB
unique_JJ
to_TO
the_DT
human_JJ
interleukin_NN
4_CD
gene_NN
confers_VBZ
responsiveness_NN
to_TO
T-cell_DT
activation_NN
signals_NNS
._.
We_PRP
have_VBP
identified_VBN
a_DT
DNA_NNP
segment_NN
that_WDT
confers_VBZ
responsiveness_NN
to_TO
antigen_JJ
stimulation_NN
signals_NNS
on_IN
the_DT
human_JJ
interleukin_NN
(_-LRB-
IL_NNP
)_-RRB-
4_CD
gene_NN
in_IN
Jurkat_NNP
cells_NNS
._.
The_DT
human_JJ
IL-4_NN
gene_NN
,_,
of_IN
10_CD
kilobases_NNS
,_,
is_VBZ
composed_VBN
of_IN
four_CD
exons_NNS
and_CC
three_CD
introns_NNS
._.
A_DT
cis-acting_JJ
element_NN
(_-LRB-
P_NNP
sequence_NN
)_-RRB-
resides_NNS
in_IN
the_DT
5'_JJ
upstream_JJ
region_NN
;_:
no_DT
additional_JJ
DNA_NN
segments_NNS
with_IN
enhancer_NN
activity_NN
were_VBD
identified_VBN
in_IN
the_DT
human_JJ
IL-4_NN
gene_NN
._.
For_IN
further_JJ
mapping_NN
purposes_NNS
,_,
a_DT
fusion_NN
promoter_NN
was_VBD
constructed_VBN
with_IN
the_DT
granulocyte/macrophage_NN
colony-stimulating_JJ
factor_NN
basic_NN
promoter_NN
containing_VBG
60_CD
base_NN
pairs_NNS
of_IN
sequence_NN
upstream_RB
from_IN
the_DT
cap_NN
site_NN
of_IN
the_DT
mouse_NN
granulocyte/macrophage_NN
colony-stimulating_NN
factor_NN
gene_NN
and_CC
various_JJ
lengths_NNS
of_IN
the_DT
5'_JJ
upstream_JJ
sequence_NN
of_IN
the_DT
IL-4_NNP
gene_NN
._.
The_DT
P_NNP
sequence_NN
was_VBD
located_VBN
between_IN
positions_NNS
-79_:
and_CC
-69_DT
relative_JJ
to_TO
the_DT
transcription_NN
start_NN
site_NN
of_IN
the_DT
human_JJ
IL-4_NN
gene_NN
,_,
and_CC
this_DT
location_NN
was_VBD
confirmed_VBN
by_IN
base-substitution_NN
mutations_NNS
._.
The_DT
plasmids_NNS
carrying_VBG
multiple_JJ
copies_NNS
of_IN
the_DT
P_NNP
sequence_NN
showed_VBD
higher_JJR
responsiveness_NN
to_TO
the_DT
stimulation_NN
._.
The_DT
binding_JJ
protein_NN
(_-LRB-
s_PRP
)_-RRB-
that_WDT
recognize_VBP
the_DT
P_NNP
sequence_NN
of_IN
the_DT
IL-4_NNP
gene_NN
were_VBD
identified_VBN
by_IN
DNA-mobility-shift_NNP
assays_NNPS
._.
The_DT
binding_NN
of_IN
NF(P)_NNP
(_-LRB-
a_DT
DNA_NN
binding_JJ
protein_NN
that_WDT
specifically_RB
recognizes_VBZ
the_DT
P_NNP
sequence_NN
)_-RRB-
to_TO
the_DT
P_NNP
sequence_NN
was_VBD
abolished_VBN
when_WRB
oligonucleotides_NNS
carrying_VBG
base_NN
substitutions_NNS
were_VBD
used_VBN
,_,
indicating_VBG
that_IN
the_DT
NF(P)_NNP
interaction_NN
is_VBZ
sequence-specific_JJ
and_CC
that_IN
binding_JJ
specificity_NN
of_IN
the_DT
protein_NN
paralleled_VBD
the_DT
sequence_NN
requirements_NNS
for_IN
IL-4_JJ
expression_NN
in_IN
vivo_NN
._.
The_DT
P_NNP
sequence_NN
does_VBZ
not_RB
share_VB
homology_NN
with_IN
the_DT
5'_JJ
upstream_JJ
sequence_NN
of_IN
the_DT
IL-2_NNP
gene_NN
,_,
even_RB
though_IN
surrounding_VBG
sequences_NNS
of_IN
the_DT
IL-4_NNP
gene_NN
share_NN
high_JJ
homology_NN
with_IN
the_DT
IL-2_JJ
gene_NN
._.
We_PRP
conclude_VBP
that_IN
a_DT
different_JJ
set_NN
of_IN
proteins_NNS
recognize_VBP
IL-2_JJ
and_CC
IL-4_JJ
genes_NNS
._.
Glucocorticoid_NNP
receptor_NN
binding_NN
in_IN
three_CD
different_JJ
cell_NN
types_NNS
in_IN
major_JJ
depressive_JJ
disorder_NN
:_:
lack_NN
of_IN
evidence_NN
of_IN
receptor_NN
binding_NN
defect_NN
._.
1_LS
._.
In_IN
order_NN
to_TO
further_RB
understand_VB
the_DT
apparent_JJ
glucocorticoid_NN
resistance_NN
in_IN
major_JJ
depressive_JJ
disorder_NN
,_,
circadian_NN
variation_NN
in_IN
cortisol_JJ
concentration_NN
,_,
dexamethasone_NN
suppression_NN
and_CC
glucocorticoid_NN
receptor_NN
binding_NN
in_IN
mononuclear_JJ
leukocytes_NNS
,_,
polymorphonuclear_NN
leukocytes_NNS
and_CC
cultured_JJ
skin_NN
fibroblasts_NNS
were_VBD
measured_VBN
in_IN
rigidly_RB
defined_VBN
major_JJ
depressive_JJ
disorder_NN
patients_NNS
and_CC
non-depressed_JJ
psychiatric_JJ
controls_NNS
._.
2_LS
._.
Mononuclear_NNP
leukocytes_VBZ
binding_JJ
to_TO
glucocorticoid_VB
correlated_VBN
significantly_RB
with_IN
polymorphonuclear_NN
leukocytes_NNS
binding_JJ
to_TO
glucocorticoid_VB
,_,
but_CC
both_DT
determinations_NNS
failed_VBD
to_TO
differentiate_VB
major_JJ
depressive_JJ
disorder_NN
and_CC
control_NN
subjects_NNS
._.
3_LS
._.
Initial_JJ
and_CC
post-dexamethasone_JJ
in_IN
vitro_NN
fibroblast_NN
binding_NN
to_TO
glucocorticoid_NN
was_VBD
not_RB
different_JJ
between_IN
major_JJ
depressive_JJ
disorder_NN
and_CC
non-depressed_JJ
control_NN
subjects_NNS
._.
4_LS
._.
The_DT
phenomenon_NN
of_IN
glucocorticoid_JJ
resistance_NN
in_IN
major_JJ
depressive_JJ
disorder_NN
remains_VBZ
unexplained_JJ
._.
Kinetics_NNP
of_IN
nuclear_JJ
translocation_NN
and_CC
turnover_NN
of_IN
the_DT
vitamin_NN
D_NN
receptor_NN
in_IN
human_JJ
HL60_CD
leukemia_NN
cells_NNS
and_CC
peripheral_JJ
blood_NN
lymphocytes_NNS
--_:
coincident_JJ
rise_NN
of_IN
DNA-relaxing_JJ
activity_NN
in_IN
nuclear_JJ
extracts_NNS
._.
High_NNP
affinity_NN
receptors_NNS
(_-LRB-
VDR_NN
)_-RRB-
for_IN
1,25-dihydroxycholecalciferol_CD
(_-LRB-
calcitriol_NN
)_-RRB-
are_VBP
expressed_VBN
in_IN
HL60_CD
human_JJ
leukemia_NN
cells_NNS
and_CC
in_IN
low_JJ
numbers_NNS
in_IN
peripheral_JJ
blood_NN
lymphocytes_NNS
(_-LRB-
PBL_NN
)_-RRB-
._.
HL60_CD
cells_NNS
,_,
expressing_VBG
some_DT
characteristics_NNS
of_IN
promyelocytes_NNS
,_,
can_MD
be_VB
induced_VBN
to_TO
monocytoid_VB
differentiation_NN
by_IN
calcitriol_NN
._.
Specific_JJ
nuclear_JJ
translocation_NN
of_IN
(3H)calcitriol/VDR_NN
was_VBD
examined_VBN
after_IN
exposure_NN
of_IN
whole_JJ
cells_NNS
to_TO
10(-9)_JJ
M/l_NNP
calcitriol_NN
in_IN
the_DT
presence_NN
and_CC
absence_NN
of_IN
a_DT
500-fold_JJ
excess_NN
of_IN
unlabeled_JJ
ligand_NN
and_CC
subsequent_JJ
isolation_NN
of_IN
nuclei_NNS
._.
Specific_JJ
nuclear_JJ
translocation_NN
of_IN
(3H)calcitriol/VDR_NNP
was_VBD
found_VBN
to_TO
be_VB
time_NN
dependent_JJ
reaching_VBG
a_DT
maximum_NN
of_IN
approximately_RB
2100_CD
binding_NN
sites/nucleus_NN
after_IN
3_CD
h_NN
of_IN
incubation_NN
in_IN
HL60_CD
cells_NNS
,_,
whereas_IN
a_DT
maximum_NN
of_IN
approximately_RB
310_CD
binding_NN
sites/nucleus_NN
was_VBD
found_VBN
after_IN
3_CD
h_NN
in_IN
PBL_NNP
._.
Pulse_JJ
exposure_NN
of_IN
HL60_NNP
to_TO
radiolabeled_DT
hormone_NN
for_IN
3_CD
h_NN
followed_VBN
by_IN
culture_NN
in_IN
medium_NN
without_IN
serum_NN
and_CC
calcitriol_JJ
lead_NN
to_TO
nuclear_JJ
retention_NN
of_IN
approximately_RB
1600_CD
radiolabeled_JJ
VDR_NN
by_IN
8_CD
h_NN
and_CC
approximately_RB
1000_CD
VDR_NN
by_IN
24_CD
h_NN
._.
Radiolabeled_VBN
VDR_NNP
disappeared_VBD
from_IN
the_DT
nuclear_JJ
compartment_NN
with_IN
a_DT
halflife_NN
of_IN
approximately_RB
30_CD
min_NN
if_IN
cells_NNS
were_VBD
cultured_VBN
with_IN
identical_JJ
concentrations_NNS
of_IN
unlabeled_JJ
hormone_NN
after_IN
the_DT
pulse_NN
(_-LRB-
pulse/chase-experiments_NNS
)_-RRB-
._.
No_DT
difference_NN
of_IN
VDR_NN
retention_NN
in_IN
pulse_NN
and_CC
pulse/chase-experiments_NNS
was_VBD
seen_VBN
in_IN
PBL_NNP
,_,
where_WRB
VDR_NNP
halflife_NN
was_VBD
approximately_RB
30_CD
min_NN
._.
No_DT
specific_JJ
translocation_NN
into_IN
the_DT
nuclear_JJ
compartment_NN
was_VBD
seen_VBN
when_WRB
isolated_VBN
nuclei_NNS
were_VBD
incubated_VBN
in_IN
(3H)calcitriol_NNP
._.
Radiolabeled_VBN
hormone/receptor_NN
complexes_NNS
of_IN
nuclei_JJ
isolated_VBN
from_IN
cells_NNS
exposed_VBN
for_IN
3_CD
h_NN
to_TO
radiolabeled_JJ
hormone_NN
--_:
in_IN
contrast_NN
to_TO
identical_JJ
experiments_NNS
with_IN
intact_JJ
cells_NNS
--_:
did_VBD
not_RB
disappear_VB
from_IN
the_DT
nuclear_JJ
compartment_NN
upon_IN
incubation_NN
of_IN
nuclei_JJ
with_IN
identical_JJ
concentrations_NNS
of_IN
the_DT
unlabeled_JJ
compound_NN
._.
The_DT
activity_NN
of_IN
DNA_NNP
relaxing_VBG
enzymes_NNS
(_-LRB-
e.g._FW
topoisomerases_NNS
I_PRP
and_CC
II_NNP
)_-RRB-
in_IN
nuclear_JJ
extracts_NNS
was_VBD
measured_VBN
using_VBG
a_DT
PBR_NNP
322-relaxation-assay_NN
._.
Enhanced_NNP
overall_JJ
enzyme_NN
activity_NN
was_VBD
found_VBN
in_IN
nuclear_JJ
extracts_NNS
by_IN
1_CD
h_NN
after_IN
incubation_NN
with_IN
calcitriol_NN
(_-LRB-
final_JJ
ethanol_NN
concentration_NN
0.0001_CD
%_NN
v/v_NN
)_-RRB-
in_IN
HL60_NNP
and_CC
PBL_NNP
._.
The_DT
enhanced_JJ
activity_NN
disappeared_VBD
after_IN
2_CD
h_NN
in_IN
PBL_NNP
,_,
whereas_IN
it_PRP
was_VBD
still_RB
enhanced_VBN
by_IN
4_CD
h_NN
in_IN
HL60_NNP
._.
No_DT
effect_NN
was_VBD
seen_VBN
in_IN
ethanol_NN
treated_VBN
controls_NNS
._.
We_PRP
conclude_VBP
that_IN
a_DT
specific_JJ
nuclear_JJ
translocation_NN
mechanism_NN
exists_VBZ
for_IN
calcitriol_NN
in_IN
both_DT
cell_NN
types_NNS
examined_VBN
,_,
most_RBS
likely_JJ
due_JJ
to_TO
translocation_NN
of_IN
receptor_NN
proteins_VBZ
after_IN
hormone_NN
binding_NN
._.
Translocated_NNP
hormone/receptor_NN
complexes_NNS
compete_VBP
for_IN
a_DT
limited_JJ
number_NN
of_IN
specific_JJ
nuclear_JJ
binding_NN
sites_NNS
._.
Enhanced_JJ
activity_NN
of_IN
topoisomerases_NNS
in_IN
nuclear_JJ
extracts_NNS
upon_IN
translocation_NN
of_IN
VDR_NNP
might_MD
reflect_VB
interaction_NN
of_IN
both_DT
within_IN
the_DT
nuclear_JJ
compartment_NN
,_,
thus_RB
initiating_VBG
DNA-unwinding_NN
,_,
a_DT
prerequisite_NN
of_IN
transcription_NN
initiation_NN
._.
The_DT
B_NNP
cell-specific_JJ
nuclear_JJ
factor_NN
OTF-2_NN
positively_RB
regulates_VBZ
transcription_NN
of_IN
the_DT
human_JJ
class_NN
II_NNP
transplantation_NN
gene_NN
,_,
DRA_NNP
._.
The_DT
promoter_NN
of_IN
the_DT
major_JJ
histocompatibility_NN
class_NN
II_NNP
gene_NN
DRA_NNP
contains_VBZ
an_DT
octamer_NN
element_NN
(_-LRB-
ATTTGCAT_NN
)_-RRB-
that_WDT
is_VBZ
required_VBN
for_IN
efficient_JJ
DRA_NNP
expression_NN
in_IN
B_NNP
cells_NNS
._.
Several_JJ
DNA-binding_JJ
proteins_NNS
are_VBP
known_VBN
to_TO
bind_NN
this_DT
sequence_NN
._.
The_DT
best_JJS
characterized_VBN
are_VBP
the_DT
B_NNP
cell-specific_JJ
OTF-2_NN
and_CC
the_DT
ubiquitous_JJ
OTF-1_NN
._.
This_DT
report_NN
directly_RB
demonstrates_VBZ
that_IN
OTF-2_JJ
but_CC
not_RB
OTF-1_JJ
regulates_VBZ
the_DT
DRA_NNP
gene_NN
._.
In_IN
vitro_NN
transcription_NN
analysis_NN
using_VBG
protein_NN
fractions_NNS
enriched_VBD
for_IN
the_DT
octamer-binding_JJ
protein_NN
OTF-2_RB
demonstrate_VBP
a_DT
positive_JJ
functional_JJ
role_NN
for_IN
OTF-2_NNP
in_IN
DRA_NNP
gene_NN
transcription_NN
._.
In_IN
contrast_NN
,_,
OTF-1-enriched_JJ
protein_NN
fractions_NNS
did_VBD
not_RB
affect_VB
DRA_NNP
gene_NN
transcription_NN
although_IN
it_PRP
functionally_RB
enhanced_VBD
the_DT
transcription_NN
of_IN
another_DT
gene_NN
._.
Recombinant_NNP
OTF-2_JJ
protein_NN
produced_VBN
by_IN
in_IN
vitro_NN
transcription/translation_NN
could_MD
also_RB
enhance_VB
DRA_NNP
gene_NN
transcription_NN
in_IN
vitro_NN
._.
In_IN
vivo_RB
transient_JJ
transfection_NN
studies_NNS
utilizing_VBG
an_DT
OTF-2_JJ
expression_NN
vector_NN
resulted_VBD
in_IN
similar_JJ
findings_NNS
:_:
that_DT
OTF-2_JJ
protein_NN
enhanced_VBN
DRA_NNP
gene_NN
transcription_NN
,_,
and_CC
that_IN
this_DT
effect_NN
requires_VBZ
an_DT
intact_JJ
octamer_NN
element_NN
._.
Together_RB
these_DT
results_NNS
constitute_VBP
the_DT
first_JJ
direct_JJ
evidence_NN
of_IN
a_DT
positive_JJ
role_NN
for_IN
the_DT
lymphoid-specific_JJ
octamer-binding_JJ
factor_NN
in_IN
DRA_NNP
gene_NN
transcription_NN
._.
(_-LRB-
Regulation_NN
of_IN
intracellular_JJ
cholesterol_NN
synthesis_NN
in_IN
hypercholesterolemia_NN
by_IN
glucocorticoids_NNS
)_-RRB-
The_DT
rate_NN
of_IN
endogenous_JJ
cholesterol_NN
synthesis_NN
in_IN
blood_NN
lymphocytes_NNS
and_CC
skin_NN
fibroblasts_NNS
from_IN
patients_NNS
with_IN
type_NN
IIa_NNP
hyperlipidemia_NN
was_VBD
found_VBN
to_TO
be_VB
increased_VBN
in_IN
comparison_NN
with_IN
healthy_JJ
donors_NNS
._.
The_DT
cells_NNS
of_IN
hyperlipidemic_JJ
patients_NNS
had_VBD
lowered_VBN
levels_NNS
of_IN
glucocorticoid_NN
receptors_NNS
concomitantly_RB
with_IN
a_DT
partial_JJ
loss_NN
of_IN
their_PRP$
sensitivity_NN
to_TO
glucocorticoids_NNS
._.
In_IN
fibroblasts_NNS
from_IN
patients_NNS
with_IN
hereditary_JJ
hypercholesteremia_NN
of_IN
homozygous_JJ
type_NN
the_DT
number_NN
of_IN
glucocorticoid_JJ
receptors_NNS
did_VBD
not_RB
exceed_VB
10_CD
%_NN
of_IN
their_PRP$
content_NN
in_IN
normal_JJ
cells_NNS
._.
The_DT
decrease_NN
of_IN
the_DT
number_NN
of_IN
glucocorticoid_JJ
receptors_NNS
in_IN
patients_NNS
with_IN
type_NN
IIa_NNP
hyperlipidemia_NN
seems_VBZ
to_TO
be_VB
a_DT
compensatory_JJ
response_NN
of_IN
cells_NNS
culminating_VBG
in_IN
activation_NN
of_IN
endogenous_JJ
cholesterol_NN
synthesis_NN
._.
Transcription_NNP
factor_NN
activation_NN
and_CC
functional_JJ
stimulation_NN
of_IN
human_JJ
monocytes_NNS
._.
Activation_NN
of_IN
expression_NN
of_IN
genes_NNS
encoding_VBG
transcription_NN
factors_NNS
:_:
c-fos_JJ
and_CC
c-jun_JJ
and_CC
formation_NN
of_IN
AP1_NNP
transcriptional_JJ
complex_NN
in_IN
human_JJ
monocytes_NNS
was_VBD
investigated_VBN
._.
It_PRP
was_VBD
found_VBN
that_IN
lipopolysaccharide_NN
induced_VBN
strongly_RB
both_DT
c-fos_NNS
and_CC
c-jun_JJ
expression_NN
as_RB
well_RB
as_IN
AP1_NNP
formation_NN
._.
Interferon_NNP
gamma_NN
activated_VBN
strongly_RB
c-fos_JJ
and_CC
weakly_JJ
c-jun_NN
and_CC
AP1_NNP
._.
Tumor_NN
necrosis_NN
factor_NN
induced_VBD
slightly_RB
c-fos_JJ
and_CC
had_VBD
almost_RB
no_DT
effect_NN
on_IN
c-jun_NN
and_CC
AP1_NNP
._.
The_DT
data_NNS
suggest_VBP
that_IN
differences_NNS
in_IN
functional_JJ
responses_NNS
elicited_VBN
in_IN
monocytes_NNS
by_IN
all_DT
three_CD
factors_NNS
may_MD
be_VB
dependent_JJ
on_IN
different_JJ
routes_NNS
on_IN
nuclear_JJ
signalling_NN
employed_VBN
by_IN
the_DT
factors_NNS
._.
Corticosteroid_NNP
receptors_NNS
and_CC
lymphocyte_NN
subsets_NNS
in_IN
mononuclear_JJ
leukocytes_NNS
in_IN
aging_VBG
._.
Plasma_NNP
cortisol_NN
and_CC
aldosterone_NN
levels_NNS
and_CC
number_NN
of_IN
related_JJ
receptors_NNS
in_IN
mononuclear_JJ
leukocytes_NNS
were_VBD
measured_VBN
in_IN
49_CD
healthy_JJ
aged_JJ
subjects_NNS
(_-LRB-
62-97_JJ
yr_NN
)_-RRB-
and_CC
in_IN
21_CD
adult_NN
controls_NNS
(_-LRB-
21-50_CD
yr_NN
)_-RRB-
._.
In_IN
all_DT
subjects_NNS
,_,
in_IN
addition_NN
,_,
lymphocyte_NN
subsets_NNS
were_VBD
determined_VBN
as_IN
an_DT
index_NN
of_IN
corticosteroid_JJ
action_NN
._.
The_DT
mean_JJ
number_NN
of_IN
type_NN
I_PRP
and_CC
type_NN
II_NNP
receptors_NNS
was_VBD
significantly_RB
lower_JJR
in_IN
aged_JJ
subjects_NNS
than_IN
in_IN
controls_NNS
(_-LRB-
respectively_RB
,_,
198_CD
+/-_,
96_CD
and_CC
272_CD
+/-_,
97_CD
receptors/cell_NN
for_IN
type_NN
I_PRP
,_,
and_CC
1,794_CD
+/-_,
803_CD
and_CC
3,339_CD
+/-_,
918_CD
for_IN
type_NN
II_NNP
receptors_NNS
)_-RRB-
._.
Plasma_NNP
aldosterone_NN
and_CC
cortisol_NN
and_CC
lymphocyte_NN
subsets_NNS
were_VBD
not_RB
different_JJ
in_IN
the_DT
two_CD
groups_NNS
._.
All_DT
of_IN
the_DT
parameters_NNS
were_VBD
also_RB
tested_VBN
for_IN
correlation_NN
,_,
and_CC
a_DT
significant_JJ
inverse_NN
correlation_NN
was_VBD
found_VBN
between_IN
age_NN
and_CC
type_NN
I_PRP
and_CC
type_NN
II_NNP
receptors_NNS
when_WRB
all_DT
subjects_NNS
were_VBD
plotted_VBN
and_CC
between_IN
aged_JJ
and_CC
CD4_NNP
and_CC
age_NN
and_CC
CD4/CD8_NN
in_IN
the_DT
aged_JJ
group_NN
._.
These_DT
data_NNS
show_VBP
that_IN
aged_JJ
subjects_NNS
have_VBP
reductions_NNS
of_IN
corticosteroid_NN
receptors_NNS
that_WDT
are_VBP
not_RB
associated_VBN
with_IN
increase_NN
of_IN
related_JJ
steroids_NNS
and_CC
that_IN
this_DT
situation_NN
probably_RB
represents_VBZ
a_DT
concomitant_NN
of_IN
the_DT
normal_JJ
aging_JJ
process_NN
._.
Stable_JJ
expression_NN
of_IN
HB24_NNP
,_,
a_DT
diverged_VBN
human_NN
homeobox_NN
gene_NN
,_,
in_IN
T_NNP
lymphocytes_NNS
induces_VBZ
genes_NNS
involved_VBN
in_IN
T_NNP
cell_NN
activation_NN
and_CC
growth_NN
._.
A_DT
diverged_VBN
homeobox_NN
gene_NN
,_,
HB24_NNP
,_,
which_WDT
is_VBZ
known_VBN
to_TO
be_VB
induced_VBN
following_VBG
lymphocyte_NN
activation_NN
,_,
was_VBD
introduced_VBN
into_IN
Jurkat_NNP
T_NNP
cells_NNS
under_IN
the_DT
control_NN
of_IN
a_DT
constitutive_JJ
promoter_NN
._.
Stable_JJ
transfectants_NNS
of_IN
HB24_NNP
were_VBD
established_VBN
that_IN
expressed_VBN
high_JJ
levels_NNS
of_IN
HB24_NNP
mRNA_NN
and_CC
possessed_VBD
an_DT
altered_JJ
phenotype_NN
suggestive_NN
of_IN
activated_JJ
T_NNP
cells_NNS
._.
A_DT
number_NN
of_IN
genes_NNS
known_VBN
to_TO
be_VB
induced_VBN
following_VBG
T_NNP
cell_NN
activation_NN
and_CC
associated_VBN
with_IN
cell_NN
growth_NN
were_VBD
increased_VBN
in_IN
the_DT
transfectants_NNS
,_,
including_VBG
c-fos_JJ
,_,
c-myc_JJ
,_,
c-myb_JJ
,_,
HLA-DR_NNP
,_,
lck_NN
,_,
NF-kappa_NNP
B_NNP
,_,
interleukin-2_NN
and_CC
interleukin-2_NN
receptor_NN
alpha_NN
(_-LRB-
IL-2R_JJ
alpha_NN
)_-RRB-
._.
Analysis_NN
of_IN
IL-2R_DT
alpha_NN
expression_NN
by_IN
transient_JJ
transfection_NN
of_IN
IL-2R_DT
alpha_NN
promoter_NN
constructs_NNS
into_IN
the_DT
HB24_NNP
transfectants_NNS
revealed_VBD
constitutive_JJ
expression_NN
(_-LRB-
about_IN
60_CD
%_NN
of_IN
phytohemagglutinin-_NNS
and_CC
phorbol_NN
ester-activated_JJ
Jurkat_NN
cells_NNS
)_-RRB-
that_WDT
was_VBD
dependent_JJ
on_IN
the_DT
kappa_NN
B_NNP
site_NN
in_IN
the_DT
IL-2R_JJ
alpha_NN
promoter_NN
._.
Furthermore_RB
,_,
as_IN
a_DT
consequence_NN
of_IN
the_DT
increased_VBN
HB24_IN
mRNA_NN
levels_NNS
,_,
the_DT
Jurkat_NNP
HB24_NNP
transfectants_NNS
proliferated_VBD
more_RBR
rapidly_RB
than_IN
control_NN
cell_NN
lines_NNS
._.
Thus_RB
,_,
stable_JJ
expression_NN
of_IN
HB24_NNP
confers_VBZ
an_DT
activation_NN
phenotype_NN
on_IN
a_DT
human_JJ
T_NNP
cell_NN
line_NN
,_,
implicating_VBG
this_DT
gene_NN
as_IN
an_DT
important_JJ
transcriptional_JJ
factor_NN
during_IN
T_NNP
cell_NN
activation_NN
and_CC
growth_NN
._.
Studies_NNS
on_IN
the_DT
biological_JJ
activity_NN
of_IN
triiodothyronine_NN
sulfate_NN
._.
Hepatic_JJ
microsomes_NNS
and_CC
isolated_VBN
hepatocytes_NNS
in_IN
short_JJ
term_NN
culture_NN
desulfate_NN
T3_NN
sulfate_NN
(_-LRB-
T3SO4_NNP
)_-RRB-
._.
We_PRP
,_,
therefore_RB
,_,
wished_VBD
to_TO
determine_VB
whether_IN
T3SO4_NNP
could_MD
mimic_VB
the_DT
action_NN
of_IN
thyroid_NN
hormone_NN
in_IN
vitro_NN
._.
T3SO4_PRP
had_VBD
no_DT
thyromimetic_JJ
effect_NN
on_IN
the_DT
activity_NN
of_IN
Ca(2+)-ATPase_JJ
in_IN
human_JJ
erythrocyte_NN
membranes_NNS
at_IN
doses_NNS
up_IN
to_TO
10,000_CD
times_NNS
the_DT
maximally_RB
effective_JJ
dose_NN
of_IN
T3_DT
(_-LRB-
10/(-10)_JJ
mol/L_NN
)_-RRB-
._.
In_IN
GH4C1_DT
pituitary_JJ
cells_NNS
,_,
T3SO4_NNP
failed_VBD
to_TO
displace_VB
(125I)T3_CD
from_IN
nuclear_JJ
receptors_NNS
in_IN
intact_JJ
cells_NNS
or_CC
soluble_JJ
preparations_NNS
._.
Thus_RB
,_,
T3SO4_NNP
was_VBD
not_RB
directly_RB
thyromimetic_JJ
in_IN
either_CC
an_DT
isolated_VBN
human_JJ
membrane_NN
system_NN
or_CC
a_DT
pituitary_JJ
cell_NN
system_NN
in_IN
which_WDT
nuclear_JJ
receptor_NN
occupancy_NN
correlates_VBZ
with_IN
GH_NNP
synthesis_NN
._.
Thyroid_NNP
hormones_NNS
inhibit_VBP
(3H)glycosaminoglycan_JJ
synthesis_NN
by_IN
cultured_JJ
human_JJ
dermal_NN
fibroblasts_NNS
,_,
and_CC
T3SO4_NNP
displayed_VBD
about_IN
0.5_CD
%_NN
the_DT
activity_NN
of_IN
T3_NNP
at_IN
72_CD
h_NN
._.
Human_JJ
fibroblasts_NNS
contained_VBN
roughly_RB
the_DT
same_JJ
level_NN
of_IN
microsomal_JJ
p-nitrophenyl_JJ
sulfatase_NN
activity_NN
as_IN
that_DT
previously_RB
observed_VBN
in_IN
hepatic_JJ
microsomes_NNS
._.
Propylthiouracil_NNP
(_-LRB-
50_CD
mumol/L_NN
)_-RRB-
did_VBD
not_RB
affect_VB
the_DT
action_NN
of_IN
T3SO4_NNP
,_,
suggesting_VBG
that_IN
deiodination_NN
was_VBD
not_RB
important_JJ
for_IN
this_DT
activity_NN
of_IN
T3SO4_NNP
._.
Thus_RB
,_,
it_PRP
appears_VBZ
T3SO4_NNP
has_VBZ
no_DT
intrinsic_JJ
biological_JJ
activity_NN
,_,
but_CC
,_,
under_IN
certain_JJ
circumstances_NNS
,_,
may_MD
be_VB
reactivated_VBN
by_IN
desulfation_NN
Nuclear_NNP
factor_NN
of_IN
activated_JJ
T_NNP
cells_NNS
contains_VBZ
Fos_NNP
and_CC
Jun_NNP
._.
The_DT
nuclear_JJ
factor_NN
NF-AT_WDT
(_-LRB-
ref._NN
1_CD
)_-RRB-
is_VBZ
induced_VBN
in_IN
T_NNP
cells_NNS
stimulated_VBN
through_IN
the_DT
T-cell_JJ
receptor/CD3_NN
complex_NN
,_,
and_CC
is_VBZ
required_VBN
for_IN
interleukin-2_JJ
(_-LRB-
IL-2_NN
)_-RRB-
gene_NN
induction_NN
._.
Although_IN
NF-AT_NNP
has_VBZ
not_RB
been_VBN
cloned_VBN
or_CC
purified_VBN
,_,
there_EX
is_VBZ
evidence_NN
that_IN
it_PRP
is_VBZ
a_DT
major_JJ
target_NN
for_IN
immunosuppression_NN
by_IN
cyclosporin_NN
A_DT
(_-LRB-
CsA_NN
)_-RRB-
and_CC
FK506_NNP
(_-LRB-
refs_JJ
2-7_CD
)_-RRB-
._.
NF-AT_JJ
induction_NN
may_MD
require_VB
two_CD
activation-dependent_JJ
events_NNS
:_:
the_DT
CsA-sensitive_JJ
translocation_NN
of_IN
a_DT
pre-existing_JJ
component_NN
and_CC
the_DT
CsA-resistant_JJ
synthesis_NN
of_IN
a_DT
nuclear_JJ
component_NN
._.
Here_RB
we_PRP
report_VBP
that_IN
the_DT
newly_RB
synthesized_VBN
nuclear_JJ
component_NN
of_IN
NF-AT_NN
is_VBZ
the_DT
transcription_NN
factor_NN
AP-1_NN
._.
We_PRP
show_VBP
that_IN
the_DT
inducible_JJ
nuclear_JJ
form_NN
of_IN
NF-AT_NNP
contains_VBZ
Fos_NNP
and_CC
Jun_NNP
proteins_NNS
._.
Furthermore_RB
,_,
we_PRP
identify_VBP
a_DT
pre-existing_JJ
NF-AT-binding_JJ
factor_NN
that_WDT
is_VBZ
present_JJ
in_IN
hypotonic_JJ
extracts_NNS
of_IN
unstimulated_JJ
T_NNP
cells_NNS
._.
On_IN
the_DT
basis_NN
of_IN
binding_NN
,_,
reconstitution_NN
and_CC
cotransfection_NN
experiments_NNS
,_,
we_PRP
propose_VBP
that_IN
activation_NN
of_IN
NF-AT_NN
occurs_VBZ
in_IN
at_IN
least_JJS
two_CD
stages_NNS
:_:
a_DT
CsA-sensitive_JJ
stage_NN
involving_VBG
modification_NN
and/or_CC
translocation_NN
of_IN
the_DT
pre-existing_JJ
NF-AT_NN
complex_NN
,_,
and_CC
a_DT
CsA-insensitive_JJ
stage_NN
involving_VBG
the_DT
addition_NN
of_IN
newly_RB
synthesized_VBN
Fos_NNP
or_CC
Fos/Jun_NNP
proteins_VBZ
to_TO
the_DT
pre-existing_JJ
complex_NN
._.
Interferon-gamma_NNP
potentiates_VBZ
the_DT
antiviral_JJ
activity_NN
and_CC
the_DT
expression_NN
of_IN
interferon-stimulated_JJ
genes_NNS
induced_VBN
by_IN
interferon-alpha_NN
in_IN
U937_NNP
cells_NNS
._.
Binding_NNP
of_IN
type_NN
I_PRP
interferon_MD
(_-LRB-
IFN-alpha/beta_NN
)_-RRB-
to_TO
specific_JJ
receptors_NNS
results_NNS
in_IN
the_DT
rapid_JJ
transcriptional_JJ
activation_NN
,_,
independent_JJ
of_IN
protein_NN
synthesis_NN
,_,
of_IN
IFN-alpha-stimulated_JJ
genes_NNS
(_-LRB-
ISGs_NNS
)_-RRB-
in_IN
human_JJ
fibroblasts_NNS
and_CC
HeLa_NNP
and_CC
Daudi_NNP
cell_NN
lines_NNS
._.
The_DT
binding_NN
of_IN
ISGF3_DT
(_-LRB-
IFN-stimulated_JJ
gene_NN
factor_NN
3_CD
)_-RRB-
to_TO
the_DT
conserved_JJ
IFN-stimulated_JJ
response_NN
element_NN
(_-LRB-
ISRE_NNP
)_-RRB-
results_NNS
in_IN
transcriptional_JJ
activation_NN
._.
This_DT
factor_NN
is_VBZ
composed_VBN
of_IN
a_DT
DNA-binding_JJ
protein_NN
(_-LRB-
ISGF3_JJ
gamma_NN
)_-RRB-
,_,
which_WDT
normally_RB
is_VBZ
present_JJ
in_IN
the_DT
cytoplasm_NN
,_,
and_CC
other_JJ
IFN-alpha-activated_JJ
proteins_NNS
which_WDT
preexist_VBP
as_IN
latent_JJ
cytoplasmic_JJ
precursors_NNS
(_-LRB-
ISGF3_JJ
alpha_NN
)_-RRB-
._.
We_PRP
have_VBP
found_VBN
that_IN
ISG_NNP
expression_NN
in_IN
the_DT
monocytic_JJ
U937_IN
cell_NN
line_NN
differs_VBZ
from_IN
most_JJS
cell_NN
lines_NNS
previously_RB
examined_VBN
._.
U937_VBG
cells_NNS
express_VBP
both_DT
type_NN
I_PRP
and_CC
type_NN
II_NNP
IFN_NNP
receptors_NNS
,_,
but_CC
only_RB
IFN-alpha_NNP
is_VBZ
capable_JJ
of_IN
inducing_VBG
antiviral_JJ
protection_NN
in_IN
these_DT
cells_NNS
._.
Pretreatment_NNP
with_IN
IFN-gamma_NNP
potentiates_VBZ
the_DT
IFN-alpha-induced_JJ
protection_NN
,_,
but_CC
IFN-gamma_NNP
alone_RB
does_VBZ
not_RB
have_VB
any_DT
antiviral_JJ
activity_NN
._.
ISG15_IN
mRNA_JJ
accumulation_NN
in_IN
U937_JJ
cells_NNS
is_VBZ
not_RB
detectable_JJ
before_IN
6_CD
h_NN
of_IN
IFN-alpha_NNP
treatment_NN
,_,
peaks_NNS
at_IN
24_CD
h_NN
,_,
and_CC
requires_VBZ
protein_NN
synthesis_NN
._.
Although_IN
IFN-gamma_NNP
alone_RB
does_VBZ
not_RB
induce_VB
ISG_NNP
expression_NN
,_,
IFN-gamma_NNP
pretreatment_NN
markedly_NN
increases_NNS
and_CC
hastens_VBZ
ISG_NNP
expression_NN
and_CC
transcriptional_JJ
induction_NN
._.
Nuclear_NNP
extracts_VBZ
assayed_VBN
for_IN
the_DT
presence_NN
of_IN
ISRE_NNP
binding_NN
factors_NNS
by_IN
electrophoretic_JJ
mobility_NN
shift_NN
assays_IN
show_NN
that_IN
ISGF3_NNP
is_VBZ
induced_VBN
by_IN
IFN-alpha_NNP
within_IN
6_CD
h_NN
from_IN
undetectable_JJ
basal_NN
levels_NNS
in_IN
untreated_JJ
U937_IN
cells_NNS
._.
Activation_NN
of_IN
ISGF3_NNP
alpha_NN
,_,
the_DT
latent_JJ
component_NN
of_IN
ISGF3_NNP
,_,
occurs_VBZ
rapidly_RB
._.
However_RB
,_,
the_DT
increase_NN
in_IN
ISGF3_NNP
activity_NN
ultimately_RB
correlates_VBZ
with_IN
the_DT
accumulation_NN
of_IN
ISGF3_DT
gamma_NN
induced_VBN
by_IN
IFN-alpha_NNP
or_CC
IFN-gamma_NNP
._.
(_-LRB-
ABSTRACT_NNP
TRUNCATED_NNP
AT_WDT
250_CD
WORDS_NNS
)_-RRB-
The_DT
mechanism_NN
of_IN
action_NN
of_IN
cyclosporin_NN
A_DT
and_CC
FK506_NNP
._.
CsA_NNP
and_CC
FK506_NNP
are_VBP
powerful_JJ
suppressors_NNS
of_IN
the_DT
immune_JJ
system_NN
,_,
most_JJS
notably_RB
of_IN
T_NNP
cells_NNS
._.
They_PRP
act_VBP
at_IN
a_DT
point_NN
in_IN
activation_NN
that_WDT
lies_VBZ
between_IN
receptor_NN
ligation_NN
and_CC
the_DT
transcription_NN
of_IN
early_JJ
genes_NNS
._.
Here_RB
,_,
Stuart_NNP
Schreiber_NNP
and_CC
Gerald_NNP
Crabtree_NNP
review_NN
recent_JJ
findings_NNS
that_IN
indicate_VBP
CsA_NNP
and_CC
FK506_NNP
operate_VBP
as_IN
prodrugs_NNS
:_:
they_PRP
bind_VBP
endogenous_JJ
intracellular_JJ
receptors_NNS
,_,
the_DT
immunophilins_NNS
,_,
and_CC
the_DT
resulting_VBG
complex_JJ
targets_NNS
the_DT
protein_NN
phosphatase_NN
,_,
calcineurin_NN
,_,
to_TO
exert_VB
the_DT
immunosuppressive_JJ
effect_NN
._.
(_-LRB-
Plasma_NN
cortisol_JJ
concentration_NN
and_CC
blood_NN
leukocyte_NN
content_NN
of_IN
glucocorticoid_JJ
receptors_NNS
in_IN
patients_NNS
with_IN
deficiency-cold_JJ
vs_JJ
deficiency-heat_JJ
syndromes_NNS
)_-RRB-
Plasma_NNP
cortisol_NN
concentration_NN
and_CC
blood_NN
leukocyte_NN
content_NN
of_IN
glucocorticoid_NN
receptors_NNS
(_-LRB-
GCR_NN
)_-RRB-
were_VBD
assayed_VBN
in_IN
20_CD
patients_NNS
with_IN
deficiency_NN
syndromes_NNS
,_,
10_CD
cold_JJ
in_IN
property_NN
(_-LRB-
deficiency-cold_JJ
)_-RRB-
,_,
the_DT
other_JJ
10_CD
hot_JJ
in_IN
property_NN
(_-LRB-
deficiency-heat_NN
)_-RRB-
,_,
and_CC
also_RB
in_IN
10_CD
healthy_JJ
individuals_NNS
as_IN
normal_JJ
control_NN
for_IN
the_DT
purpose_NN
of_IN
investigating_VBG
the_DT
nature_NN
of_IN
cold_JJ
and_CC
heat_NN
syndromes_NNS
._.
As_IN
a_DT
result_NN
,_,
the_DT
cases_NNS
of_IN
deficiency-cold_JJ
syndrome_NN
(_-LRB-
DCS_NNP
)_-RRB-
had_VBD
a_DT
normal_JJ
concentration_NN
of_IN
plasma_NN
cortisol_NN
but_CC
a_DT
lowered_VBD
content_NN
of_IN
GCR_NNP
in_IN
leukocytes_NNS
when_WRB
compared_VBN
with_IN
the_DT
normal_JJ
control_NN
(_-LRB-
P_NNP
less_RBR
than_IN
0.05_CD
)_-RRB-
;_:
the_DT
cases_NNS
of_IN
deficiency-heat_NN
syndrome_NN
(_-LRB-
DHS_NNP
)_-RRB-
had_VBD
a_DT
higher_JJR
concentration_NN
of_IN
plasma_NN
cortisol_NN
than_IN
the_DT
normal_JJ
control_NN
(_-LRB-
P_NNP
less_RBR
than_IN
0.05_CD
)_-RRB-
and_CC
a_DT
slightly_RB
higher_JJR
content_NN
of_IN
GCR_NNP
in_IN
leukocytes_NNS
._.
It_PRP
was_VBD
concluded_VBN
that_IN
the_DT
DCS_NNP
is_VBZ
characterized_VBN
by_IN
diminished_JJ
biological_JJ
effects_NNS
of_IN
adrenocortical_JJ
activity_NN
,_,
while_IN
the_DT
DHS_NNP
,_,
by_IN
augmented_JJ
biological_JJ
effects_NNS
of_IN
adrenocortical_JJ
activity_NN
._.
Specific_JJ
NF-kappa_NNP
B_NNP
subunits_NNS
act_VBP
in_IN
concert_NN
with_IN
Tat_NNP
to_TO
stimulate_VB
human_JJ
immunodeficiency_NN
virus_NN
type_NN
1_CD
transcription_NN
._.
NF-kappa_NNP
B_NNP
is_VBZ
a_DT
protein_NN
complex_NN
which_WDT
functions_VBZ
in_IN
concert_NN
with_IN
the_DT
tat-I_JJ
gene_NN
product_NN
to_TO
stimulate_VB
human_JJ
immunodeficiency_NN
virus_NN
(_-LRB-
HIV_NNP
)_-RRB-
transcription_NN
._.
To_TO
determine_VB
whether_IN
specific_JJ
members_NNS
of_IN
the_DT
NF-kappa_NNP
B_NNP
family_NN
contribute_VBP
to_TO
this_DT
effect_NN
,_,
we_PRP
have_VBP
examined_VBN
the_DT
abilities_NNS
of_IN
different_JJ
NF-kappa_NNP
B_NNP
subunits_NNS
to_TO
act_VB
with_IN
Tat-I_NNP
to_TO
stimulate_VB
transcription_NN
of_IN
HIV_NNP
in_IN
Jurkat_NNP
T-leukemia_NNP
cells_NNS
._.
We_PRP
have_VBP
found_VBN
that_IN
the_DT
p49_FW
(_-LRB-
100_CD
)_-RRB-
DNA_NN
binding_NN
subunit_NN
,_,
together_RB
with_IN
p65_NN
,_,
can_MD
act_VB
in_IN
concert_NN
with_IN
Tat-I_NNP
to_TO
stimulate_VB
the_DT
expression_NN
of_IN
HIV-CAT_JJ
plasmid_NN
._.
Little_JJ
effect_NN
was_VBD
observed_VBN
with_IN
50-kDa_JJ
forms_NNS
of_IN
p105_DT
NF-kappa_NNP
B_NNP
or_CC
rel_NN
,_,
in_IN
combination_NN
with_IN
p65_NN
or_CC
full-length_JJ
c-rel_NN
,_,
which_WDT
do_VBP
not_RB
stimulate_VB
the_DT
HIV_NNP
enhancer_NN
in_IN
these_DT
cells_NNS
._.
These_DT
findings_NNS
suggest_VBP
that_IN
the_DT
combination_NN
of_IN
p49_DT
(_-LRB-
100_CD
)_-RRB-
and_CC
p65_VBD
NF-kappa_NNP
B_NNP
can_MD
act_VB
in_IN
concert_NN
with_IN
the_DT
tat-I_JJ
gene_NN
product_NN
to_TO
stimulate_VB
the_DT
synthesis_NN
of_IN
HIV_NNP
RNA_NNP
._.
Activation_NN
of_IN
the_DT
human_JJ
immunodeficiency_NN
virus_NN
type_NN
1_CD
enhancer_NN
is_VBZ
not_RB
dependent_JJ
on_IN
NFAT-1_JJ
._.
The_DT
function_NN
of_IN
a_DT
putative_JJ
NFAT-1_JJ
site_NN
in_IN
the_DT
human_JJ
immunodeficiency_NN
virus_NN
type_NN
1_CD
enhancer_NN
has_VBZ
been_VBN
analyzed_VBN
._.
Activation_NN
by_IN
the_DT
T-cell_NN
antigen_NN
receptor_NN
is_VBZ
minimal_JJ
in_IN
Jurkat_NNP
cells_NNS
and_CC
is_VBZ
mediated_VBN
by_IN
the_DT
kappa_NN
B_NNP
sites_NNS
._.
The_DT
putative_JJ
NFAT-1_JJ
region_NN
is_VBZ
not_RB
required_VBN
for_IN
the_DT
response_NN
to_TO
anti-CD3_JJ
or_CC
to_TO
mitogens_NNS
in_IN
T-cell_NN
,_,
B-cell_NNP
,_,
or_CC
monocyte/macrophage_NN
leukemia_NN
lines_NNS
,_,
nor_CC
is_VBZ
it_PRP
a_DT
cis-acting_JJ
negative_JJ
regulatory_JJ
element_NN
._.
Protein_NNP
kinase_NN
C_NNP
activation_NN
and_CC
protooncogene_NN
expression_NN
in_IN
differentiation/retrodifferentiation_NN
of_IN
human_JJ
U-937_CC
leukemia_NN
cells_NNS
._.
Human_JJ
U-937_JJ
leukemia_NN
cells_NNS
differentiate_VBP
along_IN
the_DT
monocytic_JJ
lineage_NN
following_VBG
3-day_JJ
exposures_NNS
to_TO
12-O-tetradecanoylphorbol-13-acetate_DT
(_-LRB-
TPA_NNP
)_-RRB-
._.
This_DT
induction_NN
of_IN
differentiation_NN
is_VBZ
accompanied_VBN
by_IN
adherence_NN
and_CC
loss_NN
of_IN
proliferation_NN
,_,
as_RB
well_RB
as_IN
expression/repression_NN
of_IN
differentiation-associated_JJ
genes_NNS
._.
Long_JJ
term_NN
culture_NN
of_IN
TPA-differentiated_JJ
U-937_JJ
cells_NNS
in_IN
the_DT
absence_NN
of_IN
phorbol_NN
ester_NN
for_IN
32-36_CD
days_NNS
resulted_VBD
in_IN
a_DT
process_NN
of_IN
retrodifferentiation_NN
._.
The_DT
retrodifferentiated_JJ
cells_NNS
detached_VBN
from_IN
the_DT
substrate_NN
and_CC
reinitiated_VBD
proliferation_NN
._.
Other_JJ
cellular_JJ
parameters_NNS
,_,
such_JJ
as_IN
glycosidase_NN
activities_NNS
,_,
cytokine_NN
release_NN
,_,
and_CC
filament_NN
expression_NN
,_,
returned_VBD
to_TO
levels_NNS
similar_JJ
to_TO
that_DT
observed_VBN
in_IN
uninduced_JJ
cells_NNS
._.
Treatment_NNP
of_IN
U-937_JJ
cells_NNS
with_IN
TPA_NNP
resulted_VBD
in_IN
a_DT
rapid_JJ
translocation_NN
of_IN
protein_NN
kinase_NN
C_NNP
(_-LRB-
PKC_NNP
)_-RRB-
from_IN
the_DT
cytosol_NN
to_TO
cell_NN
membrane_NN
fractions_NNS
within_IN
2-8_CD
min_NN
._.
Increased_VBN
levels_NNS
of_IN
membrane-associated_JJ
PKC_NNP
activity_NN
persisted_VBD
until_IN
17-29_CD
days_NNS
._.
However_RB
,_,
longer_JJR
periods_NNS
of_IN
incubation_NN
were_VBD
associated_VBN
with_IN
a_DT
return_NN
to_TO
the_DT
distribution_NN
of_IN
PKC_NNP
in_IN
control_NN
cells_NNS
._.
Activation_NN
of_IN
PKC_NNP
has_VBZ
been_VBN
implicated_VBN
in_IN
the_DT
regulation_NN
of_IN
certain_JJ
immediate_JJ
early_JJ
response_NN
genes_NNS
,_,
and_CC
in_IN
the_DT
present_JJ
studies_NNS
,_,
TPA_NNP
rapidly_RB
induced_VBD
c-fos_JJ
and_CC
c-jun_JJ
gene_NN
expression_NN
._.
Levels_NNP
of_IN
c-fos_JJ
and_CC
c-jun_JJ
transcripts_NNS
remained_VBD
elevated_JJ
during_IN
periods_NNS
of_IN
PKC_NNP
activation_NN
and_CC
also_RB
returned_VBD
to_TO
levels_NNS
observed_VBN
in_IN
control_NN
cells_NNS
by_IN
30-36_CD
days_NNS
,_,
when_WRB
the_DT
cells_NNS
entered_VBN
retrodifferentiation_NN
._.
Staurosporine_NNP
,_,
a_DT
nonspecific_JJ
inhibitor_NN
of_IN
PKC_NNP
,_,
partially_RB
blocked_VBD
TPA-induced_NNP
adherence_NN
and_CC
growth_NN
inhibition_NN
and_CC
concomitantly_RB
prevented_VBD
TPA-induced_NNP
c-fos_NNS
and_CC
c-jun_JJ
gene_NN
expression_NN
._.
(_-LRB-
ABSTRACT_NNP
TRUNCATED_NNP
AT_WDT
250_CD
WORDS_NNS
)_-RRB-
The_DT
promoter_NN
of_IN
the_DT
CD19_NNP
gene_NN
is_VBZ
a_DT
target_NN
for_IN
the_DT
B-cell-specific_JJ
transcription_NN
factor_NN
BSAP_NNP
._.
The_DT
CD19_NNP
protein_NN
is_VBZ
expressed_VBN
on_IN
the_DT
surface_NN
of_IN
all_DT
B-lymphoid_JJ
cells_NNS
with_IN
the_DT
exception_NN
of_IN
terminally_RB
differentiated_JJ
plasma_NN
cells_NNS
and_CC
has_VBZ
been_VBN
implicated_VBN
as_IN
a_DT
signal-transducing_NN
receptor_NN
in_IN
the_DT
control_NN
of_IN
proliferation_NN
and_CC
differentiation_NN
._.
Here_RB
we_PRP
demonstrate_VBP
complete_JJ
correlation_NN
between_IN
the_DT
expression_NN
pattern_NN
of_IN
the_DT
CD19_NNP
gene_NN
and_CC
the_DT
B-cell-specific_JJ
transcription_NN
factor_NN
BSAP_NNP
in_IN
a_DT
large_JJ
panel_NN
of_IN
B-lymphoid_JJ
cell_NN
lines_NNS
._.
The_DT
human_JJ
CD19_NNP
gene_NN
has_VBZ
been_VBN
cloned_VBN
,_,
and_CC
several_JJ
BSAP-binding_JJ
sites_NNS
have_VBP
been_VBN
mapped_VBN
by_IN
in_IN
vitro_NN
protein-DNA_NN
binding_NN
studies_NNS
._.
In_IN
particular_JJ
,_,
a_DT
high-affinity_JJ
BSAP-binding_JJ
site_NN
instead_RB
of_IN
a_DT
TATA_NNP
sequence_NN
is_VBZ
located_VBN
in_IN
the_DT
-30_NN
promoter_NN
region_NN
upstream_RB
of_IN
a_DT
cluster_NN
of_IN
heterogeneous_JJ
transcription_NN
start_VB
sites_NNS
._.
Moreover_RB
,_,
this_DT
site_NN
is_VBZ
occupied_VBN
by_IN
BSAP_NNP
in_IN
vivo_RB
in_IN
a_DT
CD19-expressing_JJ
B-cell_NN
line_NN
but_CC
not_RB
in_IN
plasma_NN
or_CC
HeLa_NNP
cells_NNS
._.
This_DT
high-affinity_NN
site_NN
has_VBZ
been_VBN
conserved_VBN
in_IN
the_DT
promoters_NNS
of_IN
both_DT
human_JJ
and_CC
mouse_NN
CD19_IN
genes_NNS
and_CC
was_VBD
furthermore_RB
shown_VBN
to_TO
confer_VB
B-cell_JJ
specificity_NN
to_TO
a_DT
beta-globin_NN
reporter_NN
gene_NN
in_IN
transient_JJ
transfection_NN
experiments_NNS
._.
In_IN
addition_NN
,_,
BSAP_NNP
was_VBD
found_VBN
to_TO
be_VB
the_DT
only_JJ
abundant_JJ
DNA-binding_JJ
activity_NN
of_IN
B-cell_JJ
nuclear_JJ
extracts_NNS
that_IN
interacts_NNS
with_IN
the_DT
CD19_NNP
promoter_NN
._.
Together_RB
,_,
this_DT
evidence_NN
strongly_RB
implicates_VBZ
BSAP_NNP
in_IN
the_DT
regulation_NN
of_IN
the_DT
CD19_NNP
gene_NN
._.
Reduced_VBN
susceptibility_NN
to_TO
HIV-1_PRP$
infection_NN
of_IN
ethyl-methanesulfonate-treated_JJ
CEM_NNP
subclones_NNS
correlates_VBZ
with_IN
a_DT
blockade_NN
in_IN
their_PRP$
protein_NN
kinase_NN
C_NNP
signaling_VBG
pathway_NN
._.
We_PRP
have_VBP
described_VBN
the_DT
isolation_NN
of_IN
chemically_RB
induced_VBN
CEM_NNP
subclones_NNS
that_WDT
express_VBP
CD4_NNP
receptors_NNS
and_CC
bind_NN
soluble_JJ
gp120_NN
,_,
yet_RB
show_VB
a_DT
markedly_NN
reduced_VBN
susceptibility_NN
to_TO
infection_NN
with_IN
HIV-1_NN
._.
Two_CD
subclones_NNS
were_VBD
found_VBN
to_TO
have_VB
an_DT
abnormal_JJ
response_NN
to_TO
the_DT
protein_NN
kinase_NN
C_NNP
(_-LRB-
PKC_NNP
)_-RRB-
activator_NN
PMA_NNP
._.
PMA_NNP
treatment_NN
induced_VBN
CD3_NNP
and_CC
CD25_NNP
(_-LRB-
IL-2R_NN
)_-RRB-
receptors_NNS
on_IN
the_DT
parental_JJ
line_NN
and_CC
on_IN
other_JJ
ethyl-methanesulfonate-derived_JJ
subclones_NNS
,_,
but_CC
not_RB
on_IN
these_DT
two_CD
mutants_NNS
._.
Direct_JJ
assays_IN
of_IN
PKC_NNP
activity_NN
were_VBD
conducted_VBN
._.
Total_JJ
cellular_JJ
PKC_NNS
enzymatic_JJ
activity_NN
was_VBD
found_VBN
to_TO
be_VB
normal_JJ
in_IN
these_DT
subclones_NNS
._.
PMA-induced_JJ
CD4_NNP
down-modulation_NN
occurred_VBD
normally_RB
._.
In_IN
addition_NN
,_,
activation_NN
of_IN
c-raf_JJ
kinase_NN
was_VBD
normal_JJ
._.
Since_IN
HIV-1_PRP$
long_JJ
terminal_NN
repeat_NN
contains_VBZ
two_CD
functional_JJ
nuclear_JJ
factor_NN
kB_NN
(_-LRB-
NF-kB_NN
)_-RRB-
regulatory_JJ
elements_NNS
,_,
we_PRP
studied_VBD
the_DT
ability_NN
of_IN
PMA_NNP
to_TO
induce_VB
NF-kB_NNP
binding_NN
activity_NN
by_IN
different_JJ
assays_NNS
._.
Chloramphenicol_NNP
acetyl_NN
transferase_NN
(_-LRB-
CAT_NN
)_-RRB-
assays_VBZ
using_VBG
the_DT
HIV-1_NN
(_-LRB-
-139_CC
)_-RRB-
long_JJ
terminal_NN
repeat-CAT_NN
construct_VB
showed_VBN
no_DT
PMA_NNP
induction_NN
of_IN
CAT_NN
activity_NN
in_IN
these_DT
subclones_NNS
(_-LRB-
unlike_IN
the_DT
parental_JJ
line_NN
and_CC
other_JJ
subclones_NNS
)_-RRB-
._.
Okadaic_JJ
acid_NN
,_,
an_DT
inhibitor_NN
of_IN
phosphatases_NNS
1_CD
and_CC
2A_CD
,_,
did_VBD
not_RB
overcome_VB
the_DT
defect_NN
in_IN
these_DT
subclones_NNS
._.
Gel_NNP
retardation_NN
assays_VBD
,_,
using_VBG
a_DT
32P-probe_NN
containing_VBG
the_DT
HIV-1_NNP
NF-kB_NNP
probe_NN
and_CC
nuclear_JJ
extracts_NNS
from_IN
PMA-treated_JJ
cells_NNS
,_,
showed_VBD
significantly_RB
reduced_VBN
induction_NN
of_IN
nuclear_JJ
NF-kB_NNP
binding_JJ
proteins_NNS
in_IN
these_DT
two_CD
subclones_NNS
compared_VBN
with_IN
wild_JJ
type_NN
CEM_NNP
and_CC
a_DT
control_NN
subclone_NN
._.
Deoxycholate_JJ
treatment_NN
of_IN
cytoplasmic_JJ
extracts_NNS
from_IN
these_DT
subclones_NNS
released_VBD
much_RB
reduced_VBN
NF-kB_NNP
binding_JJ
proteins_NNS
from_IN
their_PRP$
cytoplasmic_JJ
pools_NNS
._.
Thus_RB
,_,
reduced_JJ
levels_NNS
of_IN
PKC-induced_JJ
nuclear_JJ
NF-kB_NN
activity_NN
in_IN
two_CD
T_NNP
cell_NN
subclones_NNS
did_VBD
not_RB
affect_VB
their_PRP$
normal_JJ
cell_NN
growth_NN
,_,
but_CC
correlated_VBD
with_IN
a_DT
pronounced_VBN
reduction_NN
in_IN
their_PRP$
susceptibility_NN
to_TO
HIV-1_PRP$
infection_NN
._.
Eicosanoids_NNS
in_IN
breast_NN
cancer_NN
patients_NNS
before_RB
and_CC
after_IN
mastectomy_NN
._.
In_IN
19_CD
patients_NNS
with_IN
a_DT
malignant_JJ
breast_NN
tumor_NN
,_,
tumor_NN
tissue_NN
and_CC
blood_NN
were_VBD
taken_VBN
to_TO
determine_VB
the_DT
eicosanoid_JJ
profile_NN
and_CC
platelet_NN
aggregation_NN
._.
Values_NNS
were_VBD
compared_VBN
with_IN
those_DT
of_IN
patients_NNS
with_IN
benign_JJ
tumors_NNS
(_-LRB-
n_NN
=_SYM
4_CD
)_-RRB-
,_,
or_CC
undergoing_VBG
a_DT
mammary_JJ
reduction_NN
(_-LRB-
n_NN
=_SYM
7_CD
)_-RRB-
._.
Postoperatively_RB
,_,
blood_NN
was_VBD
taken_VBN
as_RB
well_RB
in_IN
order_NN
to_TO
compare_VB
pre-_NNS
and_CC
postoperative_JJ
values_NNS
._.
Eicosanoids_NNS
were_VBD
measured_VBN
in_IN
peripheral_JJ
blood_NN
monocytes_NNS
and_CC
mammary_JJ
tissue_NN
by_IN
means_NNS
of_IN
HPLC_NNP
;_:
furthermore_RB
,_,
TXA2_NNP
,_,
6-keto-PGF1_JJ
alpha_NN
,_,
and_CC
PGE2_NNS
were_VBD
determined_VBN
by_IN
RIA_NNP
._.
Differences_NNS
in_IN
pre-_NNS
and_CC
postoperative_JJ
values_NNS
of_IN
cancer_NN
patients_NNS
were_VBD
seen_VBN
in_IN
plasma_NN
RIA_NNP
values_VBZ
:_:
PGE2_NNP
and_CC
6-k-PGF1_JJ
alpha_NN
were_VBD
significantly_RB
higher_JJR
preoperatively_NN
when_WRB
compared_VBN
with_IN
postoperatively_RB
,_,
however_RB
,_,
such_JJ
differences_NNS
were_VBD
seen_VBN
in_IN
the_DT
control_NN
groups_NNS
as_RB
well_RB
._.
Compared_VBN
to_TO
benign_JJ
tumor_NN
or_CC
mammary_JJ
reduction_NN
test_NN
material_NN
the_DT
eicosanoid_JJ
profile_NN
of_IN
tissue_NN
obtained_VBN
from_IN
malignant_JJ
mammary_NN
tumors_NNS
showed_VBD
important_JJ
differences_NNS
._.
Except_IN
for_IN
PGF2_NNP
alpha_NN
,_,
HHT_NNP
and_CC
15-HETE_VB
no_DT
detectable_JJ
quantities_NNS
of_IN
eicosanoids_NNS
were_VBD
found_VBN
in_IN
the_DT
non-tumor_JJ
material_NN
,_,
whereas_IN
in_IN
the_DT
malignant_JJ
tumor_NN
material_NN
substantial_JJ
quantities_NNS
of_IN
a_DT
number_NN
of_IN
eicosanoid_JJ
metabolites_NNS
were_VBD
present_JJ
._.
Statistically_RB
significant_JJ
correlations_NNS
could_MD
be_VB
established_VBN
between_IN
patient/histopathology_NN
data_NNS
and_CC
the_DT
results_NNS
of_IN
the_DT
platelet_NN
aggregation_NN
assays_VBZ
,_,
e.g._FW
between_IN
menopausal_JJ
status_NN
and_CC
ADP_NNP
aggregation_NN
;_:
oestrogen_NN
receptor_NN
(_-LRB-
+/-_NNS
)_-RRB-
and_CC
collagen_NN
and_CC
arachidonic_JJ
acid_NN
aggregation_NN
,_,
inflammatory_JJ
cell_NN
infiltration_NN
score_NN
and_CC
arachidonic_JJ
acid_NN
aggregation_NN
and_CC
fibrosis_NN
score_NN
and_CC
ADP_NNP
aggregation_NN
._.
The_DT
results_NNS
show_VBP
that_IN
eicosanoid_JJ
synthesis_NN
in_IN
material_NN
from_IN
mammary_JJ
cancer_NN
patients_NNS
is_VBZ
different_JJ
from_IN
that_DT
in_IN
benign_JJ
mammary_JJ
tissue_NN
._.
The_DT
implications_NNS
,_,
in_IN
particular_JJ
,_,
in_IN
relation_NN
to_TO
future_JJ
prognosis_NN
of_IN
the_DT
patient_NN
,_,
remain_VBP
obscure_JJ
._.
c-myc_JJ
mRNA_JJ
expression_NN
in_IN
minor_JJ
salivary_NN
glands_NNS
of_IN
patients_NNS
with_IN
Sjogren_NNP
's_POS
syndrome_NN
._.
c-myc_JJ
protooncogene_NN
is_VBZ
implicated_VBN
in_IN
the_DT
pathogenesis_NN
of_IN
B_NNP
cell_NN
lymphoid_NN
malignancies_NNS
and_CC
high_JJ
levels_NNS
of_IN
c-myc_JJ
mRNA_JJ
expression_NN
are_VBP
observed_VBN
in_IN
activated_JJ
blood_NN
mononuclear_NN
cells_NNS
._.
Sjogren_NNP
's_POS
syndrome_NN
(_-LRB-
SS_NNP
)_-RRB-
is_VBZ
characterized_VBN
by_IN
lymphocytic_JJ
infiltrates_NNS
of_IN
exocrine_NN
glands_NNS
,_,
remarkable_JJ
B_NNP
cell_NN
hyperreactivity_NN
and_CC
a_DT
strong_JJ
predisposition_NN
to_TO
B_NNP
cell_NN
neoplasia_NN
._.
In_IN
this_DT
study_NN
,_,
c-myc_JJ
protooncogene_NN
mRNA_NN
expression_NN
in_IN
29_CD
labial_JJ
minor_JJ
salivary_NN
gland_NN
biopsies_NNS
from_IN
patients_NNS
with_IN
primary_JJ
SS_NNP
and_CC
15_CD
controls_NNS
was_VBD
examined_VBN
using_VBG
in_IN
situ_FW
hybridization_NN
histochemistry_NN
._.
Two_CD
40mer_JJ
oligonucleotides_NNS
from_IN
the_DT
1st_JJ
and_CC
the_DT
2nd_NNP
exon_NN
of_IN
the_DT
c-myc_JJ
gene_NN
,_,
labeled_VBN
with_IN
35S_CD
,_,
were_VBD
used_VBN
as_IN
probes_NNS
._.
To_TO
detect_VB
the_DT
origin_NN
of_IN
the_DT
cell_NN
hybridized_VBN
with_IN
a_DT
c-myc_JJ
probe_NN
,_,
a_DT
combined_VBN
immunochemistry_NN
in_IN
situ_FW
hybridization_NN
histochemistry_NN
technique_NN
was_VBD
used_VBN
._.
High_NNP
c-myc_JJ
mRNA_NN
expression_NN
was_VBD
detected_VBN
on_IN
acinar_NN
epithelial_NN
cells_NNS
._.
c-myc_JJ
did_VBD
not_RB
correlate_VB
with_IN
c-fos_JJ
and_CC
c-jun_JJ
protein_NN
expression_NN
._.
Stronger_JJR
c-myc_JJ
mRNA_NN
expression_NN
was_VBD
detected_VBN
in_IN
labial_JJ
salivary_JJ
glands_NNS
of_IN
patients_NNS
with_IN
longer_JJR
disease_NN
duration_NN
(_-LRB-
p_NN
less_RBR
than_IN
or_CC
equal_JJ
to_TO
0.002_CD
)_-RRB-
and_CC
more_RBR
intense_JJ
T_NNP
lymphocyte_NN
infiltrates_NNS
(_-LRB-
p_NN
less_JJR
than_IN
0.05_CD
)_-RRB-
although_IN
these_DT
patients_NNS
revealed_VBD
no_DT
hypergammaglobulinemia_NN
._.
No_DT
correlation_NN
was_VBD
observed_VBN
between_IN
c-myc_JJ
mRNA_NN
and_CC
B_NNP
lymphocyte_NN
monoclonicity_NN
or_CC
lymphoma_NN
._.
In_IN
conclusion_NN
,_,
strong_JJ
c-myc_JJ
mRNA_NN
expression_NN
was_VBD
observed_VBN
on_IN
epithelial_JJ
cells_NNS
of_IN
labial_JJ
salivary_NN
glands_NNS
from_IN
patients_NNS
with_IN
primary_JJ
SS_NNP
._.
Our_PRP$
findings_NNS
may_MD
indicate_VB
the_DT
presence_NN
of_IN
a_DT
reactivated_VBN
virus_NN
hosted_VBD
in_IN
these_DT
cells_NNS
._.
Cytoplasmic_JJ
domain_NN
heterogeneity_NN
and_CC
functions_NNS
of_IN
IgG_NNP
Fc_NNP
receptors_NNS
in_IN
B_NNP
lymphocytes_NNS
._.
B_NNP
lymphocytes_NNS
and_CC
macrophages_NNS
express_VBP
closely_RB
related_VBN
immunoglobulin_NN
G_NNP
(_-LRB-
IgG_NN
)_-RRB-
Fc_NN
receptors_NNS
(_-LRB-
Fc_NNP
gamma_NN
RII_NNP
)_-RRB-
that_WDT
differ_VBP
only_RB
in_IN
the_DT
structures_NNS
of_IN
their_PRP$
cytoplasmic_JJ
domains_NNS
._.
Because_IN
of_IN
cell_NN
type-specific_JJ
alternative_NN
messenger_NN
RNA_NNP
splicing_NN
,_,
B-cell_NNP
Fc_NNP
gamma_NNP
RII_NNP
contains_VBZ
an_DT
insertion_NN
of_IN
47_CD
amino_IN
acids_NNS
that_IN
participates_NNS
in_IN
determining_VBG
receptor_NN
function_NN
in_IN
these_DT
cells_NNS
._.
Transfection_NN
of_IN
an_DT
Fc_JJ
gamma_NN
RII-negative_JJ
B-cell_JJ
line_NN
with_IN
complementary_JJ
DNA_NNP
's_POS
encoding_VBG
the_DT
two_CD
splice_NN
products_NNS
and_CC
various_JJ
receptor_NN
mutants_NNS
indicated_VBD
that_IN
the_DT
insertion_NN
was_VBD
responsible_JJ
for_IN
preventing_VBG
both_DT
Fc_NNP
gamma_NN
RII-mediated_JJ
endocytosis_NN
and_CC
Fc_JJ
gamma_NN
RII-mediated_JJ
antigen_JJ
presentation_NN
._.
The_DT
insertion_NN
was_VBD
not_RB
required_VBN
for_IN
Fc_NNP
gamma_NNP
RII_NNP
to_TO
modulate_VB
surface_NN
immunoglobulin-triggered_JJ
B-cell_JJ
activation_NN
._.
Instead_RB
,_,
regulation_NN
of_IN
activation_NN
involved_VBN
a_DT
region_NN
of_IN
the_DT
cytoplasmic_JJ
domain_NN
common_JJ
to_TO
both_DT
the_DT
lymphocyte_NN
and_CC
macrophage_NN
receptor_NN
isoforms_VBZ
._.
In_IN
contrast_NN
,_,
the_DT
insertion_NN
did_VBD
contribute_VB
to_TO
the_DT
formation_NN
of_IN
caps_NNS
in_IN
response_NN
to_TO
receptor_NN
cross-linking_NN
,_,
consistent_JJ
with_IN
suggestions_NNS
that_IN
the_DT
lymphocyte_NN
but_CC
not_RB
macrophage_JJ
form_NN
of_IN
the_DT
receptor_NN
can_MD
associate_VB
with_IN
the_DT
detergent-insoluble_JJ
cytoskeleton_NN
._.
Every_DT
enhancer_NN
works_VBZ
with_IN
every_DT
promoter_NN
for_IN
all_DT
the_DT
combinations_NNS
tested_VBN
:_:
could_MD
new_JJ
regulatory_JJ
pathways_NNS
evolve_VBP
by_IN
enhancer_NN
shuffling_VBG
?_.
The_DT
promoters_NNS
and_CC
enhancers_NNS
of_IN
cell_NN
type-specific_JJ
genes_NNS
are_VBP
often_RB
conserved_VBN
in_IN
evolution_NN
,_,
and_CC
hence_RB
one_PRP
might_MD
expect_VB
that_IN
a_DT
given_VBN
enhancer_NN
has_VBZ
evolved_VBN
to_TO
work_VB
best_RB
with_IN
its_PRP$
own_JJ
promoter_NN
._.
While_IN
this_DT
expectation_NN
may_MD
be_VB
realized_VBN
in_IN
some_DT
cases_NNS
,_,
we_PRP
have_VBP
not_RB
found_VBN
evidence_NN
for_IN
it_PRP
._.
A_DT
total_NN
of_IN
27_CD
combinations_NNS
of_IN
different_JJ
promoters_NNS
and_CC
enhancers_NNS
were_VBD
tested_VBN
by_IN
transfection_NN
into_IN
cultured_JJ
cells_NNS
._.
We_PRP
found_VBD
that_IN
the_DT
relative_JJ
efficiency_NN
of_IN
the_DT
enhancers_NNS
is_VBZ
approximately_RB
the_DT
same_JJ
,_,
irrespective_JJ
of_IN
the_DT
type_NN
of_IN
promoter_NN
used_VBN
,_,
i.e._FW
,_,
there_EX
was_VBD
no_DT
strong_JJ
preference_NN
for_IN
any_DT
given_VBN
enhancer/promoter_NN
combination_NN
._.
Notably_RB
,_,
we_PRP
do_VBP
not_RB
see_VB
particularly_RB
strong_JJ
transcription_NN
when_WRB
the_DT
immunoglobulin_NN
kappa_NN
enhancer_NN
(_-LRB-
or_CC
the_DT
immunoglobulin_NN
heavy_JJ
chain_NN
enhancer_NN
)_-RRB-
is_VBZ
used_VBN
to_TO
activate_VB
a_DT
kappa_NN
gene_NN
promoter_NN
._.
We_PRP
propose_VBP
that_IN
a_DT
generally_RB
permissive_JJ
enhancer/promoter_NN
interaction_NN
is_VBZ
of_IN
evolutionary_JJ
benefit_NN
for_IN
higher_JJR
eukaryotes_NNS
:_:
by_IN
enhancer_NN
shuffling_VBG
,_,
genes_NNS
could_MD
be_VB
easily_RB
brought_VBN
under_IN
a_DT
new_JJ
type_NN
of_IN
inducibility/cell_NN
type_NN
specificity_NN
._.
Heterodimerization_NNP
and_CC
transcriptional_JJ
activation_NN
in_IN
vitro_NN
by_IN
NF-kappa_NNP
B_NNP
proteins_VBZ
._.
The_DT
NF-kappa_NNP
B_NNP
family_NN
of_IN
transcription_NN
proteins_NNS
represents_VBZ
multiple_JJ
DNA_NN
binding_NN
,_,
rel_NN
related_VBN
polypeptides_NNS
that_WDT
contribute_VBP
to_TO
regulation_NN
of_IN
genes_NNS
involved_VBN
in_IN
immune_JJ
responsiveness_NN
and_CC
inflammation_NN
,_,
as_RB
well_RB
as_IN
activation_NN
of_IN
the_DT
HIV_NN
long_RB
terminal_JJ
repeat_NN
._.
In_IN
this_DT
study_NN
multiple_JJ
NF-kappa_NNP
B_NNP
related_VBD
polypeptides_NNS
ranging_VBG
from_IN
85_CD
to_TO
45_CD
kDa_NN
were_VBD
examined_VBN
for_IN
their_PRP$
capacity_NN
to_TO
interact_VB
with_IN
the_DT
PRDII_NNP
regulatory_JJ
element_NN
of_IN
interferon_NN
beta_NN
and_CC
were_VBD
shown_VBN
to_TO
possess_VB
distinct_JJ
intrinsic_JJ
DNA_NN
binding_NN
affinities_NNS
for_IN
this_DT
NF-kappa_NNP
B_NNP
site_NN
and_CC
form_NN
multiple_JJ
DNA_NNP
binding_NN
homo-_NNS
and_CC
heterodimer_NN
complexes_NNS
in_IN
co-renaturation_NN
experiments_NNS
._.
Furthermore_RB
,_,
using_VBG
DNA_NN
templates_NNS
containing_VBG
two_CD
copies_NNS
of_IN
the_DT
PRDII_NNP
domain_NN
linked_VBN
to_TO
the_DT
rabbit_NN
beta_NN
globin_NN
gene_NN
,_,
the_DT
purified_VBN
polypeptides_NNS
specifically_RB
stimulated_VBD
NF-kappa_NNP
B_NNP
dependent_JJ
transcription_NN
in_IN
an_DT
in_IN
vitro_NN
reconstitution_NN
assay_NN
as_IN
heterodimers_NNS
but_CC
not_RB
as_IN
p50_DT
homodimers_NNS
._.
These_DT
experiments_NNS
emphasize_VBP
the_DT
role_NN
of_IN
NF-kappa_NNP
B_NNP
dimerization_NN
as_IN
a_DT
distinct_JJ
level_NN
of_IN
transcriptional_JJ
control_NN
that_WDT
may_MD
permit_VB
functional_JJ
diversification_NN
of_IN
a_DT
limited_JJ
number_NN
of_IN
regulatory_JJ
proteins_NNS
._.
Oct2_NNP
transactivation_NN
from_IN
a_DT
remote_JJ
enhancer_NN
position_NN
requires_VBZ
a_DT
B-cell-restricted_JJ
activity_NN
._.
Previous_JJ
cotransfection_NN
experiments_NNS
had_VBD
demonstrated_VBN
that_IN
ectopic_JJ
expression_NN
of_IN
the_DT
lymphocyte-specific_JJ
transcription_NN
factor_NN
Oct2_NNP
could_MD
efficiently_RB
activate_VB
a_DT
promoter_NN
containing_VBG
an_DT
octamer_NN
motif_NN
._.
Oct2_NNP
expression_NN
was_VBD
unable_JJ
to_TO
stimulate_VB
a_DT
multimerized_JJ
octamer_NN
enhancer_NN
element_NN
in_IN
HeLa_NNP
cells_NNS
,_,
however_RB
._.
We_PRP
have_VBP
tested_VBN
a_DT
variety_NN
of_IN
Oct2_NNP
isoforms_VBZ
generated_VBN
by_IN
alternative_JJ
splicing_NN
for_IN
the_DT
capability_NN
to_TO
activate_VB
an_DT
octamer_NN
enhancer_NN
in_IN
nonlymphoid_JJ
cells_NNS
and_CC
a_DT
B-cell_JJ
line_NN
._.
Our_PRP$
analyses_NNS
show_VBP
that_IN
several_JJ
Oct2_NNS
isoforms_VBZ
can_MD
stimulate_VB
from_IN
a_DT
remote_JJ
position_NN
but_CC
that_IN
this_DT
stimulation_NN
is_VBZ
restricted_VBN
to_TO
B_NNP
cells_NNS
._.
This_DT
result_NN
indicates_VBZ
the_DT
involvement_NN
of_IN
either_DT
a_DT
B-cell-specific_JJ
cofactor_NN
or_CC
a_DT
specific_JJ
modification_NN
of_IN
a_DT
cofactor_NN
or_CC
the_DT
Oct2_NNP
protein_NN
in_IN
Oct2-mediated_JJ
enhancer_NN
activation_NN
._.
Mutational_JJ
analyses_NNS
indicate_VBP
that_IN
the_DT
carboxy-terminal_JJ
domain_NN
of_IN
Oct2_NNP
is_VBZ
critical_JJ
for_IN
enhancer_NN
activation_NN
._.
Moreover_RB
,_,
this_DT
domain_NN
conferred_VBD
enhancing_VBG
activity_NN
when_WRB
fused_VBN
to_TO
the_DT
Oct1_NNP
protein_NN
,_,
which_WDT
by_IN
itself_PRP
was_VBD
unable_JJ
to_TO
stimulate_VB
from_IN
a_DT
remote_JJ
position_NN
._.
The_DT
glutamine-rich_JJ
activation_NN
domain_NN
present_NN
in_IN
the_DT
amino-terminal_JJ
portion_NN
of_IN
Oct2_NNP
and_CC
the_DT
POU_NNP
domain_NN
contribute_VBP
only_RB
marginally_RB
to_TO
the_DT
transactivation_NN
function_NN
from_IN
a_DT
distal_JJ
position_NN
._.
Induction_NN
of_IN
the_DT
POU_NNP
domain_NN
transcription_NN
factor_NN
Oct-2_NNP
during_IN
T-cell_DT
activation_NN
by_IN
cognate_JJ
antigen_NN
._.
Oct-2_NNP
is_VBZ
a_DT
transcription_NN
factor_NN
that_WDT
binds_VBZ
specifically_RB
to_TO
octamer_JJ
DNA_NNP
motifs_NNS
in_IN
the_DT
promoters_NNS
of_IN
immunoglobulin_NN
and_CC
interleukin-2_JJ
genes_NNS
._.
All_DT
tumor_NN
cell_NN
lines_NNS
from_IN
the_DT
B-cell_NN
lineage_NN
and_CC
a_DT
few_JJ
from_IN
the_DT
T-cell_NN
lineage_NN
express_VBP
Oct-2_NNP
._.
To_TO
address_VB
the_DT
role_NN
of_IN
Oct-2_NNP
in_IN
the_DT
T-cell_NN
lineage_NN
,_,
we_PRP
studied_VBD
the_DT
expression_NN
of_IN
Oct-2_NNP
mRNA_NN
and_CC
protein_NN
in_IN
nontransformed_JJ
human_JJ
and_CC
mouse_NN
T_NNP
cells_NNS
._.
Oct-2_NNP
was_VBD
found_VBN
in_IN
CD4+_NNP
and_CC
CD8+_NNP
T_NNP
cells_NNS
prepared_VBN
from_IN
human_JJ
peripheral_NN
blood_NN
and_CC
in_IN
mouse_NN
lymph_NN
node_VBZ
T_NNP
cells_NNS
._.
In_IN
a_DT
T-cell_NN
clone_NN
specific_JJ
for_IN
pigeon_NN
cytochrome_NN
c_NN
in_IN
the_DT
context_NN
of_IN
I-Ek_NNP
,_,
Oct-2_NNP
was_VBD
induced_VBN
by_IN
antigen_JJ
stimulation_NN
,_,
with_IN
the_DT
increase_NN
in_IN
Oct-2_JJ
protein_NN
seen_VBN
first_JJ
at_IN
3_CD
h_NN
after_IN
activation_NN
and_CC
continuing_VBG
for_IN
at_IN
least_JJS
24_CD
h_NN
._.
Oct-2_NNP
mRNA_NN
induction_NN
during_IN
antigen-driven_JJ
T-cell_NN
activation_NN
was_VBD
blocked_VBN
by_IN
cyclosporin_NN
A_DT
,_,
as_RB
well_RB
as_IN
by_IN
protein_NN
synthesis_NN
inhibitors_NNS
._.
These_DT
results_NNS
suggest_VBP
that_IN
Oct-2_NNP
participates_NNS
in_IN
transcriptional_JJ
regulation_NN
during_IN
T-cell_DT
activation_NN
._.
The_DT
relatively_RB
delayed_VBN
kinetics_NNS
of_IN
Oct-2_NNP
induction_NN
suggests_VBZ
that_IN
Oct-2_NNP
mediates_VBZ
the_DT
changes_NNS
in_IN
gene_NN
expression_NN
which_WDT
occur_VBP
many_JJ
hours_NNS
or_CC
days_NNS
following_VBG
antigen_JJ
stimulation_NN
of_IN
T_NNP
lymphocytes_NNS
._.
(_-LRB-
Changes_NNS
in_IN
plasma_NN
interleukin-1_NN
and_CC
their_PRP$
possible_JJ
relationship_NN
with_IN
the_DT
changes_NNS
in_IN
glucocorticoid_NN
receptor_NN
in_IN
aged_JJ
long-distance_JJ
runner_NN
)_-RRB-
For_IN
the_DT
study_NN
of_IN
the_DT
changes_NNS
in_IN
plasma_NN
interleukin-1_NN
(_-LRB-
IL-1_NN
)_-RRB-
and_CC
their_PRP$
possible_JJ
relationship_NN
with_IN
the_DT
changes_NNS
in_IN
glucocorticoid_NN
receptor_NN
(_-LRB-
GR_CD
)_-RRB-
,_,
plasma_NN
IL-1_NN
and_CC
GR_CD
in_IN
peripheral_JJ
blood_NN
leukocytes_NNS
in_IN
aged_JJ
long-distance_JJ
runner_NN
were_VBD
measured_VBN
simultaneously_RB
._.
The_DT
activity_NN
of_IN
IL-1_NN
was_VBD
expressed_VBN
as_IN
its_PRP$
ability_NN
to_TO
stimulate_VB
3H-TdR_JJ
incorporation_NN
in_IN
the_DT
thymocytes_NNS
of_IN
C57_DT
mice_NNS
._.
GR_CD
was_VBD
determined_VBN
by_IN
whole_JJ
cell_NN
assay_NN
with_IN
3H-Dex_JJ
._.
The_DT
results_NNS
showed_VBD
that_IN
the_DT
activity_NN
of_IN
plasma_NN
IL-1_NN
in_IN
aged_JJ
long-distance_NN
runner_NN
was_VBD
209_CD
%_NN
,_,
223_CD
%_NN
and_CC
145_CD
%_NN
of_IN
the_DT
control_NN
at_IN
14.7-18.7_CD
,_,
3.8-7.0_CD
and_CC
1.5-2.6_CD
KD_NNP
fractions_NNS
._.
The_DT
GR_CD
in_IN
peripheral_JJ
blood_NN
leukocytes_NNS
in_IN
aged_JJ
runner_NN
was_VBD
65_CD
%_NN
of_IN
the_DT
control_NN
._.
Possible_JJ
relationship_NN
between_IN
the_DT
changes_NNS
in_IN
IL-1_NN
and_CC
GR_CD
in_IN
aged_JJ
long-distance_JJ
runner_NN
and_CC
its_PRP$
physiological_JJ
significance_NN
are_VBP
discussed_VBN
._.
Transcription_NNP
factor_NN
AP-2_NNP
activates_VBZ
gene_NN
expression_NN
of_IN
HTLV-I_NNP
._.
The_DT
HTLV-I_NNP
LTR_NNP
contains_VBZ
three_CD
conserved_JJ
regulatory_JJ
elements_NNS
known_VBN
as_IN
21_CD
base_NN
pair_NN
repeats_NNS
which_WDT
are_VBP
required_VBN
for_IN
stimulation_NN
of_IN
gene_NN
expression_NN
by_IN
the_DT
transactivator_NN
protein_NN
tax_NN
._.
Mutagenesis_NN
indicates_VBZ
that_IN
the_DT
21_CD
bp_NN
repeats_NNS
can_MD
be_VB
subdivided_VBN
into_IN
three_CD
motifs_NNS
,_,
A_DT
,_,
B_NNP
and_CC
C_NNP
,_,
each_DT
of_IN
which_WDT
influences_VBZ
the_DT
level_NN
of_IN
tax_NN
activation_NN
._.
The_DT
A_DT
site_NN
in_IN
the_DT
21_CD
bp_NN
repeat_NN
has_VBZ
strong_JJ
homology_NN
with_IN
previously_RB
described_VBN
binding_JJ
sites_NNS
for_IN
the_DT
transcription_NN
factor_NN
AP-2_NN
._.
We_PRP
demonstrated_VBD
that_IN
AP-2_JJ
mRNA_NN
was_VBD
present_JJ
in_IN
T-lymphocytes_NNS
and_CC
that_IN
cellular_JJ
factors_NNS
from_IN
both_DT
non-transformed_JJ
and_CC
transformed_VBN
T-lymphocytes_NNS
specifically_RB
bound_VBN
to_TO
the_DT
consensus_NN
motif_NN
for_IN
AP-2_NNP
in_IN
each_DT
21_CD
bp_NN
._.
To_TO
determine_VB
the_DT
role_NN
of_IN
AP-2_NNP
in_IN
the_DT
regulation_NN
of_IN
the_DT
HTLV-I_NNP
LTR_NNP
gene_NN
expression_NN
,_,
we_PRP
used_VBD
an_DT
AP-2_JJ
cDNA_NN
in_IN
DNA_NNP
binding_NN
and_CC
transient_JJ
expression_NN
assays_RB
._.
Gel_NNP
retardation_NN
and_CC
methylation_NN
interference_NN
studies_NNS
revealed_VBD
that_IN
bacterially_RB
produced_VBN
AP-2_JJ
bound_VBN
specifically_RB
and_CC
with_IN
high_JJ
affinity_NN
to_TO
all_DT
three_CD
21_CD
bp_NN
repeats_NNS
,_,
and_CC
that_IN
it_PRP
required_VBD
the_DT
core_NN
sequence_NN
AGGC_NN
for_IN
specific_JJ
binding_NN
._.
Binding_NNP
of_IN
AP-2_NNP
prevented_VBD
the_DT
subsequent_JJ
binding_NN
of_IN
members_NNS
of_IN
the_DT
CREB/ATF_NNP
family_NN
to_TO
an_DT
adjacent_JJ
regulatory_JJ
motif_NN
in_IN
the_DT
21_CD
bp_NN
repeat_NN
._.
Transfection_NN
of_IN
an_DT
AP-2_JJ
expression_NN
construct_VB
into_IN
T-lymphocytes_NNS
activated_VBN
gene_NN
expression_NN
from_IN
the_DT
HTLV-I_JJ
LTR_NNP
._.
At_IN
least_JJS
two_CD
21_CD
bp_NN
repeats_NNS
were_VBD
required_VBN
for_IN
high_JJ
levels_NNS
of_IN
AP-2_NN
activation_NN
and_CC
mutagenesis_NN
of_IN
the_DT
AP-2_JJ
consensus_NN
binding_NN
sequences_NNS
in_IN
the_DT
21_CD
bp_NN
repeats_NNS
eliminate_VBP
this_DT
activation_NN
._.
(_-LRB-
ABSTRACT_NNP
TRUNCATED_NNP
AT_WDT
250_CD
WORDS_NNS
)_-RRB-
Cell_NNP
cycle-dependent_NN
initiation_NN
and_CC
lineage-dependent_JJ
abrogation_IN
of_IN
GATA-1_JJ
expression_NN
in_IN
pure_JJ
differentiating_NN
hematopoietic_JJ
progenitors_NNS
._.
The_DT
programmed_VBD
activation/repression_NN
of_IN
transcription_NN
factors_NNS
in_IN
early_JJ
hematopoietic_JJ
differentiation_NN
has_VBZ
not_RB
yet_RB
been_VBN
explored_VBN
._.
The_DT
DNA-binding_JJ
protein_NN
GATA-1_NN
is_VBZ
required_VBN
for_IN
normal_JJ
erythroid_NN
development_NN
and_CC
regulates_VBZ
erythroid-expressed_JJ
genes_NNS
in_IN
maturing_VBG
erythroblasts_NNS
._.
We_PRP
analyzed_VBD
GATA-1_JJ
expression_NN
in_IN
early_JJ
human_JJ
adult_NN
hematopoiesis_NN
by_IN
using_VBG
an_DT
in_IN
vitro_NN
system_NN
in_IN
which_WDT
"_''
pure_JJ
"_''
early_JJ
hematopoietic_JJ
progenitors_NNS
are_VBP
induced_VBN
to_TO
gradual_JJ
and_CC
synchronized_JJ
differentiation_NN
selectively_RB
along_IN
the_DT
erythroid_NN
or_CC
granulocyte-macrophage_NN
pathway_NN
by_IN
differential_JJ
treatment_NN
with_IN
hematopoietic_JJ
growth_NN
factors_NNS
._.
The_DT
GATA-1_NNP
gene_NN
,_,
though_IN
virtually_RB
silent_JJ
in_IN
quiescent_JJ
progenitors_NNS
,_,
is_VBZ
activated_VBN
after_IN
entrance_NN
into_IN
the_DT
cell_NN
cycle_NN
upon_IN
stimulation_NN
with_IN
hematopoietic_JJ
growth_NN
factors_NNS
._.
Subsequently_RB
,_,
increasing_VBG
expression_NN
along_IN
the_DT
erythroid_FW
pathway_NN
contrasts_VBZ
with_IN
an_DT
abrupt_JJ
downregulation_NN
in_IN
the_DT
granulocyte-macrophage_JJ
lineage_NN
._.
These_DT
results_NNS
suggest_VBP
a_DT
microenvironment-directed_JJ
,_,
two-step_JJ
model_NN
for_IN
GATA-1_JJ
expression_NN
in_IN
differentiating_VBG
hematopoietic_JJ
progenitors_NNS
that_WDT
involves_VBZ
(_-LRB-
i_NN
)_-RRB-
cycle-dependent_NN
initiation_NN
and_CC
(_-LRB-
ii_NNS
)_-RRB-
lineage-dependent_JJ
maintenance_NN
or_CC
suppression_NN
._.
Hypothetically_RB
,_,
on/off_IN
switches_NNS
of_IN
lineage-restricted_JJ
transactivators_NNS
may_MD
underlie_VB
the_DT
binary_JJ
fate_NN
decisions_NNS
of_IN
hematopoietic_JJ
progenitors_NNS
._.
(_-LRB-
Age-related_JJ
changes_NNS
in_IN
glucocorticoid_JJ
and_CC
mineralocorticoid_JJ
receptors_NNS
in_IN
lymphocytes_NNS
of_IN
healthy_JJ
persons_NNS
and_CC
patients_NNS
with_IN
hypertension_NN
)_-RRB-
It_PRP
has_VBZ
been_VBN
found_VBN
that_IN
the_DT
number_NN
of_IN
glucocorticoid_JJ
receptors_NNS
in_IN
lymphocytes_NNS
of_IN
the_DT
peripheral_JJ
blood_NN
of_IN
healthy_JJ
elderly_JJ
subjects_NNS
increases_VBZ
,_,
while_IN
the_DT
number_NN
of_IN
mineralocorticoid_JJ
receptors_NNS
decreases_VBZ
._.
The_DT
mechanisms_NNS
of_IN
hormone-receptor_NN
interactions_NNS
in_IN
hypertension_NN
are_VBP
activated_VBN
:_:
the_DT
number_NN
of_IN
glucocorticoid_JJ
and_CC
mineralocorticoid_JJ
binding_NN
sites_NNS
grows_VBZ
in_IN
hypertensive_JJ
patients_NNS
._.
Still_RB
a_DT
more_JJR
essential_JJ
rise_NN
in_IN
the_DT
number_NN
of_IN
receptors_NNS
is_VBZ
observed_VBN
in_IN
mid-age_JJ
hypertensive_JJ
patients_NNS
than_IN
in_IN
elderly_JJ
ones_NNS
._.
In_IN
vivo_JJ
footprint_NN
analysis_NN
of_IN
the_DT
HLA-DRA_NNP
gene_NN
promoter_NN
:_:
cell-specific_JJ
interaction_NN
at_IN
the_DT
octamer_NN
site_NN
and_CC
up-regulation_NN
of_IN
X_NNP
box_NN
binding_NN
by_IN
interferon_NN
gamma_NN
._.
Analysis_NN
of_IN
the_DT
major_JJ
histocompatibility_NN
complex_JJ
class_NN
II_NNP
gene_NN
promoter_NN
DRA_NNP
has_VBZ
previously_RB
identified_VBN
at_IN
least_JJS
five_CD
cis-acting_JJ
regions_NNS
required_VBN
for_IN
maximal_JJ
expression_NN
._.
We_PRP
have_VBP
examined_VBN
the_DT
DRA_NNP
promoter_NN
for_IN
protein-DNA_NN
interactions_NNS
in_IN
the_DT
intact_JJ
cell_NN
,_,
which_WDT
may_MD
mediate_VB
transcriptional_JJ
activation_NN
._.
Using_VBG
in_IN
vivo_DT
genomic_JJ
footprinting_NN
we_PRP
identified_VBD
interactions_NNS
in_IN
B-cell_JJ
lines_NNS
at_IN
the_DT
octamer_NN
site_NN
and_CC
the_DT
Y_NNP
,_,
X1_NNP
,_,
and_CC
X2_NNP
boxes_NNS
._.
Class_NN
II_NNP
antigen_VBN
expressing_VBG
T-cell_NN
lines_NNS
maintained_VBD
contacts_NNS
identical_JJ
to_TO
B-cell_JJ
lines_NNS
,_,
while_IN
class_NN
II-negative_JJ
T-cell_NN
lines_NNS
exhibited_VBD
no_DT
interactions_NNS
._.
In_IN
lymphoid_JJ
cell_NN
lines_NNS
,_,
the_DT
octamer_NN
site_NN
is_VBZ
occupied_VBN
and_CC
required_VBN
for_IN
maximal_JJ
expression_NN
._.
This_DT
is_VBZ
most_RBS
likely_JJ
due_JJ
to_TO
the_DT
presence_NN
of_IN
the_DT
lymphoid-specific_JJ
OTF-2_JJ
factor_NN
._.
In_IN
contrast_NN
,_,
the_DT
class_NN
II-positive_JJ
nonlymphoid_JJ
glioblastoma_NN
cell_NN
line_NN
does_VBZ
not_RB
exhibit_VB
interactions_NNS
at_IN
the_DT
octamer_NN
site_NN
despite_IN
the_DT
presence_NN
of_IN
the_DT
ubiquitous_JJ
OTF-1_JJ
factor_NN
and_CC
an_DT
open_JJ
binding_NN
site_NN
._.
Thus_RB
,_,
the_DT
DRA_NNP
promoter_NN
discriminates_NNS
against_IN
OTF-1_JJ
activation_NN
at_IN
the_DT
level_NN
of_IN
DNA_NNP
binding_NN
in_IN
the_DT
glioblastoma_NN
line_NN
._.
Interferon_NNP
gamma_NN
induces_VBZ
class_NN
II_NNP
expression_NN
in_IN
this_DT
glioblastoma_NN
cell_NN
line_NN
and_CC
,_,
in_IN
parallel_JJ
,_,
up-regulates_JJ
X1_NNP
and_CC
X2_NNP
box_NN
protein-DNA_NN
interactions_NNS
,_,
while_IN
all_DT
other_JJ
interactions_NNS
remain_VBP
unchanged_JJ
._.
These_DT
results_NNS
suggest_VBP
that_IN
interferon_NN
gamma_NN
functions_NNS
on_IN
a_DT
poised_JJ
promoter_NN
by_IN
altering_VBG
weak_JJ
,_,
nonproductive_JJ
interactions_NNS
at_IN
the_DT
X_NNP
boxes_NNS
to_TO
strong_JJ
interactions_NNS
._.
These_DT
findings_NNS
provide_VBP
direct_JJ
in_IN
vivo_JJ
evidence_NN
to_TO
strongly_RB
suggest_VB
that_IN
the_DT
modulation_NN
of_IN
X1_NNP
and_CC
X2_NNP
interactions_NNS
is_VBZ
an_DT
important_JJ
constituent_NN
of_IN
the_DT
interferon_NN
gamma_NN
induction_NN
pathway_NN
._.
Simple_NN
derivation_NN
of_IN
TFIID-dependent_JJ
RNA_NNP
polymerase_NN
II_NNP
transcription_NN
systems_NNS
from_IN
Schizosaccharomyces_NNP
pombe_NN
and_CC
other_JJ
organisms_NNS
,_,
and_CC
factors_NNS
required_VBN
for_IN
transcriptional_JJ
activation_NN
._.
Resolution_NN
of_IN
whole_JJ
cell_NN
extract_VB
through_IN
two_CD
chromatographic_JJ
steps_NNS
yields_NNS
a_DT
single_JJ
protein_NN
fraction_NN
requiring_VBG
only_RB
the_DT
addition_NN
of_IN
TFIID_NNP
for_IN
the_DT
initiation_NN
of_IN
transcription_NN
at_IN
RNA_NNP
polymerase_NN
II_NNP
promoters_NNS
._.
This_DT
approach_NN
allows_VBZ
the_DT
convenient_JJ
generation_NN
of_IN
RNA_NNP
polymerase_NN
II_NNP
transcription_NN
systems_NNS
from_IN
Saccharomyces_NNP
cerevisiae_NNS
,_,
human_JJ
lymphocytes_NNS
,_,
and_CC
Schizosaccharomyces_NNP
pombe_NN
._.
TFIIDs_NNS
from_IN
all_DT
three_CD
organisms_NNS
are_VBP
interchangeable_JJ
among_IN
all_DT
three_CD
systems_NNS
._.
The_DT
S._NNP
cerevisiae_NN
and_CC
Sch._NNP
pombe_NN
systems_NNS
support_VBP
effects_NNS
of_IN
acidic_JJ
activator_NN
proteins_NNS
,_,
provided_VBD
a_DT
further_JJ
protein_NN
fraction_NN
from_IN
S._NNP
cerevisiae_NNS
is_VBZ
supplied_VBN
._.
This_DT
further_JJ
fraction_NN
is_VBZ
distinct_JJ
from_IN
the_DT
mediator_NN
of_IN
transcriptional_JJ
activation_NN
described_VBD
previously_RB
and_CC
represents_VBZ
a_DT
second_JJ
component_NN
in_IN
addition_NN
to_TO
general_JJ
initiation_NN
factors_NNS
that_WDT
may_MD
facilitate_VB
a_DT
response_NN
to_TO
acidic_JJ
activators_NNS
._.
NF-kappa_NNP
B-dependent_NNP
induction_NN
of_IN
the_DT
NF-kappa_NNP
B_NNP
p50_VBD
subunit_NN
gene_NN
promoter_NN
underlies_NNS
self-perpetuation_NN
of_IN
human_JJ
immunodeficiency_NN
virus_NN
transcription_NN
in_IN
monocytic_JJ
cells_NNS
._.
The_DT
molecular_JJ
mechanisms_NNS
underlying_VBG
the_DT
sustained_VBN
nuclear_JJ
translocation_NN
of_IN
NF-kappa_NNP
B_NNP
observed_VBD
in_IN
U937_DT
monocytic_JJ
cells_NNS
chronically_RB
infected_VBN
with_IN
human_JJ
immunodeficiency_NN
virus_NN
(_-LRB-
HIV_NN
)_-RRB-
were_VBD
studied_VBN
._.
The_DT
activity_NN
of_IN
the_DT
promoter_NN
regulating_VBG
the_DT
synthesis_NN
of_IN
the_DT
p105_NN
precursor_NN
of_IN
the_DT
NF-kappa_NNP
B_NNP
p50_NN
subunit_NN
was_VBD
enhanced_VBN
in_IN
these_DT
cells_NNS
._.
Deletions_NNS
in_IN
this_DT
promoter_NN
indicated_VBD
that_IN
this_DT
upregulation_NN
was_VBD
mediated_VBN
through_IN
the_DT
NF-kappa_NNP
B-_NNP
but_CC
not_RB
the_DT
AP-1-binding_JJ
motif_NN
,_,
by_IN
bona_NN
fide_NN
p50/p65_VBD
heterodimers_NNS
._.
Analysis_NN
of_IN
cytosolic_JJ
extracts_NNS
indicated_VBD
that_IN
NF-kappa_NNP
B_NNP
levels_NNS
were_VBD
increased_VBN
in_IN
HIV-infected_JJ
cells_NNS
._.
In_IN
contrast_NN
to_TO
the_DT
transient_NN
NF-kappa_NNP
B_NNP
activation_NN
induced_VBN
by_IN
phorbol_NN
ester_NN
,_,
the_DT
permanent_JJ
NF-kappa_NNP
B_NNP
translocation_NN
induced_VBN
by_IN
HIV_NNP
infection_NN
was_VBD
not_RB
dependent_JJ
on_IN
PKC_JJ
isoenzymes_NNS
alpha_NN
and_CC
beta_NN
as_IN
shown_VBN
by_IN
the_DT
use_NN
of_IN
a_DT
specific_JJ
inhibitor_NN
(_-LRB-
GF_NN
109203X_JJ
)_-RRB-
._.
These_DT
observations_NNS
indicate_VBP
that_IN
during_IN
chronic_JJ
HIV_NN
infection_NN
of_IN
U937_DT
cells_NNS
,_,
continuous_JJ
NF-kappa_NN
B_NNP
(_-LRB-
p50/p65_NN
)_-RRB-
translocation_NN
results_NNS
in_IN
p105_DT
promoter_NN
upregulation_NN
with_IN
subsequent_JJ
cytosolic_JJ
NF-kappa_NN
B_NNP
accumulation_NN
,_,
ready_JJ
for_IN
further_JJ
translocation_NN
._.
This_DT
HIV-mediated_JJ
mechanism_NN
results_NNS
in_IN
a_DT
self-perpetuating_JJ
loop_NN
of_IN
NF-kappa_NNP
B_NNP
production_NN
._.
The_DT
development_NN
of_IN
functionally_RB
responsive_JJ
T_NNP
cells_NNS
._.
The_DT
work_NN
reviewed_VBN
in_IN
this_DT
article_NN
separates_VBZ
T_NNP
cell_NN
development_NN
into_IN
four_CD
phases_NNS
._.
First_NNP
is_VBZ
an_DT
expansion_NN
phase_NN
prior_RB
to_TO
TCR_NNP
rearrangement_NN
,_,
which_WDT
appears_VBZ
to_TO
be_VB
correlated_VBN
with_IN
programming_NN
of_IN
at_IN
least_JJS
some_DT
response_NN
genes_NNS
for_IN
inducibility_NN
._.
This_DT
phase_NN
can_MD
occur_VB
to_TO
some_DT
extent_NN
outside_IN
of_IN
the_DT
thymus_NN
._.
However_RB
,_,
the_DT
profound_JJ
T_NNP
cell_NN
deficit_NN
of_IN
nude_JJ
mice_NNS
indicates_VBZ
that_IN
the_DT
thymus_NN
is_VBZ
by_IN
far_RB
the_DT
most_RBS
potent_JJ
site_NN
for_IN
inducing_VBG
the_DT
expansion_NN
per_IN
se_NN
,_,
even_RB
if_IN
other_JJ
sites_NNS
can_MD
induce_VB
some_DT
response_NN
acquisition_NN
._.
Second_NNP
is_VBZ
a_DT
controlled_JJ
phase_NN
of_IN
TCR_NNP
gene_NN
rearrangement_NN
._.
The_DT
details_NNS
of_IN
the_DT
regulatory_JJ
mechanism_NN
that_WDT
selects_VBZ
particular_JJ
loci_NNS
for_IN
rearrangement_NN
are_VBP
still_RB
not_RB
known_VBN
._.
It_PRP
seems_VBZ
that_IN
the_DT
rearrangement_NN
of_IN
the_DT
TCR_NNP
gamma_NN
loci_NNS
in_IN
the_DT
gamma_NN
delta_NN
lineage_NN
may_MD
not_RB
always_RB
take_VB
place_NN
at_IN
a_DT
developmental_JJ
stage_NN
strictly_RB
equivalent_JJ
to_TO
the_DT
rearrangement_NN
of_IN
TCR_NNP
beta_NN
in_IN
the_DT
alpha_NN
beta_NN
lineage_NN
,_,
and_CC
it_PRP
is_VBZ
not_RB
clear_JJ
just_RB
how_WRB
early_RB
the_DT
two_CD
lineages_NNS
diverge_VBP
._.
In_IN
the_DT
TCR_NNP
alpha_NN
beta_NN
lineage_NN
,_,
however_RB
,_,
the_DT
final_JJ
gene_NN
rearrangement_JJ
events_NNS
are_VBP
accompanied_VBN
by_IN
rapid_JJ
proliferation_NN
and_CC
an_DT
interruption_NN
in_IN
cellular_JJ
response_NN
gene_NN
inducibility_NN
._.
The_DT
loss_NN
of_IN
conventional_JJ
responsiveness_NN
is_VBZ
probably_RB
caused_VBN
by_IN
alterations_NNS
at_IN
the_DT
level_NN
of_IN
signaling_NN
,_,
and_CC
may_MD
be_VB
a_DT
manifestation_NN
of_IN
the_DT
physiological_JJ
state_NN
that_WDT
is_VBZ
a_DT
precondition_NN
for_IN
selection_NN
._.
Third_NNP
is_VBZ
the_DT
complex_JJ
process_NN
of_IN
selection_NN
._.
Whereas_IN
peripheral_JJ
T_NNP
cells_NNS
can_MD
undergo_VB
forms_NNS
of_IN
positive_JJ
selection_NN
(_-LRB-
by_IN
antigen-driven_JJ
clonal_JJ
expansion_NN
)_-RRB-
and_CC
negative_JJ
selection_NN
(_-LRB-
by_IN
abortive_JJ
stimulation_NN
leading_VBG
to_TO
anergy_NN
or_CC
death_NN
)_-RRB-
,_,
neither_DT
is_VBZ
exactly_RB
the_DT
same_JJ
phenomenon_NN
that_WDT
occurs_VBZ
in_IN
the_DT
thymic_JJ
cortex_NN
._.
Negative_JJ
selection_NN
in_IN
the_DT
cortex_NN
appears_VBZ
to_TO
be_VB
a_DT
suicidal_JJ
inversion_NN
of_IN
antigen_JJ
responsiveness_NN
:_:
instead_RB
of_IN
turning_VBG
on_IN
IL-2_JJ
expression_NN
,_,
the_DT
activated_JJ
cell_NN
destroys_VBZ
its_PRP$
own_JJ
chromatin_NN
._.
The_DT
genes_NNS
that_WDT
need_VBP
to_TO
be_VB
induced_VBN
for_IN
this_DT
response_NN
are_VBP
not_RB
yet_RB
identified_VBN
,_,
but_CC
it_PRP
is_VBZ
unquestionably_RB
a_DT
form_NN
of_IN
activation_NN
._.
It_PRP
is_VBZ
interesting_JJ
that_IN
in_IN
humans_NNS
and_CC
rats_NNS
,_,
cortical_JJ
thymocytes_NNS
undergoing_VBG
negative_JJ
selection_NN
can_MD
still_RB
induce_VB
IL-2R_JJ
alpha_NN
expression_NN
and_CC
even_RB
be_VB
rescued_VBN
in_IN
vitro_NN
,_,
if_IN
exogenous_JJ
IL-2_NN
is_VBZ
provided_VBN
._.
Perhaps_RB
murine_JJ
thymocytes_NNS
are_VBP
denied_VBN
this_DT
form_NN
of_IN
rescue_NN
because_IN
they_PRP
shut_VBD
off_RP
IL-2R_DT
beta_NN
chain_NN
expression_NN
at_IN
an_DT
earlier_JJR
stage_NN
or_CC
because_IN
they_PRP
may_MD
be_VB
uncommonly_RB
Bcl-2_JJ
deficient_NN
(_-LRB-
cf._DT
Sentman_NNP
et_NNP
al._RB
,_,
1991_CD
;_:
Strasser_NNP
et_NNP
al._RB
,_,
1991_CD
)_-RRB-
._.
Even_RB
so_RB
,_,
medullary_NN
thymocytes_NNS
remain_VBP
at_IN
least_JJS
partially_RB
susceptible_JJ
to_TO
negative_JJ
selection_NN
even_RB
as_IN
they_PRP
continue_VBP
to_TO
mature_VB
._.
SRC-related_JJ
proto-oncogenes_NNS
and_CC
transcription_NN
factors_NNS
in_IN
primary_JJ
human_JJ
T_NNP
cells_NNS
:_:
modulation_NN
by_IN
cyclosporin_NN
A_DT
and_CC
FK506_NNP
._.
Activation_NN
of_IN
T_NNP
lymphocytes_NNS
induces_VBZ
transcription_NN
of_IN
genes_NNS
encoding_VBG
for_IN
lymphokines_NNS
._.
Interleukin-2_NNP
(_-LRB-
IL-2_NN
)_-RRB-
gene_NN
expression_NN
is_VBZ
controlled_VBN
transcriptionally_RB
by_IN
the_DT
cooperative_JJ
activity_NN
of_IN
specific_JJ
trans-activating_JJ
factors_NNS
that_WDT
bind_VBP
to_TO
the_DT
IL-2_JJ
enhancer_NN
._.
Cyclosporin_NNP
A_DT
(_-LRB-
CsA_NN
)_-RRB-
and_CC
FK506_NNP
inhibit_VBP
the_DT
production_NN
of_IN
IL-2_NN
in_IN
T_NNP
lymphocytes_NNS
at_IN
the_DT
level_NN
of_IN
gene_NN
transcription_NN
._.
A_DT
member_NN
of_IN
the_DT
src_JJ
gene_NN
family_NN
,_,
the_DT
lymphocyte-specific_JJ
protein_NN
tyrosine_NN
kinase_NN
,_,
p56lck_NN
,_,
has_VBZ
been_VBN
implicated_VBN
in_IN
IL-2_JJ
production_NN
._.
CsA_NNP
was_VBD
found_VBN
not_RB
to_TO
inhibit_VB
lck_JJ
gene_NN
expression_NN
,_,
nor_CC
the_DT
activity_NN
of_IN
the_DT
lck_JJ
gene_NN
product_NN
._.
However_RB
,_,
CsA_NNP
and_CC
FK506_NNP
inhibit_VBP
the_DT
appearance_NN
of_IN
DNA_NNP
binding_NN
activity_NN
of_IN
factors_NNS
that_WDT
bind_VBP
to_TO
the_DT
NF-AT_NN
and_CC
AP-1_NN
sites_NNS
in_IN
the_DT
IL-2_JJ
enhancer_NN
._.
Since_IN
the_DT
induction_NN
of_IN
NF-AT_NNP
and_CC
AP-1_NNP
is_VBZ
induced_VBN
by_IN
the_DT
same_JJ
stimuli_NNS
that_WDT
stimulate_VB
IL-2_JJ
production_NN
,_,
these_DT
results_NNS
indicate_VBP
that_IN
the_DT
immunosuppressant_JJ
action_NN
of_IN
CsA_NNP
and_CC
FK506_NNP
is_VBZ
exerted_VBN
at_IN
the_DT
level_NN
of_IN
these_DT
trans-activating_JJ
factors_NNS
._.
TAR-independent_JJ
transactivation_NN
by_IN
Tat_NNPS
in_IN
cells_NNS
derived_VBN
from_IN
the_DT
CNS_NNP
:_:
a_DT
novel_NN
mechanism_NN
of_IN
HIV-1_PRP$
gene_NN
regulation_NN
._.
The_DT
Tat_NNPS
protein_NN
of_IN
human_JJ
immunodeficiency_NN
virus_NN
type_NN
1_CD
(_-LRB-
HIV-1_NN
)_-RRB-
is_VBZ
essential_JJ
for_IN
productive_JJ
infection_NN
and_CC
is_VBZ
a_DT
potential_JJ
target_NN
for_IN
antiviral_JJ
therapy_NN
._.
Tat_NNPS
,_,
a_DT
potent_JJ
activator_NN
of_IN
HIV-1_PRP$
gene_NN
expression_NN
,_,
serves_VBZ
to_TO
greatly_RB
increase_VB
the_DT
rate_NN
of_IN
transcription_NN
directed_VBN
by_IN
the_DT
viral_JJ
promoter_NN
._.
This_DT
induction_NN
,_,
which_WDT
seems_VBZ
to_TO
be_VB
an_DT
important_JJ
component_NN
in_IN
the_DT
progression_NN
of_IN
acquired_VBN
immune_JJ
deficiency_NN
syndrome_NN
(_-LRB-
AIDS_NNP
)_-RRB-
,_,
may_MD
be_VB
due_JJ
to_TO
increased_VBN
transcriptional_JJ
initiation_NN
,_,
increased_VBD
transcriptional_JJ
elongation_NN
,_,
or_CC
a_DT
combination_NN
of_IN
these_DT
processes_NNS
._.
Much_JJ
attention_NN
has_VBZ
been_VBN
focused_VBN
on_IN
the_DT
interaction_NN
of_IN
Tat_NNPS
with_IN
a_DT
specific_JJ
RNA_NNP
target_NN
termed_VBD
TAR_JJ
(_-LRB-
transactivation_NN
responsive_JJ
)_-RRB-
which_WDT
is_VBZ
present_JJ
in_IN
the_DT
leader_NN
sequence_NN
of_IN
all_DT
HIV-1_JJ
mRNAs_NNS
._.
This_DT
interaction_NN
is_VBZ
believed_VBN
to_TO
be_VB
an_DT
important_JJ
component_NN
of_IN
the_DT
mechanism_NN
of_IN
transactivation_NN
._.
In_IN
this_DT
report_NN
we_PRP
demonstrate_VBP
that_IN
in_IN
certain_JJ
CNS-derived_JJ
cells_NNS
Tat_NNP
is_VBZ
capable_JJ
of_IN
activating_VBG
HIV-1_NN
through_IN
a_DT
TAR-independent_JJ
pathway_NN
._.
A_DT
Tat-responsive_JJ
element_NN
is_VBZ
found_VBN
upstream_RB
within_IN
the_DT
viral_JJ
promoter_NN
that_IN
in_IN
glial-derived_JJ
cell_NN
lines_NNS
allows_VBZ
transactivation_NN
in_IN
the_DT
absence_NN
of_IN
TAR_NN
._.
Deletion_NNP
mapping_NN
and_CC
hybrid_JJ
promoter_NN
constructs_NNS
demonstrate_VBP
that_IN
the_DT
newly_RB
identified_VBN
Tat-responsive_JJ
element_NN
corresponds_NNS
to_TO
a_DT
sequence_NN
within_IN
the_DT
viral_JJ
long_JJ
terminal_NN
repeat_NN
(_-LRB-
LTR_NNP
)_-RRB-
previously_RB
identified_VBN
as_IN
the_DT
HIV-1_NN
enhancer_NN
,_,
or_CC
NF-kappa_NNP
B_NNP
domain_NN
._.
DNA_NNP
band-shift_NN
analysis_NN
reveals_VBZ
NF-kappa_NNP
B_NNP
binding_NN
activity_NN
in_IN
glial_JJ
cells_NNS
that_WDT
differs_VBZ
from_IN
that_DT
present_JJ
in_IN
T_NNP
lymphoid_VBD
cells_NNS
._.
Further_RB
,_,
we_PRP
observe_VBP
that_IN
TAR-deleted_JJ
mutants_NNS
of_IN
HIV-1_PRP$
demonstrate_VBP
normal_JJ
late_JJ
gene_NN
expression_NN
in_IN
glial_JJ
cells_NNS
as_IN
evidenced_VBN
by_IN
syncytia_NN
formation_NN
and_CC
production_NN
of_IN
viral_JJ
p24_NN
antigen_NN
._.
(_-LRB-
ABSTRACT_NNP
TRUNCATED_NNP
AT_WDT
250_CD
WORDS_NNS
)_-RRB-
Bcl-2_NN
:_:
a_DT
repressor_NN
of_IN
lymphocyte_JJ
death_NN
._.
The_DT
genes_NNS
and_CC
mechanisms_NNS
that_IN
control_NN
programmed_VBD
cell_NN
death_NN
are_VBP
currently_RB
the_DT
subject_NN
of_IN
intense_JJ
study_NN
._.
The_DT
bcl-2_JJ
gene_NN
,_,
a_DT
repressor_NN
of_IN
lymphocyte_JJ
death_NN
,_,
is_VBZ
perhaps_RB
the_DT
best_JJS
understood_VBN
of_IN
the_DT
programmed_JJ
cell_NN
death_NN
associated_VBN
genes_NNS
._.
Here_RB
,_,
Stanley_NNP
Korsmeyer_NNP
provides_VBZ
a_DT
brief_JJ
overview_NN
of_IN
bcl-2_CD
,_,
concentrating_VBG
on_IN
its_PRP$
roles_NNS
in_IN
B-_NNP
and_CC
T-cell_NNP
development_NN
and_CC
in_IN
oncogenesis_NN
._.
Mitogen_NN
stimulation_NN
of_IN
T-cells_NNS
increases_NNS
c-Fos_JJ
and_CC
c-Jun_JJ
protein_NN
levels_NNS
,_,
AP-1_NN
binding_NN
and_CC
AP-1_JJ
transcriptional_JJ
activity_NN
._.
We_PRP
have_VBP
analysed_VBN
the_DT
effect_NN
of_IN
mitogenic_JJ
lectins_NNS
on_IN
c-Fos_JJ
and_CC
c-Jun_JJ
protein_NN
levels_NNS
as_RB
well_RB
as_IN
on_IN
activator_NN
protein-1_NN
(_-LRB-
AP-1_NN
)_-RRB-
binding_NN
and_CC
enhancer_NN
activity_NN
in_IN
Jurkat_NNP
T-cells_NNS
._.
Both_DT
c-Fos_NNS
and_CC
c-Jun_JJ
protein_NN
levels_NNS
were_VBD
increased_VBN
after_IN
Con_NNP
A_NNP
and_CC
PHA_NNP
stimulation_NN
._.
Since_IN
T-cell_DT
stimulation_NN
increases_VBZ
both_DT
intracellular_JJ
Ca2+_JJ
and_CC
cAMP_JJ
levels_NNS
and_CC
activates_NNS
protein_NN
kinase_NN
C_NNP
(_-LRB-
PKC_NNP
)_-RRB-
,_,
the_DT
possible_JJ
involvement_NN
of_IN
these_DT
intracellular_JJ
messengers_NNS
in_IN
c-Fos_JJ
and_CC
c-Jun_JJ
induction_NN
was_VBD
tested_VBN
._.
PMA_NNP
,_,
which_WDT
directly_RB
activates_VBZ
PKC_NNP
,_,
mimicked_VBD
the_DT
effect_NN
of_IN
the_DT
lectins_NNS
on_IN
c-Fos_JJ
and_CC
c-Jun_JJ
,_,
but_CC
elevation_NN
of_IN
either_DT
intracellular_JJ
Ca2+_JJ
or_CC
cAMP_JJ
levels_NNS
had_VBD
little_RB
or_CC
no_DT
effect_NN
._.
The_DT
mitogen-induced_JJ
increase_NN
of_IN
c-Fos_JJ
and_CC
c-Jun_JJ
immunoreactivity_NN
was_VBD
inhibited_VBN
by_IN
H-7_NNP
,_,
a_DT
kinase_NN
inhibitor_NN
with_IN
relatively_RB
high_JJ
specificity_NN
for_IN
PKC_NNP
,_,
and_CC
less_RBR
efficiently_RB
by_IN
H-8_CD
,_,
a_DT
structurally_RB
related_VBN
kinase_NN
inhibitor_NN
less_RBR
active_JJ
on_IN
PKC_NNP
,_,
but_CC
more_RBR
active_JJ
on_IN
cyclic_JJ
nucleotide-dependent_JJ
kinases_NNS
._.
Con_NNP
A_DT
stimulation_NN
was_VBD
found_VBN
to_TO
increase_VB
both_DT
binding_NN
of_IN
AP-1_NN
to_TO
the_DT
AP-1_JJ
consensus_NN
sequence_NN
,_,
TRE_NNP
,_,
and_CC
AP-1_NNP
enhancer_NN
activity_NN
,_,
in_IN
Jurkat_NNP
cells_NNS
._.
PMA_NNP
was_VBD
also_RB
found_VBN
to_TO
increase_VB
the_DT
AP-1_JJ
enhancer_NN
activity_NN
,_,
whereas_IN
elevation_NN
of_IN
Ca2+_NNP
or_CC
cAMP_NNS
had_VBD
only_RB
minor_JJ
effects_NNS
._.
We_PRP
conclude_VBP
that_IN
stimulation_NN
with_IN
mitogenic_JJ
lectins_NNS
is_VBZ
sufficient_JJ
to_TO
increase_VB
both_DT
c-Fos_NNS
and_CC
c-Jun_JJ
protein_NN
levels_NNS
,_,
AP-1_NN
binding_NN
and_CC
AP-1_JJ
enhancer_NN
activity_NN
in_IN
Jurkat_NNP
cells_NNS
and_CC
that_IN
they_PRP
act_VBP
via_IN
mechanisms_NNS
that_WDT
could_MD
involve_VB
the_DT
activation_NN
of_IN
PKC_NNP
._.
Functional_JJ
interaction_NN
between_IN
the_DT
two_CD
zinc_NN
finger_NN
domains_NNS
of_IN
the_DT
v-erb_NN
A_DT
oncoprotein_NNP
._.
The_DT
v-erb_NN
A_DT
oncogene_NN
of_IN
avian_JJ
erythroblastosis_NN
virus_NN
is_VBZ
a_DT
mutated_JJ
and_CC
virally_RB
transduced_VBN
copy_NN
of_IN
a_DT
host_NN
cell_NN
gene_NN
encoding_VBG
a_DT
thyroid_NN
hormone_NN
receptor_NN
._.
The_DT
protein_NN
expressed_VBN
by_IN
the_DT
v-erb_NN
A_DT
oncogene_NN
binds_NNS
to_TO
DNA_NNP
and_CC
acts_VBZ
as_IN
a_DT
dominant_JJ
negative_JJ
inhibitor_NN
of_IN
both_DT
the_DT
thyroid_NN
hormone_NN
receptor_NN
and_CC
the_DT
closely_RB
related_VBN
retinoic_JJ
acid_NN
receptor_NN
._.
The_DT
v-erb_NN
A_DT
protein_NN
has_VBZ
sustained_VBN
two_CD
amino_IN
acid_NN
alterations_NNS
within_IN
its_PRP$
DNA-binding_JJ
domain_NN
relative_JJ
to_TO
that_DT
of_IN
c-erb_JJ
A_NNP
,_,
one_CD
of_IN
which_WDT
,_,
at_IN
serine_NN
61_CD
,_,
is_VBZ
known_VBN
to_TO
be_VB
important_JJ
for_IN
v-erb_NN
A_DT
function_NN
in_IN
the_DT
neoplastic_JJ
cell_NN
._.
We_PRP
report_VBP
here_RB
that_IN
the_DT
second_JJ
alteration_NN
,_,
at_IN
threonine_CD
78_CD
,_,
also_RB
plays_VBZ
an_DT
important_JJ
,_,
although_IN
more_RBR
indirect_JJ
,_,
role_NN
:_:
alteration_NN
of_IN
the_DT
sequence_NN
at_IN
threonine_CD
78_CD
such_JJ
that_IN
it_PRP
resembles_VBZ
that_IN
of_IN
c-erb_NN
A_DT
can_MD
act_VB
as_IN
an_DT
intragenic_JJ
suppressor_NN
and_CC
can_MD
partially_RB
restore_VB
function_NN
to_TO
a_DT
v-erb_NN
A_DT
protein_NN
rendered_VBD
defective_JJ
due_JJ
to_TO
a_DT
mutation_NN
at_IN
position_NN
61_CD
._.
Threonine_DT
78_CD
lies_NNS
within_IN
the_DT
D-box_NN
of_IN
the_DT
v-erb_NN
A_DT
protein_NN
,_,
a_DT
region_NN
thought_VBD
to_TO
mediate_VB
receptor-receptor_JJ
dimerizations_NNS
,_,
and_CC
is_VBZ
not_RB
in_IN
physical_JJ
proximity_NN
to_TO
the_DT
serine_NN
at_IN
position_NN
61_CD
._.
It_PRP
therefore_RB
appears_VBZ
that_IN
an_DT
indirect_JJ
interaction_NN
occurs_VBZ
between_IN
these_DT
two_CD
sites_NNS
and_CC
that_IN
this_DT
interaction_NN
is_VBZ
crucial_JJ
for_IN
v-erb_JJ
A_DT
function_NN
._.
Pax-5_DT
encodes_VBZ
the_DT
transcription_NN
factor_NN
BSAP_NNP
and_CC
is_VBZ
expressed_VBN
in_IN
B_NNP
lymphocytes_NNS
,_,
the_DT
developing_VBG
CNS_NNS
,_,
and_CC
adult_NN
testis_NN
._.
BSAP_NNP
has_VBZ
been_VBN
identified_VBN
previously_RB
as_IN
a_DT
transcription_NN
factor_NN
that_WDT
is_VBZ
expressed_VBN
at_IN
early_RB
,_,
but_CC
not_RB
late_RB
,_,
stages_NNS
of_IN
B-cell_JJ
differentiation_NN
._.
Biochemical_NNP
purification_NN
and_CC
cDNA_NN
cloning_NN
has_VBZ
now_RB
revealed_VBN
that_IN
BSAP_NNP
belongs_VBZ
to_TO
the_DT
family_NN
of_IN
paired_JJ
domain_NN
proteins_VBZ
._.
BSAP_NNP
is_VBZ
encoded_VBN
by_IN
the_DT
Pax-5_NNP
gene_NN
and_CC
has_VBZ
been_VBN
highly_RB
conserved_VBN
between_IN
human_JJ
and_CC
mouse_NN
._.
An_DT
intact_JJ
paired_JJ
domain_NN
was_VBD
shown_VBN
to_TO
be_VB
both_DT
necessary_JJ
and_CC
sufficient_JJ
for_IN
DNA_NNP
binding_NN
of_IN
BSAP_NNP
._.
Binding_NNP
studies_NNS
with_IN
several_JJ
BSAP_NNP
recognition_NN
sequences_NNS
demonstrated_VBD
that_IN
the_DT
sequence_NN
specificity_NN
of_IN
BSAP_NNP
differs_NNS
from_IN
that_DT
of_IN
the_DT
distantly_RB
related_VBN
paired_VBN
domain_NN
protein_NN
Pax-1_NNP
._.
During_IN
embryogenesis_NN
,_,
the_DT
BSAP_NNP
gene_NN
is_VBZ
transiently_RB
expressed_VBN
in_IN
the_DT
mesencephalon_NN
and_CC
spinal_JJ
cord_NN
with_IN
a_DT
spatial_JJ
and_CC
temporal_JJ
expression_NN
pattern_NN
that_WDT
is_VBZ
distinct_JJ
from_IN
that_DT
of_IN
other_JJ
Pax_NNP
genes_NNS
in_IN
the_DT
developing_VBG
central_JJ
nervous_JJ
system_NN
(_-LRB-
CNS_NNP
)_-RRB-
._.
Later_RB
,_,
the_DT
expression_NN
of_IN
the_DT
BSAP_NNP
gene_NN
shifts_NNS
to_TO
the_DT
fetal_NN
liver_NN
where_WRB
it_PRP
correlates_VBZ
with_IN
the_DT
onset_NN
of_IN
B_NNP
lymphopoiesis_NN
._.
BSAP_NNP
expression_NN
persists_NNS
in_IN
B_NNP
lymphocytes_NNS
and_CC
is_VBZ
also_RB
seen_VBN
in_IN
the_DT
testis_NN
of_IN
the_DT
adult_NN
mouse_NN
._.
All_DT
of_IN
this_DT
evidence_NN
indicates_VBZ
that_IN
the_DT
transcription_NN
factor_NN
BSAP_NNP
may_MD
not_RB
only_RB
play_VB
an_DT
important_JJ
role_NN
in_IN
B-cell_NNP
differentiation_NN
but_CC
also_RB
in_IN
neural_JJ
development_NN
and_CC
spermatogenesis_NN
._.
Okadaic_JJ
acid_NN
is_VBZ
a_DT
potent_JJ
inducer_NN
of_IN
AP-1_NNP
,_,
NF-kappa_NNP
B_NNP
,_,
and_CC
tumor_NN
necrosis_NN
factor-alpha_NN
in_IN
human_JJ
B_NNP
lymphocytes_NNS
._.
Treatment_NNP
of_IN
human_JJ
B_NNP
lymphocytes_NNS
with_IN
an_DT
optimal_JJ
concentration_NN
of_IN
okadaic_JJ
acid_NN
,_,
an_DT
inhibitor_NN
of_IN
phosphatases_NNS
1_CD
and_CC
2A_CD
,_,
resulted_VBD
in_IN
the_DT
induction_NN
of_IN
the_DT
transcription_NN
factor_NN
,_,
AP-1_NNP
and_CC
a_DT
marked_JJ
increase_NN
in_IN
NF-kappa_NNP
B_NNP
levels_NNS
._.
In_IN
contrast_NN
,_,
no_DT
effect_NN
on_IN
the_DT
levels_NNS
of_IN
the_DT
octamer_NN
binding_JJ
proteins_NNS
,_,
Oct-1_NNP
or_CC
Oct-2_NNP
,_,
were_VBD
found_VBN
._.
Since_IN
both_DT
AP-1_NNP
and_CC
NF-kappa_NNP
B_NNP
have_VBP
been_VBN
reported_VBN
to_TO
be_VB
important_JJ
in_IN
the_DT
induction_NN
of_IN
the_DT
tumor_NN
necrosis_NN
factor-alpha_NN
(_-LRB-
TNF-alpha_NNP
)_-RRB-
gene_NN
we_PRP
examined_VBD
the_DT
effects_NNS
of_IN
okadaic_JJ
acid_NN
on_IN
TNF-alpha_NNP
mRNA_NN
levels_NNS
._.
Treatment_NNP
with_IN
okadaic_JJ
acid_NN
resulted_VBD
in_IN
a_DT
striking_JJ
increase_NN
in_IN
TNF-alpha_NNP
mRNA_.
transcripts_NNS
within_IN
1_CD
h_NN
of_IN
stimulation_NN
and_CC
large_JJ
amounts_NNS
of_IN
TNF-alpha_NNP
were_VBD
released_VBN
into_IN
the_DT
culture_NN
media_NNS
._.
Although_IN
okadaic_JJ
acid_NN
provides_VBZ
a_DT
potent_JJ
inductive_JJ
signal_NN
for_IN
AP-1_NNP
and_CC
NF-kappa_NNP
B_NNP
it_PRP
did_VBD
not_RB
induce_VB
either_DT
B_NNP
cell_NN
proliferation_NN
or_CC
immunoglobulin_NN
secretion_NN
._.
A_DT
novel_NN
Ets-related_NNP
transcription_NN
factor_NN
,_,
Elf-1_NNP
,_,
binds_NNS
to_TO
human_JJ
immunodeficiency_NN
virus_NN
type_NN
2_CD
regulatory_JJ
elements_NNS
that_WDT
are_VBP
required_VBN
for_IN
inducible_JJ
trans_NNS
activation_NN
in_IN
T_NNP
cells_NNS
._.
Human_JJ
immunodeficiency_NN
virus_NN
type_NN
1_CD
(_-LRB-
HIV-1_NN
)_-RRB-
and_CC
HIV-2_PRP$
are_VBP
structurally_RB
related_VBN
retroviruses_NNS
which_WDT
both_DT
cause_NN
AIDS_NNP
in_IN
humans_NNS
._.
Although_IN
both_DT
viruses_NNS
establish_VBP
latency_RB
in_IN
quiescent_JJ
human-peripheral-blood_JJ
T_NNP
cells_NNS
,_,
the_DT
asymptomatic_JJ
phase_NN
of_IN
HIV-2_PRP$
infection_NN
may_MD
be_VB
more_JJR
prolonged_JJ
than_IN
that_DT
of_IN
HIV-1_NN
._.
The_DT
latent_JJ
phases_NNS
of_IN
both_DT
HIV-1_NNP
and_CC
HIV-2_PRP$
infection_NN
have_VBP
been_VBN
shown_VBN
to_TO
be_VB
disrupted_VBN
by_IN
T-cell_DT
activation_NN
,_,
a_DT
process_NN
that_WDT
requires_VBZ
host_NN
cell_NN
transcription_NN
factors_NNS
._.
In_IN
the_DT
case_NN
of_IN
HIV-1_NN
,_,
the_DT
transcription_NN
factor_NN
NF-kappa_NNP
B_NNP
is_VBZ
sufficient_JJ
for_IN
inducible_JJ
transcriptional_JJ
activation_NN
._.
In_IN
contrast_NN
,_,
factors_NNS
in_IN
addition_NN
to_TO
NF-kappa_NNP
B_NNP
are_VBP
required_VBN
to_TO
activate_VB
HIV-2_PRP$
transcription_NN
in_IN
infected_JJ
T_NNP
cells_NNS
._.
In_IN
this_DT
report_NN
,_,
we_PRP
demonstrate_VBP
that_IN
a_DT
novel_NN
Ets-related_NNP
transcription_NN
factor_NN
,_,
Elf-1_NNP
,_,
binds_NNS
specifically_RB
to_TO
two_CD
purine-rich_JJ
motifs_NNS
in_IN
the_DT
HIV-2_NN
enhancer_NN
._.
Mutagenesis_NN
experiments_NNS
demonstrated_VBD
that_IN
these_DT
Elf-1_JJ
binding_NN
sites_NNS
are_VBP
required_VBN
for_IN
induction_NN
of_IN
HIV-2_PRP$
transcription_NN
following_VBG
T-cell-receptor-mediated_JJ
T-cell_NN
activation_NN
._.
Moreover_RB
,_,
Elf-1_NNP
is_VBZ
the_DT
only_JJ
factor_NN
present_NN
in_IN
activated_JJ
T-cell_JJ
nuclear_JJ
extracts_NNS
that_IN
binds_NNS
to_TO
these_DT
sites_NNS
in_IN
electrophoretic_JJ
mobility_NN
shift_NN
assays_VBZ
._.
Thus_RB
,_,
Elf-1_NNP
is_VBZ
a_DT
novel_NN
transcription_NN
factor_NN
that_WDT
appears_VBZ
to_TO
be_VB
required_VBN
for_IN
the_DT
T-cell-receptor-mediated_JJ
trans_NNS
activation_NN
of_IN
HIV-2_PRP$
gene_NN
expression_NN
._.
These_DT
results_NNS
may_MD
explain_VB
differences_NNS
in_IN
the_DT
clinical_JJ
spectra_NN
of_IN
diseases_NNS
caused_VBN
by_IN
HIV-1_NNP
and_CC
HIV-2_NNP
and_CC
may_MD
also_RB
have_VB
implications_NNS
for_IN
the_DT
design_NN
of_IN
therapeutic_JJ
approaches_NNS
to_TO
HIV-2_PRP$
infection_NN
._.
Human_JJ
immunodeficiency_NN
virus_NN
type_NN
1_CD
Nef_JJ
protein_NN
inhibits_VBZ
NF-kappa_NNP
B_NNP
induction_NN
in_IN
human_JJ
T_NNP
cells_NNS
._.
Human_JJ
immunodeficiency_NN
virus_NN
type_NN
1_CD
(_-LRB-
HIV-1_NN
)_-RRB-
can_MD
establish_VB
a_DT
persistent_JJ
and_CC
latent_JJ
infection_NN
in_IN
CD4+_NNP
T_NNP
lymphocytes_NNS
(_-LRB-
W.C.Greene_NNP
,_,
N.Engl.J._NNP
Med.324_NNP
:_:
308-317_CD
,_,
1991_CD
;_:
S.M.Schnittman_NNP
,_,
M.C.Psallidopoulos_NNP
,_,
H.C._NNP
Lane_NNP
,_,
L.Thompson_NNP
,_,
M.Baseler_NNP
,_,
F.Massari_NNP
,_,
C.H.Fox_NNP
,_,
N.P.Salzman_NNP
,_,
and_CC
A.S.Fauci_NNP
,_,
Science_NNP
245_CD
:_:
305-308_CD
,_,
1989_CD
)_-RRB-
._.
Production_NN
of_IN
HIV-1_NN
from_IN
latently_RB
infected_VBN
cells_NNS
requires_VBZ
host_NN
cell_NN
activation_NN
by_IN
T-cell_NN
mitogens_NNS
(_-LRB-
T.Folks_NNS
,_,
D.M.Powell_NNP
,_,
M.M.Lightfoote_NNP
,_,
S.Benn_NNP
,_,
M.A._NNP
Martin_NNP
,_,
and_CC
A.S.Fauci_NNP
,_,
Science_NNP
231_CD
:_:
600-602_CD
,_,
1986_CD
;_:
D.Zagury_NNP
,_,
J._NNP
Bernard_NNP
,_,
R.Leonard_NNP
,_,
R.Cheynier_NNP
,_,
M.Feldman_NNP
,_,
P.S.Sarin_NNP
,_,
and_CC
R.C._NNP
Gallo_NNP
,_,
Science_NNP
231_CD
:_:
850-853_CD
,_,
1986_CD
)_-RRB-
._.
This_DT
activation_NN
is_VBZ
mediated_VBN
by_IN
the_DT
host_NN
transcription_NN
factor_NN
NF-kappa_NN
B_NNP
(_-LRB-
G.Nabel_NN
and_CC
D.Baltimore_NNP
,_,
Nature_NN
(_-LRB-
London_NNP
)_-RRB-
326_CD
:_:
711-717_CD
,_,
1987_CD
)_-RRB-
._.
We_PRP
report_VBP
here_RB
that_IN
the_DT
HIV-1-encoded_JJ
Nef_JJ
protein_NN
inhibits_VBZ
the_DT
induction_NN
of_IN
NF-kappa_NNP
B_NNP
DNA-binding_NN
activity_NN
by_IN
T-cell_JJ
mitogens_NNS
._.
However_RB
,_,
Nef_NNP
does_VBZ
not_RB
affect_VB
the_DT
DNA-binding_JJ
activity_NN
of_IN
other_JJ
transcription_NN
factors_NNS
implicated_VBN
in_IN
HIV-1_PRP$
regulation_NN
,_,
including_VBG
SP-1_JJ
,_,
USF_NNP
,_,
URS_NNP
,_,
and_CC
NF-AT_NNP
._.
Additionally_RB
,_,
Nef_NNP
inhibits_VBZ
the_DT
induction_NN
of_IN
HIV-1-_NNP
and_CC
interleukin_JJ
2-directed_JJ
gene_NN
expression_NN
,_,
and_CC
the_DT
effect_NN
on_IN
HIV-1_PRP$
transcription_NN
depends_VBZ
on_IN
an_DT
intact_JJ
NF-kappa_NNP
B-binding_NNP
site_NN
._.
These_DT
results_NNS
indicate_VBP
that_IN
defective_JJ
recruitment_NN
of_IN
NF-kappa_NNP
B_NNP
may_MD
underlie_VB
Nef_NNP
's_POS
negative_JJ
transcriptional_JJ
effects_NNS
on_IN
the_DT
HIV-1_NN
and_CC
interleukin_NN
2_CD
promoters_NNS
._.
Further_JJ
evidence_NN
suggests_VBZ
that_IN
Nef_NNP
inhibits_VBZ
NF-kappa_NNP
B_NNP
induction_NN
by_IN
interfering_VBG
with_IN
a_DT
signal_NN
derived_VBN
from_IN
the_DT
T-cell_NN
receptor_NN
complex_NN
._.
(_-LRB-
Effect_NN
of_IN
antihypertensive_JJ
therapy_NN
with_IN
captopril_NN
on_IN
gluco-_NNS
and_CC
mineralocorticoid_JJ
receptors_NNS
of_IN
peripheral_JJ
blood_NN
lymphocytes_NNS
in_IN
hypertensive_JJ
patients_NNS
of_IN
various_JJ
age_NN
)_-RRB-
Binding_NNP
of_IN
3H-dexamethasone_JJ
and_CC
3H-aldosterone_JJ
by_IN
peripheral_JJ
lymphocyte_NN
receptors_NNS
was_VBD
investigated_VBN
in_IN
healthy_JJ
persons_NNS
and_CC
hypertensive_JJ
patients_NNS
before_RB
and_CC
after_IN
2-week_JJ
captopril_NN
treatment_NN
._.
The_DT
number_NN
of_IN
glucocorticoid_JJ
and_CC
mineralocorticoid_JJ
binding_NN
sites_NNS
was_VBD
increased_VBN
in_IN
hypertensives_NNS
vs_IN
normotensives_NNS
._.
The_DT
treatment_NN
with_IN
the_DT
ACE_NNP
inhibitor_NN
captopril_NN
led_VBD
to_TO
activation_NN
of_IN
hormone-receptor_NN
interactions_NNS
._.
There_EX
was_VBD
a_DT
more_JJR
marked_JJ
rise_NN
of_IN
the_DT
number_NN
of_IN
receptors_NNS
in_IN
middle-aged_JJ
(_-LRB-
44-55_CD
years_NNS
)_-RRB-
hypertensives_VBZ
vs_JJ
elderly_JJ
(_-LRB-
61-80_JJ
years_NNS
)_-RRB-
subjects_NNS
after_IN
captopril_NN
treatment_NN
._.
Leukotriene_NNP
B4_NNP
transcriptionally_RB
activates_VBZ
interleukin-6_JJ
expression_NN
involving_VBG
NK-chi_NNP
B_NNP
and_CC
NF-IL6_NNP
._.
Leukotriene_NNP
B4_NNP
(_-LRB-
LTB4_NNP
)_-RRB-
is_VBZ
a_DT
notable_JJ
participant_NN
in_IN
inflammation_NN
and_CC
chemotaxis_NN
._.
It_PRP
is_VBZ
,_,
however_RB
,_,
still_RB
unclear_JJ
whether_IN
LTB4_NNP
acts_VBZ
in_IN
this_DT
regard_NN
directly_RB
or_CC
indirectly_RB
by_IN
stimulating_VBG
the_DT
release_NN
of_IN
chemotactic_NN
and_CC
inflammatory_NN
cytokines_NNS
._.
Here_RB
we_PRP
report_VBP
that_IN
LTB4_NNP
induces_VBZ
synthesis_NN
of_IN
interleukin_NN
(_-LRB-
IL_NNP
)_-RRB-
-6_RB
by_IN
human_JJ
blood_NN
monocytes_NNS
through_IN
transcriptional_JJ
activation_NN
of_IN
the_DT
IL-6_NNP
gene_NN
._.
We_PRP
furthermore_RB
demonstrate_VBP
that_IN
this_DT
process_NN
involves_VBZ
activation_NN
of_IN
the_DT
transcription_NN
factor_NN
NF-chi_NNP
B_NNP
and_CC
,_,
to_TO
a_DT
lesser_JJR
extent_NN
,_,
of_IN
NF-IL6_NNP
,_,
while_IN
the_DT
activity_NN
of_IN
the_DT
transcription_NN
factor_NN
AP-1_NN
,_,
shown_VBN
to_TO
otherwise_RB
confer_VB
IL-6_DT
inducibility_NN
,_,
appeared_VBD
to_TO
be_VB
unaffected_JJ
by_IN
LTB4_NNP
._.
Involvement_NN
of_IN
NF-chi_NNP
B_NNP
and_CC
NF-IL6_NNP
in_IN
induction_NN
of_IN
IL-6_DT
transcription_NN
by_IN
monocytes_NNS
was_VBD
demonstrated_VBN
using_VBG
deleted_JJ
forms_NNS
of_IN
the_DT
IL-6_NN
promoter_NN
._.
Activation_NN
of_IN
the_DT
IL-6_NN
promoter_NN
by_IN
LTB4_NNP
was_VBD
not_RB
only_RB
associated_VBN
with_IN
accumulation_NN
of_IN
the_DT
respective_JJ
transcripts_NNS
but_CC
resulted_VBD
in_IN
synthesis_NN
of_IN
functional_JJ
IL-6_JJ
protein_NN
as_RB
well_RB
._.
In_IN
addition_NN
,_,
LTB4_NNP
mediated_VBD
transactivation_NN
of_IN
a_DT
heterologous_JJ
promoter_NN
construct_VB
containing_VBG
the_DT
NF-chi_NNP
B_NNP
or_CC
the_DT
NF-IL6_NNP
enhancer_NN
,_,
but_CC
not_RB
the_DT
AP-1_NN
enhancer_NN
._.
The_DT
signaling_VBG
events_NNS
mediating_VBG
this_DT
effect_NN
appeared_VBD
to_TO
involve_VB
the_DT
release_NN
of_IN
H2O2_NNP
,_,
since_IN
LTB4_NNP
failed_VBD
to_TO
induce_VB
NF-chi_NNP
B_NNP
or_CC
NF-IL6_NNP
in_IN
the_DT
presence_NN
of_IN
the_DT
scavenger_NN
of_IN
H2O2_NNP
,_,
N-acetyl-L-cysteine_NNP
._.
Estrogen_NN
binding_NN
sites_NNS
in_IN
peripheral_JJ
blood_NN
monocytes_NNS
and_CC
effects_NNS
of_IN
danazol_NN
on_IN
their_PRP$
sites_NNS
in_IN
vitro_NN
._.
1_CD
._.
This_DT
study_NN
was_VBD
designed_VBN
to_TO
investigate_VB
the_DT
presence_NN
of_IN
estrogen_NN
type_NN
I_PRP
(_-LRB-
high_JJ
affinity_NN
,_,
low_JJ
capacity_NN
)_-RRB-
and_CC
type_NN
II_NNP
(_-LRB-
low_JJ
affinity_NN
,_,
high_JJ
capacity_NN
)_-RRB-
binding_NN
sites_NNS
in_IN
human_JJ
peripheral_NN
blood_NN
monocytes_NNS
and_CC
the_DT
effects_NNS
of_IN
danazol_NN
on_IN
these_DT
sites_NNS
._.
2_LS
._.
These_DT
two_CD
types_NNS
of_IN
estrogen_NN
binding_NN
sites_NNS
existed_VBD
in_IN
human_JJ
peripheral_NN
blood_NN
monocytes_NNS
._.
3_LS
._.
Danazol_NNP
bound_VBD
to_TO
these_DT
sites_NNS
in_IN
high_JJ
concentration_NN
(_-LRB-
10(-6)_JJ
M_NNP
,_,
clinical_JJ
serum_NN
concentration_NN
during_IN
danazol_JJ
therapy_NN
)_-RRB-
and_CC
decreased_VBD
the_DT
number_NN
of_IN
both_DT
sites_NNS
._.
4_LS
._.
It_PRP
is_VBZ
suggested_VBN
that_IN
danazol_NN
has_VBZ
an_DT
anti-estrogenic_JJ
action_NN
to_TO
the_DT
monocytes_NNS
through_IN
the_DT
competition_NN
and_CC
suppression_NN
of_IN
estrogen_NN
binding_NN
sites_NNS
as_IN
seen_VBN
in_IN
the_DT
estrogen_NN
target_NN
organ_NN
._.
(_-LRB-
Mechanism_NN
of_IN
action_NN
of_IN
steroid_JJ
hormones_NNS
._.
I_PRP
._.
Estrogens_NNP
)_-RRB-
The_DT
steroid_NN
hormone_NN
are_VBP
very_RB
versatile_JJ
molecules_NNS
:_:
although_IN
they_PRP
are_VBP
related_VBN
among_IN
them_PRP
by_IN
their_PRP$
chemical_NN
structure_NN
,_,
they_PRP
have_VBP
very_RB
diverse_JJ
functions_NNS
and_CC
including_VBG
antagonic_JJ
._.
Their_PRP$
action_NN
mechanism_NN
is_VBZ
not_RB
completely_RB
cleared_VBN
._.
The_DT
estrogens_NNS
participate_VBP
in_IN
the_DT
regulation_NN
of_IN
practically_RB
all_DT
the_DT
reproductive_JJ
and_CC
sexual_JJ
events_NNS
of_IN
the_DT
female_NN
,_,
although_IN
the_DT
intracellular_JJ
actions_NNS
by_IN
which_WDT
they_PRP
take_VBP
place_NN
are_VBP
not_RB
well_RB
known_VBN
and_CC
the_DT
proposed_VBN
models_NNS
do_VBP
not_RB
adequately_RB
satisfy_VB
the_DT
questions_NNS
._.
Currently_RB
it_PRP
is_VBZ
accepted_VBN
the_DT
existence_NN
of_IN
a_DT
cytoplasmic_JJ
and/or_CC
nuclear_JJ
receptor_NN
,_,
without_IN
explaining_VBG
satisfactorily_RB
how_WRB
the_DT
hormones_NNS
come_VBP
to_TO
the_DT
nucleus_NN
._.
The_DT
endocrine_JJ
events_NNS
that_WDT
are_VBP
rapidly_RB
expressed_VBN
(_-LRB-
seconds_NNS
)_-RRB-
are_VBP
due_JJ
to_TO
a_DT
possible_JJ
interaction_NN
with_IN
cellular_JJ
membrane_NN
._.
The_DT
purpose_NN
of_IN
this_DT
review_NN
is_VBZ
to_TO
analyze_VB
and_CC
concilliate_VB
the_DT
reported_VBN
data_NNS
on_IN
the_DT
mechanism_NN
of_IN
action_NN
of_IN
estrogens_NNS
._.
Stable_JJ
expression_NN
of_IN
transdominant_JJ
Rev_NNP
protein_NN
in_IN
human_JJ
T_NNP
cells_NNS
inhibits_VBZ
human_JJ
immunodeficiency_NN
virus_NN
replication_NN
._.
The_DT
human_JJ
immunodeficiency_NN
virus_NN
(_-LRB-
HIV_NNP
)_-RRB-
Rev_NNP
protein_NN
is_VBZ
essential_JJ
for_IN
viral_JJ
structural_JJ
protein_NN
expression_NN
(_-LRB-
Gag_NNP
,_,
Pol_NNP
,_,
and_CC
Env_NNP
)_-RRB-
and_CC
,_,
hence_RB
,_,
for_IN
viral_JJ
replication_NN
._.
In_IN
transient_NN
transfection_NN
assays_VBZ
,_,
mutant_JJ
forms_NNS
of_IN
Rev_NNP
have_VBP
been_VBN
identified_VBN
that_IN
inhibit_VB
wild-type_JJ
Rev_NNP
activity_NN
and_CC
therefore_RB
suppress_NN
viral_JJ
replication_NN
._.
To_TO
determine_VB
whether_IN
such_JJ
transdominant_JJ
Rev_NNP
proteins_NNS
could_MD
provide_VB
long-term_JJ
protection_NN
against_IN
HIV_NNP
infection_NN
without_IN
affecting_VBG
T_NNP
cell_NN
function_NN
,_,
T_NNP
leukemia_NN
cell_NN
lines_NNS
were_VBD
stably_RB
transduced_VBN
with_IN
a_DT
retroviral_JJ
vector_NN
encoding_VBG
a_DT
transdominant_JJ
mutant_NN
of_IN
the_DT
Rev_NNP
protein_NN
,_,
M10_NNP
._.
While_IN
all_PDT
the_DT
M10-expressing_JJ
cell_NN
lines_NNS
remained_VBD
infectable_JJ
by_IN
HIV-1_NN
,_,
these_DT
same_JJ
cells_NNS
failed_VBN
to_TO
support_VB
a_DT
productive_JJ
replication_NN
cycle_NN
when_WRB
infected_VBN
with_IN
a_DT
cloned_JJ
isolate_NN
of_IN
HIV-1_NN
._.
In_IN
addition_NN
,_,
two_CD
out_IN
of_IN
three_CD
M10-expressing_JJ
CEM_NNP
clones_NNS
were_VBD
also_RB
resistant_JJ
to_TO
highly_RB
productive_JJ
infection_NN
by_IN
a_DT
heterogeneous_JJ
HIV-1_NN
pool_NN
._.
Expression_NN
of_IN
M10_NNP
did_VBD
not_RB
affect_VB
induction_NN
of_IN
HIV_NNP
transcription_NN
mediated_VBN
by_IN
the_DT
kappa_NN
B_NNP
regulatory_JJ
element_NN
or_CC
Tat_NNPS
._.
Importantly_RB
,_,
constitutive_JJ
expression_NN
of_IN
Rev_NNP
M10_NNP
did_VBD
not_RB
alter_VB
the_DT
secretion_NN
of_IN
interleukin_NN
2_CD
in_IN
response_NN
to_TO
mitogen_NN
stimulation_NN
of_IN
EL-4_NN
and_CC
Jurkat_NNP
cells_NNS
._.
The_DT
inhibition_NN
of_IN
HIV_NNP
infection_NN
in_IN
cells_NNS
stably_RB
expressing_VBG
a_DT
transdominant_JJ
Rev_NNP
protein_NN
,_,
in_IN
the_DT
absence_NN
of_IN
any_DT
deleterious_JJ
effect_NN
on_IN
T_NNP
cell_NN
function_NN
,_,
suggests_VBZ
that_IN
such_PDT
a_DT
strategy_NN
could_MD
provide_VB
a_DT
therapeutic_JJ
effect_NN
in_IN
the_DT
T_NNP
lymphocytes_NNS
of_IN
acquired_VBN
immunodeficiency_NN
syndrome_NN
patients_NNS
._.
Glucocorticoid_JJ
receptor_NN
in_IN
patients_NNS
with_IN
lupus_JJ
nephritis_NN
:_:
relationship_NN
between_IN
receptor_NN
levels_NNS
in_IN
mononuclear_NN
leukocytes_NNS
and_CC
effect_NN
of_IN
glucocorticoid_JJ
therapy_NN
._.
We_PRP
investigated_VBD
the_DT
clinical_JJ
significance_NN
of_IN
glucocorticoid_NN
receptor_NN
determination_NN
in_IN
20_CD
patients_NNS
with_IN
systemic_JJ
lupus_NN
erythematosus_NN
(_-LRB-
SLE_NNP
)_-RRB-
who_WP
afterwards_RB
developed_VBD
nephrotic_JJ
syndrome_NN
._.
Glucocorticoid_NNP
receptor_NN
concentrations_NNS
in_IN
mononuclear_NN
leukocytes_NNS
(_-LRB-
MNL_NNP
)_-RRB-
in_IN
these_DT
patients_NNS
were_VBD
comparable_JJ
with_IN
those_DT
in_IN
both_DT
other_JJ
patients_NNS
with_IN
SLE_NNP
and_CC
healthy_JJ
persons_NNS
._.
Improvement_NN
in_IN
urinary_JJ
protein_NN
excretion_NN
and_CC
in_IN
disease_NN
activity_NN
,_,
which_WDT
was_VBD
scored_VBN
according_VBG
to_TO
the_DT
SLE_NNP
Disease_NNP
Activity_NNP
Index_NNP
system_NN
of_IN
the_DT
University_NNP
of_IN
Toronto_NNP
,_,
closely_RB
related_VBN
to_TO
the_DT
glucocorticoid_NN
receptor_NN
concentrations_NNS
in_IN
MNL_NNP
isolated_VBD
from_IN
the_DT
corresponding_JJ
patients_NNS
._.
In_IN
summary_NN
,_,
glucocorticoid_NN
receptor_NN
determination_NN
in_IN
patients_NNS
with_IN
lupus_JJ
nephritis_NN
may_MD
be_VB
a_DT
predictive_JJ
clue_NN
for_IN
assessing_VBG
responsiveness_NN
to_TO
glucocorticoid_JJ
therapy_NN
._.
Selection_NNP
of_IN
optimal_JJ
kappa_NN
B/Rel_NNP
DNA-binding_NNP
motifs_NNS
:_:
interaction_NN
of_IN
both_DT
subunits_NNS
of_IN
NF-kappa_NNP
B_NNP
with_IN
DNA_NNP
is_VBZ
required_VBN
for_IN
transcriptional_JJ
activation_NN
._.
Analysis_NN
of_IN
the_DT
p50_NN
and_CC
p65_VBD
subunits_NNS
of_IN
the_DT
NF-kappa_NNP
B_NNP
transcription_NN
factor_NN
complex_NN
has_VBZ
revealed_VBN
that_IN
both_DT
proteins_NNS
can_MD
interact_VB
with_IN
related_JJ
DNA_NN
sequences_NNS
through_IN
either_DT
homo-_NNS
or_CC
heterodimer_NN
formation_NN
._.
In_IN
addition_NN
,_,
the_DT
product_NN
of_IN
the_DT
proto-oncogene_NN
c-rel_NN
can_MD
bind_NN
to_TO
similar_JJ
DNA_NN
motifs_NNS
by_IN
itself_PRP
or_CC
as_IN
a_DT
heterodimer_NN
with_IN
p50_NN
or_CC
p65_VB
._.
However_RB
,_,
these_DT
studies_NNS
have_VBP
used_VBN
a_DT
limited_JJ
number_NN
of_IN
known_VBN
kappa_NN
B_NNP
DNA_NNP
motifs_NNS
,_,
and_CC
the_DT
question_NN
of_IN
the_DT
optimal_JJ
DNA_NNP
sequences_NNS
preferred_VBN
by_IN
each_DT
homodimer_NN
has_VBZ
not_RB
been_VBN
addressed_VBN
._.
Using_VBG
purified_VBN
recombinant_JJ
p50_NN
,_,
p65_VBD
,_,
and_CC
c-Rel_JJ
proteins_NNS
,_,
optimal_JJ
DNA-binding_NN
motifs_NNS
were_VBD
selected_VBN
from_IN
a_DT
pool_NN
of_IN
random_JJ
oligonucleotides_NNS
._.
Alignment_NNP
of_IN
the_DT
selected_VBN
sequences_NNS
allowed_VBD
us_PRP
to_TO
predict_VB
a_DT
consensus_NN
sequence_NN
for_IN
binding_NN
of_IN
the_DT
individual_JJ
homodimeric_JJ
Rel-related_JJ
proteins_NNS
,_,
and_CC
DNA-protein_NNP
binding_JJ
analysis_NN
of_IN
the_DT
selected_VBN
DNA_NN
sequences_NNS
revealed_VBD
sequence_NN
specificity_NN
of_IN
the_DT
proteins_NNS
._.
Contrary_JJ
to_TO
previous_JJ
assumptions_NNS
,_,
we_PRP
observed_VBD
that_IN
p65_DT
homodimers_NNS
can_MD
interact_VB
with_IN
a_DT
subset_NN
of_IN
DNA_NNP
sequences_NNS
not_RB
recognized_VBN
by_IN
p50_NN
homodimers_NNS
._.
Differential_JJ
binding_NN
affinities_NNS
were_VBD
also_RB
obtained_VBN
with_IN
p50-_NNS
and_CC
c-Rel-selected_JJ
sequences_NNS
._.
Using_VBG
either_CC
a_DT
p50-_NNS
or_CC
p65-selected_JJ
kappa_NN
B_NNP
motif_NN
,_,
which_WDT
displayed_VBD
differential_JJ
binding_NN
with_IN
respect_NN
to_TO
the_DT
other_JJ
protein_NN
,_,
little_JJ
to_TO
no_DT
binding_NN
was_VBD
observed_VBN
with_IN
the_DT
heterodimeric_JJ
NF-kappa_NNP
B_NNP
complex_NN
._.
Similarly_RB
,_,
in_IN
transfection_NN
experiments_NNS
in_IN
which_WDT
the_DT
selective_JJ
kappa_NN
B_NNP
binding_NN
sites_NNS
were_VBD
used_VBN
to_TO
drive_VB
the_DT
expression_NN
of_IN
a_DT
chloramphenicol_NN
acetyltransferase_NN
reporter_NN
construct_VB
,_,
the_DT
p65-_NNS
and_CC
p50-selected_JJ
motifs_NNS
were_VBD
activated_VBN
only_RB
in_IN
the_DT
presence_NN
of_IN
p65_PRP
and_CC
p50/65_VB
(_-LRB-
a_DT
chimeric_JJ
protein_NN
with_IN
the_DT
p50_NN
DNA_NNP
binding_NN
domain_NN
and_CC
p65_VBD
activation_NN
domain_NN
)_-RRB-
expression_NN
vectors_NNS
,_,
respectively_RB
,_,
and_CC
neither_RB
demonstrated_VBD
a_DT
significant_JJ
response_NN
to_TO
stimuli_NNS
that_IN
induce_VB
NF-kappa_NNP
B_NNP
activity_NN
._.
These_DT
findings_NNS
demonstrate_VBP
that_IN
interaction_NN
of_IN
both_DT
subunits_NNS
of_IN
the_DT
heterodimeric_JJ
NF-kappa_NNP
B_NNP
complex_JJ
with_IN
DNA_NN
is_VBZ
required_VBN
for_IN
DNA_NNP
binding_NN
and_CC
transcriptional_JJ
activation_NN
and_CC
suggest_VB
that_IN
transcriptional_JJ
activation_NN
mediated_VBN
by_IN
the_DT
individual_JJ
rel-related_JJ
proteins_NNS
will_MD
differ_VB
dramatically_RB
,_,
depending_VBG
on_IN
the_DT
specific_JJ
kappa_NN
B_NNP
motifs_NNS
present_RB
._.
Characterization_NNP
of_IN
a_DT
new_JJ
tissue-specific_JJ
transcription_NN
factor_NN
binding_NN
to_TO
the_DT
simian_JJ
virus_NN
40_CD
enhancer_NN
TC-II_NNP
(_-LRB-
NF-kappa_NN
B_NNP
)_-RRB-
element_NN
._.
We_PRP
have_VBP
biochemically_RB
and_CC
functionally_RB
characterized_VBD
a_DT
new_JJ
transcription_NN
factor_NN
,_,
NP-TCII_NNP
,_,
which_WDT
is_VBZ
present_JJ
in_IN
nuclei_JJ
from_IN
unstimulated_JJ
T_NNP
and_CC
B_NNP
lymphocytes_NNS
but_CC
is_VBZ
not_RB
found_VBN
in_IN
nonhematopoietic_JJ
cells_NNS
._.
This_DT
factor_NN
has_VBZ
a_DT
DNA-binding_NN
specificity_NN
similar_JJ
to_TO
that_DT
of_IN
NF-kappa_NNP
B_NNP
but_CC
is_VBZ
unrelated_JJ
to_TO
this_DT
or_CC
other_JJ
Rel_JJ
proteins_NNS
by_IN
functional_JJ
and_CC
biochemical_JJ
criteria_NNS
._.
It_PRP
can_MD
also_RB
be_VB
distinguished_VBN
from_IN
other_JJ
previously_RB
described_VBN
lymphocyte-specific_JJ
DNA-binding_JJ
proteins_NNS
._.
The_DT
candidate_NN
oncoprotein_IN
Bcl-3_NN
is_VBZ
an_DT
antagonist_NN
of_IN
p50/NF-kappa_DT
B-mediated_JJ
inhibition_NN
._.
The_DT
candidate_NN
oncogene_IN
bcl-3_NN
was_VBD
discovered_VBN
as_IN
a_DT
translocation_NN
into_IN
the_DT
immunoglobulin_NN
alpha-locus_NN
in_IN
some_DT
cases_NNS
of_IN
B-cell_NN
chronic_NN
lymphocytic_JJ
leukaemias_NNS
._.
The_DT
protein_NN
Bcl-3_NN
contains_VBZ
seven_CD
so-called_JJ
ankyrin_JJ
repeats_NNS
._.
Similar_JJ
repeat_NN
motifs_NNS
are_VBP
found_VBN
in_IN
a_DT
number_NN
of_IN
diverse_JJ
regulatory_JJ
proteins_NNS
but_CC
the_DT
motifs_NNS
of_IN
Bcl-3_NN
are_VBP
most_RBS
closely_RB
related_VBN
to_TO
those_DT
found_VBN
in_IN
I_PRP
kappa_VBD
B_NNP
proteins_NNS
in_IN
which_WDT
the_DT
ankyrin_NN
repeat_NN
domain_NN
is_VBZ
thought_VBN
to_TO
be_VB
directly_RB
involved_VBN
in_IN
inhibition_NN
of_IN
NF-kappa_NNP
B_NNP
activity_NN
._.
No_DT
biological_JJ
function_NN
has_VBZ
yet_RB
been_VBN
described_VBN
for_IN
Bcl-3_JJ
,_,
but_CC
it_PRP
was_VBD
noted_VBN
recently_RB
that_IN
Bcl-3_JJ
interferes_NNS
with_IN
DNA-binding_NN
of_IN
the_DT
p50_NN
subunit_NN
of_IN
NF-kappa_NNP
B_NNP
in_IN
vitro_NN
._.
Here_RB
we_PRP
demonstrate_VBP
that_IN
Bcl-3_NN
can_MD
aid_VB
kappa_NN
B_NNP
site-dependent_NN
transcription_NN
in_IN
vivo_NN
by_IN
counteracting_VBG
the_DT
inhibitory_JJ
effects_NNS
of_IN
p50/NF-kappa_NN
B_NNP
homodimers_NNS
._.
Bcl-3_NN
may_MD
therefore_RB
aid_VB
activation_NN
of_IN
select_JJ
NF-kappa_NNP
B-regulated_NNP
genes_NNS
,_,
including_VBG
those_DT
of_IN
the_DT
human_JJ
immunodeficiency_NN
virus_NN
._.
A_DT
microtitre_NN
assay_NN
system_NN
for_IN
glucocorticoid_JJ
receptors_NNS
:_:
decreased_VBN
receptor_NN
concentration_NN
in_IN
myocardial_JJ
infarction_NN
._.
A_DT
major_JJ
difficulty_NN
in_IN
determination_NN
of_IN
glucocorticoid_NN
receptor_NN
sites_NNS
is_VBZ
the_DT
very_RB
complicated_JJ
assay_NN
procedure_NN
._.
Therefore_RB
,_,
we_PRP
describe_VBP
a_DT
microtitre_NN
assay_NN
system_NN
for_IN
glucocorticoid_JJ
receptors_NNS
which_WDT
is_VBZ
a_DT
whole-cell_JJ
competitive_JJ
binding_NN
radioassay_NN
using_VBG
(3H)-dexamethasone_JJ
as_IN
radioligand_NN
._.
This_DT
modification_NN
of_IN
a_DT
previously_RB
described_VBN
protocol_NN
simplifies_NNS
and_CC
reduces_VBZ
laboratory_NN
work_NN
and_CC
allows_VBZ
assay_NN
reproducibility_NN
to_TO
be_VB
controlled_VBN
more_RBR
reliably_RB
._.
Thus_RB
enabled_VBD
to_TO
perform_VB
the_DT
test_NN
on_IN
multiple_JJ
blood_NN
samples_NNS
in_IN
parallel_JJ
,_,
we_PRP
investigated_VBD
cardiac_JJ
infarction_NN
patients_NNS
over_IN
a_DT
12-day_JJ
period_NN
to_TO
test_VB
if_IN
glucocorticoid_NN
receptor_NN
binding_NN
is_VBZ
altered_VBN
in_IN
this_DT
'_''
stressful_JJ
'_''
disease_NN
._.
On_IN
the_DT
first_JJ
day_NN
of_IN
the_DT
disease_NN
,_,
glucocorticoid_NN
receptor_NN
capacity_NN
was_VBD
significantly_RB
decreased_VBN
without_IN
alteration_NN
of_IN
the_DT
receptor-ligand_JJ
affinity_NN
,_,
whereas_IN
on_IN
days_NNS
4_CD
and_CC
12_CD
the_DT
number_NN
of_IN
receptor_NN
sites_NNS
was_VBD
normal_JJ
again_RB
._.
This_DT
result_NN
fits_VBZ
well_RB
into_IN
the_DT
general_JJ
observation_NN
of_IN
stress-induced_JJ
down-regulation_NN
of_IN
immune_JJ
responses_NNS
._.
Regulation_NN
of_IN
c-jun_JJ
expression_NN
during_IN
induction_NN
of_IN
monocytic_JJ
differentiation_NN
by_IN
okadaic_JJ
acid_NN
._.
The_DT
present_JJ
work_NN
has_VBZ
examined_VBN
the_DT
effects_NNS
of_IN
okadaic_JJ
acid_NN
,_,
an_DT
inhibitor_NN
of_IN
type_NN
1_CD
and_CC
2A_JJ
protein_NN
phosphatases_NNS
,_,
on_IN
the_DT
regulation_NN
of_IN
c-jun_JJ
expression_NN
during_IN
monocytic_JJ
differentiation_NN
of_IN
U-937_DT
leukemia_NN
cells_NNS
._.
The_DT
results_NNS
demonstrate_VBP
that_IN
okadaic_JJ
acid_NN
treatment_NN
is_VBZ
associated_VBN
with_IN
induction_NN
of_IN
a_DT
differentiated_JJ
monocyte_NN
phenotype_NN
characterized_VBN
by_IN
:_:
(_-LRB-
a_DT
)_-RRB-
growth_NN
arrest_NN
;_:
(_-LRB-
b_NN
)_-RRB-
increases_VBZ
in_IN
Mac-1_JJ
cell_NN
surface_NN
antigen_JJ
expression_NN
;_:
(_-LRB-
c_NN
)_-RRB-
down-regulation_NN
of_IN
c-myc_JJ
transcripts_NNS
;_:
and_CC
(_-LRB-
d_NN
)_-RRB-
induction_NN
of_IN
tumor_NN
necrosis_NN
factor_NN
gene_NN
expression_NN
._.
This_DT
induction_NN
of_IN
monocytic_JJ
differentiation_NN
was_VBD
associated_VBN
with_IN
transient_NN
increases_NNS
in_IN
c-jun_JJ
mRNA_NN
levels_NNS
,_,
which_WDT
were_VBD
maximal_JJ
at_IN
6_CD
h_NN
._.
Similar_JJ
effects_NNS
were_VBD
obtained_VBN
for_IN
the_DT
c-fos_JJ
gene_NN
._.
Run-on_JJ
analysis_NN
demonstrated_VBN
detectable_JJ
levels_NNS
of_IN
c-jun_JJ
transcription_NN
in_IN
U-937_JJ
cells_NNS
and_CC
that_IN
this_DT
rate_NN
is_VBZ
increased_VBN
approximately_RB
40-fold_JJ
following_VBG
okadaic_JJ
acid_NN
exposure_NN
._.
c-jun_JJ
mRNA_NN
levels_NNS
were_VBD
superinduced_VBN
in_IN
cells_NNS
treated_VBN
with_IN
both_DT
okadaic_JJ
acid_NN
and_CC
cycloheximide_NN
,_,
whereas_IN
inhibition_NN
of_IN
protein_NN
synthesis_NN
had_VBD
little_RB
,_,
if_IN
any_DT
,_,
effect_NN
on_IN
okadaic_JJ
acid-induced_JJ
c-jun_NN
transcription_NN
._.
The_DT
half-life_NN
of_IN
c-jun_JJ
mRNA_NN
was_VBD
similar_JJ
(_-LRB-
45-50_JJ
min_NN
)_-RRB-
in_IN
both_DT
untreated_JJ
and_CC
okadaic_JJ
acid-induced_JJ
cells_NNS
._.
In_IN
contrast_NN
,_,
treatment_NN
with_IN
both_DT
okadaic_JJ
acid_NN
and_CC
cycloheximide_NN
was_VBD
associated_VBN
with_IN
stabilization_NN
(_-LRB-
t_NN
1/2_CD
=_SYM
90_CD
min_NN
)_-RRB-
of_IN
c-jun_NN
transcripts_NNS
._.
Taken_VBN
together_RB
,_,
these_DT
findings_NNS
indicate_VBP
that_IN
the_DT
induction_NN
of_IN
c-jun_JJ
transcription_NN
by_IN
okadaic_JJ
acid_NN
is_VBZ
controlled_VBN
primarily_RB
by_IN
a_DT
transcriptional_JJ
mechanism_NN
._.
Since_IN
previous_JJ
studies_NNS
have_VBP
demonstrated_VBN
that_IN
the_DT
c-jun_JJ
gene_NN
is_VBZ
autoinduced_VBN
by_IN
Jun/AP-1_NNP
,_,
we_PRP
also_RB
studied_VBD
transcription_NN
of_IN
c-jun_NN
promoter_NN
(_-LRB-
positions_NNS
-132/+170_NN
)_-RRB-
-reporter_NN
gene_NN
constructs_NNS
with_IN
and_CC
without_IN
a_DT
mutated_JJ
AP-1_JJ
element_NN
._.
(_-LRB-
ABSTRACT_NNP
TRUNCATED_NNP
AT_WDT
250_CD
WORDS_NNS
)_-RRB-
Activation_NN
of_IN
NF-kappa_NNP
B_NNP
by_IN
interleukin_NN
2_CD
in_IN
human_JJ
blood_NN
monocytes_NNS
._.
We_PRP
report_VBP
here_RB
that_IN
interleukin_NN
2_CD
(_-LRB-
IL-2_NN
)_-RRB-
acts_VBZ
on_IN
human_JJ
blood_NN
monocytes_NNS
by_IN
enhancing_VBG
binding_JJ
activity_NN
of_IN
the_DT
transcription_NN
factor_NN
NF-kappa_NNP
B_NNP
to_TO
its_PRP$
consensus_NN
sequence_NN
in_IN
the_DT
5'_JJ
regulatory_JJ
enhancer_NN
region_NN
of_IN
the_DT
IL-2_NN
receptor_NN
alpha_NN
chain_NN
(_-LRB-
p55_NN
)_-RRB-
._.
Similarly_RB
,_,
IL-2_DT
activates_NNS
NF-kappa_NNP
B_NNP
in_IN
the_DT
human_JJ
monocytic_JJ
cell_NN
line_NN
U_NNP
937_CD
,_,
but_CC
not_RB
in_IN
resting_VBG
human_JJ
T-cells_NNS
._.
This_DT
effect_NN
is_VBZ
detectable_JJ
within_IN
15_CD
min_NN
and_CC
peaks_NNS
1_CD
h_NN
after_IN
exposure_NN
to_TO
IL-2_NNP
._.
Enhanced_JJ
NF-kappa_NNP
B_NNP
binding_NN
activity_NN
is_VBZ
followed_VBN
by_IN
functional_JJ
activation_NN
in_IN
that_DT
inducibility_NN
of_IN
the_DT
IL-2_NN
receptor_NN
alpha_NN
chain_NN
is_VBZ
mediated_VBN
by_IN
enhanced_JJ
NF-kappa_NNP
B_NNP
binding_NN
and_CC
that_IN
a_DT
heterologous_NN
promoter_NN
containing_VBG
the_DT
NF-kappa_NNP
B_NNP
consensus_NN
sequence_NN
(_-LRB-
-291_JJ
to_TO
-245_DT
)_-RRB-
of_IN
the_DT
IL-2_NN
receptor_NN
alpha_NN
chain_NN
gene_NN
is_VBZ
activated_VBN
._.
In_IN
addition_NN
,_,
IL-2_NNP
is_VBZ
capable_JJ
of_IN
increasing_VBG
transcript_NN
levels_NNS
of_IN
the_DT
p50_NN
gene_NN
coding_NN
for_IN
the_DT
p50_NN
subunit_NN
of_IN
the_DT
NF-kappa_NNP
B_NNP
transcription_NN
factor_NN
,_,
whereas_IN
mRNA_JJ
levels_NNS
of_IN
the_DT
p65_NN
NF-kappa_NNP
B_NNP
gene_NN
remained_VBD
unchanged_JJ
._.
Single_NNP
point_NN
estimation_NN
of_IN
glucocorticoid_JJ
receptors_NNS
in_IN
lymphocytes_NNS
of_IN
normal_JJ
subjects_NNS
and_CC
of_IN
children_NNS
under_IN
long_JJ
term_NN
glucocorticoid_NN
treatment_NN
._.
A_DT
single_JJ
point_NN
assay_NN
of_IN
glucocorticoid_JJ
receptors_NNS
(_-LRB-
GR_CD
)_-RRB-
in_IN
human_JJ
lymphocytes_NNS
based_VBN
on_IN
the_DT
measurement_NN
of_IN
specific_JJ
dexamethasone_NN
binding_NN
has_VBZ
been_VBN
developed_VBN
and_CC
compared_VBN
with_IN
a_DT
common_JJ
multi-point_JJ
Scatchard_JJ
analysis_NN
._.
The_DT
assay_NN
conditions_NNS
-_:
concentration_NN
of_IN
the_DT
ligand_NN
20_CD
nmol/l_NN
,_,
incubation_IN
time_NN
2_CD
h_NN
and_CC
the_DT
cell_NN
count_NN
2-6_CC
mil._NN
cells/tube_NN
in_IN
the_DT
assay_NN
volume_NN
0.25_CD
ml_NN
were_VBD
found_VBN
to_TO
be_VB
optimal_JJ
._.
An_DT
attempt_NN
was_VBD
also_RB
undertaken_VBN
to_TO
use_VB
a_DT
cell_NN
harvester_NN
for_IN
the_DT
separation_NN
of_IN
cells_NNS
from_IN
unbound_JJ
ligand_NN
._.
Though_IN
specifically_RB
bound_VBN
dexamethasone_NN
measured_VBN
by_IN
whole-cell_JJ
assay_NN
and_CC
that_IN
using_VBG
cell_NN
harvester_NN
correlated_VBN
well_RB
,_,
almost_RB
by_IN
one_CD
order_NN
lower_JJR
values_NNS
obtained_VBN
with_IN
the_DT
latter_JJ
method_NN
render_NN
it_PRP
non-applicable_JJ
for_IN
receptor_NN
quantitation_NN
._.
The_DT
results_NNS
from_IN
9_CD
healthy_JJ
volunteers_NNS
(_-LRB-
average_NN
GR_CD
concentration_NN
7131_CD
+/-_,
1256_CD
sites/cell_NN
)_-RRB-
correlated_VBN
excellently_RB
with_IN
those_DT
obtained_VBN
by_IN
the_DT
Scatchard_NNP
analysis_NN
._.
The_DT
single_JJ
point_NN
assay_NN
has_VBZ
been_VBN
also_RB
applied_VBN
for_IN
determination_NN
of_IN
GH_NNP
in_IN
10_CD
children_NNS
treated_VBN
with_IN
large_JJ
doses_NNS
of_IN
prednisone_NN
._.
The_DT
average_JJ
values_NNS
from_IN
healthy_JJ
volunteers_NNS
did_VBD
not_RB
differ_VB
significantly_RB
from_IN
those_DT
found_VBN
in_IN
these_DT
children_NNS
,_,
though_RB
much_RB
broader_JJR
range_NN
was_VBD
found_VBN
in_IN
patients_NNS
._.
A_DT
novel_NN
B_NNP
cell-derived_VBD
coactivator_NN
potentiates_NNS
the_DT
activation_NN
of_IN
immunoglobulin_JJ
promoters_NNS
by_IN
octamer-binding_JJ
transcription_NN
factors_NNS
._.
A_DT
novel_NN
B_NNP
cell-restricted_JJ
activity_NN
,_,
required_VBN
for_IN
high_JJ
levels_NNS
of_IN
octamer/Oct-dependent_JJ
transcription_NN
from_IN
an_DT
immunoglobulin_NN
heavy_NN
chain_NN
(_-LRB-
IgH_NNP
)_-RRB-
promoter_NN
,_,
was_VBD
detected_VBN
in_IN
an_DT
in_IN
vitro_NN
system_NN
consisting_VBG
of_IN
HeLa_NNP
cell-derived_JJ
extracts_NNS
complemented_VBN
with_IN
fractionated_JJ
B_NNP
cell_NN
nuclear_JJ
proteins_NNS
._.
The_DT
factor_NN
responsible_JJ
for_IN
this_DT
activity_NN
was_VBD
designated_VBN
Oct_NNP
coactivator_NN
from_IN
B_NNP
cells_NNS
(_-LRB-
OCA-B_NNP
)_-RRB-
._.
OCA-B_NNP
stimulates_VBZ
the_DT
transcription_NN
from_IN
an_DT
IgH_NNP
promoter_NN
in_IN
conjunction_NN
with_IN
either_DT
Oct-1_NNP
or_CC
Oct-2_NNP
but_CC
shows_VBZ
no_DT
significant_JJ
effect_NN
on_IN
the_DT
octamer/Oct-dependent_JJ
transcription_NN
of_IN
the_DT
ubiquitously_NN
expressed_VBD
histone_NN
H2B_IN
promoter_NN
and_CC
the_DT
transcription_NN
of_IN
USF-_NNP
and_CC
Sp1-regulated_JJ
promoters_NNS
._.
Taken_VBN
together_RB
,_,
our_PRP$
results_NNS
suggest_VBP
that_IN
OCA-B_NNP
is_VBZ
a_DT
tissue-_NNS
,_,
promoter-_NNS
,_,
and_CC
factor-specific_JJ
coactivator_NN
and_CC
that_DT
OCA-B_NNP
may_MD
be_VB
a_DT
major_JJ
determinant_NN
for_IN
B_NNP
cell-specific_JJ
activation_NN
of_IN
immunoglobulin_JJ
promoters_NNS
._.
In_IN
light_NN
of_IN
the_DT
evidence_NN
showing_VBG
physical_JJ
and_CC
functional_JJ
interactions_NNS
between_IN
Oct_NNP
factors_NNS
and_CC
OCA-B_NNP
,_,
we_PRP
propose_VBP
a_DT
mechanism_NN
of_IN
action_NN
for_IN
OCA-B_NNP
and_CC
discuss_VB
the_DT
implications_NNS
of_IN
OCA-B_NNP
for_IN
the_DT
transcriptional_JJ
regulation_NN
of_IN
other_JJ
tissue-specific_JJ
promoters_NNS
._.
The_DT
regulation_NN
of_IN
the_DT
human_JJ
tumor_NN
necrosis_NN
factor_NN
alpha_NN
promoter_NN
region_NN
in_IN
macrophage_NN
,_,
T_NNP
cell_NN
,_,
and_CC
B_NNP
cell_NN
lines_NNS
._.
The_DT
1311-base_JJ
pair_NN
human_JJ
tumor_NN
necrosis_NN
factor_NN
(_-LRB-
TNF_NN
)_-RRB-
alpha_NN
promoter_NN
region_NN
was_VBD
fused_VBN
to_TO
the_DT
luciferase_NN
(_-LRB-
Luc_NNP
)_-RRB-
reporter_NN
gene_NN
and_CC
studied_VBN
in_IN
a_DT
transient_JJ
transfection_NN
system_NN
in_IN
three_CD
TNF_NNP
producing_VBG
cell_NN
lines_NNS
,_,
the_DT
U937_NNP
macrophage_NN
cell_NN
line_NN
,_,
the_DT
MLA_NNP
144_CD
T_NNP
cell_NN
line_NN
,_,
and_CC
the_DT
729-6_CD
B_NNP
cell_NN
line_NN
._.
This_DT
full_JJ
length_NN
promoter_NN
construct_VB
can_MD
be_VB
induced_VBN
by_IN
phorbol_NN
13-myristate_JJ
acetate_NN
(_-LRB-
PMA_NNP
)_-RRB-
in_IN
each_DT
of_IN
these_DT
cell_NN
types_NNS
._.
Analysis_NN
of_IN
a_DT
series_NN
of_IN
5'-truncations_NNS
showed_VBD
several_JJ
peaks_NNS
of_IN
basal_NN
and_CC
PMA_NNP
induced_VBD
activity_NN
suggesting_VBG
the_DT
presence_NN
of_IN
several_JJ
positive_JJ
and_CC
negative_JJ
regulatory_JJ
elements_NNS
._.
A_DT
PMA_NNP
responsive_JJ
element_NN
was_VBD
localized_VBN
to_TO
a_DT
region_NN
between_IN
-95_NN
and_CC
-36_DT
bp_NN
relative_JJ
to_TO
the_DT
transcription_NN
start_NN
site_NN
._.
Within_IN
this_DT
region_NN
,_,
single_JJ
AP-2-_NNP
and_CC
AP-1-like_JJ
consensus_NN
sequences_NNS
were_VBD
noted_VBN
._.
These_DT
AP-2_NNP
and_CC
AP-1_NNP
sites_NNS
were_VBD
each_DT
modified_VBN
with_IN
a_DT
double_JJ
point_NN
mutation_NN
._.
A_DT
modest_JJ
(_-LRB-
20-50_CD
%_NN
)_-RRB-
reduction_NN
in_IN
TNF_NNP
promoter_NN
activity_NN
was_VBD
observed_VBN
with_IN
the_DT
AP-2_NNP
site_NN
mutation_NN
._.
However_RB
,_,
mutation_NN
of_IN
the_DT
AP-1_NNP
site_NN
markedly_RB
diminished_VBD
both_DT
the_DT
basal_NN
and_CC
PMA-activated_JJ
promoter_NN
activity_NN
._.
Also_RB
co-transfections_NNS
of_IN
the_DT
wild-type_JJ
promoter_NN
construct_VB
with_IN
an_DT
AP-1/c-jun_JJ
expression_NN
vector_NN
resulted_VBD
in_IN
augmented_JJ
basal_NN
and_CC
PMA-induced_JJ
promoter_NN
activity_NN
._.
Redox_JJ
status_NN
of_IN
cells_NNS
influences_VBZ
constitutive_JJ
or_CC
induced_JJ
NF-kappa_NNP
B_NNP
translocation_NN
and_CC
HIV_PRP$
long_JJ
terminal_NN
repeat_NN
activity_NN
in_IN
human_JJ
T_NNP
and_CC
monocytic_JJ
cell_NN
lines_NNS
._.
We_PRP
have_VBP
tested_VBN
the_DT
hypothesis_NN
that_IN
cellular_JJ
activation_NN
events_NNS
occurring_VBG
in_IN
T_NNP
lymphocytes_NNS
and_CC
monocytes_NNS
and_CC
mediated_VBN
through_IN
translocation_NN
of_IN
the_DT
transcription_NN
factor_NN
NF-kappa_NNP
B_NNP
are_VBP
dependent_JJ
upon_IN
the_DT
constitutive_JJ
redox_NN
status_NN
of_IN
these_DT
cells_NNS
._.
We_PRP
used_VBD
phenolic_JJ
,_,
lipid-soluble_JJ
,_,
chain-breaking_NN
antioxidants_NNS
(_-LRB-
butylated_CC
hydroxyanisole_NN
(_-LRB-
BHA_NNP
)_-RRB-
,_,
nordihydroquairetic_JJ
acid_NN
,_,
or_CC
alpha-tocopherol_NN
(_-LRB-
vitamin_NN
E_NNP
)_-RRB-
to_TO
show_VB
that_DT
peroxyl_NN
radical_JJ
scavenging_NN
in_IN
unstimulated_JJ
and_CC
PMA-_NNP
or_CC
TNF-stimulated_JJ
cells_NNS
blocks_NNS
the_DT
functions_NNS
depending_VBG
on_IN
NF-kappa_NNP
B_NNP
activation_NN
._.
BHA_NNP
was_VBD
found_VBN
to_TO
suppress_VB
not_RB
only_RB
PMA-_NNP
or_CC
TNF-induced_NNP
,_,
but_CC
also_RB
constitutive_JJ
,_,
HIV-enhancer_NNP
activity_NN
concomitant_NN
to_TO
an_DT
inhibition_NN
of_IN
NF-kappa_NNP
B_NNP
binding_NN
activity_NN
in_IN
both_DT
lymphoblastoid_JJ
T_NNP
(_-LRB-
J.Jhan_NNP
)_-RRB-
and_CC
monocytic_JJ
(_-LRB-
U937_NN
)_-RRB-
cell_NN
lines_NNS
._.
This_DT
was_VBD
also_RB
true_JJ
for_IN
KBF_NNP
(_-LRB-
p50_NN
homodimer_NN
)_-RRB-
binding_NN
activity_NN
in_IN
U937_JJ
cells_NNS
._.
Secretion_NNP
of_IN
TNF_NNP
,_,
the_DT
product_NN
of_IN
another_DT
NF-kappa_NNP
B-dependent_NNP
gene_NN
,_,
was_VBD
abolished_VBN
by_IN
BHA_NNP
in_IN
PMA-stimulated_NNP
U937_IN
cells_NNS
._.
The_DT
anti-oxidative_JJ
effect_NN
of_IN
BHA_NNP
was_VBD
accompanied_VBN
by_IN
an_DT
increase_NN
in_IN
thiol_NN
,_,
but_CC
not_RB
glutathione_NN
,_,
content_NN
in_IN
stimulated_VBN
and_CC
unstimulated_JJ
T_NNP
cell_NN
,_,
whereas_IN
TNF_NNP
stimulation_NN
itself_PRP
barely_RB
modified_VBN
the_DT
cellular_JJ
thiol_NN
level_NN
._.
Oxidative_JJ
stress_NN
obtained_VBN
by_IN
the_DT
addition_NN
of_IN
H2O2_NNP
to_TO
the_DT
culture_NN
medium_NN
of_IN
J.Jhan_NNP
or_CC
U937_IN
cells_NNS
could_MD
not_RB
by_IN
itself_PRP
induce_VB
NF-kappa_NNP
B_NNP
activation_NN
._.
These_DT
observations_NNS
suggest_VBP
that_IN
TNF_NNP
and_CC
PMA_NNP
do_VBP
not_RB
lead_VB
to_TO
NF-kappa_NNP
B_NNP
activation_NN
through_IN
induction_NN
of_IN
changes_NNS
in_IN
the_DT
cell_NN
redox_NN
status_NN
._.
Rather_RB
,_,
TNF_NNP
and_CC
PMA_NNP
can_MD
exert_VB
their_PRP$
effect_NN
only_RB
if_IN
cells_NNS
are_VBP
in_IN
an_DT
appropriate_JJ
redox_NN
status_NN
,_,
because_IN
prior_JJ
modification_NN
toward_IN
reduction_NN
with_IN
BHA_NNP
treatment_NN
prevents_VBZ
this_DT
activation_NN
._.
It_PRP
appears_VBZ
that_IN
a_DT
basal_NN
redox_NN
equilibrium_NN
tending_VBG
toward_IN
oxidation_NN
is_VBZ
a_DT
prerequisite_NN
for_IN
full_JJ
activation_NN
of_IN
transduction_NN
pathways_NNS
regulating_VBG
the_DT
activity_NN
of_IN
NF-kappa_NNP
B-dependent_NNP
genes_NNS
._.
Expression_NN
of_IN
c-fos_JJ
,_,
c-jun_JJ
and_CC
jun_NN
B_NNP
in_IN
peripheral_JJ
blood_NN
lymphocytes_NNS
from_IN
young_JJ
and_CC
elderly_JJ
adults_NNS
._.
The_DT
expression_NN
of_IN
c-fos_JJ
,_,
c-jun_JJ
and_CC
jun_NN
B_NNP
proto-oncogenes_NNS
was_VBD
studied_VBN
in_IN
phytohemagglutinin_NN
(_-LRB-
PHA_NNP
)_-RRB-
activated_VBN
peripheral_JJ
blood_NN
lymphocytes_NNS
(_-LRB-
PBL_NN
)_-RRB-
from_IN
young_JJ
and_CC
aged_JJ
humans_NNS
._.
Specific_JJ
mRNAs_NNS
for_IN
c-fos_JJ
and_CC
c-jun_JJ
were_VBD
detectable_VBN
within_IN
30_CD
min_NN
after_IN
cell_NN
activation_NN
and_CC
reached_VBD
maximal_JJ
levels_NNS
within_IN
2_CD
h_NN
._.
Both_DT
c-fos_NNS
and_CC
jun_NN
B_NNP
mRNAs_NNS
decreased_VBD
to_TO
pre-activation_VB
levels_NNS
within_IN
6_CD
h_NN
,_,
while_IN
c-jun_JJ
mRNA_NNS
remained_VBD
elevated_JJ
._.
In_IN
PHA-activated_JJ
PBL_NNP
,_,
no_DT
age-related_JJ
differences_NNS
were_VBD
observed_VBN
in_IN
c-fos_JJ
or_CC
jun_NN
B_NN
mRNA_NN
expression_NN
._.
However_RB
,_,
c-jun_JJ
mRNA_NN
levels_NNS
decreased_VBD
significantly_RB
(_-LRB-
1.73_CD
+/-_:
0.08_CD
vs._IN
1.16_CD
+/-_CD
0.09_CD
arbitrary_JJ
units_NNS
,_,
P_NNP
&lt[[SEMICOLON]]_NNP
0.01_CD
,_,
young_JJ
vs._JJ
old_JJ
)_-RRB-
in_IN
PBL_NNP
from_IN
elderly_JJ
individuals_NNS
activated_VBN
with_IN
PHA_NNP
._.
Because_IN
previous_JJ
work_NN
has_VBZ
demonstrated_VBN
that_IN
T_NNP
cells_NNS
from_IN
elderly_JJ
individuals_NNS
may_MD
display_VB
normal_JJ
proliferative_JJ
responses_NNS
when_WRB
activated_JJ
via_IN
the_DT
anti-CD2_JJ
pathway_NN
,_,
c-jun_NN
and_CC
jun_NN
B_NNP
mRNA_NN
expression_NN
was_VBD
also_RB
studied_VBN
in_IN
anti-CD2-activated_JJ
purified_VBN
T_NNP
cells_NNS
._.
No_DT
age-related_JJ
differences_NNS
were_VBD
found_VBN
in_IN
the_DT
expression_NN
of_IN
either_DT
of_IN
these_DT
two_CD
proto-oncogenes_NNS
by_IN
anti-CD2_JJ
activated_JJ
T_NNP
cells_NNS
._.
These_DT
results_NNS
suggest_VBP
that_IN
the_DT
decreased_VBN
IL-2_NN
production_NN
and_CC
proliferative_JJ
response_NN
displayed_VBN
by_IN
PHA-activated_JJ
PBL_NNS
from_IN
elderly_JJ
adults_NNS
may_MD
be_VB
related_VBN
to_TO
age-related_JJ
changes_NNS
in_IN
c-jun_NN
mRNA_NN
expression_NN
and_CC
in_IN
the_DT
ratio_NN
of_IN
c-fos_JJ
to_TO
c-jun_JJ
mRNA_NN
._.
Characterization_NNP
of_IN
a_DT
novel_NN
T_NNP
lymphocyte_NN
protein_NN
which_WDT
binds_VBZ
to_TO
a_DT
site_NN
related_VBN
to_TO
steroid/thyroid_VB
hormone_NN
receptor_NN
response_NN
elements_NNS
in_IN
the_DT
negative_JJ
regulatory_JJ
sequence_NN
of_IN
the_DT
human_JJ
immunodeficiency_NN
virus_NN
long_RB
terminal_JJ
repeat_NN
._.
We_PRP
have_VBP
previously_RB
identified_VBN
a_DT
T_NNP
lymphocyte_NN
protein_NN
which_WDT
binds_VBZ
to_TO
a_DT
site_NN
within_IN
the_DT
LTR_NNP
of_IN
the_DT
human_JJ
immunodeficiency_NN
virus_NN
type_NN
1_CD
(_-LRB-
HIV-1_NN
)_-RRB-
and_CC
exerts_VBZ
an_DT
inhibitory_JJ
effect_NN
on_IN
virus_NN
gene_NN
expression_NN
._.
The_DT
palindromic_JJ
site_NN
(_-LRB-
site_NN
B_NNP
)_-RRB-
recognized_VBN
by_IN
this_DT
protein_NN
is_VBZ
related_VBN
to_TO
the_DT
palindromic_JJ
binding_NN
sites_NNS
of_IN
members_NNS
of_IN
the_DT
steroid/thyroid_NN
hormone_NN
receptor_NN
family_NN
._.
Here_RB
we_PRP
characterize_VBP
the_DT
T_NNP
cell_NN
protein_NN
binding_NN
to_TO
this_DT
site_NN
as_IN
a_DT
100_CD
kD_JJ
protein_NN
which_WDT
is_VBZ
most_RBS
abundant_JJ
in_IN
T_NNP
cells_NNS
and_CC
which_WDT
binds_NNS
to_TO
site_NN
B_NNP
as_IN
a_DT
200_CD
kD_NN
complex_NN
._.
This_DT
protein_NN
is_VBZ
distinct_JJ
from_IN
other_JJ
members_NNS
of_IN
the_DT
steroid/thyroid_NN
hormone_NN
receptor_NN
family_NN
including_VBG
the_DT
COUP_NNP
protein_NN
which_WDT
has_VBZ
a_DT
closely_RB
related_JJ
DNA_NNP
binding_NN
specificity_NN
._.
A_DT
mechanism_NN
for_IN
the_DT
antiinflammatory_JJ
effects_NNS
of_IN
corticosteroids_NNS
:_:
the_DT
glucocorticoid_NN
receptor_NN
regulates_VBZ
leukocyte_NN
adhesion_NN
to_TO
endothelial_JJ
cells_NNS
and_CC
expression_NN
of_IN
endothelial-leukocyte_JJ
adhesion_NN
molecule_NN
1_CD
and_CC
intercellular_JJ
adhesion_NN
molecule_NN
1_CD
._.
Corticosteroids_NNS
are_VBP
the_DT
preeminent_JJ
antiinflammatory_JJ
agents_NNS
although_IN
the_DT
molecular_JJ
mechanisms_NNS
that_WDT
impart_VBP
their_PRP$
efficacy_NN
have_VBP
not_RB
been_VBN
defined_VBN
._.
The_DT
endothelium_NN
plays_VBZ
a_DT
critical_JJ
role_NN
in_IN
inflammation_NN
by_IN
directing_VBG
circulating_VBG
leukocytes_NNS
into_IN
extravascular_JJ
tissues_NNS
by_IN
expressing_VBG
adhesive_JJ
molecules_NNS
for_IN
leukocytes_NNS
(_-LRB-
e.g._FW
,_,
endothelial-leukocyte_JJ
adhesion_NN
molecule_NN
1_CD
(_-LRB-
ELAM-1_NN
)_-RRB-
and_CC
intercellular_JJ
adhesion_NN
molecule_NN
1_CD
(_-LRB-
ICAM-1_NN
)_-RRB-
._.
We_PRP
therefore_RB
determined_VBD
whether_IN
corticosteroids_NNS
suppress_NN
inflammation_NN
by_IN
inhibiting_VBG
endothelial_JJ
expression_NN
of_IN
adhesion_NN
molecules_NNS
for_IN
neutrophils_NNS
(_-LRB-
polymorphonuclear_NN
leukocytes_NNS
)_-RRB-
._.
Preincubation_NN
of_IN
endothelial_JJ
cells_NNS
with_IN
endotoxin_NN
(_-LRB-
lipopolysaccharide_NN
(_-LRB-
LPS_NNP
)_-RRB-
,_,
1_CD
microgram/ml_NN
)_-RRB-
led_VBN
to_TO
a_DT
4-fold_JJ
increase_NN
in_IN
subsequent_JJ
adherence_NN
of_IN
polymorphonuclear_NN
leukocytes_NNS
(_-LRB-
P_NNP
<_NNP
0.0001_CD
,_,
n_RB
=_SYM
10_CD
)_-RRB-
to_TO
endothelial_JJ
cells_NNS
,_,
an_DT
increase_NN
that_WDT
was_VBD
markedly_RB
attenuated_VBN
when_WRB
endothelial_JJ
cells_NNS
were_VBD
treated_VBN
with_IN
dexamethasone_NN
(_-LRB-
IC50_IN
<_NN
1_CD
nM_NN
,_,
P_NNP
<_NNP
0.0001_CD
,_,
n_RB
=_SYM
6_CD
or_CC
7_CD
)_-RRB-
during_IN
preincubation_NN
with_IN
LPS_NNP
._.
Moreover_RB
,_,
the_DT
steroid_NN
receptor_NN
agonist_NN
cortisol_NN
(_-LRB-
10_CD
microM_NN
)_-RRB-
,_,
but_CC
not_RB
its_PRP$
inactive_JJ
metabolite_NN
tetrahydrocortisol_NN
(_-LRB-
10_CD
microM_NN
)_-RRB-
,_,
diminished_VBD
LPS-induced_JJ
endothelial_NN
cell_NN
adhesiveness_NN
._.
Further_JJ
evidence_NN
that_IN
the_DT
action_NN
of_IN
dexamethasone_NN
was_VBD
mediated_VBN
through_IN
ligation_NN
of_IN
corticosteroid_NN
receptors_NNS
(_-LRB-
human_JJ
glucocorticoid_NN
receptors_NNS
(_-LRB-
hGRs_NN
)_-RRB-
)_-RRB-
was_VBD
provided_VBN
by_IN
experiments_NNS
utilizing_VBG
the_DT
steroid_JJ
antagonist_NN
RU-486_NNP
._.
RU-486_NNP
(_-LRB-
10_CD
microM_NN
)_-RRB-
,_,
which_WDT
prevents_VBZ
translocation_NN
of_IN
ligated_JJ
hGR_NN
to_TO
the_DT
nucleus_JJ
by_IN
inhibiting_VBG
dissociation_NN
of_IN
hGR_NN
from_IN
heat_NN
shock_NN
protein_NN
90_CD
,_,
completely_RB
aborted_VBN
the_DT
effect_NN
of_IN
dexamethasone_NN
on_IN
adhesiveness_NN
of_IN
endothelial_JJ
cells_NNS
(_-LRB-
P_NNP
<_NNP
0.0005_CD
,_,
n_RB
=_SYM
3_CD
)_-RRB-
._.
Treatment_NNP
of_IN
endothelial_JJ
cells_NNS
with_IN
LPS_NNP
(_-LRB-
1_CD
microgram/ml_NN
)_-RRB-
stimulated_VBN
transcription_NN
of_IN
ELAM-1_JJ
,_,
as_IN
shown_VBN
by_IN
Northern_JJ
blot_NN
analysis_NN
,_,
and_CC
expression_NN
of_IN
membrane-associated_JJ
ELAM-1_NN
and_CC
ICAM-1_NN
,_,
as_IN
shown_VBN
by_IN
quantitative_JJ
immunofluorescence_NN
(_-LRB-
both_DT
P_NNP
<_NNP
0.001_CD
,_,
n_RB
=_SYM
9_CD
)_-RRB-
._.
Dexamethasone_NN
markedly_RB
inhibited_VBD
LPS-stimulated_JJ
accumulation_NN
of_IN
mRNA_NN
for_IN
ELAM-1_NN
and_CC
expression_NN
of_IN
ELAM-1_JJ
and_CC
ICAM-1_JJ
(_-LRB-
IC50_IN
<_NN
10_CD
nM_NNS
,_,
both_DT
P_NNP
<_NNP
0.001_CD
,_,
n_RB
=_SYM
4-9_CD
)_-RRB-
;_:
inhibition_NN
of_IN
expression_NN
by_IN
dexamethasone_NN
was_VBD
reversed_VBN
by_IN
RU-486_NNP
(_-LRB-
both_DT
P_NNP
<_NNP
0.005_CD
,_,
n_RB
=_SYM
4-6_CD
)_-RRB-
._.
As_IN
in_IN
the_DT
adhesion_NN
studies_NNS
,_,
cortisol_NN
but_CC
not_RB
tetrahydrocortisol_JJ
inhibited_JJ
expression_NN
of_IN
ELAM-1_JJ
and_CC
ICAM-1_JJ
(_-LRB-
both_DT
P_NNP
<_NNP
0.005_CD
,_,
n_RB
=_SYM
3_CD
or_CC
4_CD
)_-RRB-
._.
In_IN
contrast_NN
,_,
sodium_NN
salicylate_NN
(_-LRB-
1_CD
mM_NN
)_-RRB-
inhibited_VBZ
neither_DT
adhesion_NN
nor_CC
expression_NN
of_IN
these_DT
adhesion_NN
molecules_NNS
._.
These_DT
studies_NNS
suggest_VBP
that_IN
antagonism_NN
by_IN
dexamethasone_NN
of_IN
endotoxin-induced_JJ
inflammation_NN
is_VBZ
a_DT
specific_JJ
instance_NN
of_IN
the_DT
general_JJ
biological_JJ
principle_NN
that_IN
the_DT
glucocorticoid_NN
receptor_NN
is_VBZ
a_DT
hormone-dependent_JJ
regulator_NN
of_IN
transcription_NN
._.
Membrane_NNP
receptors_NNS
for_IN
aldosterone_NN
:_:
a_DT
novel_NN
pathway_NN
for_IN
mineralocorticoid_JJ
action_NN
._.
Rapid_NNP
nongenomic_JJ
in_IN
vitro_NN
effects_NNS
of_IN
aldosterone_NN
on_IN
intracellular_JJ
electrolytes_NNS
,_,
cell_NN
volume_NN
,_,
and_CC
Na(+)-H+_JJ
antiport_NN
have_VBP
been_VBN
found_VBN
in_IN
human_JJ
mononuclear_NN
leukocytes_NNS
(_-LRB-
HML_NN
)_-RRB-
._.
Binding_NNP
of_IN
125I-labeled_JJ
aldosterone_NN
to_TO
plasma_NN
membranes_NNS
of_IN
HML_NNP
shares_NNS
important_JJ
features_NNS
with_IN
these_DT
functional_JJ
data_NNS
._.
This_DT
includes_VBZ
a_DT
very_RB
low_JJ
apparent_JJ
dissociation_NN
constant_JJ
(_-LRB-
Kd_NN
)_-RRB-
of_IN
0.1_CD
nM_NNS
for_IN
both_DT
aldosterone_NN
and_CC
the_DT
effect_NN
on_IN
the_DT
Na(+)-H(+)-antiport_NNP
,_,
a_DT
high_JJ
turnover_NN
rate_NN
,_,
and_CC
the_DT
almost_RB
exclusive_JJ
binding_NN
selectivity_NN
for_IN
aldosterone_NN
._.
Dexamethasone_NN
,_,
RU_NNP
26988_CD
,_,
corticosterone_NN
,_,
ouabain_RB
,_,
amiloride_IN
,_,
and_CC
18-hydroxyprogesterone_JJ
were_VBD
inactive_JJ
as_IN
ligands_NNS
._.
Deoxycorticosterone_NNP
acetate_NN
had_VBD
an_DT
intermediate_JJ
activity_NN
with_IN
an_DT
apparent_JJ
Kd_NNP
of_IN
100_CD
nM_NNS
._.
These_DT
findings_NNS
are_VBP
the_DT
first_JJ
to_TO
demonstrate_VB
membrane_NN
binding_NN
of_IN
aldosterone_NN
being_VBG
compatible_JJ
with_IN
major_JJ
aspects_NNS
of_IN
its_PRP$
nongenomic_JJ
effects_NNS
._.
Reticuloendotheliosis_NNP
virus_NN
long_RB
terminal_JJ
repeat_NN
elements_NNS
are_VBP
efficient_JJ
promoters_NNS
in_IN
cells_NNS
of_IN
various_JJ
species_NNS
and_CC
tissue_NN
origin_NN
,_,
including_VBG
human_JJ
lymphoid_NN
cells_NNS
._.
Promiscuous_JJ
transcriptional_JJ
activity_NN
of_IN
the_DT
reticuloendotheliosis_NN
virus_NN
(_-LRB-
REV_NNS
)_-RRB-
long_RB
terminal_JJ
repeat_NN
(_-LRB-
LTR_NNP
)_-RRB-
was_VBD
detected_VBN
in_IN
transient_JJ
expression_NN
assays_IN
using_VBG
LTR-chloramphenicol_NNP
acetyltransferase-encoding_JJ
gene_NN
chimeras_NNS
,_,
and_CC
cells_NNS
of_IN
diverse_JJ
species_NNS
and_CC
tissue_NN
type_NN
;_:
levels_NNS
of_IN
expression_NN
from_IN
two_CD
different_JJ
REV_NNS
LTRs_NNS
correlate_VBP
with_IN
reports_NNS
of_IN
pathogenicity_NN
of_IN
the_DT
respective_JJ
viruses_NNS
in_IN
vivo_NN
._.
REVs_NNS
do_VBP
not_RB
encode_VB
a_DT
transactivator_NN
targeted_VBN
to_TO
the_DT
viral_JJ
LTR_NNP
,_,
and_CC
cells_NNS
infected_VBN
with_IN
Marek_NNP
's_POS
disease_NN
virus_NN
,_,
a_DT
herpesvirus_NN
with_IN
an_DT
overlapping_JJ
host_NN
range_NN
,_,
do_VBP
not_RB
express_VB
factors_NNS
that_WDT
preferentially_RB
enhance_VB
expression_NN
from_IN
REV_NNP
or_CC
avian_JJ
sarcoma/leukemia_NN
virus_NN
LTRs_NNS
._.
REV_NN
LTRs_NNS
work_VBP
efficiently_RB
in_IN
human_JJ
lymphoid_NN
cells_NNS
,_,
and_CC
are_VBP
viable_JJ
alternatives_NNS
to_TO
promoters_NNS
commonly_RB
used_VBN
for_IN
expression_NN
of_IN
cloned_VBN
genes_NNS
._.
They_PRP
may_MD
also_RB
prove_VB
useful_JJ
in_IN
the_DT
identification_NN
of_IN
new_JJ
,_,
ubiquitous_JJ
cellular_JJ
transcription_NN
factors_NNS
._.
Natural_JJ
variants_NNS
of_IN
the_DT
HIV-1_JJ
long_JJ
terminal_NN
repeat_NN
:_:
analysis_NN
of_IN
promoters_NNS
with_IN
duplicated_JJ
DNA_NNP
regulatory_JJ
motifs_NNS
._.
Sequence_NN
variation_NN
in_IN
the_DT
long_JJ
terminal_NN
repeat_NN
(_-LRB-
LTR_NNP
)_-RRB-
region_NN
of_IN
HIV-1_NNP
was_VBD
analyzed_VBN
in_IN
viral_JJ
isolates_NNS
of_IN
17_CD
infected_JJ
individuals_NNS
._.
Two_CD
classes_NNS
of_IN
LTR_NNP
size_NN
variants_NNS
were_VBD
found_VBN
._.
One_CD
HIV-1_NN
variant_NN
was_VBD
detected_VBN
containing_VBG
an_DT
additional_JJ
binding_NN
site_NN
for_IN
the_DT
transcription_NN
factor_NN
Sp1_NNP
._.
Another_DT
LTR_NN
size_NN
variation_NN
was_VBD
observed_VBN
in_IN
four_CD
patients_NNS
in_IN
a_DT
region_NN
just_RB
upstream_RB
of_IN
the_DT
NF-kappa_NNP
B_NNP
enhancer_NN
._.
This_DT
variation_NN
was_VBD
the_DT
result_NN
of_IN
a_DT
duplication_NN
of_IN
a_DT
short_JJ
DNA_NN
sequence_NN
(_-LRB-
CTG-motif_JJ
)_-RRB-
._.
Cell_NNP
culture_NN
experiments_NNS
demonstrated_VBD
that_IN
the_DT
natural_JJ
variant_NN
with_IN
four_CD
Sp1_NNP
sites_NNS
had_VBD
a_DT
slightly_RB
higher_JJR
promoter_NN
activity_NN
and_CC
viral_JJ
replication_NN
rate_NN
than_IN
the_DT
isogenic_JJ
control_NN
LTR_NNP
with_IN
three_CD
Sp1_NNP
sites_NNS
._.
No_DT
positive_JJ
effect_NN
of_IN
the_DT
duplicated_JJ
CTG-motif_NN
could_MD
be_VB
detected_VBN
._.
In_IN
order_NN
to_TO
measure_VB
small_JJ
differences_NNS
in_IN
virus_NN
production_NN
more_RBR
accurately_RB
,_,
equal_JJ
amounts_NNS
of_IN
a_DT
size_NN
variant_NN
and_CC
the_DT
wild-type_JJ
plasmid_NN
were_VBD
cotransfected_VBN
into_IN
T-cells_NNS
._.
The_DT
virus_NN
with_IN
four_CD
Sp1_NNP
sites_NNS
did_VBD
outgrow_VB
the_DT
three_CD
Sp1_NNP
virus_NN
in_IN
35_CD
days_NNS
of_IN
culture_NN
and_CC
CTG-monomer_NN
virus_NN
outcompeted_VBD
the_DT
CTG-dimer_NN
virus_NN
in_IN
42_CD
days_NNS
._.
Based_VBN
on_IN
these_DT
results_NNS
we_PRP
estimate_VBP
a_DT
5-10_CD
%_NN
difference_NN
in_IN
virus_NN
production_NN
of_IN
the_DT
LTR_NNP
variants_VBZ
when_WRB
compared_VBN
to_TO
that_DT
of_IN
wild-type_JJ
._.
SCL_NNP
and_CC
related_VBN
hemopoietic_JJ
helix-loop-helix_NN
transcription_NN
factors_NNS
._.
The_DT
helix-loop-helix_NN
(_-LRB-
HLH_NNP
)_-RRB-
proteins_NNS
are_VBP
a_DT
family_NN
of_IN
transcription_NN
factors_NNS
that_WDT
include_VBP
proteins_VBZ
critical_JJ
to_TO
differentiation_NN
and_CC
development_NN
in_IN
species_NNS
ranging_VBG
from_IN
plants_NNS
to_TO
mammals_NNS
._.
Five_CD
members_NNS
of_IN
this_DT
family_NN
(_-LRB-
MYC_NNP
,_,
SCL_NNP
,_,
TAL-2_JJ
,_,
LYL-1_JJ
and_CC
E2A_JJ
)_-RRB-
are_VBP
implicated_VBN
in_IN
oncogenic_JJ
events_NNS
in_IN
human_JJ
lymphoid_NN
tumors_NNS
because_IN
of_IN
their_PRP$
consistent_JJ
involvement_NN
in_IN
chromosomal_NN
translocations_NNS
._.
Although_IN
activated_VBN
in_IN
T_NNP
cell_NN
leukemias_NNS
,_,
expression_NN
of_IN
SCL_NNP
and_CC
LYL-1_NNP
is_VBZ
low_JJ
or_CC
undetectable_JJ
in_IN
normal_JJ
T_NNP
cell_NN
populations_NNS
._.
SCL_NNP
is_VBZ
expressed_VBN
in_IN
erythroid_NN
,_,
megakaryocyte_NN
and_CC
mast_NN
cell_NN
populations_NNS
(_-LRB-
the_DT
same_JJ
cell_NN
lineages_NNS
as_IN
GATA-1_NNP
,_,
a_DT
zinc-finger_NN
transcription_NN
factor_NN
)_-RRB-
._.
In_IN
addition_NN
,_,
both_DT
SCL_NNP
and_CC
GATA-1_NNP
undergo_VBP
coordinate_VB
modulation_NN
during_IN
chemically_RB
induced_VBN
erythroid_JJ
differentiation_NN
of_IN
mouse_NN
erythroleukemia_NN
cells_NNS
and_CC
are_VBP
down-modulated_JJ
during_IN
myeloid_JJ
differentiation_NN
of_IN
human_JJ
K562_NNP
cells_NNS
,_,
thus_RB
implying_VBG
a_DT
role_NN
for_IN
SCL_NNP
in_IN
erythroid_JJ
differentiation_NN
events_NNS
._.
However_RB
,_,
in_IN
contrast_NN
to_TO
GATA-1_NNP
,_,
SCL_NNP
is_VBZ
expressed_VBN
in_IN
the_DT
developing_VBG
brain_NN
._.
Studies_NNS
of_IN
the_DT
function_NN
of_IN
SCL_NNP
suggest_VBP
it_PRP
is_VBZ
also_RB
important_JJ
in_IN
proliferation_NN
and_CC
self-renewal_JJ
events_NNS
in_IN
erythroid_JJ
cells_NNS
._.
Transcription_NN
of_IN
the_DT
hypersensitive_JJ
site_NN
HS2_IN
enhancer_NN
in_IN
erythroid_JJ
cells_NNS
._.
In_IN
the_DT
human_JJ
genome_NN
,_,
the_DT
erythroid-specific_JJ
hypersensitive_JJ
site_NN
HS2_IN
enhancer_NN
regulates_VBZ
the_DT
transcription_NN
of_IN
the_DT
downstream_NN
beta-like_JJ
globin_NN
genes_NNS
10-50_CD
kilobases_NNS
away_RB
._.
The_DT
mechanism_NN
of_IN
HS2_NNP
enhancer_NN
function_NN
is_VBZ
not_RB
known_VBN
._.
The_DT
present_JJ
study_NN
employs_VBZ
RNA_NNP
protection_NN
assays_IN
to_TO
analyze_VB
the_DT
transcriptional_JJ
status_NN
of_IN
the_DT
HS2_NNP
enhancer_NN
in_IN
transfected_JJ
recombinant_NN
chloramphenicol_NN
acetyltransferase_NN
(_-LRB-
CAT_NN
)_-RRB-
plasmids_NNS
._.
In_IN
erythroid_JJ
K562_NNP
cells_NNS
in_IN
which_WDT
the_DT
HS2_NNP
enhancer_NN
is_VBZ
active_JJ
,_,
the_DT
HS2_NNP
sequence_NN
directs_VBZ
the_DT
synthesis_NN
of_IN
long_JJ
enhancer_NN
transcripts_NNS
that_WDT
are_VBP
initiated_VBN
apparently_RB
from_IN
within_IN
the_DT
enhancer_NN
and_CC
elongated_VBD
through_IN
the_DT
intervening_NN
DNA_NN
into_IN
the_DT
cis-linked_JJ
CAT_NNP
gene_NN
._.
In_IN
nonerythroid_JJ
HL-60_JJ
cells_NNS
in_IN
which_WDT
the_DT
HS2_NNP
enhancer_NN
is_VBZ
inactive_JJ
,_,
long_JJ
enhancer_NN
transcripts_NNS
are_VBP
not_RB
detectable_JJ
._.
Splitting_VBG
the_DT
HS2_NNP
enhancer_NN
between_IN
two_CD
tandem_NN
Ap1_IN
sites_NNS
abolishes_VBZ
the_DT
synthesis_NN
of_IN
a_DT
group_NN
of_IN
long_JJ
enhancer_NN
transcripts_NNS
and_CC
results_NNS
in_IN
loss_NN
of_IN
enhancer_NN
function_NN
and_CC
transcriptional_JJ
silencing_NN
of_IN
the_DT
cis-linked_JJ
CAT_NNP
gene_NN
._.
In_IN
directing_VBG
the_DT
synthesis_NN
of_IN
RNA_NNP
through_IN
the_DT
intervening_NN
DNA_NN
and_CC
the_DT
gene_NN
by_IN
a_DT
tracking_NN
and_CC
transcription_NN
mechanism_NN
,_,
the_DT
HS2_NNP
enhancer_NN
may_MD
(_-LRB-
i_FW
)_-RRB-
open_VB
up_RP
the_DT
chromatin_NN
structure_NN
of_IN
a_DT
gene_NN
domain_NN
and_CC
(_-LRB-
ii_NNS
)_-RRB-
deliver_VBP
enhancer_NN
binding_JJ
proteins_NNS
to_TO
the_DT
promoter_NN
sequence_NN
where_WRB
they_PRP
may_MD
stimulate_VB
the_DT
transcription_NN
of_IN
the_DT
gene_NN
at_IN
Phorbol_NN
ester_NN
reduces_VBZ
constitutive_JJ
nuclear_JJ
NF_NNP
kappa_NN
B_NNP
and_CC
inhibits_VBZ
HIV-1_JJ
production_NN
in_IN
mature_JJ
human_JJ
monocytic_NN
cells_NNS
._.
NF_NNP
kappa_NN
B_NNP
is_VBZ
a_DT
potent_JJ
mediator_NN
of_IN
specific_JJ
gene_NN
expression_NN
in_IN
human_JJ
monocytes_NNS
and_CC
has_VBZ
been_VBN
shown_VBN
to_TO
play_VB
a_DT
role_NN
in_IN
transcription_NN
of_IN
the_DT
HIV-1_NN
genome_NN
in_IN
promonocytic_JJ
leukemias_NNS
._.
There_EX
is_VBZ
little_JJ
information_NN
available_JJ
on_IN
the_DT
response_NN
of_IN
NF_NNP
kappa_NN
B_NNP
to_TO
cytokines_NNS
in_IN
normal_JJ
human_JJ
monocytes_NNS
._.
We_PRP
have_VBP
used_VBN
a_DT
32P-labeled_JJ
oligonucleotide_JJ
derived_VBN
from_IN
human_JJ
immunodeficiency_NN
virus_NN
(_-LRB-
HIV-1_NN
)_-RRB-
long_JJ
terminal_NN
repeat_NN
,_,
which_WDT
contains_VBZ
a_DT
tandem_NN
repeat_NN
of_IN
the_DT
NF_NNP
kappa_NN
B_NNP
binding_NN
sequence_NN
,_,
as_IN
a_DT
probe_NN
in_IN
a_DT
gel_NN
retardation_NN
assay_NN
to_TO
study_VB
this_DT
transcription_NN
factor_NN
._.
Using_VBG
this_DT
assay_NN
,_,
we_PRP
have_VBP
detected_VBN
NF_NNP
kappa_NN
B_NNP
in_IN
extracts_NNS
of_IN
nuclei_NNS
from_IN
normal_JJ
human_JJ
monocytes_NNS
._.
Treatment_NNP
of_IN
normal_JJ
monocytes_NNS
with_IN
12-0-tetradecanoyl_JJ
phorbol-13-acetate_NN
(_-LRB-
TPA_NNP
)_-RRB-
for_IN
4-24_CD
h_NN
caused_VBD
the_DT
complete_JJ
disappearance_NN
of_IN
NF_NNP
kappa_NN
B_NNP
from_IN
nuclear_JJ
extracts_NNS
of_IN
monocytes_NNS
._.
A_DT
similar_JJ
result_NN
was_VBD
obtained_VBN
with_IN
the_DT
mature_JJ
monocytic_JJ
leukemia_NN
cell_NN
line_NN
THP-1_NN
._.
The_DT
constitutive_JJ
transcription_NN
factor_NN
SP1_NNP
was_VBD
unaffected_JJ
by_IN
addition_NN
of_IN
TPA_NNP
._.
The_DT
disappearance_NN
of_IN
NF_NNP
kappa_NN
B_NNP
from_IN
the_DT
nucleus_NN
was_VBD
concentration_NN
dependent_JJ
between_IN
10_CD
and_CC
50_CD
ng/ml_NN
of_IN
phorbol_NN
ester_NN
._.
In_IN
THP-1_JJ
cells_NNS
,_,
TPA_NNP
also_RB
induced_VBD
a_DT
new_JJ
,_,
faster-migrating_JJ
NF_NNP
kappa_NN
B_NNP
species_NNS
not_RB
induced_VBN
in_IN
monocytes_NNS
._.
Protein_NNP
kinase_NN
C_NNP
inhibitor_NN
staurosporine_NN
,_,
but_CC
not_RB
cyclic_JJ
nucleotide-dependent_JJ
protein_NN
kinase_NN
inhibitor_NN
HA-1004_NNP
,_,
also_RB
dramatically_RB
reduced_VBD
constitutive_JJ
levels_NNS
of_IN
nuclear_JJ
NF_NNP
kappa_NN
B_NNP
._.
Finally_RB
,_,
TPA_NNP
addition_NN
to_TO
monocytes_NNS
infected_VBN
with_IN
HIV-1_PRP$
inhibited_JJ
HIV-1_NN
replication_NN
,_,
as_IN
determined_VBN
by_IN
reverse_NN
transcriptase_NN
assays_VBD
,_,
in_IN
a_DT
concentration-dependent_JJ
manner_NN
._.
These_DT
results_NNS
are_VBP
in_IN
striking_JJ
contrast_NN
to_TO
the_DT
increase_NN
in_IN
nuclear_JJ
NF_NNP
kappa_NN
B_NNP
and_CC
HIV-1_PRP$
replication_NN
induced_VBN
by_IN
phorbol_NN
esters_NNS
in_IN
promonocytic_JJ
leukemia_NN
cells_NNS
U937_.
and_CC
HL-60_JJ
,_,
and_CC
emphasize_VBP
the_DT
importance_NN
of_IN
studying_VBG
cytokine_JJ
regulation_NN
of_IN
HIV-1_PRP$
in_IN
normal_JJ
monocytes_NNS
._.
Ablation_NNP
of_IN
transplanted_JJ
HTLV-I_JJ
Tax-transformed_JJ
tumors_NNS
in_IN
mice_NNS
by_IN
antisense_DT
inhibition_NN
of_IN
NF-kappa_NNP
B_NNP
(_-LRB-
published_VBN
erratum_NN
appears_VBZ
in_IN
Science_NNP
1993_CD
Mar_NNP
12_CD
;_:
259_CD
(_-LRB-
5101_CD
)_-RRB-
:_:
1523_CD
)_-RRB-
Mice_NNP
transgenic_NN
for_IN
the_DT
human_JJ
T_NNP
cell_NN
leukemia_NN
virus_NN
(_-LRB-
HTLV-I_NNP
)_-RRB-
Tax_NNP
gene_NN
develop_VB
fibroblastic_JJ
tumors_NNS
that_WDT
express_VBP
NF-kappa_NNP
B-inducible_NNP
early_JJ
genes_NNS
._.
In_IN
vitro_NN
inhibition_NN
of_IN
NF-kappa_NNP
B_NNP
expression_NN
by_IN
antisense_JJ
oligodeoxynucleotides_NNS
(_-LRB-
ODNs_NNS
)_-RRB-
inhibited_VBN
growth_NN
of_IN
these_DT
culture-adapted_JJ
Tax-transformed_JJ
fibroblasts_NNS
as_RB
well_RB
as_IN
an_DT
HTLV-I-transformed_JJ
human_JJ
lymphocyte_NN
line_NN
._.
In_IN
contrast_NN
,_,
antisense_JJ
inhibition_NN
of_IN
Tax_NNP
itself_PRP
had_VBD
no_DT
apparent_JJ
effect_NN
on_IN
cell_NN
growth_NN
._.
Mice_NNP
treated_VBD
with_IN
antisense_NN
to_TO
NF-kappa_NNP
B_NNP
ODNs_NNP
showed_VBD
rapid_JJ
regression_NN
of_IN
transplanted_JJ
fibrosarcomas_NNS
._.
This_DT
suggests_VBZ
that_IN
NF-kappa_NNP
B_NNP
expression_NN
may_MD
be_VB
necessary_JJ
for_IN
the_DT
maintenance_NN
of_IN
the_DT
malignant_JJ
phenotype_NN
and_CC
provides_VBZ
a_DT
therapeutic_JJ
approach_NN
for_IN
HTLV-I-associated_JJ
disease_NN
._.
Inhibition_NN
of_IN
anti-CD3_JJ
monoclonal_JJ
antibody-induced_JJ
T-cell_NN
proliferation_NN
by_IN
dexamethasone_NN
,_,
isoproterenol_NN
,_,
or_CC
prostaglandin_NN
E2_.
either_DT
alone_RB
or_CC
in_IN
combination_NN
._.
1_LS
._.
The_DT
purpose_NN
of_IN
these_DT
studies_NNS
was_VBD
to_TO
investigate_VB
the_DT
modulation_NN
of_IN
the_DT
proliferation_NN
of_IN
human_JJ
T_NNP
cells_NNS
obtained_VBN
from_IN
peripheral_JJ
blood_NN
by_IN
dexamethasone_NN
(_-LRB-
DEX_NNP
)_-RRB-
,_,
isoproterenol_FW
(_-LRB-
ISO_NN
)_-RRB-
,_,
and_CC
prostaglandin_NN
E2_NNS
(_-LRB-
PGE2_NN
)_-RRB-
._.
The_DT
former_JJ
two_CD
substances_NNS
interact_NN
with_IN
T_NNP
cells_NNS
via_IN
the_DT
glucocorticoid_NN
and_CC
beta-adrenergic_JJ
receptors_NNS
respectively_RB
._.
When_WRB
occupied_VBN
by_IN
their_PRP$
natural_JJ
ligands_NNS
,_,
glucocorticosteroids_NNS
and_CC
catecholamines_NNS
,_,
these_DT
receptors_NNS
have_VBP
a_DT
role_NN
in_IN
modulating_VBG
T-cell_JJ
function_NN
during_IN
stress_NN
._.
During_IN
the_DT
inflammatory_JJ
response_NN
increased_VBD
levels_NNS
of_IN
PGE2_DT
bind_NN
to_TO
their_PRP$
receptors_NNS
on_IN
T_NNP
cells_NNS
and_CC
thus_RB
alter_VB
responsiveness_NN
._.
Proliferation_NN
of_IN
T_NNP
cells_NNS
was_VBD
induced_VBN
by_IN
immobilized_JJ
anti-CD3_JJ
monoclonal_JJ
antibody_NN
(_-LRB-
mAb_NN
)_-RRB-
in_IN
the_DT
presence_NN
or_CC
absence_NN
of_IN
an_DT
additional_JJ
costimulatory_NN
signal_NN
delivered_VBN
by_IN
anti-CD28_DT
mAb_NN
._.
2_LS
._.
Various_NNP
physiologic_NN
concentrations_NNS
of_IN
DEX_NNP
,_,
ISO_NNP
,_,
or_CC
PGE2_NNP
were_VBD
added_VBN
at_IN
the_DT
time_NN
of_IN
initiation_NN
of_IN
the_DT
cultures_NNS
and_CC
subsequent_JJ
proliferation_NN
of_IN
the_DT
unstimulated_JJ
T_NNP
cells_NNS
was_VBD
determined_VBN
._.
The_DT
results_NNS
demonstrate_VBP
that_IN
physiologic_NN
concentrations_NNS
of_IN
all_DT
three_CD
of_IN
these_DT
agents_NNS
inhibit_VBP
the_DT
anti-CD3_JJ
mAb-induced_JJ
proliferation_NN
of_IN
T_NNP
cells_NNS
._.
3_LS
._.
Although_IN
DEX_NNP
and_CC
PGE2_NNP
were_VBD
equipotent_JJ
in_IN
suppressing_VBG
T-cell_JJ
proliferation_NN
,_,
ISO_NNP
was_VBD
much_RB
less_RBR
effective_JJ
._.
4_CD
._.
Because_IN
concomitant_JJ
elevations_NNS
in_IN
the_DT
peripheral_JJ
levels_NNS
of_IN
these_DT
substances_NNS
may_MD
occur_VB
,_,
experiments_NNS
were_VBD
performed_VBN
to_TO
determine_VB
the_DT
T-cell_JJ
inhibitory_JJ
effects_NNS
of_IN
DEX_NNP
together_RB
with_IN
either_DT
PGE2_NNP
or_CC
ISO_NNP
._.
Synergistic_JJ
suppression_NN
of_IN
T-cell_DT
proliferation_NN
was_VBD
observed_VBN
when_WRB
various_JJ
concentrations_NNS
of_IN
DEX_NNP
and_CC
PGE2_NNP
,_,
but_CC
not_RB
DEX_NNP
and_CC
ISO_NNP
,_,
were_VBD
added_VBN
to_TO
cultures_NNS
._.
This_DT
synergistic_JJ
suppression_NN
could_MD
not_RB
be_VB
explained_VBN
by_IN
an_DT
increase_NN
in_IN
cAMP_JJ
accumulation_NN
in_IN
T_NNP
cells_NNS
stimulated_VBN
with_IN
DEX_NNP
and_CC
PGE2_NNP
._.
5_CD
._.
Finally_RB
,_,
the_DT
addition_NN
of_IN
anti-CD28_DT
mAb_NN
to_TO
anti-CD3_DT
mAb-stimulated_JJ
T_NNP
cells_NNS
overcame_JJ
much_RB
of_IN
the_DT
suppression_NN
of_IN
proliferation_NN
induced_VBN
by_IN
PGE2_NNP
or_CC
ISO_NNP
but_CC
less_RBR
so_RB
than_IN
that_DT
induced_VBN
by_IN
DEX_NNP
._.
Targeted_NNP
degradation_NN
of_IN
c-Fos_NNS
,_,
but_CC
not_RB
v-Fos_JJ
,_,
by_IN
a_DT
phosphorylation-dependent_JJ
signal_NN
on_IN
c-Jun_NN
._.
The_DT
proto-oncogene_NN
products_NNS
c-Fos_JJ
and_CC
c-Jun_JJ
heterodimerize_NN
through_IN
their_PRP$
leucine_NN
zippers_NNS
to_TO
form_VB
the_DT
AP-1_JJ
transcription_NN
factor_NN
._.
The_DT
transcriptional_JJ
activity_NN
of_IN
the_DT
heterodimer_NN
is_VBZ
regulated_VBN
by_IN
signal-dependent_JJ
phosphorylation_NN
and_CC
dephosphorylation_NN
events_NNS
._.
The_DT
stability_NN
of_IN
c-Fos_NNS
was_VBD
found_VBN
to_TO
also_RB
be_VB
controlled_VBN
by_IN
intracellular_JJ
signal_NN
transduction_NN
._.
In_IN
transient_JJ
expression_NN
and_CC
in_IN
vitro_NN
degradation_NN
experiments_NNS
,_,
the_DT
stability_NN
of_IN
c-Fos_NNS
was_VBD
decreased_VBN
when_WRB
the_DT
protein_NN
was_VBD
dimerized_VBN
with_IN
phosphorylated_JJ
c-Jun_NN
._.
c-Jun_JJ
protein_NN
isolated_VBN
from_IN
phorbol_JJ
ester-induced_JJ
cells_NNS
did_VBD
not_RB
target_VB
c-Fos_NNS
for_IN
degradation_NN
,_,
which_WDT
suggests_VBZ
that_IN
c-Fos_NNS
is_VBZ
transiently_RB
stabilized_VBN
after_IN
stimulation_NN
of_IN
cell_NN
growth_NN
._.
v-Fos_JJ
protein_NN
,_,
the_DT
retroviral_JJ
counterpart_NN
of_IN
c-Fos_JJ
,_,
was_VBD
not_RB
susceptible_JJ
to_TO
degradation_NN
targeted_VBN
by_IN
c-Jun_JJ
._.
Mutations_NNS
in_IN
the_DT
Pit-1_NNP
gene_NN
in_IN
children_NNS
with_IN
combined_JJ
pituitary_NN
hormone_NN
deficiency_NN
._.
Pit-1_NNP
is_VBZ
a_DT
pituitary-specific_JJ
transcription_NN
factor_NN
that_WDT
binds_VBZ
to_TO
and_CC
transactivates_NNS
promoters_NNS
of_IN
growth_NN
hormone_NN
and_CC
prolactin_NN
genes_NNS
._.
In_IN
three_CD
unrelated_JJ
Japanese_JJ
children_NNS
with_IN
combined_JJ
pituitary_NN
hormone_NN
deficiency_NN
,_,
we_PRP
identified_VBD
three_CD
point_NN
mutations_NNS
in_IN
the_DT
Pit-1_NNP
gene_NN
,_,
Pro24Leu_NNP
,_,
Arg143Gln_NNP
,_,
and_CC
Arg271Trp_JJ
,_,
located_VBN
on_IN
the_DT
major_JJ
transactivation_NN
region_NN
,_,
POU-specific_NNP
domain_NN
,_,
and_CC
POU-homeodomain_JJ
,_,
respectively_RB
._.
Calcitriol_NNP
:_:
a_DT
hematolymphopoietrope_NN
?_.
(_-LRB-
editorial_NN
)_-RRB-
A_DT
MEDLINE_NNP
search_NN
of_IN
the_DT
English-language_JJ
literature_NN
was_VBD
conducted_VBN
using_VBG
the_DT
indexing_NN
terms_NNS
'_POS
immunology_NN
,_,
calcitriol_NN
and_CC
vitamin_NN
D_NNP
'_''
to_TO
identify_VB
studies_NNS
indicating_VBG
a_DT
role_NN
for_IN
calcitriol_NN
as_IN
a_DT
primary_JJ
immunomodulator_NN
._.
Sixty-six_CD
papers_NNS
published_VBN
between_IN
January_NNP
1956_CD
and_CC
June_NNP
1991_CD
were_VBD
identified_VBN
._.
Forty-five_CD
of_IN
these_DT
reports_NNS
are_VBP
cited_VBN
in_IN
this_DT
review_NN
._.
The_DT
data_NNS
strongly_RB
suggest_VBP
an_DT
endocrine_NN
,_,
autocrine_NN
and/or_CC
paracrine_NN
role_NN
for_IN
calcitriol_NN
in_IN
immune_JJ
regulation_NN
._.
No_DT
unifying_NN
hypothesis_NN
has_VBZ
yet_RB
emerged_VBN
explaining_VBG
this_DT
collection_NN
of_IN
data_NNS
._.
This_DT
paper_NN
provides_VBZ
a_DT
brief_JJ
review_NN
of_IN
immune_JJ
properties_NNS
currently_RB
attributed_VBN
to_TO
calcitriol_VB
._.
Activation_NN
of_IN
protein_NN
kinase_NN
C_NNP
and_CC
elevation_NN
of_IN
cAMP_JJ
interact_NN
synergistically_RB
to_TO
raise_VB
c-Fos_JJ
and_CC
AP-1_JJ
activity_NN
in_IN
Jurkat_NNP
cells_NNS
._.
We_PRP
have_VBP
earlier_RB
found_VBN
that_IN
in_IN
Jurkat_NNP
cells_NNS
activation_NN
of_IN
protein_NN
kinase_NN
C_NNP
(_-LRB-
PKC_NNP
)_-RRB-
enhances_VBZ
the_DT
cyclic_JJ
adenosine_NN
monophosphate_NN
(_-LRB-
cAMP_NN
)_-RRB-
accumulation_NN
induced_VBN
by_IN
adenosine_NN
receptor_NN
stimulation_NN
or_CC
activation_NN
of_IN
Gs_NNP
._.
Here_RB
we_PRP
have_VBP
therefore_RB
examined_VBN
the_DT
effect_NN
of_IN
the_DT
phorbol_NN
ester_NN
PMA_NNP
(_-LRB-
phorbol_NN
12-myristate_JJ
13-acetate_JJ
)_-RRB-
which_WDT
stimulates_VBZ
PKC_NNP
and_CC
a_DT
combination_NN
of_IN
the_DT
adenosine_NN
receptor_NN
agonist_NN
NECA_NNP
(_-LRB-
5'-(N-ethyl)-carboxamido_JJ
adenosine_NN
)_-RRB-
and_CC
forskolin_NN
to_TO
raise_VB
cAMP_NNS
,_,
on_IN
the_DT
levels_NNS
of_IN
c-Fos_NNS
and_CC
Jun_NNP
and_CC
on_IN
the_DT
binding_NN
and_CC
transcriptional_JJ
activity_NN
of_IN
the_DT
transcription_NN
factor_NN
,_,
activator_NN
protein-1_NN
(_-LRB-
AP-1_NN
)_-RRB-
._.
PMA_NNP
treatment_NN
caused_VBD
a_DT
concentration-_NNS
and_CC
time-dependent_NN
increase_NN
in_IN
both_DT
c-Fos_NNS
and_CC
Jun_NNP
immunoreactivity_NN
in_IN
contrast_NN
to_TO
cAMP_VB
elevation_NN
that_WDT
had_VBD
only_RB
a_DT
slight_JJ
effect_NN
._.
Both_DT
PMA_NNP
and_CC
the_DT
combination_NN
of_IN
NECA_NNP
and_CC
forskolin_IN
acted_VBN
together_RB
either_CC
to_TO
increase_VB
(_-LRB-
c-Fos_NNS
)_-RRB-
or_CC
decrease_VB
(_-LRB-
Jun_NNP
)_-RRB-
protein_NN
levels_NNS
as_RB
well_RB
as_IN
increasing_VBG
AP-1_NN
binding_NN
,_,
as_IN
judged_VBN
by_IN
gel-shift_JJ
assay_NN
,_,
and_CC
AP-1_NNP
transcriptional_JJ
activity_NN
._.
Furthermore_RB
there_EX
was_VBD
a_DT
clear-cut_JJ
synergy_NN
between_IN
the_DT
PKC_NNP
stimulator_NN
and_CC
the_DT
cAMP_JJ
elevating_NN
agents_NNS
._.
The_DT
results_NNS
demonstrate_VBP
that_IN
the_DT
simultaneous_JJ
activation_NN
of_IN
PKC_NNP
and_CC
elevation_NN
of_IN
cAMP_JJ
leads_NNS
to_TO
an_DT
enhanced_JJ
AP-1_NN
transcriptional_JJ
activity_NN
in_IN
a_DT
T-leukemia_NNP
cell_NN
line_NN
,_,
suggesting_VBG
that_IN
the_DT
previously_RB
observed_VBN
interaction_NN
between_IN
the_DT
parallel_JJ
signal_NN
transduction_NN
pathways_NNS
may_MD
have_VB
functional_JJ
consequences_NNS
at_IN
the_DT
level_NN
of_IN
gene_NN
transcription_NN
._.
The_DT
use_NN
of_IN
interferon-gamma-treated_JJ
U937_JJ
cells_NNS
in_IN
chemiluminescence_NN
assays_VBZ
to_TO
detect_VB
red_JJ
cell_NN
,_,
platelet_NN
and_CC
granulocyte_NN
antibodies_NNS
of_IN
potential_JJ
clinical_JJ
significance_NN
._.
The_DT
chemiluminescent_NN
(_-LRB-
CL_NN
)_-RRB-
response_NN
of_IN
interferon-gamma-treated_JJ
U937_NNS
(_-LRB-
IFN-U937_DT
)_-RRB-
cells_NNS
to_TO
sensitized_JJ
target_NN
cells_NNS
has_VBZ
been_VBN
used_VBN
to_TO
detect_VB
red_JJ
cell_NN
,_,
platelet_NN
and_CC
granulocyte_NN
antibodies_NNS
._.
A_DT
clone_NN
of_IN
U937_NNP
cells_NNS
was_VBD
selected_VBN
which_WDT
expressed_VBD
Fc_NN
receptor_NN
I_PRP
(_-LRB-
Fc_NNP
gamma_NN
RI_NNP
)_-RRB-
and_CC
which_WDT
,_,
after_IN
incubation_NN
with_IN
IFN-gamma_NNP
for_IN
72_CD
h_NN
,_,
was_VBD
capable_JJ
of_IN
generating_VBG
high_JJ
levels_NNS
of_IN
lucigenin-enhanced_JJ
CL_NN
._.
The_DT
CL_NN
responses_NNS
of_IN
IFN-U937_JJ
cells_NNS
and_CC
peripheral_JJ
blood_NN
human_NN
monocytes_NNS
to_TO
sensitized_JJ
red_JJ
cells_NNS
,_,
platelets_NNS
or_CC
granulocytes_NNS
were_VBD
then_RB
compared_VBN
._.
Assays_IN
using_VBG
monocytes_NNS
or_CC
IFN-U937_JJ
cells_NNS
were_VBD
of_IN
comparable_JJ
sensitivity_NN
for_IN
detection_NN
of_IN
antibodies_NNS
against_IN
all_DT
three_CD
types_NNS
of_IN
target_NN
cell_NN
._.
In_IN
addition_NN
,_,
the_DT
use_NN
of_IN
IFN-U937_JJ
cells_NNS
reduced_VBN
interassay_JJ
variation_NN
and_CC
simplified_JJ
assay_NN
performance_NN
._.
The_DT
potential_JJ
clinical_JJ
usefulness_NN
of_IN
these_DT
CL_NN
assays_.
was_VBD
suggested_VBN
by_IN
the_DT
ability_NN
of_IN
both_DT
monocytes_NNS
and_CC
IFN-U937_JJ
cells_NNS
to_TO
respond_VB
to_TO
red_JJ
cells_NNS
,_,
platelets_NNS
or_CC
granulocytes_NNS
sensitized_VBN
with_IN
sera_NN
from_IN
pregnant_JJ
women_NNS
whose_WP$
babies_NNS
had_VBD
either_DT
haemolytic_JJ
disease_NN
of_IN
the_DT
newborn_JJ
(_-LRB-
HDN_NN
)_-RRB-
,_,
alloimmune_DT
thrombocytopenia_NN
or_CC
alloimmune_DT
neutropenia_NN
respectively_RB
._.
In_IN
addition_NN
,_,
monocytes_NNS
and_CC
IFN-U937_JJ
cells_NNS
both_DT
responded_VBD
to_TO
red_JJ
cells_NNS
sensitized_VBN
with_IN
antibodies_NNS
against_IN
a_DT
variety_NN
of_IN
specificities_NNS
of_IN
assumed_VBN
(_-LRB-
although_IN
not_RB
documented_VBN
)_-RRB-
clinical_JJ
significance_NN
for_IN
blood_NN
transfusion_NN
recipients_NNS
._.
In_IN
contrast_NN
,_,
monocytes_NNS
and_CC
IFN-U937_JJ
cells_NNS
responded_VBD
only_RB
weakly_RB
to_TO
red_JJ
cells_NNS
sensitized_VBN
with_IN
either_DT
anti-D_JJ
in_IN
sera_NN
from_IN
mothers_NNS
of_IN
babies_NNS
unaffected_VBN
by_IN
HDN_NNP
,_,
or_CC
with_IN
antisera_NN
containing_VBG
high_JJ
titre_NN
antibodies_NNS
with_IN
specificities_NNS
not_RB
normally_RB
associated_VBN
with_IN
significantly_RB
reduced_VBN
red_JJ
cell_NN
survival_NN
._.
Photoaffinity_NNP
labeling_NN
of_IN
plasma_NN
membrane_NN
receptors_NNS
for_IN
aldosterone_NN
from_IN
human_JJ
mononuclear_NN
leukocytes_NNS
._.
Non-genomic_JJ
effects_NNS
of_IN
aldosterone_NN
on_IN
the_DT
sodium-proton-antiport_NN
have_VBP
been_VBN
shown_VBN
in_IN
human_JJ
mononuclear_NN
leukocytes_NNS
which_WDT
could_MD
be_VB
related_VBN
to_TO
a_DT
new_JJ
aldosterone_NN
membrane_NN
receptor_NN
._.
In_IN
the_DT
present_JJ
paper_NN
plasma_NN
membranes_NNS
from_IN
human_JJ
mononuclear_NN
leukocytes_NNS
were_VBD
covalently_RB
photolabeled_VBN
with_IN
a_DT
(125I)-aldosterone_JJ
derivative_NN
._.
Sodium_NNP
dodecyl_JJ
sulfate-polyacrylamide_JJ
gel_NN
electrophoresis_NN
showed_VBD
significant_JJ
aldosterone_NN
binding_NN
at_IN
a_DT
molecular_JJ
weight_NN
of_IN
approximately_RB
50000_CD
Dalton_NNP
which_WDT
was_VBD
absent_JJ
with_IN
1_CD
microM_JJ
cold_JJ
aldosterone_NN
,_,
but_CC
not_RB
cortisol_JJ
in_IN
the_DT
binding_JJ
media_NNS
._.
The_DT
presence_NN
of_IN
the_DT
sulfhydryl_NN
agent_NN
dithiothreitol_NNP
did_VBD
not_RB
affect_VB
results_NNS
suggesting_VBG
the_DT
absence_NN
of_IN
disulfide_JJ
bridges_NNS
in_IN
the_DT
steroid_NN
binding_JJ
domain_NN
of_IN
the_DT
receptor_NN
._.
These_DT
data_NNS
are_VBP
the_DT
first_JJ
to_TO
define_VB
the_DT
molecular_JJ
weight_NN
of_IN
the_DT
membrane_NN
receptor_NN
for_IN
aldosterone_NN
._.
Alpha-lipoic_JJ
acid_NN
is_VBZ
a_DT
potent_JJ
inhibitor_NN
of_IN
NF-kappa_NNP
B_NNP
activation_NN
in_IN
human_JJ
T_NNP
cells_NNS
._.
Acquired_VBN
immunodeficiency_NN
syndrome_NN
(_-LRB-
AIDS_NNP
)_-RRB-
results_VBZ
from_IN
infection_NN
with_IN
a_DT
human_JJ
immunodeficiency_NN
virus_NN
(_-LRB-
HIV_NNP
)_-RRB-
._.
The_DT
long_JJ
terminal_NN
repeat_NN
(_-LRB-
LTR_NNP
)_-RRB-
region_NN
of_IN
HIV_NNP
proviral_JJ
DNA_NN
contains_VBZ
binding_JJ
sites_NNS
for_IN
nuclear_JJ
factor_NN
kappa_NN
B_NNP
(_-LRB-
NF-kappa_NN
B_NNP
)_-RRB-
,_,
and_CC
this_DT
transcriptional_JJ
activator_NN
appears_VBZ
to_TO
regulate_VB
HIV_NNP
activation_NN
._.
Recent_JJ
findings_NNS
suggest_VBP
an_DT
involvement_NN
of_IN
reactive_JJ
oxygen_NN
species_NNS
(_-LRB-
ROS_NNP
)_-RRB-
in_IN
signal_NN
transduction_NN
pathways_NNS
leading_VBG
to_TO
NF-kappa_NNP
B_NNP
activation_NN
._.
The_DT
present_JJ
study_NN
was_VBD
based_VBN
on_IN
reports_NNS
that_IN
antioxidants_NNS
which_WDT
eliminate_VBP
ROS_NNS
should_MD
block_VB
the_DT
activation_NN
of_IN
NF-kappa_NNP
B_NNP
and_CC
subsequently_RB
HIV_NNP
transcription_NN
,_,
and_CC
thus_RB
antioxidants_NNS
can_MD
be_VB
used_VBN
as_IN
therapeutic_JJ
agents_NNS
for_IN
AIDS_NNP
._.
Incubation_NNP
of_IN
Jurkat_NNP
T_NNP
cells_NNS
(_-LRB-
1_CD
x_NN
10(6)_JJ
cells/ml_NN
)_-RRB-
with_IN
a_DT
natural_JJ
thiol_NN
antioxidant_NN
,_,
alpha-lipoic_JJ
acid_NN
,_,
prior_RB
to_TO
the_DT
stimulation_NN
of_IN
cells_NNS
was_VBD
found_VBN
to_TO
inhibit_VB
NF-kappa_NNP
B_NNP
activation_NN
induced_NN
by_IN
tumor_NN
necrosis_NN
factor-alpha_NN
(_-LRB-
25_CD
ng/ml_NN
)_-RRB-
or_CC
by_IN
phorbol_NN
12-myristate_JJ
13-acetate_JJ
(_-LRB-
50_CD
ng/ml_NN
)_-RRB-
._.
The_DT
inhibitory_JJ
action_NN
of_IN
alpha-lipoic_JJ
acid_NN
was_VBD
found_VBN
to_TO
be_VB
very_RB
potent_JJ
as_IN
only_RB
4_CD
mM_NN
was_VBD
needed_VBN
for_IN
a_DT
complete_JJ
inhibition_NN
,_,
whereas_IN
20_CD
mM_NN
was_VBD
required_VBN
for_IN
N-acetylcysteine_NNP
._.
These_DT
results_NNS
indicate_VBP
that_IN
alpha-lipoic_JJ
acid_NN
may_MD
be_VB
effective_JJ
in_IN
AIDS_NNP
therapeutics_NNS
._.
Activation_NN
of_IN
lymphokine_NN
genes_NNS
in_IN
T_NNP
cells_NNS
:_:
role_NN
of_IN
cis-acting_JJ
DNA_NNP
elements_NNS
that_WDT
respond_VBP
to_TO
T_NNP
cell_NN
activation_NN
signals_NNS
._.
Activation_NN
of_IN
T_NNP
cells_NNS
is_VBZ
initiated_VBN
by_IN
the_DT
recognition_NN
of_IN
antigen_NN
on_IN
antigen_JJ
presenting_VBG
cells_NNS
to_TO
exert_VB
the_DT
effector_NN
functions_NNS
in_IN
immune_JJ
and_CC
inflammatory_JJ
responses_NNS
._.
Two_CD
types_NNS
of_IN
helper_NN
T_NNP
cell_NN
(_-LRB-
Th_NNP
)_-RRB-
clones_NNS
(_-LRB-
Th1_NNP
and_CC
Th2_NNP
)_-RRB-
are_VBP
defined_VBN
on_IN
the_DT
basis_NN
of_IN
different_JJ
patterns_NNS
of_IN
cytokine_NN
(_-LRB-
lymphokine_NN
)_-RRB-
secretion_NN
._.
They_PRP
determine_VBP
the_DT
outcome_NN
of_IN
an_DT
antigenic_JJ
response_NN
toward_IN
humoral_JJ
or_CC
cell-mediated_JJ
immunity_NN
._.
Although_IN
lymphokine_JJ
genes_NNS
are_VBP
coordinately_RB
regulated_VBN
upon_IN
antigen_JJ
stimulation_NN
,_,
they_PRP
are_VBP
regulated_VBN
by_IN
the_DT
mechanisms_NNS
common_JJ
to_TO
all_DT
as_RB
well_RB
as_IN
those_DT
which_WDT
are_VBP
unique_JJ
to_TO
each_DT
gene_NN
._.
For_IN
most_JJS
lymphokine_NN
genes_NNS
,_,
a_DT
combination_NN
of_IN
phorbol_NN
esters_NNS
(_-LRB-
phorbol_NN
12-myristate_JJ
13_CD
acetate_NN
,_,
PMA_NNP
)_-RRB-
and_CC
calcium_NN
ionophores_NNS
(_-LRB-
A23187_NN
)_-RRB-
is_VBZ
required_VBN
for_IN
their_PRP$
maximal_JJ
induction_NN
._.
Yet_RB
phorbol_JJ
ester_NN
alone_RB
or_CC
calcium_VB
ionophore_RB
alone_RB
produce_VB
several_JJ
lymphokines_NNS
._.
The_DT
production_NN
of_IN
the_DT
granulocyte-macrophage_JJ
colony_NN
stimulating_NN
factor_NN
(_-LRB-
GM-CSF_NNP
)_-RRB-
is_VBZ
completely_RB
dependent_JJ
on_IN
the_DT
two_CD
signals_NNS
._.
We_PRP
have_VBP
previously_RB
found_VBN
a_DT
cis-acting_JJ
region_NN
spanning_VBG
the_DT
GM-CSF_NNP
promoter_NN
region_NN
(_-LRB-
positions_NNS
-95_NN
to_TO
+27_VB
)_-RRB-
that_WDT
confers_VBZ
inducibility_NN
to_TO
reporter_NN
genes_NNS
in_IN
transient_JJ
transfection_NN
assays_VBZ
._.
Further_JJ
analysis_NN
identified_VBN
three_CD
elements_NNS
required_VBN
for_IN
efficient_JJ
induction_NN
,_,
referred_VBD
to_TO
as_IN
GM2_NNP
,_,
GC-box_NNP
and_CC
conserved_VBD
lymphokine_JJ
element_NN
(_-LRB-
CLE0_NN
)_-RRB-
._.
GM2_NNP
defines_VBZ
a_DT
binding_JJ
site_NN
for_IN
protein_NN
(_-LRB-
s_PRP
)_-RRB-
whose_WP$
binding_NN
is_VBZ
inducible_JJ
by_IN
PMA_NNP
._.
One_CD
protein_NN
,_,
NF-GM2_NNP
is_VBZ
similar_JJ
to_TO
the_DT
transcription_NN
factor_NN
NF-kB_NNP
._.
GC-box_NN
is_VBZ
a_DT
binding_JJ
site_NN
for_IN
constitutively_RB
bound_JJ
proteins_NNS
._.
CLEO_NN
defines_VBZ
a_DT
binding_JJ
site_NN
for_IN
protein_NN
(_-LRB-
s_PRP
)_-RRB-
whose_WP$
optimum_JJ
binding_NN
is_VBZ
stimulated_VBN
by_IN
PMA_NNP
and_CC
A23187_NNP
._.
Viral_JJ
trans-activators_NNS
such_JJ
as_IN
Tax_NNP
(_-LRB-
human_NN
T_NNP
cell_NN
leukemia_NN
virus-1_NN
,_,
HTLV-1_NN
)_-RRB-
and_CC
E2_NNP
(_-LRB-
bovine_NN
papilloma_NN
virus_NN
,_,
BPV_NNP
)_-RRB-
proteins_NNS
are_VBP
other_JJ
agents_NNS
which_WDT
activate_VBP
lymphokine_NN
gene_NN
expression_NN
by_IN
bypassing_VBG
T_NNP
cell_NN
receptor_NN
(_-LRB-
TCR_NN
)_-RRB-
mediated_VBN
signaling_VBG
._.
The_DT
trans-activation_NN
domain_NN
of_IN
E2_NNP
and_CC
Tax_NNP
is_VBZ
interchangeable_JJ
although_IN
they_PRP
have_VBP
no_DT
obvious_JJ
sequence_NN
homology_NN
between_IN
them_PRP
._.
The_DT
viral_JJ
trans-activators_NNS
appear_VBP
to_TO
target_VB
specific_JJ
DNA_NN
binding_JJ
protein_NN
such_JJ
as_IN
NF-kB_NNP
and_CC
Sp1_NNP
to_TO
cis-acting_JJ
DNA_NNP
site_NN
and_CC
promote_VB
lymphokine_NN
gene_NN
expression_NN
without_IN
TCR-mediated_JJ
stimulation_NN
._.
I_PRP
kappa_VBD
B/MAD-3_JJ
masks_NNS
the_DT
nuclear_JJ
localization_NN
signal_NN
of_IN
NF-kappa_NNP
B_NNP
p65_.
and_CC
requires_VBZ
the_DT
transactivation_NN
domain_NN
to_TO
inhibit_VB
NF-kappa_NNP
B_NNP
p65_VBD
DNA_NNP
binding_NN
._.
The_DT
active_JJ
nuclear_JJ
form_NN
of_IN
the_DT
NF-kappa_NNP
B_NNP
transcription_NN
factor_NN
complex_NN
is_VBZ
composed_VBN
of_IN
two_CD
DNA_NNP
binding_NN
subunits_NNS
,_,
NF-kappa_NNP
B_NNP
p65_.
and_CC
NF-kappa_NNP
B_NNP
p50_NN
,_,
both_DT
of_IN
which_WDT
share_NN
extensive_JJ
N-terminal_JJ
sequence_NN
homology_NN
with_IN
the_DT
v-rel_NN
oncogene_IN
product_NN
._.
The_DT
NF-kappa_NNP
B_NNP
p65_.
subunit_NN
provides_VBZ
the_DT
transactivation_NN
activity_NN
in_IN
this_DT
complex_JJ
and_CC
serves_VBZ
as_IN
an_DT
intracellular_JJ
receptor_NN
for_IN
a_DT
cytoplasmic_JJ
inhibitor_NN
of_IN
NF-kappa_NNP
B_NNP
,_,
termed_VBD
I_PRP
kappa_VB
B_NNP
._.
In_IN
contrast_NN
,_,
NF-kappa_NNP
B_NNP
p50_NN
alone_RB
fails_VBZ
to_TO
stimulate_VB
kappa_NN
B-directed_JJ
transcription_NN
,_,
and_CC
based_VBN
on_IN
prior_JJ
in_IN
vitro_NN
studies_NNS
,_,
is_VBZ
not_RB
directly_RB
regulated_VBN
by_IN
I_PRP
kappa_VBD
B_NNP
._.
To_TO
investigate_VB
the_DT
molecular_JJ
basis_NN
for_IN
the_DT
critical_JJ
regulatory_JJ
interaction_NN
between_IN
NF-kappa_NNP
B_NNP
and_CC
I_PRP
kappa_VBD
B/MAD-3_JJ
,_,
a_DT
series_NN
of_IN
human_JJ
NF-kappa_NNP
B_NNP
p65_VBD
mutants_NNS
was_VBD
identified_VBN
that_IN
functionally_RB
segregated_VBN
DNA_NNP
binding_NN
,_,
I_PRP
kappa_VBD
B-mediated_JJ
inhibition_NN
,_,
and_CC
I_PRP
kappa_VBD
B-induced_JJ
nuclear_JJ
exclusion_NN
of_IN
this_DT
transcription_NN
factor_NN
._.
Results_NNS
from_IN
in_IN
vivo_JJ
expression_NN
studies_NNS
performed_VBN
with_IN
these_DT
NF-kappa_NNP
B_NNP
p65_VBZ
mutants_NNS
revealed_VBD
the_DT
following_VBG
:_:
1_LS
)_-RRB-
I_PRP
kappa_VB
B/MAD-3_JJ
completely_RB
inhibits_VBZ
NF-kappa_NNP
B_NNP
p65-dependent_JJ
transcriptional_JJ
activation_NN
mediated_VBN
through_IN
the_DT
human_JJ
immunodeficiency_NN
virus_NN
type_NN
1_CD
kappa_NN
B_NNP
enhancer_NN
in_IN
human_JJ
T_NNP
lymphocytes_NNS
,_,
2_CD
)_-RRB-
the_DT
binding_NN
of_IN
I_PRP
kappa_VBD
B/MAD-3_JJ
to_TO
NF-kappa_NNP
B_NNP
p65_.
is_VBZ
sufficient_JJ
to_TO
retarget_VB
NF-kappa_NNP
B_NNP
p65_VBD
from_IN
the_DT
nucleus_JJ
to_TO
the_DT
cytoplasm_NN
,_,
3_CD
)_-RRB-
selective_JJ
deletion_NN
of_IN
the_DT
functional_JJ
nuclear_JJ
localization_NN
signal_NN
present_NN
in_IN
the_DT
Rel_NNP
homology_NN
domain_NN
of_IN
NF-kappa_NNP
B_NNP
p65_VBD
disrupts_VBG
its_PRP$
ability_NN
to_TO
engage_VB
I_PRP
kappa_VB
B/MAD-3_JJ
,_,
and_CC
4_CD
)_-RRB-
the_DT
unique_JJ
C-terminus_NN
of_IN
NF-kappa_NNP
B_NNP
p65_VBD
attenuates_VBG
its_PRP$
own_JJ
nuclear_JJ
localization_NN
and_CC
contains_VBZ
sequences_NNS
that_WDT
are_VBP
required_VBN
for_IN
I_PRP
kappa_VBD
B-mediated_JJ
inhibition_NN
of_IN
NF-kappa_NNP
B_NNP
p65_VBD
DNA_NNP
binding_NN
activity_NN
._.
Together_RB
,_,
these_DT
findings_NNS
suggest_VBP
that_IN
the_DT
nuclear_JJ
localization_NN
signal_NN
and_CC
transactivation_NN
domain_NN
of_IN
NF-kappa_NNP
B_NNP
p65_TO
constitute_VB
a_DT
bipartite_JJ
system_NN
that_WDT
is_VBZ
critically_RB
involved_VBN
in_IN
the_DT
inhibitory_JJ
function_NN
of_IN
I_PRP
kappa_VBD
B/MAD-3_JJ
._.
Unexpectedly_RB
,_,
our_PRP$
in_IN
vivo_JJ
studies_NNS
also_RB
demonstrate_VBP
that_IN
I_PRP
kappa_VBD
B/MAD-3_JJ
binds_NNS
directly_RB
to_TO
NF-kappa_NNP
B_NNP
p50_NN
._.
This_DT
interaction_NN
is_VBZ
functional_JJ
as_IN
it_PRP
leads_VBZ
to_TO
retargeting_VBG
of_IN
NF-kappa_NNP
B_NNP
p50_NN
from_IN
the_DT
nucleus_JJ
to_TO
the_DT
cytoplasm_NN
._.
However_RB
,_,
no_DT
loss_NN
of_IN
DNA_NNP
binding_NN
activity_NN
is_VBZ
observed_VBN
,_,
presumably_RB
reflecting_VBG
the_DT
unique_JJ
C-terminal_JJ
domain_NN
that_WDT
is_VBZ
distinct_JJ
from_IN
that_DT
present_JJ
in_IN
NF-kappa_NNP
B_NNP
p65_VBD
._.
Surrogate_VB
thyroglobulin_NN
receptors_NNS
and_CC
T_NNP
cell_NN
proliferation_NN
in_IN
Hashimoto_NNP
's_POS
thyroiditis_NN
._.
Immunoglobulin_NNP
molecules_NNS
on_IN
the_DT
surface_NN
of_IN
a_DT
B_NNP
lymphocyte_NN
are_VBP
the_DT
endogenous_JJ
"_``
receptors_NNS
"_''
to_TO
which_WDT
specific_JJ
antigens_NNS
bind_NN
._.
Studies_NNS
in_IN
mice_NNS
have_VBP
shown_VBN
that_IN
a_DT
monoclonal_JJ
antibody_NN
,_,
conjugated_VBN
with_IN
palmitate_NN
to_TO
provide_VB
a_DT
lipid_JJ
tail_NN
,_,
can_MD
be_VB
inserted_VBN
into_IN
the_DT
cell_NN
membrane_NN
to_TO
provide_VB
a_DT
"_``
surrogate_JJ
"_''
antigen_NN
receptor_NN
._.
We_PRP
have_VBP
investigated_VBN
whether_IN
a_DT
palmitate_NN
conjugate_NN
of_IN
a_DT
human_JJ
monoclonal_NN
antibody_NN
specific_JJ
for_IN
thyroglobulin_NN
(_-LRB-
TG_NN
)_-RRB-
could_MD
function_VB
as_IN
a_DT
surrogate_NN
TG_NN
receptor_NN
on_IN
blood_NN
mononuclear_NN
cells_NNS
separated_VBN
into_IN
fractions_NNS
enriched_VBN
for_IN
T_NNP
cells_NNS
or_CC
depleted_VBN
of_IN
T_NNP
cells_NNS
(_-LRB-
non-T_JJ
cells_NNS
)_-RRB-
._.
Using_VBG
flow_NN
cytometry_NN
,_,
we_PRP
detected_VBD
surrogate_JJ
TG_NNP
receptors_NNS
on_IN
non-T_JJ
(_-LRB-
but_CC
not_RB
on_IN
T_NNP
)_-RRB-
cells_NNS
from_IN
11_CD
of_IN
11_CD
individuals_NNS
studied_VBD
(_-LRB-
5_CD
Hashimoto_NNP
patients_NNS
and_CC
6_CD
control_NN
donors_NNS
)_-RRB-
._.
In_IN
contrast_NN
,_,
endogenous_JJ
TG_NNP
receptors_NNS
could_MD
only_RB
be_VB
detected_VBN
on_IN
non-T_JJ
cells_NNS
from_IN
1_CD
of_IN
3_CD
Hashimoto_NNP
patients_NNS
and_CC
from_IN
0_CD
of_IN
4_CD
control_NN
donors_NNS
._.
Because_IN
of_IN
the_DT
efficient_JJ
binding_NN
of_IN
TG_NNP
by_IN
surrogate_JJ
receptors_NNS
on_IN
non-T_JJ
cells_NNS
,_,
we_PRP
assessed_VBD
the_DT
ability_NN
of_IN
such_JJ
cells_NNS
to_TO
present_VB
TG_NNP
to_TO
T_NNP
cells_NNS
._.
Proliferation_NN
in_IN
response_NN
to_TO
TG_NNP
was_VBD
observed_VBN
in_IN
T_NNP
cells_NNS
from_IN
only_RB
1_CD
of_IN
5_CD
Hashimoto_NNP
patients_NNS
._.
This_DT
low_JJ
frequency_NN
of_IN
response_NN
was_VBD
no_DT
different_JJ
from_IN
that_DT
previously_RB
detected_VBN
using_VBG
cultures_NNS
of_IN
T_NNP
cells_NNS
and_CC
autologous_JJ
dendritic_NN
cells_NNS
._.
Therefore_RB
,_,
the_DT
successful_JJ
generation_NN
of_IN
surrogate_JJ
receptors_NNS
on_IN
non-T_JJ
cells_NNS
is_VBZ
not_RB
associated_VBN
with_IN
more_RBR
efficient_JJ
TG_JJ
presentation_NN
of_IN
T_NNP
cells_NNS
._.
Furthermore_RB
,_,
the_DT
significance_NN
of_IN
the_DT
present_JJ
study_NN
is_VBZ
that_IN
the_DT
T_NNP
cells_NNS
,_,
not_RB
the_DT
antigen-presenting_JJ
cells_NNS
,_,
are_VBP
likely_JJ
to_TO
be_VB
the_DT
limiting_VBG
element_NN
in_IN
the_DT
T_NNP
cell_NN
proliferative_JJ
response_NN
to_TO
TG_NNP
and_CC
other_JJ
thyroid_JJ
autoantigens_NNS
._.
Aldosterone-specific_NNP
membrane_NN
receptors_NNS
and_CC
rapid_JJ
non-genomic_JJ
actions_NNS
of_IN
mineralocorticoids_NNS
._.
Functional_JJ
studies_NNS
in_IN
extrarenal_JJ
,_,
non-epithelial_JJ
cells_NNS
such_JJ
as_IN
smooth_JJ
muscle_NN
cells_NNS
and_CC
more_JJR
recently_RB
circulating_VBG
human_JJ
lymphocytes_NNS
have_VBP
provided_VBN
increasing_VBG
evidence_NN
that_IN
aldosterone_NN
produces_VBZ
not_RB
only_RB
classical_JJ
genomic_JJ
effects_NNS
,_,
but_CC
also_RB
rapid_JJ
,_,
non-genomic_JJ
effects_NNS
on_IN
transmembrane_NN
electrolyte_NN
movements_NNS
._.
These_DT
involve_VBP
activation_NN
of_IN
the_DT
sodium/proton_NN
exchanger_NN
of_IN
the_DT
cell_NN
membrane_NN
at_IN
very_RB
low_JJ
,_,
physiological_JJ
concentrations_NNS
of_IN
aldosterone_NN
with_IN
an_DT
acute_JJ
onset_NN
within_IN
1-2_JJ
min_NN
._.
A_DT
second_JJ
messenger_NN
cascade_NN
involved_VBN
is_VBZ
the_DT
inositol_NN
1,4,5-trisphosphate/calcium_JJ
pathway_NN
which_WDT
responds_VBZ
over_IN
the_DT
same_JJ
rapid_JJ
time_NN
course_NN
._.
Such_JJ
changes_NNS
clearly_RB
can_MD
not_RB
be_VB
explained_VBN
by_IN
genomic_JJ
mechanisms_NNS
,_,
which_WDT
are_VBP
responsible_JJ
for_IN
later_RB
effects_NNS
than_IN
the_DT
membrane_NN
related_VBN
rapid_JJ
responses_NNS
._.
The_DT
mechanisms_NNS
underlying_VBG
these_DT
rapid_JJ
effects_NNS
of_IN
aldosterone_NN
on_IN
electrolytes_NNS
have_VBP
been_VBN
extensively_RB
studied_VBN
in_IN
human_JJ
lymphocytes_NNS
,_,
which_WDT
thus_RB
may_MD
represent_VB
valuable_JJ
tools_NNS
in_IN
the_DT
delineation_NN
of_IN
the_DT
receptor-effector_NN
mechanisms_NNS
involved_VBN
._.
The_DT
unique_JJ
characteristics_NNS
of_IN
this_DT
new_JJ
pathway_NN
for_IN
steroid_JJ
action_NN
include_VBP
its_PRP$
rapid_JJ
time_NN
course_NN
,_,
10,000-fold_JJ
selectivity_NN
for_IN
aldosterone_NN
over_IN
cortisol_NN
and_CC
the_DT
ineffectiveness_NN
of_IN
spironolactones_NNS
,_,
classical_JJ
mineralocorticoid_NN
antagonists_NNS
,_,
as_IN
antagonists_NNS
of_IN
the_DT
response_NN
._.
Cellular_NNP
immune_JJ
and_CC
cytokine_JJ
pathways_NNS
resulting_VBG
in_IN
tissue_NN
factor_NN
expression_NN
and_CC
relevance_NN
to_TO
septic_JJ
shock_NN
._.
Cells_NNP
of_IN
monocyte_NN
lineage_NN
serve_VBP
as_IN
effector_NN
cells_NNS
in_IN
the_DT
cellular_JJ
immune_JJ
response_NN
._.
In_IN
addition_NN
,_,
they_PRP
respond_VBP
to_TO
LPS_NNP
and_CC
cytokines_NNS
with_IN
activation_NN
and_CC
expression_NN
of_IN
inflammatory_NN
effector_NN
gene_NN
products_NNS
similar_JJ
to_TO
those_DT
elicited_VBN
by_IN
the_DT
antigen_NN
driven_VBN
response_NN
._.
The_DT
response_NN
to_TO
antigen_JJ
proceeds_NNS
at_IN
the_DT
T_NNP
helper_NN
cell_NN
level_NN
through_IN
two_CD
independent_JJ
forms_NNS
of_IN
cellular_JJ
collaboration_NN
,_,
contact_NN
and_CC
lymphokine_NN
._.
We_PRP
review_VBP
the_DT
control_NN
of_IN
expression_NN
of_IN
the_DT
Tissue_NN
Factor_NN
(_-LRB-
TF_NN
)_-RRB-
gene_NN
and_CC
the_DT
function_NN
of_IN
the_DT
TF_NNP
protein_NN
._.
The_DT
enhanced_JJ
initiation_NN
of_IN
transcription_NN
of_IN
the_DT
TF_NNP
gene_NN
appears_VBZ
to_TO
require_VB
engagement_NN
of_IN
a_DT
56_CD
bp_NN
LPS_NNP
Response_NNP
Element_NNP
,_,
an_DT
enhancer_NN
that_WDT
is_VBZ
engaged_VBN
by_IN
both_DT
AP-1_NNP
type_NN
heterodimeric_JJ
complexes_NNS
as_RB
well_RB
as_IN
NF_NNP
kappa_NN
B_NNP
like_IN
heterodimeric_JJ
complexes_NNS
._.
Dissociation_NN
of_IN
NF_NNP
kappa_NN
B_NNP
from_IN
Ig_NNP
kappa_NN
B_NNP
by_IN
cytokine_NN
and_CC
LPS_NNP
stimulation_NN
,_,
and_CC
possibly_RB
activated_VBN
T_NNP
cells_NNS
,_,
may_MD
represent_VB
a_DT
common_JJ
pathway_NN
to_TO
induction_NN
of_IN
the_DT
TF_NN
and_CC
other_JJ
inflammatory_JJ
genes_NNS
._.
Enhancement_NN
of_IN
expression_NN
of_IN
TF_NNP
is_VBZ
observed_VBN
upon_IN
adhesion_NN
of_IN
Mo_NNP
to_TO
endothelial_JJ
cells_NNS
and_CC
extracellular_JJ
matrix_NN
proteins_NNS
,_,
as_RB
well_RB
as_IN
upon_IN
engagement_NN
of_IN
leukocyte_NN
integrins_NNS
._.
The_DT
biological_JJ
effects_NNS
that_WDT
follow_VBP
from_IN
expression_NN
of_IN
TF_NNP
by_IN
vascular_JJ
cells_NNS
have_VBP
been_VBN
resolved_VBN
by_IN
analysis_NN
of_IN
function_NN
aided_VBN
by_IN
the_DT
use_NN
of_IN
recombinant_NN
full_JJ
length_NN
TF_RB
and_CC
truncated_VBD
surface_NN
domain_NN
of_IN
TF_NNP
._.
The_DT
rules_NNS
of_IN
assembly_NN
of_IN
the_DT
cognate_JJ
ligands_NNS
of_IN
TF_NN
,_,
namely_RB
the_DT
zymogen_NN
plasma_NN
factors_NNS
VII_NNP
and_CC
the_DT
serine_NN
protease_NN
factor_NN
VIIa_NNP
,_,
with_IN
the_DT
soluble_JJ
surface_NN
domain_NN
of_IN
TF_NNP
in_IN
free_JJ
solution_NN
,_,
in_IN
the_DT
presence_NN
of_IN
phospholipid_JJ
surfaces_NNS
and_CC
cell_NN
surface_NN
and_CC
of_IN
the_DT
anchored_VBN
TF_NN
molecule_NN
have_VBP
been_VBN
described_VBN
._.
It_PRP
is_VBZ
evident_JJ
that_IN
assembly_NN
of_IN
the_DT
surface_NN
domain_NN
of_IN
TF_NNP
with_IN
VIIa_NNP
to_TO
form_VB
the_DT
binary_JJ
TF.VIIa_NNP
complex_NN
induces_VBZ
a_DT
significant_JJ
increase_NN
in_IN
the_DT
Kcat_NNP
of_IN
the_DT
catalytic_JJ
domain_NN
of_IN
VIIa_NNP
for_IN
small_JJ
peptidyl_NN
substrates_NNS
and_CC
more_JJR
profoundly_RB
for_IN
protein_NN
substrate_NN
._.
This_DT
provides_VBZ
substantial_JJ
evidence_NN
for_IN
an_DT
allosteric_JJ
effect_NN
on_IN
the_DT
catalytic_JJ
cleft_NN
of_IN
VIIa_NNP
that_WDT
is_VBZ
imparted_VBN
by_IN
binding_NN
to_TO
TF_NNP
,_,
its_PRP$
cognate_JJ
catalytic_JJ
cofactor_NN
._.
It_PRP
is_VBZ
also_RB
evident_JJ
that_IN
the_DT
TF.VIIa_NNP
complex_NN
is_VBZ
proteolytically_RB
active_JJ
and_CC
can_MD
activate_VB
the_DT
zymogen_NN
plasma_NN
factor_NN
X_NNP
to_TO
the_DT
serine_NN
protease_NN
Xa_NNP
in_IN
free_JJ
solution_NN
,_,
inferring_NN
that_WDT
extended_VBD
substrate_JJ
recognition_NN
by_IN
induced_JJ
structural_JJ
loci_NNS
of_IN
the_DT
TF.VIIa_NNP
complex_NN
are_VBP
created_VBN
from_IN
either_RB
or_CC
both_DT
proteins_NNS
to_TO
constitute_VB
a_DT
new_JJ
recognition_NN
structure_NN
._.
It_PRP
is_VBZ
also_RB
evident_JJ
that_IN
association_NN
of_IN
X_NNP
with_IN
charged_VBN
phospholipid_JJ
surfaces_NNS
enhances_VBZ
the_DT
proteolytic_JJ
activation_NN
of_IN
this_DT
zymogen_NN
by_IN
increasing_VBG
recognition_NN
and_CC
susceptibility_NN
of_IN
the_DT
sessile_NN
peptide_NN
bond_NN
deduced_VBN
from_IN
the_DT
markedly_NN
decreased_VBD
Km_NNP
and_CC
increased_VBD
Kcat_NNP
._.
